Multi-functional hematopoietic fusion proteins between sequence rearranged G-CSF receptor agonists and other hematopoietic factors

ABSTRACT

Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a continuation of U.S. patentapplication Ser. No. 09/510,238, filed Feb. 22, 2002, pending, which isa divisional of U.S. patent application Ser. No. 08/835,162 filed Apr.4, 1997, now issued as U.S. Pat. No. 6,066,318 on May 23, 2000, which isa continuation-in-part of PCT/US 96/15774 filed Oct. 4, 1996 whichclaims priority under 35 U.S.C. §119(e) of U.S. Provisional Pat. App.Ser. No. 60/004,834, filed Oct. 5, 1995, now abandoned.

REFERENCE TO A “SEQUENTIAL LISTING,” A TABLE, OR A COMPTUER PROGRAMLISTING APPENDIX SUBMITTED ON A DISKETTE

[0002] This application includes a computer program listing appendix,pursuant to 37 CFR 1.96, contained on a diskette, which is incorporatedfully into this application by this reference.

[0003] The diskette is labeled as follows:

[0004] Applicant: Feng, et al.

[0005] Title: Multi-Functional Hematopoietic Fusion Proteins BetweenSequence Rearranged G-CSF Receptor Agonists and Other HematopoieticFactors

[0006] Recorded: Oct. 23, 2003

[0007] Atty No.: 126181-1058

[0008] Serial No.: Unknown

[0009] Filing Date: Oct. 27, 2003

[0010] The diskette contains the following file in ASCII file format:File Name File size Creation Date Sequence.txt 574 kb Oct. 23, 2003

BACKGROUND OF THE INVENTION

[0011] The present invention relates to multi-functional hematopoieticreceptor agonists.

[0012] Colony stimulating factors (CSFs) which stimulate thedifferentiation and/or proliferation of bone marrow cells have generatedmuch interest because of their therapeutic potential for restoringdepressed levels of hematopoietic stem cell-derived cells. CSFs in bothhuman and murine systems have been identified and distinguishedaccording to their activities. For example, granulocyte-CSF (G-CSF) andmacrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilicgranulocyte and macrophage colonies, respectively, while GM-CSF andinterleukin-3 (IL-3) have broader activities and stimulate the formationof both macrophage, neutrophilic and eosinophilic granulocyte colonies.IL-3 also stimulates the formation of mast, megakaryocyte and pure andmixed erythroid colonies.

DESCRIPTION OF RELATED ART

[0013] U.S. Pat. No. 4,877,729 and U.S. Pat. No. 4,959,455 disclosehuman IL-3 and gibbon IL-3 cDNAs and the protein sequences for whichthey code. The hIL-3 disclosed has serine rather than proline atposition 8 in the protein sequence.

[0014] International Patent Application (PCT) Wo 88/00598 disclosesgibbon- and human-like IL-3. The hIL-3 contains a Ser⁸->Pro⁸replacement. Suggestions are made to replace Cys by Ser, therebybreaking the disulfide bridge, and to replace one or more amino acids atthe glycosylation sites.

[0015] U.S. Pat. No. 4,810,643 discloses the DNA sequence encoding humanG-CSF.

[0016] WO 91/02754 discloses a fusion protein comprised of GM-CSF andIL-3 which has increased biological activity compared to GM-CSF or IL-3alone. Also disclosed are nonglycosylated IL-3 and GM-CSF analogproteins as components of the multi-functional hematopoietic receptoragonist.

[0017] WO 92/04455 discloses fusion proteins composed of IL-3 fused to alymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9,IL-11, EPO and G-CSF.

[0018] WO 95/21197 and WO 95/21254 disclose fusion proteins capable ofbroad multi-functional hematopoietic properties.

[0019] GB 2,285,446 relates to the c-mpl ligand (thrombopoietin) andvarious forms of thrombopoietin which are shown to influence thereplication, differentiation and maturation of megakaryocytes andmegakaryocytes progenitors which may be used for the treatment ofthrombocytopenia.

[0020] EP 675,201 A1 relates to the c-mpl ligand (Megakaryocyte growthand development factor (MGDF), allelic variations of c-mpl ligand andc-mpl ligand attached to water soluble polymers such as polyethyleneglycol.

[0021] WO 95/21920 provides the murine and human c-mpl ligand andpolypeptide fragments thereof. The proteins are useful for in vivo andex vivo therapy for stimulating platelet production.

Rearrangement of Protein Sequences

[0022] In evolution, rearrangements of DNA sequences serve an importantrole in generating a diversity of protein structure and function. Geneduplication and exon shuffling provide an important mechanism to rapidlygenerate diversity and thereby provide organisms with a competitiveadvantage, especially since the basal mutation rate is low (Doolittle,Protein Science 1:191-200, 1992).

[0023] The development of recombinant DNA methods has made it possibleto study the effects of sequence transposition on protein folding,structure and function. The approach used in creating new sequencesresembles that of naturally occurring pairs of proteins that are relatedby linear reorganization of their amino acid sequences (Cunningham, etal., Proc. Natl. Acad. Sci. U.S.A. 76:3218-3222, 1979; Teather & Erfle,J. Bacteriol. 172: 3837-3841, 1990; Schimming et al., Eur. J. Biochem.204: 13-19, 1992; Yamiuchi and Minamikawa, FEBS Lett. 260:127-130, 1991;MacGregor et al., FEBS Lett. 378:263-266). The first in vitroapplication of this type of rearrangement to proteins was described byGoldenberg and Creighton (J. Mol. Biol. 165:407-413, 1983). A newN-terminus is selected at an internal site (breakpoint) of the originalsequence, the new sequence having the same order of amino acids as theoriginal from the breakpoint until it reaches an amino acid that is ator near the original C-terminus. At this point the new sequence isjoined, either directly or through an additional portion of sequence(linker), to an amino acid that is at or near the original N-terminus,and the new sequence continues with the same sequence as the originaluntil it reaches a point that is at or near the amino acid that wasN-terminal to the breakpoint site of the original sequence, this residueforming the new C-terminus of the chain.

[0024] This approach has been applied to proteins which range in sizefrom 58 to 462 amino acids (Goldenberg & Creighton, J. Mol. Biol.165:407-413, 1983; Li & Coffino, Mol. Cell. Biol. 13:2377-2383, 1993).The proteins examined have represented a broad range of structuralclasses, including proteins that contain predominantly a-helix(interleukin-4; Kreitman et al., Cytokine 7:311-318, 1995), b-sheet(interleukin-1; Horlick et al., Protein Eng. 5:427-431, 1992), ormixtures of the two (yeast phosphoribosyl anthranilate isomerase; Lugeret al., Science 243:206-210, 1989). Broad categories of protein functionare represented in these sequence reorganization studies: Enzymes T4lysozyme Zhang et al., Biochemistry 32: 12311-12318, 1993; Zhang et al.,Nature Struct. Biol. 1: 434-438 (1995). dihydrofolate Buchwalder et al.,Biochemistry reductase 31: 1621-1630, 1994; Protasova et al., Prot. Eng.7: 1373-1377, 1995). ribonuclease T1 Mullins et al., J. Am. Chem. Soc.116: 5529-5533, 1994; Garrett et al., Protein Science 5: 204-211, 1996).Bacillus b-glucanse Hahn et al., Proc. Natl. Acad. Sci. U.S.A. 91:10417-10421, 1994). aspartate Yang & Schachman, Proc. Natl. Acad.transcarbamoylase Sci. U.S.A. 90: 11980-11984, 1993). phosphoribosylLuger et al., Science 243: 206-210 anthranilate (1989; Luger et al.,Prot. Eng. Isomerase 3: 249-258, 1990). pepsin/pepsinogen Lin et al.,Protein Science 4: 159-166, 1995). glyceraldehyde-3- Vignais et al.,Protein Science phosphate dehydro- 4: 994-1000, 1995). genase ornithineLi & Coffino, Mol. Cell. Biol. decarboxylase 13: 2377-2383, 1993). yeastRitco-Vonsovici et al., Biochemistry phosphoglycerate 34: 16543-16551,1995). dehydrogenase Enzyme Inhibitor basic pancreatic Goldenberg &Creighton, J. Mol. trypsin inhibitor Biol. 165: 407-413, 1983).Cytokines interleukin-1b Horlick et al., Protein Eng. 5: 427-431, 1992).interleukin-4 Kreitman et al., Cytokine 7: 311-318, 1995). TyrosineKinase Recognition Domain a-spectrin SH3 Viguera, et al., J. Mol. Biol.domain 247: 670-681, 1995). Transmembrane Protein omp A Koebnik &Kramer, J. Mol. Biol. 250: 617-626, 1995). Chimeric Proteininterleukin-4- Kreitman et al., Proc. Natl. Acad. Pseudomonas Sci.U.S.A. 91: 6889-6893, 1994). exotoxin

[0025] The results of these studies have been highly variable. In manycases substantially lower activity, solubility or thermodynamicstability were observed (E. coli dihydrofolate reductase, aspartatetranscarbamoylase, phosphoribosyl anthranilate isomerase,glyceraldehyde-3-phosphate dehydrogenase, ornithine decarboxylase, ompA, yeast phosphoglycerate dehydrogenase). In other cases, the sequencerearranged protein appeared to have many nearly identical properties asits natural counterpart (basic pancreatic trypsin inhibitor, T4lysozyme, ribonuclease Tl, Bacillus b-glucanase, interleukin-1b,a-spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases,an unexpected improvement over some properties of the natural sequencewas observed, e.g., the solubility and refolding rate for rearrangeda-spectrin SH3 domain sequences, and the receptor affinity andanti-tumor activity of transposed interleukin-4-Pseudomonas exotoxinfusion molecule (Kreitman et al., Proc. Natl. Acad. Sci. U.S.A.91:6889-6893, 1994; Kreitman et al., Cancer Res. 55:3357-3363, 1995).

[0026] The primary motivation for these types of studies has been tostudy the role of short-range and long-range interactions in proteinfolding and stability. Sequence rearrangements of this type convert asubset of interactions that are long-range in the original sequence intoshort-range interactions in the new sequence, and vice versa. The factthat many of these sequence rearrangements are able to attain aconformation with at least some activity is persuasive evidence thatprotein folding occurs by multiple folding pathways (Viguera, et al., J.Mol. Biol. 247:670-681, 1995). In the case of the SH3 domain ofa-spectrin, choosing new termini at locations that corresponded tob-hairpin turns resulted in proteins with slightly less stability, butwhich were nevertheless able to fold.

[0027] The positions of the internal breakpoints used in the studiescited here are found exclusively on the surface of proteins, and aredistributed throughout the linear sequence without any obvious biastowards the ends or the middle (the variation in the relative distancefrom the original N-terminus to the breakpoint is ca. 10 to 80% of thetotal sequence length). The linkers connecting the original N- andC-termini in these studies have ranged from 0 to 9 residues. In one case(Yang & Schachman, Proc. Natl. Acad. Sci. U.S.A. 90:11980-11984, 1993),a portion of sequence has been deleted from the original C-terminalsegment, and the connection made from the truncated C-terminus to theoriginal N-terminus. Flexible hydrophilic residues such as Gly and Serare frequently used in the linkers. Viguera, et al. (J. Mol. Biol.247:670-681, 1995) compared joining the original N- and C-termini with3- or 4-residue linkers; the 3-residue linker was less thermodynamicallystable. Protasova et al. (Protein Eng. 7:1373-1377, 1994) used 3- or5-residue linkers in connecting the original N-termini of E. colidihydrofolate reductase; only the 3-residue linker produced protein ingood yield.

BRIEF SUMMARY OF THE INVENTION

[0028] Novel hematopoietic proteins of this invention are represented bythe formulas:

R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁

[0029] wherein R₁ and R₂ are independently selected from the groupconsisting of;

[0030] (I) A polypeptide comprising; a modified human G-CSF amino acidsequence of the formula: 1 Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu (SEQ IDNO: 1) 10 Pro Gln Ser Xaa Leu Leu Xaa Xaa Xaa     20 Glu Gln Val Xaa LysXaa Gln Gly Xaa         30 Gly Ala Xaa Leu Gln Glu Xaa Leu Xaa            40 Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu                 50Xaa Xaa Val Xaa Xaa Gly His Ser Xaa                     60 Gly Ile ProTrp Ala Pro Leu Ser Ser                         70 Xaa Pro Ser Xaa AlaLeu Xaa Leu Ala                             80 Gly Xaa Leu Ser Gln LeuHis Ser Gly                                 90 Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu 100 Gly Pro Thr Leu XaaThr Leu Gln Xaa     110 Asp Val Ala Asp Phe Ala Xaa Thr Ile         120Trp Gln Gln Met Glu Xaa Xaa Gly Met             130 Ala Pro Ala Leu GlnPro Thr Gln Gly                 140 Ala Met Pro Ala Phe Ala Ser Ala Xaa                    150 Gln Xaa Xaa Ala Gly Gly Val Leu Val                        160 Ala Ser Xaa Leu Gln Xaa Phe Leu Xaa                            170 Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu AlaGln Pro

[0031] wherein

[0032] Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;

[0033] Xaa at position 2 is Pro or Leu;

[0034] Xaa at position 3 is Leu, Arg, Tyr or Ser;

[0035] Xaa at position 13 is Phe, Ser, His, Thr or Pro;

[0036] Xaa at position 16 is Lys, Pro, Ser, Thr or His;

[0037] Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg;

[0038] Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys;

[0039] Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;

[0040] Xaa at position 24 is Ile, Pro, Tyr or Leu;

[0041] Xaa at position 27 is Asp, or Gly;

[0042] Xaa at position 30 is Ala, Ile, Leu or Gly;

[0043] Xaa at position 34 is Lys or Ser;

[0044] Xaa at position 36 is Cys or Ser;

[0045] Xaa at position 42 is Cys or Ser;

[0046] Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg,Cys, or Leu;

[0047] Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp,Gln, or Thr;

[0048] Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala;

[0049] Xaa at position 47 is Leu or Thr;

[0050] Xaa at position 49 is Leu, Phe, Arg or Ser;

[0051] Xaa at position 50 is Leu, Ile, His, Pro or Tyr;

[0052] Xaa at position 54 is Leu or His;

[0053] Xaa at position 64 is Cys or Ser;

[0054] Xaa at position 67 is Gln, Lys, Leu or Cys;

[0055] Xaa at position 70 is Gln, Pro, Leu, Arg or Ser;

[0056] Xaa at position 74 is Cys or Ser;

[0057] Xaa at position 104 is Asp, Gly or Val;

[0058] Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly;

[0059] Xaa at position 115 is Thr, His, Leu or Ala;

[0060] Xaa at position 120 is Gln, Gly, Arg, Lys or His

[0061] Xaa at position 123 is Glu, Arg, Phe or Thr

[0062] Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gln or Glu;

[0063] Xaa at position 146 is Arg or Gln;

[0064] Xaa at position 147 is Arg or Gln;

[0065] Xaa at position 156 is His, Gly or Ser;

[0066] Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly;

[0067] Xaa at position 162 is Glu, Leu, Gly or Trp;

[0068] Xaa at position 163 is Val, Gly, Arg or Ala;

[0069] Xaa at position 169 is Arg, Ser, Leu, Arg or Cys;

[0070] Xaa at position 170 is His, Arg or Ser;

[0071] wherein optionally 1-11 amino acids from the N-terminus and 1-5from the C-terminus can be deleted; and

[0072] wherein the N-terminus is joined to the C-terminus directly orthrough a linker capable of joining the N-terminus to the C-terminus andhaving new C- and N-termini at amino acids; 38-39 39-40 40-41 41-4242-43 43-44 45-46 48-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-5959-60 60-61 61-62 62-63 63-64 64-65 65-66 66-67 67-68 68-69 69-70 70-7171-72 91-92 92-93 93-94 94-95 95-96 96-97 97-98 98-99  99-100 123-124124-125 125-126 126-127 128-129 128-129 129-130 130-131 131-132 132-133133-134 134-135 135-136 136-137 137-138 138-139 139-140 140-141 141-142or 142-143;

[0073] (II) A polypeptide comprising; a modified hIL-3 amino acidsequence of the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu (SEQ ID NO:2) 1               5 Lys Thr Ser Trp Val Asn Cys Xaa Xaa10                  15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    20                  25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa        30                  35 Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa            40                  45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa55                  60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    65                  70 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa        75                  80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa            85                  90 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa100                 105 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    110                 115 Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr        120                 125 Thr Leu Ser Leu Ala Ile Phe;            130

[0074] wherein

[0075] Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

[0076] Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

[0077] Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

[0078] Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

[0079] Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln,Asn, Thr, Ser or Val;

[0080] Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn,Gln, Leu, Val or Gly;

[0081] Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu,Ser, or Arg;

[0082] Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

[0083] Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

[0084] Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

[0085] Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

[0086] Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

[0087] Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

[0088] Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, orLys;

[0089] Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

[0090] Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

[0091] Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

[0092] Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr,Arg, Ala, Phe, Ile or Met;

[0093] Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

[0094] Xaa at position 36 is Asp, Leu, or Val;

[0095] Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

[0096] Xaa at position 38 is Asn, or Ala;

[0097] Xaa at position 40 is Leu, Trp, or Arg;

[0098] Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

[0099] Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu,Val, Glu, Phe, Tyr, Ile, Met or Ala;

[0100] Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser;

[0101] Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,Glu, Asn, Gln, Ala or Pro;

[0102] Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys,Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

[0103] Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln,Lys, His, Ala, Tyr, Ile, Val or Gly;

[0104] Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

[0105] Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu,Lys, Thr, Ala, Met, Val or Asn;

[0106] Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

[0107] Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,Ala, Ile, Val, His, Phe, Met or Gln;

[0108] Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

[0109] Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

[0110] Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, orMet;

[0111] Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn,Lys, His, Ala or Leu;

[0112] Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

[0113] Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His,Thr, Ala, Tyr, Phe, Leu, Val or Lys;

[0114] Xaa at position 57 is Asn or Gly;

[0115] Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

[0116] Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

[0117] Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

[0118] Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

[0119] Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

[0120] Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

[0121] Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

[0122] Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

[0123] Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

[0124] Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, orHis;

[0125] Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

[0126] Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, orLeu;

[0127] Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

[0128] Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln,Trp, or Asn;

[0129] Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

[0130] Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

[0131] Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

[0132] Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser,Gln, or Leu;

[0133] Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, orAsp;

[0134] Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

[0135] Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

[0136] Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

[0137] Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

[0138] Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

[0139] Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn,His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

[0140] Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

[0141] Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

[0142] Xaa at position 85 is Leu, Asn, Val, or Gln;

[0143] Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

[0144] Xaa at position 87 is Leu, Ser, Trp, or Gly;

[0145] Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

[0146] Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, orSer;

[0147] Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

[0148] Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

[0149] Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ileor Leu;

[0150] Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

[0151] Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys,His, Ala, or Pro;

[0152] Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr,Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

[0153] Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

[0154] Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

[0155] Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu,Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

[0156] Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly,Ser, Phe, or His;

[0157] Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, orPro;

[0158] Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr,Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

[0159] Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

[0160] Xaa at position 103 is Asp, or Ser;

[0161] Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,Gln, Lys, Ala, Phe, or Gly;

[0162] Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,Leu, Lys, Ile, Asp, or His;

[0163] Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

[0164] Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His,Ser, Ala or Pro;

[0165] Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

[0166] Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His,Glu, Ser, or Trp;

[0167] Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

[0168] Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

[0169] Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,Lys, Leu, Ile, Val or Asn;

[0170] Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

[0171] Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,Trp, or Met;

[0172] Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

[0173] Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

[0174] Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

[0175] Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

[0176] Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

[0177] Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

[0178] Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,Ile, Tyr, or Cys;

[0179] Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

[0180] wherein optionally from 1 to 14 amino acids can be deleted fromthe N-terminus and/or from 1 to 15 amino acids can be deleted from theC-terminus; and wherein from 0 to 44 of the amino acids designated byXaa are different from the corresponding amino acids of native (1-133)human interleukin-3; and

[0181] wherein the N-terminus is joined to the C-terminus directly orthrough a linker (L₂) capable of joining the N-terminus to theC-terminus and having new C- and N-termini at amino acids; 26-27 27-2828-29 29-30 30-31 31-32 32-33 33-34 34-35 35-36 36-37 37-38 38-39 39-4040-41 41-42 49-50 50-51 51-52 52-53 53-54 54-55 64-65 65-66 66-67 67-6868-69 69-70 70-71 71-72 72-73 82-83 83-84 84-85 85-86 86-87 87-88 88-8989-90 90-91 91-92 92-93 97-98 98-99  99-100 100-101 101-102 102-103 or103-104;

[0182] or

[0183] (III) A polypeptide comprising; a modified human c-mpl ligandamino acid sequence of the formula: SerProAlaProProAlaCysAspLeuArgValLeu(SEQ ID NO: 3) 1           5              10SerLysLeuLeuArgAspSerHisValLeuHisSer       15             20ArgLeuSerGlnCysProGluValHisProLeuPro 25             30             35ThrProValLeuLeuProAlaValAspPheSerLeu          40             45GlyGluTrpLysThrGlnMetGluGluThrLysAla    50             55             60GlnAspIleLeuGlyAlaValThrLeuLeuLeuGlu             65             70GlyValMetAlaAlaArgGlyGlnLeuGlyProThr       75             80CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln 85             90             95ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu          100            105GlyThrGlnXaaXaaXaaXaaGlyArgThrThrAla   110            115            120HisLysAspProAsnAlaIlePheLeuSerPheGln             125            130HisLeuLeuArgGlyLysValArgPheLeuMetLeu       135            140ValGlyGlySerThrLeuCysValArgArgAlaPro 145         150               155ProThrThrAlaValProSerArgThrSerLeuVal          160            165LeuThrLeuAsnGluLeuProAsnArgThrSerGly   170            175            180LeuLeuGluThrAsnPheThrAlaSerAlaArgThr             185            190ThrGlySerGlyLeuLeuLysTrpGlnGlnGlyPhe       195            200ArgAlaLysIleProGlyLeuLeuAsnGlnThrSer 205            210            215ArgSerLeuAspGlnIleProGlyTyrLeuAsnArg          220            225IleHisGluLeuLeuAsnGlyThrArgGlyLeuPhe   230            235            240ProGlyProSerArgArgThrLeuGlyAlaProAsp             245            250IleSerSerGlyThrSerAspThrGlySerLeuPro       255            260ProAsnLeuGlnProGlyTyrSerProSerProThr 265            270            275HisProProThrGlyGlnTyrThrLeuPheProLeu          280            285ProProThrLeuProThrProValValGlnLeuHis   290            295            300ProLeuLeuProAspProSerAlaProThrProThr             305            310ProThrSerProLeuLeuAsnThrSerTyrThrHis       315            320SerGlnAsnLeuSerGlnGluGly 325            330   332 153

[0184] wherein;

[0185] Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met;

[0186] Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile,Trp, or Met;

[0187] Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile,Trp, or Met;

[0188] Xaa at position 115 is deleted or Gln, Gly, Ser, Thr, Tyr, orAsn; and

[0189] wherein the N-terminus is joined to the C-terminus directly orthrough a linker (L₂) capable of joining the N-terminus to theC-terminus and having new C- and N-termini at amino acids; 26-27 27-2828-29 29-30 30-31 32-33 33-34 34-35 36-37 37-38 38-39 40-41 41-42 42-4343-44 44-45 46-47 47-48 48-49 50-51 51-52 52-53 53-54 54-55 55-56 56-5757-58 58-59 59-60 78-79 79-80 80-81 81-82 82-83 83-84 84-85 85-86 86-8787-88 88-89 108-109 109-110 110-111 111-112 112-113 113-114 114-115115-116 116-117 117-118 118-119 119-120 120-121 121-122 122-123 123-124124-125 125-126 126-127 or 127-128;

[0190] or

[0191] (IV) A polypeptide comprising; a modified hIL-3 amino acidsequence of the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu (SEQ ID NO:2) 1               5 Lys Thr Ser Trp Val Asn Cys Xaa Xaa10                  15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    20                  25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa        30                  35 Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa            40                  45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa55                  60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    65                  70 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa        75                  80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa            85                  90 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa100                 105 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa    110                 115 Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr        120                 125 Thr Leu Ser Leu Ala Ile Phe            130

[0192] wherein

[0193] Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;

[0194] Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;

[0195] Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

[0196] Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;

[0197] Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln,Asn, Thr, Ser or Val;

[0198] Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn,Gln, Leu, Val or Gly;

[0199] Xaa at position 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu,Ser, or Arg;

[0200] Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;

[0201] Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;

[0202] Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

[0203] Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

[0204] Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;

[0205] Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;

[0206] Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, orLys;

[0207] Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;

[0208] Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;

[0209] Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;

[0210] Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr,Arg, Ala, Phe, Ile or Met;

[0211] Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;

[0212] Xaa at position 36 is Asp, Leu, or Val;

[0213] Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;

[0214] Xaa at position 38 is Asn, or Ala;

[0215] Xaa at position 40 is Leu, Trp, or Arg;

[0216] Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

[0217] Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu,Val, Glu, Phe, Tyr, Ile, Met or Ala;

[0218] Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser;

[0219] Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,Glu, Asn, Gln, Ala or Pro;

[0220] Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys,Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;

[0221] Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln,Lys, His, Ala, Tyr, Ile, Val or Gly;

[0222] Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

[0223] Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu,Lys, Thr, Ala, Met, Val or Asn;

[0224] Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

[0225] Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,Ala, Ile, Val, His, Phe, Met or Gln;

[0226] Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

[0227] Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

[0228] Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, orMet;

[0229] Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn,Lys, His, Ala or Leu;

[0230] Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

[0231] Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His,Thr, Ala, Tyr, Phe, Leu, Val or Lys;

[0232] Xaa at position 57 is Asn or Gly;

[0233] Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

[0234] Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

[0235] Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

[0236] Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

[0237] Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;

[0238] Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

[0239] Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

[0240] Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

[0241] Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

[0242] Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, orHis;

[0243] Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

[0244] Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, orLeu;

[0245] Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

[0246] Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln,Trp, or Asn;

[0247] Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

[0248] Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

[0249] Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;

[0250] Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser,Gln, or Leu;

[0251] Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, orAsp;

[0252] Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;

[0253] Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

[0254] Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;

[0255] Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

[0256] Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;

[0257] Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn,His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

[0258] Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

[0259] Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

[0260] Xaa at position 85 is Leu, Asn, Val, or Gln;

[0261] Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

[0262] Xaa at position 87 is Leu, Ser, Trp, or Gly;

[0263] Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

[0264] Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, orSer;

[0265] Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;

[0266] Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

[0267] Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ileor Leu;

[0268] Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

[0269] Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys,His, Ala, or Pro;

[0270] Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr,Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;

[0271] Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

[0272] Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

[0273] Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu,Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

[0274] Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly,Ser, Phe, or His;

[0275] Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, orPro;

[0276] Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr,Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

[0277] Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

[0278] Xaa at position 103 is Asp, or Ser;

[0279] Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,Gln, Lys, Ala, Phe, or Gly;

[0280] Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,Leu, Lys, Ile, Asp, or His;

[0281] Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

[0282] Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His,Ser, Ala or Pro;

[0283] Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

[0284] Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His,Glu, Ser, or Trp;

[0285] Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

[0286] Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

[0287] Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,Lys, Leu, Ile, Val or Asn;

[0288] Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

[0289] Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,Trp, or Met;

[0290] Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

[0291] Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

[0292] Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

[0293] Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

[0294] Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;

[0295] Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;

[0296] Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,Ile, Tyr, or Cys;

[0297] Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

[0298] wherein optionally from 1 to 14 amino acids can be deleted fromthe N-terminus and/or from 1 to 15 amino acids can be deleted from theC-terminus; and wherein from 1 to 44 of the amino acids designated byXaa are different from the corresponding amino acids of native (1-133)human interleukin-3;

[0299] or

[0300] (V) a colony stimulating factor; and wherein L₁ is a linkercapable of linking R₁ to R₂;

[0301] with the proviso that at least R₁ or R₂ is selected from thepolypeptide of formula (I), (II), or (III); and

[0302] said hematopoietic protein can optionally be immediately precededby (methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).

[0303] The more preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (I) above are; 38-39, 39-40,40-41, 41-42, 48-49, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60,60-61, 61-62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96-97,125-126, 126-127, 127-128, 128-129, 129-130, 130-131, 131-132, 132-133,133-134, 134-135, 135-136, 136-137, 137-138, 138-139, 139-140, 140-141and 141-142.

[0304] The most preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (I) above are; 38-39, 48-49,96-97, 125-126, 132-133 and 141-142.

[0305] The more preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (II) above are; 28-29, 29-30,30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40,66-67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89,89-90, 90-91, 98-99, 99-100, 100-101 and 101-102.

[0306] The most preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (II) above are; 34-35, 69-70and 90-91.

[0307] The more preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (III) above or the amino acidsequence of (SEQ ID NO:256) are; 80-81, 81-82, 82-83, 83-84, 84-85,85-86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114,114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122,122-123, 123-124, 124-125, 125-126 and 126-127.

[0308] The most preferred breakpoints at which new C-terminus andN-terminus can be made in the polypeptide (III) above or the amino acidsequence of (SEQ ID NO:256) are; 81-82, 108-109, 115-116, 119-120,122-123 and 125-126.

[0309] The invention is also intended to include multifunctionalreceptor agoinist which comprises a sequence rearranged c-mpl receptoragonist in which the cysteine at position 7 and/or 151 are substitutedwith another amino acid. Preferably, the substitution at position 7 and151 is Ser, Ala, Gly, His, Asn, Asp, Thr, Phe or Thr. More preferably,the substitution at position 7 and 151 is Ser, Ala, Gly, His or Asn.

[0310] The multifunctional receptor agonist of the present invention canalso be represented by the following formula:

(T¹)a-(L¹)_(b)-X¹(L)c-X²-(L²)d-(T²)e X¹-(L)c-X²-(L)-yl-(L)c-Y²

[0311] in which:

[0312] X¹ is a peptide comprising an amino acid sequence correspondingto the sequence of residues n+1 through J of the original protein havingamino acids residues numbered sequentially 1 through J with an aminoterminus at residue 1;

[0313] L is an optional linker;

[0314] X² is a peptide comprising an amino acid sequence of residues 1through n of the original protein;

[0315] Y¹ is a peptide comprising an amino acid sequence correspondingto the sequence of residues n=1 through K of the original protein havingamino acids residues numbered sequentially 1 through K with an aminoterminus at residue 1;

[0316] Y² is a peptide comprising an amino acid sequence of residues 1through n of the original protein;

[0317] L¹ and L² are optional peptide spacers:

[0318] n is an integer ranging from 1 to J-1;

[0319] b, c, and d are each independently 0 or 1;

[0320] a and e are either 0 or 1, provided that both a and e cannot bothbe 0; and

[0321] T¹ and T² are proteins.

[0322] Additionally, the present invention relates to recombinantexpression vectors comprising nucleotide sequences encoding themulti-functional hematopoietic receptor agonists, related microbialexpression systems, and processes for making the multi-functionalhematopoietic receptor agonists. The invention also relates topharmaceutical compositions containing the multi-functionalhematopoietic receptor agonists, and methods for using themulti-functional hematopoietic receptor agonists.

[0323] In addition to the use of the multi-functional hematopoieticreceptor agonists of the present invention in vivo, it is envisionedthat in vitro uses would include the ability to stimulate bone marrowand blood cell activation and growth before infusion into patients.

BRIEF DESCRIPTION OF THE FIGURES

[0324]FIG. 1 schematically illustrates the sequence rearrangement of aprotein. The N-terminus (N) and the C-terminus (C) of the native proteinare joined through a linker, or joined directly. The protein is openedat a breakpoint creating a new N-terminus (new N) and a new C-terminus(new-C) resulting in a protein with a new linear amino acid sequence. Arearranged molecule may be synthesized de novo as linear molecule andnot go through the steps of joining the original N-terminus and theC-terminus and opening of the protein at the breakpoint.

[0325]FIG. 2 shows a schematic of Method I, for creating new proteins inwhich the original N-terminus and C-terminus of the native protein arejoined with a linker and different N-terminus and C-terminus of theprotein are created. In the example shown the sequence rearrangementresults in a new gene encoding a protein with a new N-terminus createdat amino acid 97 of the original protein, the original C-terminus (a.a.174) joined to the amino acid 11 (a.a. 1-10 are deleted) through alinker region and a new C-terminus created at amino acid 96 of theoriginal sequence.

[0326]FIG. 3 shows a schematic of Method II, for creating new proteinsin which the original N-terminus and C-terminus of the native proteinare joined without a linker and different N-terminus and C-terminus ofthe protein are created. In the example shown the sequence rearrangementresults in a new gene encoding a protein with a new N-terminus createdat amino acid 97 of the original protein, the original C-terminus (a.a.174) joined to the original N-terminus and a new C-terminus created atamino acid 96 of the original sequence.

[0327]FIG. 4 shows a schematic of Method III, for creating new proteinsin which the original N-terminus and C-terminus of the native proteinare joined with a linker and different N-terminus and C-terminus of theprotein are created. In the example shown the sequence rearrangementresults in a new gene encoding a protein with a new N-terminus createdat amino acid 97 of the original protein, the original C-terminus (a.a.174) joined to amino acid 1 through a linker region and a new C-terminuscreated at amino acid 96 of the original sequence.

DETAILED DESCRIPTION OF THE INVENTION

[0328] The present invention encompasses multi-functional hematopoieticreceptor agonists formed from covalently linked polypeptides, each ofwhich may act through a different and specific cell receptor to initiatecomplementary biological activities. Hematopoiesis requires a complexseries of cellular events in which stem cells generate continuously intolarge populations of maturing cells in all major lineages. There arecurrently at least 20 known regulators with hematopoietic proliferativeactivity. Most of these proliferative regulators can only stimulate oneor another type of colony formation in vitro, the precise pattern ofcolony formation stimulated by each regulator is quite distinctive. Notwo regulators stimulate exactly the same pattern of colony formation,as evaluated by colony numbers or, more importantly, by the lineage andmaturation pattern of the cells making up the developing colonies.Proliferative responses can most readily be analyzed in simplified invitro culture systems. Three quite different parameters can bedistinguished: alteration in colony size, alteration in colony numbersand cell lineage. Two or more factors may act on the progenitor cell,inducing the formation of larger number of progeny thereby increasingthe colony size. Two or more factors may allow increased number ofprogenitor cells to proliferate either because distinct subsets ofprogenitors cells exist that respond exclusively to one factor orbecause some progenitors require stimulation by two or more factorsbefore being able to respond. Activation of additional receptors on acell by the use of two or more factors is likely to enhance the mitoticsignal because of coalescence of initially differing signal pathwaysinto a common final pathway reaching the nucleus (Metcalf, Nature339:27, 1989). Other mechanisms could explain synergy. For example, ifone signaling pathway is limited by an intermediate activation of anadditional signaling pathway which is caused by a second factor, thenthis may result in a super additive response. In some cases, activationof one receptor type can induce an enhanced expression of otherreceptors (Metcalf, Blood 82:3515-3523, 1993). Two or more factors mayresult in a different pattern of cell lineages than from a singlefactor. The use of multi-functional hematopoietic receptor agonists mayhave a potential clinical advantage resulting from a proliferativeresponse that is not possible by any single factor.

[0329] The receptors of hematopoietic and other growth factors can begrouped into two distinct families of related proteins: (1) tyrosinekinase receptors, including those for epidermal growth factor, M-CSF(Sherr, Blood 75:1, 1990) and SCF (Yarden et al., EMBO J. 6:3341, 1987):and (2) hematopoietic receptors, not containing a tyrosine kinasedomain, but exhibiting obvious homology in their extracellular domain(Bazan, PNAS USA 87:6934-6938, 1990). Included in this latter group areerythropoietin (EPO) (D'Andrea et al., Cell 57:277, 1989), GM-CSF(Gearing et al., EMBO J. 8:3667, 1989), IL-3 (Kitamura et al., Cell66:1165, 1991), G-CSF (Fukunaga et al., J. Bio. Chem. 265:14008-15,1990), IL-4 (Harada et al., PNAS USA 87:857, 1990), IL-5 (Takaki et al.,EMBO J. 9:4367, 1990), IL-6 (Yamasaki et al., Science 241:825, 1988),IL-7 (Goodwin et al., Cell 60:941-51, 1990), LIF (Gearing et al., EMBOJ. 10:2839, 1991) and IL-2 (Cosman et al., Mol-Immunol. 23: 935-94,1986). Most of the latter group of receptors exists in a high-affinityform as heterodimers. After ligand binding, the specific a-chains becomeassociated with at least one other receptor chain (b-chain, g-chain).Many of these factors share a common receptor subunit. The a-chains forGM-CSF, IL-3 and IL-5 share the same b-chain (Kitamura et al., Cell66:1165, 1991), Takaki et al., EMBO J. 10:2833-8, 1991) and receptorcomplexes for IL-6, LIF and IL-11 share a common b-chain (gp130) (Tagaet al., Cell 58:573-81, 1989; Gearing et al., Science 255:1434-7, 1992).The receptor complexes of IL-2, IL-4, IL-7, IL-9 and IL-15 share acommon g-chain (Kondo et al., Science 262:1874, 1993; Russell et al.,Science 266: 1042-1045, 1993; Noguchi et al., Science 262:1877, 1993;Giri et al., EMBO J. 13:2822-2830, 1994).

[0330] The use of a multiply acting hematopoietic factor may also have apotential advantage by reducing the demands placed on factor-producingcells and their induction systems. If there are limitations in theability of a cell to produce a factor, then by lowering the requiredconcentrations of each of the factors, and using them in combination mayusefully reduce demands on the factor-producing cells. The use of amultiply acting hematopoietic factor may lower the amount of the factorsthat would be needed, probably reducing the likelihood of adverseside-effects.

[0331] Novel compounds of this invention are represented by a formulaselected from the group consisting of:

R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, and R₂-R₁

[0332] Where R₁ and R₂ are as defined above.

[0333] R₂ is preferably a colony stimulating factor with a different butcomplementary activity than R₁. By complementary activity is meantactivity which enhances or changes the response to another cellmodulator. The R₁ polypeptide is joined either directly or through alinker segment to the R₂ polypeptide. The term “directly” definesmulti-functional hematopoietic receptor agonists in which thepolypeptides are joined without a peptide linker. Thus L₁ represents achemical bond or polypeptide segment to which both R₁ and R₂ are joinedin frame, most commonly L₁ is a linear peptide to which R₁ and R₂ arejoined by amide bonds linking the carboxy terminus of R₁ to the aminoterminus of L₁ and carboxy terminus of L₁ to the amino terminus of R₂.By “joined in frame” is meant that there is no translation terminationor disruption between the reading frames of the DNA encoding R₁ and R₂.

[0334] A non-exclusive list of other growth factors, i.e. colonystimulating factors (CSFs), are cytokines, lymphokines, interleukins, orhematopoietic growth factors which can be joined to (I), (II) or (III)include GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF), M-CSF,erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8,IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, human growthhormone, and stem cell factor (SCF) also known as steel factor or c-kitligand. Additionally, this invention encompasses the use of modified R₁or R₂ molecules or mutated or modified DNA sequences encoding these R₁or R₂ molecules. The present invention also includes multi-functionalhematopoietic receptor agonists in which R₁ or R₂ is an hIL-3 variant,c-mpl ligand variant, or G-CSF variant. A “hIL-3 variant” is defined asa hIL-3 molecule which has amino acid substitutions and/or portions ofhIL-3 deleted as disclosed in WO 94/12638, WO 94/12639 and WO 95/00646,as well as other variants known in the art. A “c-mpl ligand variant” isdefined an c-mpl ligand molecule which has amino acid substitutionsand/or portions of c-mpl ligand deleted, disclosed in U.S. applicationSer. No. 08/383,035 as well as other variants known in the art. A “G-CSFvariant” is defined an G-CSF molecule which has amino acid substitutionsand/or portions of G-CSF deleted, as disclosed herein, as well as othervariants known in the art.

[0335] The linking group (L₁) is generally a polypeptide of between 1and 500 amino acids in length. The linkers joining the two molecules arepreferably designed to (1) allow the two molecules to fold and actindependently of each other, (2) not have a propensity for developing anordered secondary structure which could interfere with the functionaldomains of the two proteins, (3) have minimal hydrophobiccharacteristics which could interact with the functional protein domainsand (4) provide steric separation of R₁ and R₂ such that R₁ and R₂ couldinteract simultaneously with their corresponding receptors on a singlecell. Typically surface amino acids in flexible protein regions includeGly, Asn and Ser. Virtually any permutation of amino acid sequencescontaining Gly, Asn and Ser would be expected to satisfy the abovecriteria for a linker sequence. Other neutral amino acids, such as Thrand Ala, may also be used in the linker sequence. Additional amino acidsmay also be included in the linkers due to the addition of uniquerestriction sites in the linker sequence to facilitate construction ofthe multi-functional hematopoietic receptor agonists.

[0336] Preferred L₁ linkers of the present invention include sequencesselected from the group of formulas: (Gly³Ser)^(n), (SEQ ID NO: 4),(Gly⁴Ser)^(n), (SEQ ID NO: 5) (Gly⁵Ser)^(n), (SEQ ID NO: 6)(Gly^(n)Ser)^(n) or (SEQ ID NO: 7) (AlaGlySer)^(n). (SEQ ID NO: 8)

[0337] One example of a highly-flexible linker is the glycine andserine-rich spacer region present within the pIII protein of thefilamentous bacteriophages, e.g. bacteriophages M13 or fd (Schaller etal., PNAS USA 72: 737-741, 1975). This region provides a long, flexiblespacer region between two domains of the pIII surface protein. Thespacer region consists of the amino acid sequence:GlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ ID NO: 9)SerGluGlyGlyGlySerGluGlyGlyGlySer GluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer.

[0338] The present invention also includes linkers in which anendopeptidase recognition sequence is included. Such a cleavage site maybe valuable to separate the individual components of themulti-functional hematopoietic receptor agonist to determine if they areproperly folded and active in vitro. Examples of various endopeptidasesinclude, but are not limited to, plasmin, enterokinase, kallikrein,urokinase, tissue plasminogen activator, clostripain, chymosin,collagenase, Russell's viper venom protease, postproline cleavageenzyme, V8 protease, Thrombin and factor Xa.

[0339] Peptide linker segments from the hinge region of heavy chainimmunoglobulins IgG, IgA, IgM, IgD or IgE provide an angularrelationship between the attached polypeptides. Especially useful arethose hinge regions where the cysteines are replaced with serines.Preferred linkers of the present invention include sequences derivedfrom murine IgG gamma 2b hinge region in which the cysteines have beenchanged to serines. These linkers may also include an endopeptidasecleavage site. Examples of such linkers include the following sequences:IleSerGluProSerGlyProIleSerThrIle (SEQ ID NO: 10)AsnProSerProProSerLysGluSerHisLys SerPro andIleGluGlyArgIleSerGluProSerGlyPro (SEQ ID NO: 11)IleSerThrIleAsnProSerProProSerLys GluSerHisLysSerPro.

[0340] The present invention is, however, not limited by the form, sizeor number of linker sequences employed and the only requirement of thelinker is that functionally it does not interfere with the folding andfunction of the individual molecules of the multi-functionalhematopoietic receptor agonist.

[0341] One aspect of the invention includes multi-functionalhematopoietic receptor agonists which comprise a sequence rearrangedc-mpl receptor agonist in which the cysteine(s) at position 7 and 151 ofc-mpl ligand, have been substituted with another amino acid. Kaushanskyet al. (Blood 86:255a Abstract 1008, 1995) teaches that all four of thecysteines at positions 7, 29, 85, and 151 are required for bioactivity.The presence of cysteines in a protein can cause problems in processingwhen the protein is being produced recombinantly in a bacterial host.Microbially produced cysteine-containing proteins may tend to formmultimers which greatly complicate purification of the protein product.Several additional purification steps, such as reduction and reoxidationof the recombinant protein may be required to obtain the protein in theproper confirmation. Removal of one of the cysteine residues, withconcurrent replacement by a chemically equivalent neutral amino acid,would be desirable, in order to simplify the isolation and purificationof the molecule. However, the successful removal of cysteines frombiologically active molecules is unpredictable, in that the tertiarystructure in the absence of the normally formed disulfide bridges, canbe substantially altered. A molecule in which a pair of cysteines atpositions 7 and 151 are substituted with another amino acid may have oneor more advantages including, but not limited to: 1) increased foldingefficiency of the heterologously expressed protein; 2) elimination ofmispaired disulfides, 3) use of milder refold conditions (ie. Guanidinevs. Urea); 4) increased purification yields, 5) increased proteinsolubility; and 6) increased protein stability.

Determination of the Linker L₂

[0342] The length of the amino acid sequence of the linker L₂ to be usedin R₁ and/or R₂ can be selected empirically or with guidance fromstructural information, or by using a combination of the two approaches.

[0343] When no structural information is available, a small series oflinkers can be prepared for testing using a design whose length isvaried in order to span a range from 0 to 50 Å and whose sequence ischosen in order to be consistent with surface exposure (hydrophilicity,Hopp & Woods, Mol. Immunol. 20: 483-489, 1983), Kyte & Doolittle, J.Mol. Biol. 157:105-132; solvent exposed surface area, Lee & Richards, J.Mol. Biol. 55:379-400, 1971) and the ability to adopt the necessaryconformation with out deranging the conformation of R¹ or R²(conformationally flexible; Karplus & Schulz, Naturwissenschaften72:212-213, 1985). Assuming an average of translation of 2.0 to 3.8 Åper residue, this would mean the length to test would be between 0 to 30residues, with 0 to 15 residues being the preferred range. Exemplary ofsuch an empirical series would be to construct linkers using a cassettesequence such as Gly-Gly-Gly-Ser (SEQ ID NO:12) repeated n times, wheren is 1, 2, 3 or 4. Those skilled in the art will recognize that thereare many such sequences that vary in length or composition that canserve as linkers with the primary consideration being that they beneither excessively long nor short (cf., Sandhu, Critical Rev. Biotech.12: 437-462, 1992); if they are too long, entropy effects will likelydestabilize the three-dimensional fold, and may also make foldingkinetically impractical, and if they are too short, they will likelydestabilize the molecule because of torsional or steric strain.

[0344] Those skilled in the analysis of protein structural informationwill recognize that using the distance between the chain ends, definedas the distance between the c-alpha carbons, can be used to define thelength of the sequence to be used, or at least to limit the number ofpossibilities that must be tested in an empirical selection of linkers.They will also recognize that it is sometimes the case that thepositions of the ends of the polypeptide chain are ill-defined instructural models derived from x-ray diffraction or nuclear magneticresonance spectroscopy data, and that when true, this situation willtherefore need to be taken into account in order to properly estimatethe length of the linker required. From those residues whose positionsare well defined are selected two residues that are close in sequence tothe chain ends, and the distance between their c-alpha carbons is usedto calculate an approximate length for a linker between them. Using thecalculated length as a guide, linkers with a range of number of residues(calculated using 2 to 3.8 Å per residue) are then selected. Theselinkers may be composed of the original sequence, shortened orlengthened as necessary, and when lengthened the additional residues maybe chosen to be flexible and hydrophilic as described above; oroptionally the original sequence may be substituted for using a seriesof linkers, one example being the Gly-Gly-Gly-Ser (SEQ ID NO:12)cassette approach mentioned above; or optionally a combination of theoriginal sequence and new sequence having the appropriate total lengthmay be used.

Determination of the Amino and Carboxyl Termini of R₁ and R₂

[0345] Sequences of R₁ and R₂ capable of folding to biologically activestates can be prepared by appropriate selection of the beginning (aminoterminus) and ending (carboxyl terminus) positions from within theoriginal polypeptide chain while using the linker sequence L₂ asdescribed above. Amino and carboxyl termini are selected from within acommon stretch of sequence, referred to as a breakpoint region, usingthe guidelines described below. A novel amino acid sequence is thusgenerated by selecting amino and carboxyl termini from within the samebreakpoint region. In many cases the selection of the new termini willbe such that the original position of the carboxyl terminus immediatelypreceded that of the amino terminus. However, those skilled in the artwill recognize that selections of termini anywhere within the region mayfunction, and that these will effectively lead to either deletions oradditions to the amino or carboxyl portions of the new sequence.

[0346] It is a central tenet of molecular biology that the primary aminoacid sequence of a protein dictates folding to the three-dimensionalstructure necessary for expression of its biological function. Methodsare known to those skilled in the art to obtain and interpretthree-dimensional structural information using x-ray diffraction ofsingle protein crystals or nuclear magnetic resonance spectroscopy ofprotein solutions. Examples of structural information that are relevantto the identification of breakpoint regions include the location andtype of protein secondary structure (alpha and 3-10 helices, paralleland anti-parallel beta sheets, chain reversals and turns, and loops;Kabsch & Sander, Biopolymers 22: 2577-2637, 1983), the degree of solventexposure of amino acid residues, the extent and type of interactions ofresidues with one another (Chothia, Ann. Rev. Biochem. 53:537-572, 1984)and the static and dynamic distribution of conformations along thepolypeptide chain (Alber & Mathews, Methods Enzymol. 154: 511-533,1987). In some cases additional information is known about solventexposure of residues; one example is a site of post-translationalattachment of carbohydrate which is necessarily on the surface of theprotein. When experimental structural information is not available, oris not feasible to obtain, methods are also available to analyze theprimary amino acid sequence in order to make predictions of proteintertiary and secondary structure, solvent accessibility and theoccurrence of turns and loops. Biochemical methods are also sometimesapplicable for empirically determining surface exposure when directstructural methods are not feasible; for example, using theidentification of sites of chain scission following limited proteolysisin order to infer surface exposure (Gentile & Salvatore, Eur. J.Biochem. 218:603-621, 1993)

[0347] Thus using either the experimentally derived structuralinformation or predictive methods (e.g., Srinivisan & Rose Proteins:Struct., Funct. & Genetics, 22: 81-99, 1995) the parental amino acidsequence is inspected to classify regions according to whether or notthey are integral to the maintenance of secondary and tertiarystructure. The occurrence of sequences within regions that are known tobe involved in periodic secondary structure (alpha and 3-10 helices,parallel and anti-parallel beta sheets) are regions that should beavoided. Similarly, regions of amino acid sequence that are observed orpredicted to have a low degree of solvent exposure are more likely to bepart of the so-called hydrophobic core of the protein and should also beavoided for selection of amino and carboxyl termini. In contrast, thoseregions that are known or predicted to be in surface turns or loops, andespecially those regions that are known not to be required forbiological activity, are the preferred sites for location of theextremes of the polypeptide chain. Continuous stretches of amino acidsequence that are preferred based on the above criteria are referred toas a breakpoint region.

Non-covalent Multifunctional Hematopoietic Growth Factors

[0348] An alternative method for connecting two hematopoietic growthfactors is by means of a non-covalent interaction. Such complexedproteins can be described by one of the formulae:

R₁-C₁+R₂-C₂; or C₁-R₁+C₂-R₂; C₁-R₁+R₂-C₂; or C₁-R₁+R₂-C₂.

[0349] R₁ and R₂ are as is defined above. Domains C₁ and C₂ are eitheridentical or non-identical chemical structures, typically proteinaceous,which can form a non-covalent, specific association. Complexes betweenC₁ and C₂ result in a one-to-one stoichiometric relationship between R₁and R₂ for each complex. Examples of domains which associate are“leucine zipper” domains of transcription factors, dimerization domainsof bacterial transcription repressors and immunoglobulin constantdomains. Covalent bonds link R₁ and C1, and R₂ and C₂, respectively. Asindicated in the formulae, the domains C1 and C₂ can be present eitherat the N-terminus or C-terminus of their corresponding hematopoieticgrowth factor (R). These multimerization domains (C₁ and C₂) includethose derived from the bZIP family of proteins (Abel et al., Nature341:24-25, 1989; Landshulz et al., Science 240:1759-1764, 1988; Pu etal., Nuc. Acid Res. 21:4348-4355, 1993; Kozarides et al., Nature336:646-651, 1988), as well as multimerization domains of thehelix-loop-helix family of proteins (Abel et al., Nature 341:24-25,1989; Murre et al., Cell 56:777-783, 1989; Tapscott et al., Science242:405-411, 1988; Fisher et al., Genes & Dev. 5:2342-2352, 1991).Preferred multi-functional hematopoietic receptor agonists of thepresent invention include colony stimulating factors dimerized by virtueof their incorporation as translational multi-functional hematopoieticreceptor agonists with the leucine zipper dimerization domains of thebZIP family proteins Fos and Jun. The leucine zipper domain of Jun iscapable of interacting with identical domains. On the other hand, theleucine zipper domain of Fos interacts with the Jun leucine zipperdomain, but does not interact with other Fos leucine zipper domains.Mixtures of Fos and Jun predominantly result in formation of Fos-Junheterodimers. Consequently, when joined to colony stimulating factors,the Jun domain can be used to direct the formation of either homo- orheterodimers. Preferential formation of heterodimers can be achieved ifone of the colony stimulating factor partners is engineered to possessthe Jun leucine zipper domain while the other is engineered to possessthe Fos zipper.

[0350] Additional peptide sequences may also be added to facilitatepurification or identification of multi-functional hematopoieticreceptor agonist proteins (e.g., poly-His). A highly antigenic peptidemay also be added that would enable rapid assay and facile purificationof the multi-functional hematopoietic receptor agonist protein by aspecific monoclonal antibody.

[0351] “Mutant amino acid sequence,” “mutant protein”, “variantprotein”, “mutein”, or “mutant polypeptide” refers to a polypeptidehaving an amino acid sequence which varies from a native sequence due toamino acid deletions, substitutions, or both, or is encoded by anucleotide sequence intentionally made variant from a native sequence.“Native sequence” refers to an amino acid or nucleic acid sequence whichis identical to a wild-type or native form of a gene or protein.

[0352] Hematopoietic growth factors can be characterized by theirability to stimulate colony formation by human hematopoietic progenitorcells. The colonies formed include erythroid, granulocyte,megakaryocyte, granulocytic macrophages and mixtures thereof. Many ofthe hematopoietic growth factors have demonstrated the ability torestore bone marrow function and peripheral blood cell populations totherapeutically beneficial levels in studies performed initially inprimates and subsequently in humans. Many or all of these biologicalactivities of hematopoietic growth factors involve signal transductionand high affinity receptor binding. Multi-functional hematopoieticreceptor agonists of the present invention may exhibit useful propertiessuch as having similar or greater biological activity when compared to asingle factor or by having improved half-life or decreased adverse sideeffects, or a combination of these properties.

[0353] Multi-functional hematopoietic receptor agonists which havelittle or no agonist activity maybe useful as antagonists, as antigensfor the production of antibodies for use in immunology or immunotherapy,as genetic probes or as intermediates used to construct other usefulhIL-3 muteins.

[0354] Biological activity of the multi-functional hematopoieticreceptor agonist proteins of the present invention can be determined byDNA synthesis in factor-dependent cell lines or by counting the colonyforming units in an in vitro bone marrow assay.

[0355] The multi-functional hematopoietic receptor agonists of thepresent invention may have an improved therapeutic profile as comparedto single acting hematopoietic agonists. For example, somemulti-functional hematopoietic receptor agonists of the presentinvention may have a similar or more potent growth factor activityrelative to other hematopoietic agonists without having a similar orcorresponding increase in side-effects.

[0356] The present invention also includes the DNA sequences which codefor the multi-functional hematopoietic receptor agonist proteins, DNAsequences which are substantially similar and perform substantially thesame function, and DNA sequences which differ from the DNAs encoding themulti-functional hematopoietic receptor agonists of the invention onlydue to the degeneracy of the genetic code. Also included in the presentinvention are the oligonucleotide intermediates used to construct themutant DNAs and the polypeptides coded for by these oligonucleotides.

[0357] Genetic engineering techniques now standard in the art (U.S. Pat.No. 4,935,233 and Sambrook et al., “Molecular Cloning A LaboratoryManual”, Cold Spring Harbor Laboratory, 1989) may be used in theconstruction of the DNA sequences of the present invention. One suchmethod is cassette mutagenesis (Wells et al., Gene 34:315-323, 1985) inwhich a portion of the coding sequence in a plasmid is replaced withsynthetic oligonucleotides that encode the desired amino acidsubstitutions in a portion of the gene between two restriction sites.

[0358] Pairs of complementary synthetic oligonucleotides encoding thedesired gene can be made and annealed to each other. The DNA sequence ofthe oligonucleotide would encode sequence for amino acids of desiredgene with the exception of those substituted and/or deleted from thesequence.

[0359] Plasmid DNA can be treated with the chosen restrictionendonucleases then ligated to the annealed oligonucleotides. The ligatedmixtures can be used to transform competent JM101 cells to resistance toan appropriate antibiotic. Single colonies can be picked and the plasmidDNA examined by restriction analysis and/or DNA sequencing to identifyplasmids with the desired genes.

[0360] Cloning of the DNA sequences of the novel multifunctionalhematopoietic agonists wherein at least one of the with the DNA sequenceof the other colony stimulating factor may be accomplished by the use ofintermediate vectors. Alternatively one gene can be cloned directly intoa vector containing the other gene. Linkers and adapters can be used forjoining the DNA sequences, as well as replacing lost sequences, where arestriction site was internal to the region of interest. Thus geneticmaterial (DNA) encoding one polypeptide, peptide linker, and the otherpolypeptide is inserted into a suitable expression vector which is usedto transform bacteria, yeast, insect cells or mammalian cells. Thetransformed organism is grown and the protein isolated by standardtechniques. The resulting product is therefore a new protein which has acolony stimulating factor joined by a linker region to a second colonystimulating factor.

[0361] Another aspect of the present invention provides plasmid DNAvectors for use in the expression of these novel multi-functionalhematopoietic receptor agonists. These vectors contain the novel DNAsequences described above which code for the novel polypeptides of theinvention. Appropriate vectors which can transform microorganismscapable of expressing the multi-functional hematopoietic receptoragonists include expression vectors comprising nucleotide sequencescoding for the multi-functional hematopoietic receptor agonists joinedto transcriptional and translational regulatory sequences which areselected according to the host cells used.

[0362] Vectors incorporating modified sequences as described above areincluded in the present invention and are useful in the production ofthe multi-functional hematopoietic receptor agonist polypeptides. Thevector employed in the method also contains selected regulatorysequences in operative association with the DNA coding sequences of theinvention and which are capable of directing the replication andexpression thereof in selected host cells.

[0363] As another aspect of the present invention, there is provided amethod for producing the novel multi-functional hematopoietic receptoragonists. The method of the present invention involves culturingsuitable cells or cell line, which has been transformed with a vectorcontaining a DNA sequence coding for expression of a novelmulti-functional hematopoietic receptor agonist. Suitable cells or celllines may be bacterial cells. For example, the various strains of E.coli are well-known as host cells in the field of biotechnology.Examples of such strains include E. coli strains JM101 (Yanish-Perron etal. Gene 33: 103-119, 1985) and MON105 (Obukowicz et al., AppliedEnvironmental Microbiology 58: 1511-1523, 1992). Also included in thepresent invention is the expression of the multi-functionalhematopoietic receptor agonist protein utilizing a chromosomalexpression vector for E. coli based on the bacteriophage Mu (Weinberg etal., Gene 126: 25-33, 1993). Various strains of B. subtilis may also beemployed in this method. Many strains of yeast cells known to thoseskilled in the art are also available as host cells for expression ofthe polypeptides of the present invention. When expressed in the E. colicytoplasm, the gene encoding the multi-functional hematopoietic receptoragonists of the present invention may also be constructed such that atthe 5′ end of the gene codons are added to encode Met⁻²-Ala⁻¹- or Met⁻¹at the N-terminus of the protein. The N termini of proteins made in thecytoplasm of E. coli are affected by post-translational processing bymethionine aminopeptidase (Ben Bassat et al., J. Bac. 169:751-757, 1987)and possibly by other peptidases so that upon expression the methionineis cleaved off the N-terminus. The multi-functional hematopoieticreceptor agonists of the present invention may include multi-functionalhematopoietic receptor agonist polypeptides having Met⁻¹, Ala⁻¹ orMet⁻²-Ala⁻¹ at the N-terminus. These mutant multi-functionalhematopoietic receptor agonists may also be expressed in E. coli byfusing a secretion signal peptide to the N-terminus. This signal peptideis cleaved from the polypeptide as part of the secretion process.

[0364] Also suitable for use in the present invention are mammaliancells, such as Chinese hamster ovary cells (CHO). General methods forexpression of foreign genes in mammalian cells are reviewed in Kaufman,R. J., 1987) Genetic Engineering, Principles and Methods, Vol. 9, J. K.Setlow, editor, Plenum Press, New York. An expression vector isconstructed in which a strong promoter capable of functioning inmammalian cells drives transcription of a eukaryotic secretion signalpeptide coding region, which is translationally joined to the codingregion for the multi-functional hematopoietic receptor agonist. Forexample, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtainedfrom Invitrogen Corp., San Diego, Calif.) can be used. The eukaryoticsecretion signal peptide coding region can be from the gene itself or itcan be from another secreted mammalian protein (Bayne, M. L. et al.,Proc. Natl. Acad. Sci. USA 84: 2638-2642, 1987). After construction ofthe vector containing the gene, the vector DNA is transfected intomammalian cells. Such cells can be, for example, the COS7, HeLa, BHK,CHO, or mouse L lines. The cells can be cultured, for example, in DMEMmedia (JRH Scientific). The polypeptide secreted into the media can berecovered by standard biochemical approaches following transientexpression for 24-72 hours after transfection of the cells or afterestablishment of stable cell lines following selection for antibioticresistance. The selection of suitable mammalian host cells and methodsfor transformation, culture, amplification, screening and productproduction and purification are known in the art. See, e.g., Gething andSambrook, Nature, 293:620-625, 1981), or alternatively, Kaufman et al,Mol. Cell. Biol., 5(7):1750-1759, 1985) or Howley et al., U.S. Pat. No.4,419,446. Another suitable mammalian cell line is the monkey COS-1 cellline. A similarly useful mammalian cell line is the CV-1 cell line.

[0365] Where desired, insect cells may be utilized as host cells in themethod of the present invention. See, e.g., Miller et al., GeneticEngineering, 8:277-298 (Plenum Press 1986) and references cited therein.In addition, general methods for expression of foreign genes in insectcells using Baculovirus vectors are described in: Summers, M. D. andSmith, G. E., 1987)—A manual of methods for Baculovirus vectors andinsect cell culture procedures, Texas Agricultural Experiment StationBulletin No. 1555. An expression vector is constructed comprising aBaculovirus transfer vector, in which a strong Baculovirus promoter(such as the polyhedron promoter) drives transcription of a eukaryoticsecretion signal peptide coding region, which is translationally joinedto the coding region for the multi-functional hematopoietic receptoragonist polypeptide. For example, the plasmid pVL1392 (obtained fromInvitrogen Corp., San Diego, Calif.) can be used. After construction ofthe vector carrying the gene encoding the multi-functional hematopoieticreceptor agonist polypeptide, two micrograms of this DNA isco-transfected with one microgram of Baculovirus DNA (see Summers &Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculoviruscarrying the multi-functional hematopoietic receptor agonist is used toinfect cells cultured, for example, in Excell 401 serum-free medium (JRHBiosciences, Lenexa, Kans.). The multi-functional hematopoietic receptoragonist secreted into the medium can be recovered by standardbiochemical approaches. Supernatants from mammalian or insect cellsexpressing the multi-functional hematopoietic receptor agonist proteincan be first concentrated using any of a number of commercialconcentration units.

[0366] The multi-functional hematopoietic receptor agonists of thepresent invention may be useful in the treatment of diseasescharacterized by decreased levels of either myeloid, erythroid,lymphoid, or megakaryocyte cells of the hematopoietic system orcombinations thereof. In addition, they may be used to activate maturemyeloid and/or lymphoid cells. Among conditions susceptible to treatmentwith the polypeptides of the present invention is leukopenia, areduction in the number of circulating leukocytes (white cells) in theperipheral blood. Leukopenia may be induced by exposure to certainviruses or to radiation. It is often a side effect of various forms ofcancer therapy, e.g., exposure to chemotherapeutic drugs, radiation andof infection or hemorrhage. Therapeutic treatment of leukopenia withthese multi-functional hematopoietic receptor agonists of the presentinvention may avoid undesirable side effects caused by treatment withpresently available drugs.

[0367] The multi-functional hematopoietic receptor agonists of thepresent invention may be useful in the treatment of neutropenia and, forexample, in the treatment of such conditions as aplastic anemia, cyclicneutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemiclupus erythematosus (SLE), leukemia, myelodysplastic syndrome andmyelofibrosis.

[0368] The multi-functional hematopoietic receptor agonist of thepresent invention may be useful in the treatment or prevention ofthrombocytopenia. Currently the only therapy for thrombocytopenia isplatelet transfusion which are costly and carry the significant risks ofinfection (HIV, HBV) and alloimmunization. The multi-functionalhematopoietic receptor agonist may alleviate or diminish the need forplatelet transfusion. Severe thrombocytopenia may result from geneticdefects such as Fanconi's Anemia, Wiscott-Aldrich, or May Hegglinsyndromes. Acquired thrombocytopenia may result from auto- orallo-antibodies as in Immune Thrombocytopenia Purpura, Systemic LupusErythromatosis, hemolytic anemia, or fetal maternal incompatibility. Inaddition, splenomegaly, disseminated intravascular coagulation,thrombotic thrombocytopenic purpura, infection or prosthetic heartvalves may result in thrombocytopenia. Severe thrombocytopenia may alsoresult from chemotherapy and/or radiation therapy or cancer.Thrombocytopenia may also result from marrow invasion by carcinoma,lymphoma, leukemia or fibrosis.

[0369] The multi-functional hematopoietic receptor agonists of thepresent invention may be useful in the mobilization of hematopoieticprogenitors and stem cells in peripheral blood. Peripheral blood derivedprogenitors have been shown to be effective in reconstituting patientsin the setting of autologous marrow transplantation. Hematopoieticgrowth factors including G-CSF and GM-CSF have been shown to enhance thenumber of circulating progenitors and stem cells in the peripheralblood. This has simplified the procedure for peripheral stem cellcollection and dramatically decreased the cost of the procedure bydecreasing the number of pheresis required. The multi-functionalhematopoietic receptor agonist may be useful in mobilization of stemcells and further enhance the efficacy of peripheral stem celltransplantation.

[0370] The multi-functional hematopoietic receptor agonists of thepresent invention may also be useful in the ex vivo expansion ofhematopoietic progenitors and stem cells. Colony stimulating factors(CSFs), such as hIL-3, have been administered alone, co-administeredwith other CSFs, or in combination with bone marrow transplantssubsequent to high dose chemotherapy to treat the neutropenia andthrombocytopenia which are often the result of such treatment. Howeverthe period of severe neutropenia and thrombocytopenia may not be totallyeliminated. The myeloid lineage, which is comprised of monocytes(macrophages), granulocytes (including neutrophils) and megakaryocytes,is critical in preventing infections and bleeding which can belife-threatening. Neutropenia and thrombocytopenia may also be theresult of disease, genetic disorders, drugs, toxins, radiation and manytherapeutic treatments such as conventional oncology therapy.

[0371] Bone marrow transplants have been used to treat this patientpopulation. However, several problems are associated with the use ofbone marrow to reconstitute a compromised hematopoietic systemincluding: 1) the number of stem cells in bone marrow, spleen, orperipheral blood is limited, 2) Graft Versus Host Disease, 3) graftrejection and 4) possible contamination with tumor cells. Stem cellsmake up a very small percentage of the nucleated cells in the bonemarrow, spleen and peripheral blood. It is clear that a dose responseexists such that a greater number of stem cells will enhancehematopoietic recovery. Therefore, the in vitro expansion of stem cellsshould enhance hematopoietic recovery and patient survival. Bone marrowfrom an allogeneic donor has been used to provide bone marrow fortransplant. However, Graft Versus Host Disease and graft rejection limitbone marrow transplantation even in recipients with HLA-matched siblingdonors. An alternative to allogeneic bone marrow transplants isautologous bone marrow transplants. In autologous bone marrowtransplants, some of the patient's own marrow is harvested prior tomyeloablative therapy, e.g. high dose chemotherapy, and is transplantedback into the patient afterwards. Autologous transplants eliminate therisk of Graft Versus Host Disease and graft rejection. However,autologous bone marrow transplants still present problems in terms ofthe limited number of stems cells in the marrow and possiblecontamination with tumor cells. The limited number of stem cells may beovercome by ex-vivo expansion of the stem cells. In addition, stem cellscan be specifically isolated, based on the presence of specific surfaceantigens such as CD34+ in order to decrease tumor cell contamination ofthe marrow graft.

[0372] The following patents contain further details on separating stemcells, CD34+ cells, culturing the cells with hematopoietic factors, theuse of the cells for the treatment of patients with hematopoieticdisorders and the use of hematopoietic factors for cell expansion andgene therapy.

[0373] U.S. Pat. No. 5,061,620 relates to compositions comprising humanhematopoietic stem cells provided by separating the stem cells fromdedicated cells.

[0374] U.S. Pat. No. 5,199,942 describes a method for autologoushematopoietic cell transplantation comprising: (1) obtaininghematopoietic progenitor cells from a patient; (2) ex-vivo expansion ofcells with a growth factor selected from the group consisting of IL-3,flt3 ligand, c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein andcombinations thereof; (3) administering cellular preparation to apatient.

[0375] U.S. Pat. No. 5,240,856 relates to a cell separator that includesan apparatus for automatically controlling the cell separation process.

[0376] WO 91/16116 describes devices and methods for selectivelyisolating and separating target cells from a mixture of cells.

[0377] WO 91/18972 describes methods for in vitro culturing of bonemarrow, by incubating suspension of bone marrow cells, using a hollowfiber bioreactor.

[0378] WO 92/18615 relates to a process for maintaining and expandingbone marrow cells, in a culture medium containing specific mixtures ofcytokines, for use in transplants.

[0379] WO 93/08268 describes a method for selectively expanding stemcells, comprising the steps of (a) separating CD34+ stem cells fromother cells and (b) incubating the separated cells in a selectivemedium, such that the stem cells are selectively expanded.

[0380] WO 93/18136 describes a process for in vitro support of mammaliancells derived from peripheral blood.

[0381] WO 93/18648 relates to a composition comprising human neutrophilprecursor cells with a high content of myeloblasts and promyelocytes fortreating genetic or acquired neutropenia.

[0382] WO 94/08039 describes a method of enrichment for humanhematopoietic stem cells by selection for cells which express c-kitprotein.

[0383] WO 94/11493 describes a stem cell population that are CD34+ andsmall in size, which are isolated using a counterflow elutriationmethod.

[0384] WO 94/27698 relates to a method combining immunoaffinityseparation and continuous flow centrifugal separation for the selectiveseparation of a nucleated heterogeneous cell population from aheterogeneous cell mixture.

[0385] WO 94/25848 describes a cell separation apparatus for collectionand manipulation of target cells.

[0386] The long term culturing of highly enriched CD34+ precursors ofhematopoietic progenitor cells from human bone marrow in culturescontaining IL-1a, IL-3, IL-6 or GM-CSF is discussed in Brandt et al J.Clin. Invest. 86:932-941, 1990).

[0387] One aspect of the present invention provides a method forselective ex-vivo expansion of stem cells. The term “stem cell” refersto the totipotent hematopoietic stem cells as well as early precursorsand progenitor cells which can be isolated from bone marrow, spleen orperipheral blood. The term “expansion” refers to the differentiation andproliferation of the cells. The present invention provides a method forselective ex-vivo expansion of stem cells, comprising the steps of: (a)separating stem cells from other cells, (b) culturing said separatedstem cells with a selective media which contains multi-functionalhematopoietic receptor agonist protein(s) and (c) harvesting said stemscells. Stem cells, as well as committed progenitor cells destined tobecome neutrophils, erythrocytes, platelets, etc. may be distinguishedfrom most other cells by the presence or absence of particularprogenitor marker antigens, such as CD34, that are present on thesurface of these cells and/or by morphological characteristics. Thephenotype for a highly enriched human stem cell fraction is reported asCD34+, Thy-1+ and lin-, but it is to be understood that the presentinvention is not limited to the expansion of this stem cell population.The CD34+ enriched human stem cell fraction can be separated by a numberof reported methods, including affinity columns or beads, magnetic beadsor flow cytometry using antibodies directed to surface antigens such asthe CD34+. Further, physical separation methods such as counterflowelutriation may be used to enrich hematopoietic progenitors. The CD34+progenitors are heterogeneous, and may be divided into severalsub-populations characterized by the presence or absence ofco-expression of different lineage associated cell surface associatedmolecules. The most immature progenitor cells do not express any knownlineage associated markers, such as HLA-DR or CD38, but they may expressCD90(thy-1). Other surface antigens such as CD33, CD38, CD41, CD71,HLA-DR or c-kit can also be used to selectively isolate hematopoieticprogenitors. The separated cells can be incubated in selected medium ina culture flask, sterile bag or in hollow fibers. Various colonystimulating factors may be utilized in order to selectively expandcells. Representative factors that have been utilized for ex-vivoexpansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF,IL-1, IL-6, IL-11, flt-3 ligand or combinations thereof. Theproliferation of the stem cells can be monitored by enumerating thenumber of stem cells and other cells, by standard techniques (e.g.hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent toincubation.

[0388] Several methods for ex-vivo expansion of stem cells have beenreported utilizing a number of selection methods and expansion usingvarious colony stimulating factors including c-kit ligand (Brandt etal., Blood 83:1507-1514 [1994], McKenna et al., Blood 86:3413-3420[1995]), IL-3 (Brandt et al., Blood 83:1507-1514 [1994], Sato et al.,Blood 82:3600-3609 [1993]), G-CSF (Sato et al., Blood 82:3600-3609[1993]), GM-CSF (Sato et al., Blood 82:3600-3609 [1993]), IL-1 (Muenchet al., Blood 81:3463-3473 [1993]), IL-6 (Sato et al., Blood82:3600-3609 [1993]), IL-11 (Lemoli et al., Exp. Hem. 21:1668-1672[1993], Sato et al., Blood 82:3600-3609 [1993]), flt-3 ligand (McKennaet al., Blood 86:3413 3420 [1995]) and/or combinations thereof (Brandtet al., Blood 83:1507 1514 [1994], Haylock et al., Blood 80:1405-1412[1992], Koller et al., Biotechnology 11:358-363 [1993], (Lemoli et al.,Exp. Hem. 21:1668-1672 [1993]), McKenna et al., Blood 86:3413-3420[1995], Muench et al., Blood 81:3463-3473 [1993], Patchen et al.,Biotherapy 7:13-26 [1994], Sato et al., Blood 82:3600-3609 [1993], Smithet al., Exp. Hem. 21:870-877 [1993], Steen et al., Stem Cells 12:214-224[1994], Tsujino et al., Exp. Hem. 21:1379-1386 [1993]). Among theindividual colony stimulating factors, hIL-3 has been shown to be one ofthe most potent in expanding peripheral blood CD34+ cells (Sato et al.,Blood 82:3600-3609 [1993], Kobayashi et al., Blood 73:1836-1841 [1989]).However, no single factor has been shown to be as effective as thecombination of multiple factors. The present invention provides methodsfor ex vivo expansion that utilize multi-functional hematopoieticreceptor agonists that are more effective than a single factor alone.

[0389] Another aspect of the invention provides methods of sustainingand/or expanding hematopoietic precursor cells which includesinoculating the cells into a culture vessel which contains a culturemedium that has been conditioned by exposure to a stromal cell line suchas HS-5 (WO 96/02662, Roecklein and Torok-Strob, Blood 85:997-1105,1995) that has been supplemented with a multi-functional hematopoieticreceptor agonist of the present invention.

[0390] Another projected clinical use of growth factors has been in thein vitro activation of hematopoietic progenitors and stem cells for genetherapy. Due to the long life-span of hematopoietic progenitor cells andthe distribution of their daughter cells throughout the entire body,hematopoietic progenitor cells are good candidates for ex vivo genetransfection. In order to have the gene of interest incorporated intothe genome of the hematopoietic progenitor or stem cell one needs tostimulate cell division and DNA replication. Hematopoietic stem cellscycle at a very low frequency which means that growth factors may beuseful to promote gene transduction and thereby enhance the clinicalprospects for gene therapy. Potential applications of gene therapy(review Crystal, Science 270:404-410 [1995]) include; 1) the treatmentof many congenital metabolic disorders and immunodeficiencies (Kay andWoo, Trends Genet. 10:253-257 [1994]), 2) neurological disorders(Friedmann, Trends Genet. 10:210-214 [1994]), 3) cancer (Culver andBlaese, Trends Genet. 10:174-178 [1994]) and 4) infectious diseases(Gilboa and Smith, Trends Genet. 10:139-144 [1994]).

[0391] There are a variety of methods, known to those with skill in theart, for introducing genetic material into a host cell. A number ofvectors, both viral and non-viral have been developed for transferringtherapeutic genes into primary cells. Viral based vectors include; 1)replication deficient recombinant retrovirus (Boris-Lawrie and Temin,Curr. Opin. Genet. Dev. 3:102-109 [1993], Boris-Lawrie and Temin, Annal.New York Acad. Sci. 716:59-71 [1994], Miller, Current Top. Microbiol.Immunol. 158:1-24 [1992]) and replication-deficient recombinantadenovirus (Berkner, BioTechniques 6:616-629 [1988], Berkner, CurrentTop. Microbiol. Immunol. 158:39-66 [1992], Brody and Crystal, Annal. NewYork Acad. Sci. 716:90-103 [1994]). Non-viral based vectors includeprotein/DNA complexes (Cristiano et al., PNAS USA. 90:2122-2126 [1993],Curiel et al., PNAS USA 88:8850-8854 [1991], Curiel, Annal. New YorkAcad. Sci. 716:36-58 [1994]), electroporation and liposome mediateddelivery such as cationic liposomes (Farhood et al., Annal. New YorkAcad. Sci. 716:23-35 [1994]).

[0392] The present invention provides an improvement to the existingmethods of expanding hematopoietic cells, which new genetic material hasbeen introduced, in that it provides methods utilizing multi-functionalhematopoietic receptor agonist proteins that have improved biologicalactivity, including an activity not seen by any single colonystimulation factor.

[0393] Many drugs may cause bone marrow suppression or hematopoieticdeficiencies. Examples of such drugs are AZT, DDI, alkylating agents andanti-metabolites used in chemotherapy, antibiotics such aschloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs,phenothiazones, tranquilizers such as meprobamate, analgesics such asaminopyrine and dipyrone, anti-convulsants such as phenyloin orcarbamazepine, antithyroids such as propylthiouracil and methimazole anddiuretics. The multi-functional hematopoietic receptor agonists of thepresent invention may be useful in preventing or treating the bonemarrow suppression or hematopoietic deficiencies which often occur inpatients treated with these drugs.

[0394] Hematopoietic deficiencies may also occur as a result of viral,microbial or parasitic infections and as a result of treatment for renaldisease or renal failure, e.g., dialysis. The multi-functionalhematopoietic receptor agonists of the present invention may be usefulin treating such hematopoietic deficiencies.

[0395] The treatment of hematopoietic deficiency may includeadministration of a pharmaceutical composition containing themulti-functional hematopoietic receptor agonists to a patient. Themulti-functional hematopoietic receptor agonists of the presentinvention may also be useful for the activation and amplification ofhematopoietic precursor cells by treating these cells in vitro with themulti-functional hematopoietic receptor agonist proteins of the presentinvention prior to injecting the cells into a patient.

[0396] Various immunodeficiencies, e.g., in T and/or B lymphocytes, orimmune disorders, e.g., rheumatoid arthritis, may also be beneficiallyaffected by treatment with the multi-functional hematopoietic receptoragonists of the present invention. Immunodeficiencies may be the resultof viral infections, e.g., HTLVI, HTLVII, HTLVIII, severe exposure toradiation, cancer therapy or the result of other medical treatment. Themulti-functional hematopoietic receptor agonists of the presentinvention may also be employed, alone or in combination with othercolony stimulating factors, in the treatment of other blood celldeficiencies, including thrombocytopenia (platelet deficiency), oranemia. Other uses for these novel polypeptides are the in vivo and exvivo treatment of patients recovering from bone marrow transplants, andin the development of monoclonal and polyclonal antibodies generated bystandard methods for diagnostic or therapeutic use.

[0397] Other aspects of the present invention are methods andtherapeutic compositions for treating the conditions referred to above.Such compositions comprise a therapeutically effective amount of one ormore of the multi-functional hematopoietic receptor agonists of thepresent invention in a mixture with a pharmaceutically acceptablecarrier. This composition can be administered either parenterally,intravenously or subcutaneously. When administered, the therapeuticcomposition for use in this invention is preferably in the form of apyrogen-free, parenterally acceptable aqueous solution. The preparationof such a parenterally acceptable protein solution, having due regard topH, isotonicity, stability and the like, is within the skill of the art.

[0398] The dosage regimen involved in a method for treating theabove-described conditions will be determined by the attending physicianconsidering various factors which modify the action of drugs, e.g., thecondition, body weight, sex and diet of the patient, the severity of anyinfection, time of administration and other clinical factors. Generally,a daily regimen may be in the range of 0.2-150 μg/kg of multi-functionalhematopoietic receptor agonist protein per kilogram of body weight.Dosages would be adjusted relative to the activity of a givenmulti-functional hematopoietic receptor agonist protein and it would notbe unreasonable to note that dosage regimens may include doses as low as0.1 microgram and as high as 1 milligram per kilogram of body weight perday. In addition, there may exist specific circumstances where dosagesof multi-functional hematopoietic receptor agonist would be adjustedhigher or lower than the range of 0.2-150 micrograms per kilogram ofbody weight. These include co-administration with other colonystimulating factors or IL-3 variants or growth factors;co-administration with chemotherapeutic drugs and/or radiation; the useof glycosylated multi-functional hematopoietic receptor agonist protein;and various patient-related issues mentioned earlier in this section. Asindicated above, the therapeutic method and compositions may alsoinclude co-administration with other human factors. A non-exclusive listof other appropriate colony stimulating factors (CSFs), cytokines,lymphokines, hematopoietic growth factors and interleukins forsimultaneous or serial co-administration with the polypeptides of thepresent invention includes GM-CSF, G-CSF, c-mpl ligand (also known asTPO or MGDF), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5,IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF,flt3 ligand, and stem cell factor (SCF) also known as steel factor orc-kit ligand, or combinations thereof. The dosage recited above would beadjusted to compensate for such additional components in the therapeuticcomposition. Progress of the treated patient can be monitored byperiodic assessment of the hematological profile, e.g., differentialcell count and the like.

Materials and Methods

[0399] Unless noted otherwise, all specialty chemicals were obtainedfrom Sigma, Co. (St. Louis, Mo.). Restriction endonucleases and T4 DNAligase were obtained from New England Biolabs (Beverly, Mass.) orBoehringer Mannheim (Indianapolis, Ind.).

Transformation of E. Coli Strains

[0400]E. coli strains, such as DH5á™ (Life Technologies, Gaithersburg,Md.) and TG1 (Amersham Corp., Arlington Heights, Ill.) are used fortransformation of ligation reactions and are the source of plasmid DNAfor transfecting mammalian cells. E. coli strains, such as JM101(Yanisch-Perron, et al., Gene, 33: 103-119, 1985) and MON₁O₅ (Obukowicz,et al., Appl. and Envir. Micr., 58: 1511-1523, 1992) can be used forexpressing the multi-functional hematopoietic receptor agonist of thepresent invention in the cytoplasm or periplasmic space.

[0401] MON105 ATCC#55204: F—, lambda-,IN(rrnD, rrE)1, rpoD+, rpoH358

[0402] DH5á™: F—, phi80dlacZdeltaM15, delta(lacZYA-argF)U169, deoR,recA1, endA1, hsdR17(rk−, mk+), phoA, supE44lamda-, thi-1, gyrA96, relA1

[0403] TG1: delta(lac-pro), supE, thi-1, hsdD5/F′(traD36, proA+B+,lacIq, lacZdeltaM15)

[0404] JM101 ATCC#33876: delta (pro lac), supE, thi, F′(traD36, proA+B+,lacIq, lacZdeltaM15)

[0405] DH5á™ Subcloning efficiency cells are purchased as competentcells and are ready for transformation using the manufacturer'sprotocol, while both E. coli strains TG1 and MON₁O₅ are renderedcompetent to take up DNA using a CaCl₂ method. Typically, 20 to 50 mL ofcells are grown in LB medium (1% bacto-tryptone, 0.5% bacto-yeastextract, 150 mM NaCl) to a density of approximately 1.0 optical densityunit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronicspectrophotometer (Rochester, N.Y.). The cells are collected bycentrifugation and resuspended in one-fifth culture volume of CaCl₂solution (50 mM CaCl₂, 10 mM Tris-Cl, pH7.4) and are held at 4° C. for30 minutes. The cells are again collected by centrifugation andresuspended in one-tenth culture volume of CaCl₂ solution. Ligated DNAis added to 0.2 mL of these cells, and the samples are held at 4° C. for30-60 minutes. The samples are shifted to 42° C. for two minutes and 1.0mL of LB is added prior to shaking the samples at 37° C. for one hour.Cells from these samples are spread on plates (LB medium plus 1.5%bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) whenselecting for ampicillin-resistant transformants, or spectinomycin (75ug/mL) when selecting for spectinomycin-resistant transformants. Theplates are incubated overnight at 37° C. Colonies are picked andinoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or75 ug/mL spectinomycin) and are grown at 37° C. while shaking.

Methods For Creation of Genes

[0406] With New N-Terminus/C-Terminus

Method I Creation of Genes with New N-Terminus/C-Terminus Which Containa Linker Region (L₂).

[0407] Genes with new N-terminus/C-terminus which contain a linkerregion (L₂) separating the original C-terminus and N-terminus can bemade essentially following the method described in L. S. Mullins, et alJ. Am. Chem. Soc. 116, 5529-5533, 1994). Multiple steps of polymerasechain reaction (PCR) amplifications are used to rearrange the DNAsequence encoding the primary amino acid sequence of the protein. Thesteps are illustrated in FIG. 2.

[0408] In the first step, the first primer set (“new start” and “linkerstart”) is used to create and amplify, from the original gene sequence,the DNA fragment (“Fragment Start”) that contains the sequence encodingthe new N-terminal portion of the new protein followed by the linker(L₂) that connects the C-terminal and N-terminal ends of the originalprotein. In the second step, the second primer set (“new stop” and“linker stop”) is used to create and amplify, from the original genesequence, the DNA fragment (“Fragment Stop”) that encodes the samelinker as used above, followed by the new C-terminal portion of the newprotein. The “new start” and “new stop” primers are designed to includethe appropriate restriction sites which allow cloning of the new geneinto expression plasmids. Typical PCR conditions are one cycle 95° C.melting for two minutes; 25 cycles 94° C. denaturation for one minute,50° C. annealing for one minute and 72° C. extension for one minute;plus one cycle 72° C. extension for seven minutes. A Perkin ElmerGeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100pmole of each primer and one ug of template DNA; and 1×PCR buffer, 200uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNApolymerase and 2 mM MgCl2. PCR reactions are performed in a Model 480DNA thermal cycler (Perkin Elmer Corporation, Norwalk, Conn.).

[0409] “Fragment Start” and “Fragment Stop”, which have complementarysequence in the linker region and the coding sequence for the two aminoacids on both sides of the linker, are joined together in a third PCRstep to make the full-length gene encoding the new protein. The DNAfragments “Fragment Start” and “Fragment Stop” are resolved on a 1% TAEgel, stained with ethidium bromide and isolated using a Qiaex GelExtraction kit (Qiagen). These fragments are combined in equimolarquantities, heated at 70° C. for ten minutes and slow cooled to allowannealing through their shared sequence in “linker start” and “linkerstop”. In the third PCR step, primers “new start” and “new stop” areadded to the annealed fragments to create and amplify the full-lengthnew N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95°C. melting for two minutes; 25 cycles 94° C. denaturation for oneminute, 60° C. annealing for one minute and 72° C. extension for oneminute; plus one cycle 72° C. extension for seven minutes. A PerkinElmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains100 pmole of each primer and approximately 0.5 ug of DNA; and 1×PCRbuffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 unitsAmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are purified usinga Wizard PCR Preps kit (Promega).

Method II Creation of Genes with New N-Terminus/C-Terminus Without aLinker Region

[0410] New N-terminus/C-terminus genes without a linker joining theoriginal N-terminus and C-terminus can be made using two steps of PCRamplification and a blunt end ligation. The steps are illustrated inFIG. 3. In the first step, the primer set (“new start” and “P-bl start”)is used to create and amplify, from the original gene sequence, the DNAfragment (“Fragment Start”) that contains the sequence encoding the newN-terminal portion of the new protein. In the second step, the primerset (“new stop” and “P-bl stop”) is used to create and amplify, fromgene sequence, the DNA fragment (“Fragment Stop”) that contains thesequence encoding the new C-terminal portion of the new protein. The“new start” and “new stop” primers are designed to include appropriaterestriction sites which allow cloning of the new gene into expressionvectors. Typical PCR conditions are one cycle 95° C. melting for twominutes; 25 cycles 94° C. denaturation for one minute, 50° C. annealingfor 45 seconds and 72° C. extension for 45 seconds. Deep Vent polymerase(New England Biolabs) is used to reduce the occurrence of overhangs inconditions recommended by the manufacturer. The “P-bl start” and “P-blstop” primers are phosphorylated at the 5′ end to aid in the subsequentblunt end ligation of “Fragment Start” and “Fragment Stop” to eachother. A 100 ul reaction contained 150 pmole of each primer and one ugof template DNA; and 1×Vent buffer (New England Biolabs), 300 uM dGTP,300 uM dATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase.PCR reactions are performed in a Model 480 DNA thermal cycler (PerkinElmer Corporation, Norwalk, Conn.). PCR reaction products are purifiedusing a Wizard PCR Preps kit (Promega).

[0411] The primers are designed to include appropriate restriction siteswhich allow for the cloning of the new gene into expression vectors.Typically “Fragment Start” is designed to create NcoI restriction site,and “Fragment Stop” is designed to create a HindIII restriction site.Restriction digest reactions are purified using a Magic DNA Clean-upSystem kit (Promega). Fragments Start and Stop are resolved on a 1% TAEgel, stained with ethidium bromide and isolated using a Qiaex GelExtraction kit (Qiagen). These fragments are combined with and annealedto the ends of the ˜3800 base pair NcoI/HindIII vector fragment ofpMON3934 by heating at 50° C. for ten minutes and allowed to slow cool.The three fragments are ligated together using T4 DNA ligase (BoehringerMannheim). The result is a plasmid containing the full-length newN-terminus/C-terminus gene. A portion of the ligation reaction is usedto transform E. coli strain DH5á cells (Life Technologies, Gaithersburg,Md.). Plasmid DNA is purified and sequence confirmed as below.

Method III Creation of New N-Terminus/C-Terminus Genes byTandem-Duplication Method

[0412] New N-terminus/C-terminus genes can be made based on the methoddescribed in R. A. Horlick, et al Protein Eng. 5:427-431, 1992).Polymerase chain reaction (PCR) amplification of the newN-terminus/C-terminus genes is performed using a tandemly duplicatedtemplate DNA. The steps are illustrated in FIG. 3.

[0413] The tandemly-duplicated template DNA is created by cloning andcontains two copies of the gene separated by DNA sequence encoding alinker connecting the original C- and N-terminal ends of the two copiesof the gene. Specific primer sets are used to create and amplify afull-length new N terminus/C-terminus gene from the tandemly-duplicatedtemplate DNA. These primers are designed to include appropriaterestriction sites which allow for the cloning of the new gene intoexpression vectors. Typical PCR conditions are one cycle 95° C. meltingfor two minutes; 25 cycles 94° C. denaturation for one minute, 50° C.annealing for one minute and 72° C. extension for one minute; plus onecycle 72° C. extension for seven minutes. A Perkin Elmer GeneAmp PCRCore Reagents kit (Perkin Elmer Corporation, Norwalk, Conn.) is used. A100 ul reaction contains 100 pmole of each primer and one ug of templateDNA; and 1×PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uMdCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl₂. PCR reactionsare performed in a Model 480 DNA thermal cycler (Perkin ElmerCorporation, Norwalk, Conn.). PCR reactions are purified using a WizardPCR Preps kit (Promega).

Cloning of New N-Terminus/C-Terminus Genes Into Multi-FunctionalReceptor Agonist Expression Vectors

[0414] The new N-terminus/C-terminus gene is digested with restrictionendonucleases to create ends that are compatible to insertion into anexpression vector containing another colony stimulating factor gene.This expression vector is likewise digested with restrictionendonucleases to form compatible ends. After purification, the gene andthe vector DNAs are combined and ligated using T4 DNA ligase. A portionof the ligation reaction is used to transform E. coli. Plasmid DNA ispurified and sequenced to confirm the correct insert. The correct clonesare grown for protein expression.

DNA Isolation and Characterization

[0415] Plasmid DNA can be isolated by a number of different methods andusing commercially available kits known to those skilled in the art. Afew such methods are shown herein. Plasmid DNA is isolated using thePromega Wizard™ Miniprep kit (Madison, Wis.), the Qiagen QIAwell Plasmidisolation kits (Chatsworth, Calif.) or Qiagen Plasmid Midi kit. Thesekits follow the same general procedure for plasmid DNA isolation.Briefly, cells are pelleted by centrifugation (5000×g), plasmid DNAreleased with sequential NaOH/acid treatment, and cellular debris isremoved by centrifugation (10000×g). The supernatant (containing theplasmid DNA) is loaded onto a column containing a DNA-binding resin, thecolumn is washed, and plasmid DNA eluted with TE. After screening forthe colonies with the plasmid of interest, the E. coli cells areinoculated into 50-100 mls of LB plus appropriate antibiotic forovernight growth at 37° C. in an air incubator while shaking. Thepurified plasmid DNA is used for DNA sequencing, further restrictionenzyme digestion, additional subcloning of DNA fragments andtransfection into mammalian, E. coli or other cells.

Sequence Confirmation

[0416] Purified plasmid DNA is resuspended in dH₂O and quantitated bymeasuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic601 UV spectrometer. DNA samples are sequenced using ABI PRISM™DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Divisionof Perkin Elmer Corporation, Lincoln City, Calif.) kits (Part Number401388 or 402078) according to the manufacturers suggested protocolusually modified by the addition of 5% DMSO to the sequencing mixture.Sequencing reactions are performed in a Model 480 DNA thermal cycler(Perkin Elmer Corporation, Norwalk, Conn.) following the recommendedamplification conditions. Samples are purified to remove excess dyeterminators with Centri-Sep™ spin columns (Princeton Separations,Adelphia, N.J.) and lyophilized. Fluorescent dye labeled sequencingreactions are resuspended in deionized formamide, and sequenced ondenaturing 4.75% polyacrylamide-8M urea gels using an ABI Model 373Aautomated DNA sequencer. Overlapping DNA sequence fragments are analyzedand assembled into master DNA contigs using Sequencher v2.1 DNA analysissoftware (Gene Codes Corporation, Ann Arbor, Mich.).

Expression of Multi-Functional Receptor Agonists in Mammalian Cells

[0417] Mammalian Cell Transfection/Production of Conditioned Media

[0418] The BHK-21 cell line can be obtained from the ATCC (Rockville,Md.). The cells are cultured in Dulbecco's modified Eagle media(DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetalbovine serum (FBS). This formulation is designated BHK growth media.Selective media is BHK growth media supplemented with 453 units/mLhygromycin B (Calbiochem, San Diego, Calif.). The BHK-21 cell line waspreviously stably transfected with the HSV transactivating protein VP16,which transactivates the IE110 promoter found on the plasmid pMON3359(See Hippenmeyer et al., Bio/Technology, pp.1037-1041, 1993). The VP16protein drives expression of genes inserted behind the IE110 promoter.BHK-21 cells expressing the transactivating protein VP16 are designatedBHK-VP16. The plasmid pMON1118 (See Highkin et al., Poultry Sci., 70:970-981, 1991) expresses the hygromycin resistance gene from the SV40promoter. A similar plasmid is available from ATCC, pSV2-hph.

[0419] BHK-VP16 cells are seeded into a 60 millimeter (mm) tissueculture dish at 3×10⁵ cells per dish 24 hours prior to transfection.Cells are transfected for 16 hours in 3 mL of “OPTIMEM”™ (Gibco-BRL,Gaithersburg, Md.) containing 10 ug of plasmid DNA containing the geneof interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug ofGibco-BRL “LIPOFECTAMINE”™ per dish. The media is subsequently aspiratedand replaced with 3 mL of growth media. At 48 hours post-transfection,media from each dish is collected and assayed for activity (transientconditioned media). The cells are removed from the dish by trypsin-EDTA,diluted 1:10 and transferred to 100 mm tissue culture dishes containing10 mL of selective media. After approximately 7 days in selective media,resistant cells grow into colonies several millimeters in diameter. Thecolonies are removed from the dish with filter paper (cut toapproximately the same size as the colonies and soaked in trypsin/EDTA)and transferred to individual wells of a 24 well plate containing 1 mLof selective media. After the clones are grown to confluence, theconditioned media is re-assayed, and positive clones are expanded intogrowth media.

Expression of Multi-Functional Receptor Agonists in E. Coli

[0420]E. coli strain MON₁O₅ or JM101 harboring the plasmid of interestare grown at 37° C. in M9 plus casamino acids medium with shaking in aair incubator Model G25 from New Brunswick Scientific (Edison, N.J.).Growth is monitored at OD600 until it reaches a value of 1.0 at whichtime Nalidixic acid (10 milligrams/mL) in 0.1 N NaOH is added to a finalconcentration of 50 μg/mL. The cultures are then shaken at 37° C. forthree to four additional hours. A high degree of aeration is maintainedthroughout culture period in order to achieve maximal production of thedesired gene product. The cells are examined under a light microscopefor the presence of inclusion bodies (IB). One mL aliquots of theculture are removed for analysis of protein content by boiling thepelleted cells, treating them with reducing buffer and electrophoresisvia SDS-PAGE (see Maniatis et al. Molecular Cloning: A LaboratoryManual, 1982). The culture is centrifuged (5000×g) to pellet the cells.

Inclusion Body preparation, Extraction, Refolding, Dialysis, DEAEChromatography, and Characterization of the Multi-FunctionalHematopoietic Receptor Agonists Which Accumulate as Inclusion Bodies inE. Coli Isolation of Inclusion Bodies

[0421] The cell pellet from a 330 mL E. coli culture is resuspended in15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl)1,3-propanediol hydrochloride (Tris-HCl), pH 8.0+1 mMethylenediaminetetraacetic acid (EDTA). These resuspended cells aresonicated using the microtip probe of a Sonicator Cell Disruptor (ModelW-375, Heat Systems-Ultrasonics, Inc., Farmingdale, New York). Threerounds of sonication in sonication buffer followed by centrifugation areemployed to disrupt the cells and wash the inclusion bodies (IB). Thefirst round of sonication is a 3 minute burst followed by a 1 minuteburst, and the final two rounds of sonication are for 1 minute each.

Extraction and Refolding of Proteins from Inclusion Body Pellets

[0422] Following the final centrifugation step, the IB pellet isresuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mMdithiothreitol (DTT) and stirred at room temperature for approximately45 minutes to allow for denaturation of the expressed protein.

[0423] The extraction solution is transferred to a beaker containing 70mL of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred whileexposed to air at 4° C. for 18 to 48 hours to allow the proteins torefold. Refolding is monitored by analysis on a Vydac (Hesperia, Ca.)C18 reversed phase high pressure liquid chromatography (RP-HPLC) column(0.46×25 cm). A linear gradient of 40% to 65% acetonitrile, containing0.1% trifluoroacetic acid (TFA), is employed to monitor the refold. Thisgradient is developed over 30 minutes at a flow rate of 1.5 mL perminute. Denatured proteins generally elute later in the gradient thanthe refolded proteins.

Purification

[0424] Following the refold, contaminating E. coli proteins are removedby acid precipitation. The pH of the refold solution is titrated tobetween pH 5.0 and pH 5.2 using 15% (v/v) acetic acid (HOAc). Thissolution is stirred at 4° C. for 2 hours and then centrifuged for 20minutes at 12,000×g to pellet any insoluble protein.

[0425] The supernatant from the acid precipitation step is dialyzedusing a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-foldexcess) of 10 mM Tris-HCl, pH 8.0 for a total of 18 hours. Dialysislowers the sample conductivity and removes urea prior to DEAEchromatography. The sample is then centrifuged (20 minutes at 12,000×g)to pellet any insoluble protein following dialysis.

[0426] A Bio-Rad Bio-Scale DEAE2 column (7×52 mm) is used for ionexchange chromatography. The column is equilibrated in a buffercontaining 10 mM Tris-HCl, pH 8.0, and a 0-to-500 mM sodium chloride(NaCl) gradient, in equilibration buffer, over 45 column volumes is usedto elute the protein. A flow rate of 1.0 mL per minute is usedthroughout the run. Column fractions (2.0 mL per fraction) are collectedacross the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Ca.)C18 column (0.46×25 cm). A linear gradient of 40% to 65% acetonitrile,containing 0.1% trifluoroacetic acid (TFA), is employed. This gradientis developed over 30 minutes at a flow rate of 1.5 mL per minute. Pooledfractions are then dialyzed against 2 changes of 4 liters(50-to-500-fold excess) of 10 mM ammonium acetate (NH4Ac), pH 4.0 for atotal of 18 hours. Dialysis is performed using a Spectra/Por 3 membranewith a MWCO of 3,500 daltons. Finally, the sample is sterile filteredusing a 0.22 μm syringe filter (μStar LB syringe filter, Costar,Cambridge, Ma.), and stored at 4° C.

[0427] In some cases the folded proteins can be affinity purified usingaffinity reagents such as mabs or receptor subunits attached to asuitable matrix. Alternatively, (or in addition) purification can beaccomplished using any of a variety of chromatographic methods such as:ion exchange, gel filtration or hydrophobic chromatography or reversedphase HPLC.

[0428] These and other protein purification methods are described indetail in Methods in Enzymology, Volume 182 ‘Guide to ProteinPurification’ edited by Murray Deutscher, Academic Press, San Diego,Calif. (1990).

Protein Characterization

[0429] The purified protein is analyzed by RP-HPLC, electrospray massspectrometry, and SDS-PAGE. The protein quantitation is done by aminoacid composition, RP-HPLC, and Bradford protein determination. In somecases tryptic peptide mapping is performed in conjunction withelectrospray mass spectrometry to confirm the identity of the protein.

AML Proliferation Assay for Bioactive Human Interleukin-3

[0430] The factor-dependent cell line AML 193 was obtained from theAmerican Type Culture Collection (ATCC, Rockville, Md.). This cell line,established from a patient with acute myelogenous leukemia, is a growthfactor dependent cell line which displayed enhanced growth in GM-CSFsupplemented medium (Lange, B., et al., Blood 70: 192, 1987; Valtieri,M., et al., J. Immunol. 138:4042, 1987). The ability of AML 193 cells toproliferate in the presence of human IL-3 has also been documented.(Santoli, D., et al., J. Immunol. 139: 348, 1987). A cell line variantwas used, AML 193 1.3, which was adapted for long term growth in IL-3 bywashing out the growth factors and starving the cytokine dependent AML193 cells for growth factors for 24 hours. The cells are then replatedat 1×10⁵ cells/well in a 24 well plate in media containing 100 U/mLIL-3. It took approximately 2 months for the cells to grow rapidly inIL-3. These cells are maintained as AML 193 1.3 thereafter bysupplementing tissue culture medium (see below) with human IL-3.

[0431] AML 193 1.3 cells are washed 6 times in cold Hanks balanced saltsolution (HBSS, Gibco, Grand Island, N.Y.) by centrifuging cellsuspensions at 250×g for 10 minutes followed by decantation of thesupernatant. Pelleted cells are resuspended in HBSS and the procedure isrepeated until six wash cycles are completed. Cells washed six times bythis procedure are resuspended in tissue culture medium at a densityranging from 2×10⁵ to 5×10⁵ viable cells/mL. This medium is prepared bysupplementing Iscove's modified Dulbecco's Medium (IMDM, Hazelton,Lenexa, Kans.) with albumin, transferrin, lipids and 2-mercaptoethanol.Bovine albumin (Boehringer-Mannheim, Indianapolis, Ind.) is added at 500μg/mL; human transferrin (Boehringer-Mannheim, Indianapolis, Ind.) isadded at 100 μg/mL; soybean lipid (Boehringer-Mannheim, Indianapolis,Ind.) is added at 50 μg/mL; and 2-mercaptoethanol (Sigma, St. Louis,Mo.) is added at 5×10⁻⁵ M.

[0432] Serial dilutions of human interleukin-3 or multi-functionalhematopoietic receptor agonist proteins are made in triplicate series intissue culture medium supplemented as stated above in 96 well Costar3596 tissue culture plates. Each well contained 50 μl of mediumcontaining interleukin-3 or multi-functional hematopoietic receptoragonist proteins once serial dilutions are completed. Control wellscontained tissue culture medium alone (negative control). AML 193 1.3cell suspensions prepared as above are added to each well by pipetting50 μl (2.5×10⁴ cells) into each well. Tissue culture plates areincubated at 37° C. with 5% CO₂ in humidified air for 3 days. On day 3,0.5 μCi ³H-thymidine (2 Ci/mM, New England Nuclear, Boston, Mass.) isadded in 50 μl of tissue culture medium. Cultures are incubated at 37°C. with 5% CO₂ in humidified air for 18-24 hours. Cellular DNA isharvested onto glass filter mats (Pharmacia LKB, Gaithersburg, Md.)using a TOMTEC cell harvester (TOMTEC, Orange, Conn.) which utilized awater wash cycle followed by a 70% ethanol wash cycle. Filter mats areallowed to air dry and then placed into sample bags to whichscintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, Mo.or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, Md.) isadded. Beta emissions of samples from individual tissue culture wellsare counted in a LKB BetaPlate model 1205 scintillation counter(Pharmacia LKB, Gaithersburg, Md.) and data is expressed as counts perminute of ³H-thymidine incorporated into cells from each tissue culturewell. Activity of each human interleukin-3 preparation ormulti-functional hematopoietic receptor agonist protein preparation isquantitated by measuring cell proliferation (³H-thymidine incorporation)induced by graded concentrations of interleukin-3 or multi-functionalhematopoietic receptor agonist. Typically, concentration ranges from0.05 pM-10⁵ pM are quantitated in these assays. Activity is determinedby measuring the dose of interleukin-3 or multi-functional hematopoieticreceptor agonist protein which provides 50% of maximal proliferation(EC₅₀=0.5×(maximum average counts per minute of ³H-thymidineincorporated per well among triplicate cultures of all concentrations ofinterleukin-3 tested—background proliferation measured by ³H-thymidineincorporation observed in triplicate cultures lacking interleukin-3).This EC₅₀ value is also equivalent to 1 unit of bioactivity. Every assayis performed with native interleukin-3 as a reference standard so thatrelative activity levels could be assigned.

[0433] Typically, the multi-functional hematopoietic receptor agonistproteins were tested in a concentration range of 2000 pM to 0.06 pMtitrated in serial 2 fold dilutions.

[0434] Activity for each sample was determined by the concentrationwhich gave 50% of the maximal response by fitting a four-parameterlogistic model to the data. It was observed that the upper plateau(maximal response) for the sample and the standard with which it wascompared did not differ. Therefore relative potency calculation for eachsample was determined from EC50 estimations for the sample and thestandard as indicated above. AML 193.1.3 cells proliferate in responseto hIL-3, hGM-CSF and hG-CSF. Therefore the following additional assayswere performed for some samples to demonstrate that the G-CSF receptoragonist portion of the multi-functional hematopoietic receptor agonistproteins was active. The proliferation assay was performed with themulti-functional hematopoietic receptor agonist plus and minusneutralizing monoclonal antibodies to the hIL-3 receptor agonistportion. In addition, a fusion molecule with the factor Xa cleavage sitewas cleaved then purified and the halves of the molecule were assayedfor proliferative activity. These experiments showed that bothcomponents of the multi-functional hematopoietic receptor agonistproteins were active.

TF1 c-mpl Ligand Dependent Proliferation Assay

[0435] The c-mpl ligand proliferative activity can be assayed using asubclone of the pluripotential human cell line TF1 (Kitamura et al., J.Cell Physiol 140:323-334. [1989]). TF1 cells are maintained in h-IL3(100 U/mL). To establish a sub-clone responsive to c-mpl ligand, cellsare maintained in passage media containing 10% supernatant from BHKcells transfected with the gene expressing the 1-153 form of c-mplligand (pMON26448). Most of the cells die, but a subset of cellssurvive. After dilution cloning, a c-mpl ligand responsive clone isselected, and these cells are split into passage media to a density of0.3×10⁶ cells/mL the day prior to assay set-up. Passage media for thesecells is the following: RPMI 1640 (Gibco), 10% FBS (Harlan, Lot #91206),10% c-mpl ligand supernatant from transfected BHK cells, 1 mM sodiumpyruvate (Gibco), 2 mM glutamine (Gibco), and 100 ug/mLpenicillin-streptomycin (Gibco). The next day, cells are harvested andwashed twice in RPMI or IMDM media with a final wash in the ATL, orassay media. ATL medium consists of the following:IMDM (Gibco), 500ug/mL of bovine serum albumin, 100 ug/mL of human transferrin, 50 ug/mLsoybean lipids, 4×10-8M beta-mercaptoethanol and 2 mL of A9909 (Sigma,antibiotic solution) per 1000 mL of ATL. Cells are diluted in assaymedia to a final density of 0.25×10⁶ cells/mL in a 96-well lowevaporation plate (Costar) to a final volume of 50 ul. Transientsupernatants (conditioned media) from transfected clones are added at avolume of 50 ul as duplicate samples at a final concentration of 50% anddiluted three-fold to a final dilution of 1.8%. Triplicate samples of adose curve of IL-3 variant pMON13288 starting at 1 ng/mL and dilutedusing three-fold dilutions to 0.0014 ng/mL is included as a positivecontrol. Plates are incubated at 5% CO₂ and 37° C. At day six ofculture, the plate is pulsed with 0.5 Ci of 3H/well (NEN) in a volume of20 ul/well and allowed to incubate at 5% CO₂ and 37° C. for four hours.The plate is harvested and counted on a Betaplate counter.

Other In Vitro Cell Based Proliferation Assays

[0436] Other in vitro cell based assays, known to those skilled in theart, may also be useful to determine the activity of themulti-functional hematopoietic receptor agonists depending on thefactors that comprise the molecule in a similar manner as described inthe AML 193.1.3 cell proliferation assay. The following are examples ofother useful assays.

[0437] TF1 proliferation assay: TF1 is a pluripotential human cell line(Kitamura et al., J. Cell Physiol 140:323-334. [1989]) that responds tohIL-3.

[0438] 32D proliferation assay: 32D is a murine IL-3 dependent cell linewhich does not respond to human IL-3 but does respond to human G-CSFwhich is not species restricted.

[0439] Baf/3 proliferation assay: Baf/3 is a murine IL-3 dependent cellline which does not respond to human IL-3 or human c-mpl ligand but doesrespond to human G-CSF which is not species restricted.

[0440] T1165 proliferation assay: T1165 cells are a IL-6 dependentmurine cell line (Nordan et al., 1986) which respond to IL-6 and IL-11.

[0441] Human Plasma Clot meg-CSF Assay: Used to assay megakaryocytecolony formation activity (Mazur et al., 1981).

Transfected Cell Lines

[0442] Cell lines such as the murine Baf/3 cell line can be transfectedwith a colony stimulating factor receptor, such as the human G-CSFreceptor or human c-mpl receptor, which the cell line does not have.These transfected cell lines can be used to determine the activity ofthe ligand for which the receptor has been transfected into the cellline.

[0443] One such transfected Baf/3 cell line was made by cloning the cDNAencoding c-mpl from a library made from a c-mpl responsive cell line andcloned into the multiple cloning site of the plasmid pcDNA3 (Invitrogen,San Diego Calif.). Baf/3 cells were transfected with the plasmid viaelectroporation. The cells were grown under G418 selection in thepresence of mouse IL-3 in Wehi conditioned media. Clones wereestablished through limited dilution.

[0444] In a similar manner the human G-CSF receptor can be transfectedinto the Baf/3 cell line and used to determine the bioactivity of themulti-functional hematopoietic receptor agoinsts.

[0445] Analysis of c-mpl Ligand Proliferative Activity

[0446] Methods

[0447] 1. Bone Marrow Proliferation Assay

[0448] a. CD34+ Cell Purification:

[0449] Bone marrow aspirates (15-20 mL) were obtained from normalallogeneic marrow donors after informed consent. Cells were diluted 1:3in phosphate buffered saline (PBS, Gibco-BRL), 30 mL were layered over15 mL Histopaque-1077 (Sigma) and centrifuged for 30 minutes at 300 RCF.The mononuclear interface layer was collected and washed in PBS. CD34+cells were enriched from the mononuclear cell preparation using anaffinity column per manufacturers instructions (CellPro, Inc, BothellWash.). After enrichment, the purity of CD34+ cells was 70% on averageas determined by using flow cytometric analysis using anti-CD34monoclonal antibody conjugated to fluorescein and anti-CD38 conjugatedto phycoerythrin (Becton Dickinson, San Jose Calif.).

[0450] Cells were resuspended at 40,000 cells/mL in X-Vivo 10 media(Bio-Whittaker, Walkersville, Md.) and 1 mL was plated in 12-well tissueculture plates (Costar). The growth factor rhIL-3 was added at 100 ng/mL(pMON5873) was added to some wells. hIL3 variants were used at 10 ng/mLto 100 ng/mL. Conditioned media from BHK cells transfected with plasmidencoding c-mpl ligand or multi-functional hematopoietic receptoragonists were tested by addition of 100 μl of supernatant added to 1 mLcultures (approximately a 10% dilution). Cells were incubated at 37° C.for 8-14 days at 5% CO₂ in a 37° C. humidified incubator.

[0451] b. Cell Harvest and Analysis:

[0452] At the end of the culture period a total cell count was obtainedfor each condition. For fluorescence analysis and ploidy determinationcells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodiumcitrate, 1 mM theophylline, 2.2 μm PGE1, 11 mM glucose, 3% w/v BSA, inPBS, pH 7.4,) (Tomer et al., Blood 70: 1735-1742, 1987) resuspended in500 μl of MK buffer containing anti-CD41a FITC antibody (1:200, AMAC,Westbrook, Me.) and washed in MK buffer. For DNA analysis cells werepermeablized in MK buffer containing 0.5% Tween 20 (Fisher, Fair LawnN.J.) for 20 min. on ice followed by fixation in 0.5% Tween-20 and 1%paraformaldehyde (Fisher Chemical) for 30 minutes followed by incubationin propidium iodide (Calbiochem, La Jolla Calif.) (50 μg/mL) withRNA-ase (400 U/mL) in 55% v/v MK buffer (200 mOsm) for 1-2 hours on ice.Cells were analyzed on a FACScan or Vantage flow cytometer (BectonDickinson, San Jose, Calif.). Green fluorescence (CD41a-FITC) wascollected along with linear and log signals for red fluorescence (PI) todetermine DNA ploidy. All cells were collected to determine the percentof cells that were CD41+. Data analysis was performed using software byLYSIS (Becton Dickinson, San Jose, Calif.). Percent of cells expressingthe CD41 antigen was obtained from flow cytometry analysis(Percent).Absolute (Abs) number of CD41+ cells/mL was calculated by: (Abs)=(CellCount)*(Percent)/100.

[0453] 2. Megakaryocyte fibrin clot assay. CD34+ enriched populationwere isolated as described above. Cells were suspended at 25,000cells/mL with or without cytokine(s) in a media consisting of a baseIscoves IMDM media supplemented with 0.3% BSA, 0.4 mg/mLapo-transferrin, 6.67 μM FeCl₂, 25 μg/mL CaCl₂, 25 μg/mL L-asparagine,500 μg/mL e-amino-n-caproic acid and penicillin/streptomycin. Prior toplating into 35 mm plates, thrombin was added (0.25 Units/mL) toinitiate clot formation. Cells were incubated at 37° C. for 13 days at5% CO₂ in a 37° C. humidified incubator.

[0454] At the end of the culture period plates were fixed withmethanol:acetone (1:3), air dried and stored at −200 C until staining. Aperoxidase immunocytochemistry staining procedure was used (Zymed,Histostain-SP. San Francisco, Calif.) using a cocktail of primarymonoclonal antibodies consisting of anti-CD41a, CD42 and CD61. Colonieswere counted after staining and classified as negative, CFU-MK (smallcolonies, 1-2 foci and less that approx. 25 cells), BFU-MK (large,multi-foci colonies with >25 cells) or mixed colonies (mixture of bothpositive and negative cells.

Methylcellulose Assay

[0455] This assay reflects the ability of colony stimulating factors tostimulate normal bone marrow cells to produce different types ofhematopoietic colonies in vitro (Bradley et al., Aust. Exp Biol. Sci.44:287-300, 1966), Pluznik et al., J. Cell Comp. Physio 66:319-324,1965).

[0456] Methods

[0457] Approximately 30 mL of fresh, normal, healthy bone marrowaspirate are obtained from individuals following informed consent. Understerile conditions samples are diluted 1:5 with a 1×PBS (#14040.059 LifeTechnologies, Gaithersburg, Md.) solution in a 50 mL conical tube(#25339-50 Corning, Corning Md.). Ficoll (Histopaque 1077 Sigma H-8889)is layered under the diluted sample and centrifuged, 300×g for 30 min.The mononuclear cell band is removed and washed two times in 1×PBS andonce with 1% BSA PBS (CellPro Co., Bothel, Wash.). Mononuclear cells arecounted and CD34+ cells are selected using the Ceprate LC (CD34) Kit(CellPro Co., Bothel, Wash.) column. This fractionation is performedsince all stem and progenitor cells within the bone marrow display CD34surface antigen.

[0458] Cultures are set up in triplicate with a final volume of 1.0 mLin a 35×10 mm petri dish (Nunc#174926). Culture medium is purchased fromTerry Fox Labs. (HCC-4230 medium (Terry Fox Labs, Vancouver, B.C.,Canada) and erythropoietin (Amgen, Thousand Oaks, Calif.) is added tothe culture media. 3,000-10,000 CD34+ cells are added per dish.Recombinant IL-3, purified from mammalian cells or E. coli, andmulti-functional hematopoietic receptor agonist proteins, in conditionedmedia from transfected mammalian cells or purified from conditionedmedia from transfected mammalian cells or E. coli, are added to givefinal concentrations ranging from 0.001 nM to 10 nM. Recombinant hIL-3,GM-CSF, c-mpl ligand and multi-functional hematopoietic receptor agonistare supplied in house. G-CSF (Neupogen) is from Amgen (Thousand OaksCalf.). Cultures are resuspended using a 3 cc syringe and 1.0 mL isdispensed per dish. Control (baseline response) cultures received nocolony stimulating factors. Positive control cultures receivedconditioned media (PHA stimulated human cells: Terry Fox Lab. H2400).Cultures are incubated at 37° C., 5% CO₂ in humidified air.

[0459] Hematopoietic colonies which are defined as greater than 50 cellsare counted on the day of peak response (days 10-11) using a Nikoninverted phase microscope with a 40× objective combination. Groups ofcells containing fewer than 50 cells are referred to as clusters.Alternatively colonies can be identified by spreading the colonies on aslide and stained or they can be picked, resuspended and spun ontocytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays

[0460] Bone marrow cells are traditionally used for in vitro assays ofhematopoietic colony stimulating factor (CSF) activity. However, humanbone marrow is not always available, and there is considerablevariability between donors. Umbilical cord blood is comparable to bonemarrow as a source of hematopoietic stem cells and progenitors(Broxmeyer et al., PNAS USA 89:4109-113, 1992; Mayani et al., Blood81:3252-3258, 1993). In contrast to bone marrow, cord blood is morereadily available on a regular basis. There is also a potential toreduce assay variability by pooling cells obtained fresh from severaldonors, or to create a bank of cryopreserved cells for this purpose. Bymodifying the culture conditions, and/or analyzing for lineage specificmarkers, it is be possible to assay specifically forgranulocyte/macrophage colonies (CFU-GM), for megakaryocyte CSFactivity, or for high proliferative potential colony forming cell(HPP-CFC) activity.

[0461] Methods

[0462] Mononuclear cells (MNC) are isolated from cord blood within 24hr. of collection, using a standard density gradient (1.077 g/mLHistopaque). Cord blood MNC have been further enriched for stem cellsand progenitors by several procedures, including immunomagneticselection for CD14-, CD34+ cells; panning for SBA-, CD34+ fraction usingcoated flasks from Applied Immune Science (Santa Clara, Calif.); andCD34+ selection using a CellPro (Bothell, Wash.) avidin column. Eitherfreshly isolated or cryopreserved CD34+ cell enriched fractions are usedfor the assay. Duplicate cultures for each serial dilution of sample(concentration range from 1 pM to 1204 pM) are prepared with 1×10⁴ cellsin 1 ml of 0.9% methycellulose containing medium without additionalgrowth factors (Methocult H4230 from Stem Cell Technologies, Vancouver,BC.). In some experiments, Methocult H4330 containing erythropoietin(EPO) was used instead of Methocult H4230, or Stem Cell Factor (SCF), 50ng/mL (Biosource International, Camarillo, Calif.) was added. Afterculturing for 7-9 days, colonies containing>30 cells are counted. Inorder to rule out subjective bias in scoring, assays are scored blind.

[0463] Additional details about recombinant DNA methods which may beused to create the variants, express them in bacteria, mammalian cellsor insect cells, purification and refold of the desired proteins andassays for determining the bioactivity of the proteins may be found inco-filed Applications WO 95/00646, WO 94/12639, WO 94/12638, WO95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and U.S. Ser. No.08/383,035 which are hereby incorporated by reference in their entirety.Further details known to those skilled in the art may be found in T.Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold SpringHarbor Laboratory, 1982) and references cited therein, incorporatedherein by reference; and in J. Sambrook, et al., Molecular Cloning, ALaboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, 1989) andreferences cited therein, are incorporated herein by reference. TABLE 1OLIGONUCLEOTIDES c-mplNcoI ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGT (SEQ ID NO:13) GCACTCCGAGTC N = A, C, G or T Ecompl ATGCACGAATTCCCTGACGCAGAGGGTGGA(SEQ ID NO: 14) c-mplHindIII TGACAAGCTTACCTGACGCAGAGGGTGGACCCT (SEQ IDNO: 15) 4L-5′ AATTCGGCAA (SEQ ID NO: 16) 4L-3′ CATGTTGCCG (SEQ ID NO:17) 5L-5′ AATTCGGCGGCAA (SEQ ID NO: 18) 5L-3′ CATGTTGCCGCCG (SEQ ID NO:19) 8L-5′ AATTCGGCGGCAACGGCGGCAA (SEQ ID NO: 20) 8L-3′CATGTTGCCGCCGTTGCCGCCG (SEQ ID NO: 21) 31-5′ CGATCCATGGAGGTTCACCCTTTGCCT(SEQ ID NO: 22) 31-3′ GATCAAGCTTATGGGCACTGGCTCAGTCT (SEQ ID NO: 23)35-5′ CGATACATGTTGCCTACACCTGTCCTG (SEQ ID NO: 24) 35-3′GATCAAGCTTAAGGGTGAACCTCTGGGCA (SEQ ID NO: 25) 39-5′CGATCCATGGTCCTGCTGCCTGCTGTG (SEQ ID NO: 26) 39-3′GATCAAGCTTAAGGTGTAGGCAAAGGGTG (SEQ ID NO: 27) 43-5′CGATCCATGGCTGTGGACTTTAGCTTGGGA (SEQ ID NO: 28) 43-3′GATCAAGCTTAAGGCAGCAGGACAGGTGT (SEQ ID NO: 29) 45-5′CGATCCATGGACTTTAGCTTGGGAGAA (SEQ ID NO: 30) 45-3′GATCAAGCTTACACAGCAGGCAGCAGGAC (SEQ ID NO: 31) 49-5′CGATCCATGGGAGAATGGAAAACCCAG (SEQ ID NO: 32) 49-3′GATCAAGCTTACAAGCTAAAGTCCACAGC (SEQ ID NO: 33) 82-5′CGATCCATGGGACCCACTTGCCTCTCA (SEQ ID NO: 34) 82-3′GATCAAGCTTACAGTTGTCCCCGTGCTGC (SEQ ID NO: 35) 109-5′CAGTCCATGGGAACCCAGCTTCCTCCA (SEQ ID NO: 36) 109-3′GATCAAGCTTAAAGGAGGCTCTGCAGGGC (SEQ ID NO: 37) 116-5′CGATCCATGGGCAGGACCACAGCTCAC (SEQ ID NO: 38) 116-3′GATCAAGCTTACTGTGGAGGAAGCTGGGTT (SEQ ID NO: 39) 120-5′CGATCCATGGCTCACAAGGATCCCAATGCC (SEQ ID NO: 40) 120-3′GATCAAGCTTATGTGGTCCTGCCCTGTGG (SEQ ID NO: 41) 123-5′CGATCCATGGATCCCAATGCCATCTTCCTG (SEQ ID NO: 42) 123-3′GATCAAGCTTACTTGTGAGCTGTGGTCCT (SEQ ID NO: 43) 126-5′CGATCCATGGCCATCTTCCTGAGCTTCCAA (SEQ ID NO: 44) 126-3′GATCAAGCTTAATTGGGATCCTTGTGAGCTGT (SEQ ID NO: 45) SYNNOXA1.REQ AATTCCGTCGTAAACTGACC TTCTATCTGA (SEQ ID NO: 46) AAACCTTGGA GAACGCGCAG GCTCAACAGTACGTAGAGGG CGGTGGAGGC TCC SYNNOXA2.REQ CCGGGGAGCC TCCACCGCCC TCTACGTACT(SEQ ID NO: 47) GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGACGG L1syn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG (SEQ ID NO: 48)GGTGGTGGCT CTAACTGCTC TATAATGAT L1syn.rev CGATCATTAT AGAGCAGTTAGAGCCACCAC (SEQ ID NO: 49) CCTGTTGTTC CTGCGCTTGC TCAAGG L3syn.forGTTACCCTTG AGCAAGCGCA GGAACAACAG (SEQ ID NO: 50) GGTGGTGGCT CTGGCGGTGGCAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT L3syn.rev CGATCATTAT AGAGCAGTTAGAACCGCCGC (SEQ ID NO: 51) CGCTGCCACC GCCAGAGCCA CCACCCTGTT GTTCCTGCGCTTGCTCAAGG 35start.seq GATCGACCAT GGCTCTGGAC CCGAACAACC (SEQ ID NO: 52)TC 34rev.seq CTCGATTACG TACAAAGGTG CAGGTGGT (SEQ ID NO: 53) 70start.seqGATCGACCAT GGCTAATGCA TCAGGTATTG (SEQ ID NO: 54) AG 69rev.seq CTCGATTACGTATTCTAAGT TCTTGACA (SEQ ID NO: 55) 91start.seq GATCGACCAT GGCTGCACCCTCTCGACATC (SEQ ID NO: 56) CA 90rev.seq CTCGATTACG TAGGCCGTGG CAGAGGGC(SEQ ID NO: 57) 101start.seq GATCGACCAT GGCTGCAGGT GACTGGCAAG (SEQ IDNO: 58) AA 100rev.seq CTCGATTACG TACTTGATGA TGATTGGA (SEQ ID NO: 59)L-11start.seq GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG (SEQ ID NO: 60)CTGCGCAAGG TGGCGTAGAA CGCG L-11stop.seq CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG(SEQ ID NO: 61) AGCTTCCTGC TCAAGTCTTT AGAG P-blstart.seq GGGCTGCGCAAGGTGGCG (SEQ ID NO: 62) P-blstop.seq ACACCATTGG GCCCTGCCAG C (SEQ IDNO: 63) 39start.seq GATCGACCAT GGCTTACAAG CTGTGCCACC (SEQ ID NO: 64) CC38stop.Seq CGATCGAAGC TTATTAGGTG GCACACAGCT (SEQ ID NO: 65) TCTCCT97start.seq GATCGACCAT GGCTCCCGAG TTGGGTCCCA (SEQ ID NO: 66) CC96stop.Seq CGATCGAAGC TTATTAGGAT ATCCCTTCCA (SEQ ID NO: 67) GGGCCT126start.seq GATCGACCAT GGCTATGGCC CCTGCCCTGC (SEQ ID NO: 68) AG125stop.Seq CGATCGAAGC TTATTATCCC AGTTCTTCCA (SEQ ID NO: 69) TCTGCT133start.seq GATCGACCAT GGCTACCCAG GGTGCCATGC (SEQ ID NO: 70) CG132stop.seq CGATCGAAGC TTATTAGGGC TGCAGGGCAG (SEQ ID NO: 71) GGGCCA142start.seq GATCGACCAT GGCTTCTGCT TTCCAGCGCC (SEQ ID NO: 72) GG141stop.Seq CGATCGAAGC TTATTAGGCG AAGGCCGGCA (SEQ ID NO: 73) TGGCACGLYXA1 GTAGAGGGCG GTGGAGGCTC C (SEQ ID NO: 74) GLYXA2 CCGGGGAGCCTCCACCGCCC TCTAC (SEQ ID NO: 75) 1GGGSfor TTCTACGCCA CCTTGCGCAGCCCGGCGGCG (SEQ ID NO: 76) GCTCTGACAT GTCTACACCA TTG 1GGGSrev CAATGGTGTAGACATGTCAG AGCCGCCGCC (SEQ ID NO: 77) GGGCTGCGCA AGGTGGCGTA GAASynnoxa1.req AATTCCGTCG TAAACTGACC TTCTATCTGA (SEQ ID NO: 240)AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC Synnoxa2.reqCCGGGGAGCC TCCACCGCCC TCTACGTACT (SEQ ID NO: 241) GTTGAGCCTG CGCGTTCTCCAAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG

[0464] TABLE 2 GENE SEQUENCES pMON30304 (SEQ ID NO: 78)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT pMON26458 (SEQ ID NO: 79)TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGCGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TCCCTCAGGGAATTCpMON28548 (SEQ ID NO: 80)TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACACGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTCGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG pMON28500 (SEQ ID NO: 81)TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGACCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG pMON28501 (SEQ ID NO: 82)TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG pMON28502 (SEQ ID NO: 83)TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACACCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCACTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGCCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG Syntan1 (SEQ ID NO: 84)CATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGGGTGGTGGCTCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTCATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTAC Syntan3 (SEQ ID NO: 85)   1CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA  51 GACCACCTGCACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC 101 TCTATCCTGA TGGACCGAAACCTTCGACTT CCAAACCTGG AGAGCTTCGT 151 AAGGGCTGTC AAGAACTTAG AAAATGCATCAGGTATTGAG GCAATTCTTC 201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACCCTCTCGACAT 251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT 351CTGGCGCTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA 401 ATTATACATCACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA 451 CCTCAATGAC GAAGACGTCTCTATCCTGAT GGACCGAAAC CTTCGACTTC 501 CAAACCTGGA GAGCTTCGTA AGGGCTGTCAAGAACTTAGA AAATGCATCA 551 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGCCCTCTGCCAC 601 GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG651 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG 701GAACAACAGT AC pMON31104 (SEQ ID NO: 86)   1 ATGGCTCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT  51 GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCGTAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG 251TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT 301 ATAATGATCGATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT 351 GTACGTAGAG GGCGGTGGAGGCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCT CCGTCTAAAGAATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTTTCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 601TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCAGCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGA GCTGGTGCTGCTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCCTCTCTGGGCAT GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTGCAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT 951GGCCCCTCCC CTGCAGCCCT AATAA pMON31105 (SEQ ID NO: 87)   1 ATGGCTAATGCATCAGCTAT TGAGGCAATT CTTCGTAATC TCCAACCATG  51 TCTGCCCTCT GCCACGGCCGCACCCTCTCG ACATCCAATC ATCATCAAGG 101 CAGGTGACTG GCAAGAATTC CGGGAAAAACTGACGTTCTA TCTGGTTACC 151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACTGCTCTATAAT 201 GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG251 ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 301CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA 351 ATACGTAGAGGGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCTCCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTCGCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTCCTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGAGCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAGCCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCAGGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACTGCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA pMON31106 (SEQ ID NO: 88)   1 ATGGCTGCACCCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA  51 AGAATTCCGG GAAAAACTGACGTTCTATCT GGTTACCCTT GAGCAAGCGC 101 AGGAACAACA GGGTGGTGGC TCTAACTGCTCTATAATGAT CGATGAAATT 151 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACCCGAACAACCT 201 CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA251 ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 301ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC 351 CTACGTAGAGGGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCTCCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTCGCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTCCTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGAGCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAGCCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCAGGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACTGCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA pMON31107 (SEQ ID NO: 89)   1 ATGGCTGCAGGTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT  51 GGTTACCCTT GAGCAAGCGCAGGAACAACA GGGTGGTGGC TCTAACTGCT 101 CTATAATGAT CGATGAAATT ATACATCACTTAAAGAGACC ACCTGCACCT 151 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTATCCTGATGGA 201 CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA251 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 301TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA 351 CTACGTAGAGGGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCTCCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTCGCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCACAGCTTCCTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC 701 ACCCCGAGGAGCTGGTGCTG CTCGCACACT CTCTGGGCAT CCCCTGGGCT 751 CCCCTGAGCT CCTGCCCCAGCCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCAGGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TCGACACACTGCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT951 GGCCCCTGCC CTGCAGCCCT AATAA pMON31108 (SEQ ID NO: 90)   1 ATGGCTCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT  51 GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATCCAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC 301AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA 351 CTTAAAGAGACCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCAATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCTACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTGGTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCACCTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTGGGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA pMON31109 (SEQID NO: 91)   1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAGCGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG 201 CGGCGGTTCT AACTGCTCTATAATGATCGA TGAAATTATA CATCACTTAA 251 AGAGACCACC TGCACCTTTG CTGGACCCGAACAACCTCAA TGACGAAGAC 301 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACCTGGAGAGCTT 351 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCTGCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAGGTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAGAGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTCCAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCTCCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCTGGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCCTGCCCTGCAG CCCTAATAA pMON31110 (SEQ ID NO: 92)   1 ATGGCTGCAC CCTCTCGACATCCAATCATC ATCAAGGCAG GTGACTGGCA  51 AGAATTCCGG GAAAAACTGA CGTTCTATCTGGTTACCCTT GAGCAAGCGC 101 AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGGCGGTTCTAAC 151 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC201 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA 251TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC 301 AAGAACTTAGAAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA 351 ACCATGTCTG CCCTCTGCCACGGCCTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTATCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTGCCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTGAGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTGTGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTGAGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGCCTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA pMON31111 (SEQ IDNO: 93)   1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT  51GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG 101 GCAGCGCCGGCGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT 151 CACTTAAAGA GACCACCTGCACCTTTGCTG GACCCGAACA ACCTCAATGA 201 CGAAGACGTC TCTATCCTGA TGGACCGAAACCTTCGACTT CCAAACCTGG 251 AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATCAGGTATTGAG 301 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC351 CTCTCGACAT CCAATCATCA TCAAGTACGT ACAGGGCGGT GGAGGCTCCC 401CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTCATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGCGCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACCGCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGCTCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTGGCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCCCTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCCGACTTTGCCA CCACCATCTG 951 CCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAGCCCTAATAA pMON13182 (SEQ ID NO: 94)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GCTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACACTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601 CTGCAGCTGGACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTGCCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAGGAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTACGCCACCTTGC 801 GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT851 TAGAGCAAGT GAGAAACATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 901CTGTGTGCCA CCTAATAA pMON13183 (SEQ ID NO: 95)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAACGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCCAGGAGCT GGTGCTGCTC GGACACTCTCTGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTCGCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTGCAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGGGTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCACCTTGCGCAGC 851 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG901 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 951TGCCACCTAA TAA pMON13184 (SEQ ID NO: 96)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGGTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGCAGCTGGACGT CGCCGACTTT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGGCCCCTGCCCT 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG 651 CTCTCAGAGCTTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG 701 GCGATGGCGC AGCGCTCCAGGAGAAGCTGT GTGCCACCTA CAAGCTGTGC 751 CACCCCGAGG AGCTGGTGCT GCTCGGACACTCTCTGGGCA TCCCCTGGGC 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCAGGCTGCTTGA 851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG901 GAAGGGATAT CCTAATAA pMON13185 (SEQ ID NO: 97)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAC AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC CTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTGGACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCTGCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGCGCA601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 701 AGAGCTTCCTGCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT 751 GGCGCAGCGC TCCAGGAGAAGCTGTGTGCC ACCTACAAGC TGTGCCACCC 801 CGAGGAGCTG GTGCTGCTCG GACACTCTCTGGCCATCCCC TGGGCTCCCC 851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTGCTTGAGCCAA 901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG951 GATATCCTAA TAA pMON13186 (SEQ ID NO: 98)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGGTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTGCCATGCCGGC CTTCGCCTCT 451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCCATCTGCAGAG 501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG551 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 601AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC 651 CTACAAGCTGTGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG 701 GCATCCCCTG GGCTCCCCTGAGCTCCTGCC CCAGCCAGGC CCTGCAGCTG 751 GCAGGCTGCT TGAGCCAACT CCATAGCGGCCTTTTCCTCT ACCAGGGGCT 801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCCACCTTGGACA 851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG901 GAAGAACTGG GATAATAA pMON13187 (SEQ ID NO: 99)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTCACG 301TTCTATCTGG TTACCCTTCA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATGCCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTGCAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC601 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA 651GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA 701 AGCTGTGCCACCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 751 CCCTGGGCTC CCCTGAGCTCCTGCCCCAGC CAGGCCCTGC AGCTGGCAGG 801 CTGCTTGAGC CAACTCCATA GCGGCCTTTTCCTCTACCAG GGGCTCCTGC 851 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTTGGACACACTG 901 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA951 ACTGGGATAA TAA pMON13188 (SEQ ID NO: 100)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGGTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTGCTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGGTGTCGTACCC 501 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA551 GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 601GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA 651 GGAGCTGGTGCTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA 701 GCTCCTGCCC CAGCCAGGCCCTGCAGCTGG CAGGCTGCTT GAGCCAACTC 751 CATAGCGGCC TTTTCCTCTA CCAGGGGCTCCTGCAGGCCC TGGAAGGGAT 801 ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTGGACGTCGCCG 851 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT901 GCCCTGCAGC CCTAATAA pMON13189 (SEQ ID NO: 101)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTCGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTCCAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCGTACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCTCGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCAGCTGGCAGGC TGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCAGGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTC GACACACTCC AGCTGGACGTCGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT951 GCAGCCCTAA TAA pMON13190 (SEQ ID NO: 102)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGGTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCCTGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTGCGCAGCCCTC 501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG551 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 601ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT 651 GGGCATCCCCTGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 701 TGGCAGGCTG CTTGAGCCAACTCCATAGCG GCCTTTTCCT CTACCAGGGG 751 CTCCTGCAGG CCCTGGAAGG GATATCCCCCGAGTTGGGTC CCACCTTGGA 801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATCTGGCAGCAGA 851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG901 CCGGCCTTCG CCTAATAA pMON13191 (SEQ ID NO: 103)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GCGCAGGAGG GGTCCTGGTTGCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAGCCCTCTGGCG 551 GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA601 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA 651CAAGCTGTGC CACCCCGAGG AGCTGGTGCT CCTCGGACAC TCTCTGGGCA 701 TCCCCTGGGCTCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 751 CGCTGCTTGA GCCAACTCCATAGCGGCCTT TTCCTCTACC AGGGGCTCCT 801 GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCCACC TTGGACACAC 851 TGCAGCTGGA CCTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATGGAA 901 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCACGGTG CCATGCCGGC951 CTTCGCCTAA TAA pMON13192 (SEQ ID NO: 104)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGGTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGCTGCTCGGACA CTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCCTGCAGCTGGC 501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGAATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAGCGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTACCGCGTTCTAC GCCACCTTGC 801 GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAGAGCTTCCTGC 851 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC901 CAGGAGAAGC TGTGTGCCAC CTAATAA pMON13193 (SEQ ID NO: 105)   1ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCGAGGAGCTGGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCAGGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGGGCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTTTCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGTCGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCACACCATT GGGCCCTGCC AGCTCCCTGCCCCAGAGCTT CCTGCTCAAG 901 TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAGCGCTCCAGGA 951 GAAGCTGTGT GCCACCTAAT AA pMON25190 (SEQ ID NO: 106)   1ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGCCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGGTCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 451 GCCACCACCA TCTGGCAGCAGATGGAAGAA CTGGGAATGG CCCCTGCCCT 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTTCGCCTCTGCT TTCCAGCGCC 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTTCCTGGAGGTG 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC651 CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA 701AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 751 AAGCTGTGCCACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT 801 CCCCTGGGCT CCCCTGAGCTCCTGCCCCAG CCAGGCCCTG CAGCTGGCAG 851 GCTGCTTGAG CCAACTCCAT AGCGGCCTTTTCCTCTACCA GGGGCTCCTG 901 CAGGCCCTGG AAGGGATATC CTAATAA pMON25191 (SEQID NO: 107)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCAAGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGACG 301 TTCTATCTGC TTACCCTTGA GCAAGCGCAG GAACAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG 451TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGGCAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCGGCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAGAGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGCCCTGCCAGCT 701 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC751 CAGGGCGATG GCCCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT 801GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT 851 GGGCTCCCCTGAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC 901 TTGAGCCAAC TCCATAGCGGCCTTTTCCTC TACCAGGGGC TCCTGCAGGC 951 CCTGGAAGGG ATATCCTAAT AA pMON13194(SEQ ID NO: 108)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAACCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGTGACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAGGAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCCAACATGGCTA 401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG 501CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCACAC 551 CATTGGGCCCTGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 601 GAGCAAGTGA GAAAGATCCAGGGCGATGGC GCAGCGCTCC AGGAGAAGCT 651 GTGTGCCACC TACAAGCTGT GCCACCCCGAGGAGCTGGTG CTGCTCGGAC 701 ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCCCAGCCAGGCC 751 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA801 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA 851CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 901 CAGCAGATGGAAGAACTGGG ATAATAA pMON13195 (SEQ ID NO: 109)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCGCCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG 601GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 651 AGTGAGAAAGATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 701 CCACCTACAA GCTGTGCCACCCCGAGGAGC TGGTGCTGCT CGGACACTCT 751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCCTGCCCCAGCC AGGCCCTGCA 801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTCCTCTACCAGG 851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA 951GATGGAAGAA CTGGGATAAT AA pMON13196 (SEQ ID NO: 110)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCCTTCGCCTCTG CTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGCTTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCTGCCAGCTCCC 551 TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG601 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG 651CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG 701 CTCCCCTGAGCTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 751 AGCCAACTCC ATAGCGGCCTTTTCCTCTAC CAGGGGCTCC TGCAGGCCCT 801 GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACACA CTGCAGCTGG 851 ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGGGA 901 ATGGCCCCTG CCCTGCAGCC CTAATAA pMON13197 (SEQ ID NO: 111)  1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGCCGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGCAGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC ACACCATTGGGCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGATCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 751CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGCGGCCTTTTCC TCTACCAGGC GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGTCCCACCTTGG ACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCAT CTGGCAGCAGATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA pMON13198 (SEQ ID NO:112)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGGAGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC 501 ACCATTGGGC CCTGCCAGCTCCCTGCCCCA GAGCTTCCTG CTCAAGTCTT 551 TAGAGCAAGT GAGAAAGATC CAGGGCGATGGCGCAGCGCT CCAGGAGAAG 601 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGGTGCTGCTCGG 651 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG701 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 751TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC 801 CACCTTGGACACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT 851 GGCAGCAGAT GGAAGAACTGGGAATGGCCC CTGCCCTGCA GCCCACCCAG 901 GGTGCCATGC CGGCCTTCGC CTAATAApMON13199 (SEQ ID NO: 113)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCCCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT 551TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 601 CAAGTGAGAAAGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 651 TGCCACCTAC AAGCTGTGCCACCCCGAGGA GCTGGTGCTC CTCGGACACT 701 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCTCCTGCCCCAG CCAGGCCCTG 751 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTTTCCTCTACCA 801 GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT851 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 901CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGCGTGC 951 CATGCCGGCCTTCGCCTAAT AA pMON31112 (SEQ ID NO: 114)   1 ATGGCTAACT GCTCTAACATGATCGATGAA ATCATCACCC ACCTGAAGCA  51 GCCACCGCTG CCGCTGCTGG ACTTCAACAACCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGAGGCATTCAAC 151 CGTGCTGTCA AGTGTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGAAAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAGAAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCTCTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGCTGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAAGGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTCC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951GCAGCCCTAA TAA pMON31113 (SEQ ID NO: 115)   1 ATGGCTAACT GCTCTAACATGATCGATGAA ATCATCACCC ACCTGAAGCA  51 GCCACCGCTG CCGCTGCTGG ACTTCAACAACCTCAATGGT GAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGAGGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGAAAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCGCTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTCGGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAGCTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAGGCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951CCCTGCCCTG CAGCCCTAAT AA pMON31114 (SEQ ID NO: 116)   1 ATGGCTAACTGCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA  51 GCCACCGCTG CCGCTGCTGGACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTCCAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGAGCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTCCAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCGTACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCCGAGGAGC 701 TGGTGCTGCTCGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCAGCTGGCAGGC TGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCAGGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGTCGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT951 GCAGCCCTAA TAA pMON31115 (SEQ ID NO: 117)   1 ATGGCTAACT GCTCTAACATGATCGATGAA ATCATCACCC ACCTGAAGCA  51 GCCACCGCTG CCGCTGCTGG ACTTCAACAACCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGAGGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGAAAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCGCTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTCGGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAGCTGGCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAGGCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951CCCTGCCCTG CAGCCCTAAT AA pMON28505 (SEQ ID NO: 118)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAG CAGACTGAGCCAGTGCCCApMON28506 (SEQ ID NO: 119)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGCTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCCGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAG TGCCCAGAGGTTCACCCTpMON28507 (SEQ ID NO: 120)CCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTCCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGCGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGCACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGCGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT CACCCTTTGCCTACACCTpMON28508 (SEQ ID NO: 121)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGCAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCT ACACCTGTCCTGCTGCCTpMON28509 (SEQ ID NO: 122)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTCCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCACGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT GTCCTGCTGCCTGCTGTGpMON28510 (SEQ ID NO: 123)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCTGCGTCAGCGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACT TTAGTTG pMON28511(SEQ ID NO: 124) GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCCACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGpMON28512 (SEQ ID NO: 125)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGACCGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACGCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG GCCCTGCAGAGCCTCCTTpMON28513 (SEQ ID NO: 126)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGCAAAGGTGCGTTTCCTGATGCTTGTAGCAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTCTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGACTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTCCAGAGCCTCCTTGGA ACCCAGCTTCCTCCACAGpMON28514 (SEQ ID NO: 127)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTCCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACApMON28515 (SEQ ID NO: 128)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTCTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGCGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC AGGACCACAGCTCACAAGpMON28516 (SEQ ID NO: 129)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA GCTCACAAGGATCCCAATpMON28519 (SEQ ID NO: 130)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCApMON28520 (SEQ ID NO: 131)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGCCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCCTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTpMON28521 (SEQ ID NO: 132)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACCTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC CCTTTGCCTACACCTpMON28522 (SEQ ID NO: 133)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGCCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGCGTCCACCCTCTGCCTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA CCTGTCCTGCTGCCTpMON28523 (SEQ ID NO: 134)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC CTGCTGCCTGCTGTGpMON28524 (SEQ ID NO: 135)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCCACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGACGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGCAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCT GTGGACTTTAGCTTGpMON28525 (SEQ ID NO: 136)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTACAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA GCACGGGGACAACTGpMON28526 (SEQ ID NO: 137)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTTpMON28527 (SEQ ID NO: 138)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGCAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGCCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGACGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTCCTGTGGACTTTAGCTTGGGAGAATGCAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGpMON28528 (SEQ ID NO: 139)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCA CAGGGCAGGACCACApMON28529 (SEQ ID NO: 140)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGACCAAGCGCAGGAACAACAGTACGTAGAGGCCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGCGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG ACCACAGCTCACAAGpMON28530 (SEQ ID NO: 141)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCT CACAAGGATCCCAATpMON28533 (SEQ ID NO: 142)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGCATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGCGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCApMON28534 (SEQ ID NO: 143)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCTGTCCTGCTGCCTGCTGTCGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGCGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT pMON28535 (SEQ ID NO: 144)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGT CCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT pMON28536 (SEQ ID NO: 145)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT pMON28537 (SEQ ID NO: 146)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTCAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTGCAAACATGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG pMON28538 (SEQ ID NO: 147)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGCCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTCGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCACAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTG pMON28539 (SEQ ID NO: 148)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGGAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCACCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG pMON28540 (SEQ ID NO: 149)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGCGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATCCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT pMON28541 (SEQ ID NO: 150)CCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG pMON28542 (SEQ ID NO: 151)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA pMON28543 (SEQ ID NO: 152)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGCCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGCAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG pMON28544 (SEQ ID NO: 153)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGACGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT pMON28545 (SEQ ID NO: 154)GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTCCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAACCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCT CACAAG pMON15981 (SEQID NO: 155)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCAAGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG 451CTGTGCCACC CCGAGGAGCT GGTGCTGCCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCCCTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGCGGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGTCCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAGATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCGGCGGCGGCTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG 901 CCCCAGAGCT TCCTGCTCAAGTCTTTAGAG CAAGTGAGGA AGATCCAGGG 951 CGATGGCGCA GCGCTCCAGG AGAAGCTGTGTGCCACCTAA TAA; pMON15982 (SEQ ID NO: 156)   1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GTCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCGACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601GGAGGGGTCC TGGTTGCTAC CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTACGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA 701 CACCATTAGG CCCTGCCAGCTCCCTGCCCC AGAGCTTCCT GCTCAAGTCT 751 TTAGAGCAAG TGAGGAAGAT CCAGGGCGATGGCGCAGCGC TCCAGGAGAA 801 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTGGTGCTGCTCG 851 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG901 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT 951CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA; pMON15965 (SEQ ID NO:157)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51ACCACCTGCA CCTTTGCTGG ACCCCAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGATCGAAAC CTTCGACTTC CAAACCTGGA CAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTCTGCT 451 TTCCAGCGCCGGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCGTTCTACGCCA CCTTGCGCAG CCCGGCGGCG 551 GCTCTGACAT GGCTACACCA TTAGGCCCTGCCAGCTCCCT GCCCCAGAGC 601 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGGGCGATGGCGC 651 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG701 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC 751TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA 801 TAGCGGCCTTTTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT 851 CCCCCGAGTT GGGTCCCACCTTGGACACAC TGCAGCTGGA CGTCGCCGAC 901 TTTGCCACCA CCATCTGGCA GCAGATGGAAGAACTGGGAA TGGCCCCTGC 951 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAATAA pMON15966 (SEQ ID NO: 158)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGC CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGTCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC 551TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC 601 TCTGACATGGCTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT 651 CCTGCTCAAG TCTTTAGAGCAAGTGAGGAA GATCCAGGGC GATGGCGCAG 701 CGCTCCAGGA GAAGCTGTGT GCCACCTACAAGCTGTGCCA CCCCGAGGAG 751 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTCCCCTGAGCTC 801 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA851 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 901CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT 951 TGCCACCACCATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA pMON15967 (SEQ ID NO: 159)   1ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTACA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG 451 GGTGCCATGC CGGCCTTCGCCTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCTGGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGCTACACCATTA 601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA651 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 701CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 751 CTGGGCATCCCCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA 801 GCTGGCAGGC TGCTTGAGCCAACTCCATAG CGGCCTTTTC CTCTACCAGG 851 GGCTCCTGCA GGCCCTGGAA GGGATATCCCCCGAGTTGGG TCCCACCTTG 901 GACACACTCC AGCTGGACGT CGCCGACTTT GCCACCACCATCTGGCAGCA 951 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA pMON15960(SEQ ID NO: 160)   1 ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGAGCTTCCTGCT  51 CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC101 AGGAGAAGCT GTGTGCCACC TACAAGCTGT CCCACCCCGA GGAGCTGGTG 151CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC 201 CAGCCAGGCCCTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 251 TTTTCCTCTA CCAGGGGCTCCTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 301 TTGGGTCCCA CCTTGGACAC ACTGCAGCTGGACGTCGCCG ACTTTGCCAC 351 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCTGCCCTGCAGC 401 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA451 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 501CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA 551 CACCATTGGGCCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT 601 TTAGAGCAAG TGAGGAAGATCCAGGGCGAT GGCGCAGCGC TCCAGGAGAA 651 GCTGTGTGCC ACCTACAAGC TGTGCCACCCCGAGGAGCTG GTGCTGCTCG 701 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTGCCCCAGCCAG 751 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT801 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC 851CCACCTTGGA CACACTCCAG CTGGACGTCG CCGACTTTGC CACCACCATC 901 TGGCAGCAGATGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA 100 TCCTGGTTGC TAGCCATCTGCAGAGCTTCC TGGAGGTGTC GTACCGCGTT 105 CTACGCCACC TTGCGCAGCC CTGATAAPMON32132 (SEQ ID NO: 249)TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGG PMON32133(SEQ ID NO: 250) TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG pMON32134 (SEQ ID NO:251) TCCCCAGCGCCGCCTGCTTGTCACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCACCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGG Pmon13181(SEQ ID NO: 257)   1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACATCACTTAAAG  51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 201 CGTAATCTCCAACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA 251 TCCAATCATC ATCAAGGCAGGTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGCAGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCTCTACTATCAA 401 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA451 CCGCATGCAA GCTT Pmon13180.Seg (SEQ ID NO: 258)   1 CCATGGCTAACTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG  51 AGACCACGTG CACCTTTGCTGGACCCGAAC AACCTCAATG ACGAAGACGT 101 CTCTATCCTG ATGGATCGAA ACCTTCGACTTCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGAGGCAATTCTT 201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggaggctcCCCGCG TGGTGGTTCT GGCGGCGGCT CCAACATGTA 401 AGGTACCGCA TGCAAGCTTpmon16017.seq (SEQ ID NO: 259)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 ACGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTTTAGGC 451 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT501 GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA 551CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG 601 GGCATCCCCTGGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT 651 GGCAGGCTGC TTGAGCCAACTCCATAGCGG CCTTTTCCTC TACCAGGGGC 701 TCCTGCAGGC CCTGGAAGGG ATATCCCCCGAGTTGGGTCC CACCTTGGAC 751 ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCTGGCAGCAGAT 801 GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC851 CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT 901AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCT 951 TGCGCAGCCCGACATGGCTA CACCA pmon16018.seq (SEQ ID NO: 260)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTCAGAGC 451 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGGAAGATCCAGG GCGATGGCGC 501 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGCCACCCCGAGG 551 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC601 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA 651TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT 701 CCCCCGAGTTGGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 751 TTTGCCACCA CCATCTGGCAGCAGATGGAA GAACTGGGAA TGGCCCCTGC 801 CCTGCAGCCC ACCCAGGGTG CCATGCCGGCCTTCGCCTCT GCTTTCCAGC 851 GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAGCTTCCTGGAG 901 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC951 ATTAGGCCCT GCCAGCTCCC TGCCC pmon16019.seq (SEQ ID NO: 261)   1ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTCCTG 451 CTCAAGTCTT TAGAGCAAGTGAGGAAGATC CAGGGCGATG GCGCAGCGCT 501 CCAGGAGAAG CTGTGTGCCA CCTACAAGCTGTGCCACCCC GAGGAGCTGG 551 TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCTGAGCTCCTGC 601 CCCAGCCACG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG651 CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG 701AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC 751 ACCACCATCTGGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA 801 GCCCACCCAG GGTGCCATGCCGGCCTTCGC CTCTGCTTTC CAGCGCCGGG 851 CAGGAGGGGT CCTGGTTGCT AGCCATCTGCAGAGCTTCCT GGAGGTGTCG 901 TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTACACCATTAGG 951 CCCTGCCAGC TCCCTGCCCC AGAGC pmon16020.seq (SEQ ID NO:262)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAGCAA 451 GTGAGGAAGATCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC 501 CACCTACAAG CTGTGCCACCCCGAGGAGCT GGTGCTGCTC GGACACTCTC 551 TGGGCATCCC CTGGGCTCCC CTGAGCTCCTGCCCCAGCCA GGCCCTGCAG 601 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCCTCTACCAGGG 651 GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG701 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 751ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT 801 GCCGGCCTTCGCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 851 CTAGCCATCT GCAGAGCTTCCTGGAGGTGT CGTACCGCGT TCTACGCCAC 901 CTTGCGCAGC CCGACATGGC TACACCATTAGGCCCTGCCA GCTCCCTGCC 951 CCAGAGCTTC CTGCTCAAGT CTTTA pmon16021.seq (SEQID NO: 263)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCAAGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCTC 451GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA 501 GGCCCTGCAGCTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC 551 TCTACCAGGG GCTCCTGCAGGCCCTGGAAG GGATATCCCC CGAGTTGGGT 601 CCCACCTTGG ACACACTGCA GCTGGACGTCGCCGACTTTG CCACCACCAT 651 CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTGCAGCCCACCC 701 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG751 GTCCTGGTTG CTAGCCATCT GCAGACCTTC CTGGAGGTGT CGTACCGCGT 801TCTACGCCAC CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA 851 GCTCCCTGCCCCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG 901 ATCCAGGGCG ATGGCGCAGCGCTCCAGGAG AAGCTGTGTG CCACCTACAA 951 GCTGTGCCAC CCCGAGGAGC TGGTGpmon16022.seq (SEQ ID NO: 264)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGCCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTCCCCTG 451 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT501 CCATAGCGGC CTTTTCCTCT ACCAGGGCCT CCTGCAGGCC CTGGAAGGGA 551TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC 601 GACTTTGCCACCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC 651 TGCCCTGCAG CCCACCCAGGGTGCCATGCC GGCCTTCGCC TCTGCTTTCC 701 AGCGCCGGGC AGGAGGGGTC CTGGTTGCTAGCCATCTGCA GAGCTTCCTG 751 GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCGACATCGCTAC 801 ACCATTAGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT851 TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 901CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG 951 ACACTCTCTGGGCATCCCCT GGGCT pmon16023.seq (SEQ ID NO: 265)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTCAGGCC 451 CTGCAGCTGG CAGGCTGCTT GAGCCAACTCCATAGCGGCC TTTTCCTCTA 501 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAGTTGGGTCCCA 551 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG601 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG 651TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC 701 TGGTTGCTAGCCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 751 CGCCACCTTG CGCAGCCCGACATGGCTACA CCATTAGGCC CTGCCAGCTC 801 CCTGCCCCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGTG AGGAAGATCC 851 AGGGCGATGG CGCACCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCTG 901 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG951 GGCTCCCCTG AGCTCCTGCC CCAGC pmon16024.seq (SEQ ID NO: 266)   1ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCAG 451 CTGGCAGGCT GCTTGAGCCAACTCCATAGC GGCCTTTTCC TCTACCAGGG 501 GCTCCTGCAG GCCCTGGAAG GGATATCCCCCGAGTTGGGT CCCACCTTGG 551 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCATCTGGCAGCAG 601 ATGGAAGAAC TGGCAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT651 GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 701CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 751 CTTGCGCAGCCCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCC 801 CCAGAGCTTC CTGCTCAAGTCTTTAGAGCA AGTGAGGAAG ATCCAGGGCG 851 ATGGCGCAGC GCTCCAGGAG AAGCTGTGTGCCACCTACAA GCTGTGCCAC 901 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCCCCTGGGCTCC 951 CCTGAGCTCC TGCCCCAGCC AGGCC pmon16125.seq (SEQ ID NO:267)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGGCA 451 GGCTGCTTGAGCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT 501 GCAGGCCCTG GAAGGGATATCCCCCGAGTT GGGTCCCACC TTGGACACAC 551 TGCAGCTGGA CGTCGCCGAC TTTGCCACCACCATCTGGCA GCAGATGGAA 601 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTGCCATGCCGGC 651 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC701 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 751CAGCCCGACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG 801 CTTCCTGCTCAAGTCTTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG 851 CAGCGCTCCA GGAGAAGCTGTGTGCCACCT ACAAGCTGTG CCACCCCGAG 901 GAGCTGGTGC TGCTCGGACA CTCTCTGGGCATCCCCTGGG CTCCCCTGAG 951 CTCCTGCCCC AGCCAGGCCC TGCAG pmon16026.seq (SEQID NO: 268)   1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCAAGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAACTG 451GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC 501 CTCTGCTTTCCAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC 551 AGAGCTTCCT GGAGGTGTCGTACCGCGTTC TACGCCACCT TGCGCAGCCC 601 GACATGGCTA CACCATTAGG CCCTGCCAGCTCCCTGCCCC AGAGCTTCCT 651 GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGATGGCGCAGCGC 701 TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG751 GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG 801CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG 851 GCCTTTTCCTCTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC 901 GAGTTGGGTC CCACCTTGGACACACTGCAG CTGGACGTCG CCGACTTTGC 951 CACCACCATC TGGCAGCAGA TGGAApmon16027.seq (SEQ ID NO: 269)   1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTGGAATG 451 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC501 TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT 551TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCCGACATG 601 GCTACACCATTAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA 651 GTCTTTAGAG CAAGTGAGGAAGATCCAGGG CGATGGCGCA GCGCTCCAGG 701 AGAAGCTGTG TGCCACCTAC AAGCTGTGCCACCCCGAGGA GCTGGTGCTG 751 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCTCCTGCCCCAG 801 CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT851 TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 901GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC 951 CATCTGGCAGCAGATGGAAG AACTG pmon16028.seq (SEQ ID NO: 270)   1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG  51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTAGCTTC 451 CTGGAGGTGT CGTACCGCGT TCTACGCCACCTTGCGCAGC CCGACATGGC 501 TACACCATTA GGCCCTGCCA GCTCCCTGCC CCAGAGCTTCCTGCTCAAGT 551 CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG601 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT 651CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC 701 AGGCCCTGCAGCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 751 CTCTACCAGG GGCTCCTGCAGGCCCTGGAA GGGATATCCC CCGAGTTGGG 801 TCCCACCTTG GACACACTGC AGCTGGACGTCGCCGACTTT GCCACCACCA 851 TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCTGCAGCCCACC 901 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG951 GGTCCTGGTT GCTAGCCATC TGCAG (SEQ ID NO: 286)   1 ATGGCTGGACCCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA  51 GGTCCGTCTC CTCCTTGGGGCCCTGCAGAG CCTCCTTGGA ACCCAGCTTC 101 CTCCACAGGG CAGGACCACA GCTCACAAGGATCCCAATGC CATCTTCCTG 151 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGATGCTTGTAGG 201 AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG251 CGCCGCCTGC TGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 301CATGTCCTTC ACACCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC 351 TACACCTGTCCTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA 401 CCCAGATGGA GGAGACCAAGGCACAGGACA TTCTGGGAGC AGTGACCCTT 451 CTGCTGGAGG GAGTGATGGC AGCACGGGGACAACTG (SEQ ID NO: 287)   1 ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCATCTTCCTGAG  51 CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG101 GGTCCACCCT CGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG 151CCGCCTGCTG CTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA 201 TGTCCTTCACAGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA 251 CACCTGTCCT GCTGCCTGCTGTGGACTTTA GCTTGGGAGA ATGGAAAACC 301 CAGATGGAGG AGACCAAGGC ACAGGACATTCTGGGAGCAG TGACCCTTCT 351 GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCCACTTGCCTCT 401 CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC451 CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT CCACAG

[0465] TABLE 3 PROTEIN SEQUENCES pMON26458pepSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ IDNO:161) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe pMON28548pepSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ IDNO:162) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaRisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg pMON28500SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu (SEQID NO:163)HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg pMON28501SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ IDNO:164) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg pMON28502SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ IDNO:165) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg 13182.Pept Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:166) Pro ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys LeuPro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser GlyGly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser GlyGly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg LysIle Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 13183.PeptAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:167) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr13184.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg(SEQ ID NO:168) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met ProAla Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser 13185.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Arg (SEQ ID NO:169) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIle Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met ProAla Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser 13186.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Arg (SEQ ID NO:170) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIle Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala ProAla Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln ArgArg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly 13187.Pept Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Arg (SEQ ID NO:171) Pro Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala ProAla Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln ArgArg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly 13188.Pept Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Arg (SEQ ID NO:172) Pro Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pro 13189.Pept Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:173) Pro Pro Ala Pro LeuLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile SerThr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pro 13190.Pept Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:174) Pro Pro Ala Pro LeuLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly SerAsn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 13191.Pept Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:175) Pro ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys LeuPro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 13192.Pept Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:176) Pro ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys LeuPro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser GlyGly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr ProLeu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr13193.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg(SEQ ID NO:177) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala GlnPro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys SerLeu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys LeuCys Ala Thr 25190.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Arg (SEQ ID NO:178) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIle Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu LeuGly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln GlyAla Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser pMON25191.Pep Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:179) Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu GluAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro IleSer Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn MetAla Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp PheAla Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu GlnPro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser 13194.Pept Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:180) ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly SerGly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly 13195.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg (SEQ ID NO:181) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly GlySer Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gln Pro ThrGln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly 13196.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg (SEQ ID NO:182) Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerArg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu GlyGly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr GlnGly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val LeuVal Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu GlnGlu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro 13197.Pept Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:183) Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu GluAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro IleSer Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn MetAla Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 13198.Pept Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:184) ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly SerGly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val LeuVal Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu GlnGlu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAla 13199.Pept Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg (SEQ ID NO:185) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly GlySer Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala MetPro Ala Phe Ala 31104.Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met (SEQ ID NO:186) Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro LeuTyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala ThrGln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Met Ala Pro Ala Leu Gln Pro 31105.Pep Asn Ala Ser Gly Ile Glu AlaIle Leu Arg Asn Leu Gln Pro Cys (SEQ ID NO:187) Leu Pro Ser Ala Thr AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe ArgGlu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln GlyGly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln SerPhe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 31106.Pep Ala Pro SerArg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln (SEQ ID NO:188) Glu PheArg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln GlnGly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val SerIle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu GlnPro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser AlaPhe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe LeuGlu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser GlyGly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His ProGlu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His SerGly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro GluLeu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro31107.Pep Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu(SEQ ID NO:189) Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly SerAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro SerPro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala GlnPro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala ProAla Leu Gln Pro 31108.Pep Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met (SEQ ID NO:190) Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly GlyGly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser AlaPhe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe LeuGlu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser GlyGly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His ProGlu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His SerGly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro GluLeu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro31109.Pep Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys(SEQ ID NO:191) Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu ValThr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser GlyGly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln SerPhe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 31110.Pep Ala Pro SerArg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln (SEQ ID NO:192) Glu PheArg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln GlnGly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln GlyAla Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser LeuGly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro 31111.Pep Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu (SEQ ID NO:193) Val Thr Leu Glu Gln Ala Gln GluGln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser IleMet Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu ArgLeu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe AlaSer Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys IleGln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe AlaThr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln PropMON15981 1 MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla(SEQ ID NO:194)ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr pMON15982MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:195) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer pMON15965MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:196) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla pMON15966MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:197) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgRisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGly pMON15967MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:198) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro pMON31112.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:199) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro pMON31113.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:200) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPropMON31114.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:201) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro pMON31115.pepMetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:202) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPropMON28505 AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro(SEQ ID NO:203)LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro pMON28506AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:204) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro pMON28507AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:205) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro pMON28508AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:206) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro pMON28509AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:207) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal pMON28510AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:208) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu pMON28511AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:209) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu pMON28512AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:210) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu pMON28513AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:211) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln pMON28514AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:212) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerC-lyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr pMON28515AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:213) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys pMON28516AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:214) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn pMON28519AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:215) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro pMON28520AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:216) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro pMON28521AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:217) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro pMON28522AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:218) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysmrelnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro pMON28523AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:219) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal pMON28524AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:220) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu pMON28525AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:221) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu pMON28526AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:222) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu pMON28527AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:223) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln pMON28528AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:224) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr pMON28529AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:225) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys pMON28530AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:226) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn pMON28533AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:227) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro pMON28534AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:228) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro pMON28535AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:229) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro pMON28536AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:230) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro pMON28537AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:231) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGlubysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaVal pMON28538AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:232) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrClnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeu pMON28539AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:233) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu pMON28540AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:234) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu pMON28541AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:235) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln pMON28542AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:236) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlncysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr pMON28543AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:237) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys pMON28544AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:238) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn pMON28545AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:239) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLyspMON32132 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis(SEQ ID NO:252)ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg PMON32133SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ IDNO:253) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg PMON32134SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis (SEQ ID NO:254) ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg pmon16017.pep  1 Met Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ ID NO:271)  16 Lys ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu Asp Val SerIle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly GlyGly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Leu Gly 151 Pro AlaSer Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu 166 Gln Val Arg LysIle Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 181 Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu 196 Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys 211 Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His 226 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly 241 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp 256 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu 271Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 286 Phe AlaSer Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala 301 Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 316 His Leu Ala Gln Pro AspMet Ala Thr Pro pmon16018.pep  1 Met Ala Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu (SEQ ID NO:272)  16 Lys Arg Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp  31 Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn  46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu GluAsn Ala Ser  61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu ProSer  76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly  31Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106 Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser Pro Gly GluPro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Leu Gly 151 Pro Ala Ser Ser Leu Pro Gln SerPhe Leu Leu Lys Ser Leu Glu 176 Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gln Glu Lys 191 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu 206 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys 221 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His 236Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly 251 Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 266 Val Ala Asp PheAla Thr Thr Ile Trp Gln Gln Met Glu Glu Leu 281 Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala 296 Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala 311 Ser His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg 326 His Leu Ala Gln Pro Asp Met Ala Thr Propmon16019.pep  1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu (SEQ ID NO:273)  16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp  31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn  46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly ProIle Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Phe Leu 151 Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala 166 Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro 181 Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 196Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys 211 Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu 226 Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp 241 Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr Thr Ile Trp Gln 256 Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro Thr Gln 271 Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly 286 Gly Val Leu Val Ala Ser His Leu Gln Ser Phe LeuGlu Val Ser 301 Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala ThrPro 316 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser pmon16020.pep  1 Met AlaAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ ID NO:274)  16Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu GlyGly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Gln 151Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu 166 Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 181 Gly His Ser LeuGly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro 196 Ser Gln Ala Leu Gln LeuAla Gly Cys Leu Ser Gln Leu His Ser 211 Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile 226 Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val 241 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly 256 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe 271 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 286His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 301 Leu AlaGln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 316 Leu Pro Gln SerPhe Leu Leu Lys Ser Leu pmon16021.pep  1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:275)  16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Leu Leu 151 Gly His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro 166 Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser 181 Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile 196 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu GlnLeu Asp Val 211 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly 226 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 241Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 256 His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 271 Leu Ala Gln ProAsp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 286 Leu Pro Gln Ser Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys 301 Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr 316 Tyr Lys Leu Cys His Pro Glu Glu Leu Valpmon16022.pep  1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu (SEQ ID NO:276)  16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp  31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn  46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly ProIle Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Pro Leu 151 Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser 166 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla 181 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu 196Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met 211 Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala 226 Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val 241 Leu Val Ala Ser His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg 256 Val Leu Arg His Leu Ala Gln ProAsp Met Ala Thr Pro Leu Gly 271 Pro Ala Ser Ser Leu Pro Gln Ser Phe LeuLeu Lys Ser Leu Glu 286 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys 301 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu 316 Leu Gly His Ser Leu Gly Ile Pro Trp Ala pmon16023.pep  1 Met AlaAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ ID NO:277)  16Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu GlyGly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Gln Ala 151Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe 166 Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu 181 Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe 196 Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro 211 Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala 226 Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gln 241 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln 256 Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu ProGln 271 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly 286Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu 301 Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 316 Pro Trp Ala ProLeu Ser Ser Cys Pro Ser pmon16024.pep  1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:278)  16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Leu Gln 151 Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr 166 Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly 181 Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr 196 Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu 211 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln 226 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 241Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp 256 Met AlaThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe 271 Leu Leu Lys SerLeu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly 286 Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His 301 Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp 316 Ala Pro Leu Ser Ser Cys Pro Ser Gln Alapmon16025.pep  1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu (SEQ ID NO:279)  16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp  31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn  46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly ProIle Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Leu Ala 151 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly 166 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr 181 Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile 196Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 211 Thr GlnGly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg 226 Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu 241 Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pro Asp Met Ala 256 Thr Pro Leu Gly Pro Ala Ser SerLeu Pro Gln Ser Phe Leu Leu 271 Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala 286 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu CysHis Pro Glu 301 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp AlaPro 316 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln pmon16026.pep  1 Met AlaAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ ID NO:280)  16Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu GlyGly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Glu Leu 151Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 166 Phe AlaSer Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala 181 Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 196 His Leu Ala Gln Pro AspMet Ala Thr Pro Leu Gly Pro Ala Ser 211 Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg 226 Lys Ile Gln Gly Asp Gly Ala Ala Leu GlnGlu Lys Leu Cys Ala 241 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His 256 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln 271 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu 286Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro 301 Glu LeuGly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp 316 Phe Ala Thr ThrIle Trp Gln Gln Met Glu pmon16027.pep  1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:281)  16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp  31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn  46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser  61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser  76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly  91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Gly Met 151 Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala 166 Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His 181 Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His Leu 196 Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro AlaSer Ser Leu 211 Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg LysIle 226 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr 241Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu 256 Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu 271 Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu 286 Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu 301 Gly Pro Thr Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala 316 Thr Thr Ile Trp Gln Gln Met Glu Glu Leupmon16028.pep  1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu (SEQ ID NO:282)  16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp  31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn  46 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser  61Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser  76 Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly  91 Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln GluGln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly ProIle Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser ProAsn Met Ala Ser Phe 151 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Asp 166 Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln SerPhe 181 Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly 196Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 211 Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp 226 Ala Pro Leu SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly 241 Cys Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu 256 Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu 271 Asp Thr Leu Gln Leu Asp Val Ala Asp PheAla Thr Thr Ile Trp 286 Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr 301 Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla 316 Gly Gly Val Leu Val Ala Ser His Leu GlnMetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis (SEQ IDNO:284) LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGln;MetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu (SEQ IDNO:285) LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeu

[0466]

1 313 174 amino acids amino acid unknown unknown protein Modified-site 1/note= “Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;” Modified-site 2/note= “Xaa at position 2 is Pro or Leu;” Modified-site 3 /note= “Xaa atposition 3 is Leu, Arg, Tyr or Ser;” Modified-site 13 /note= “Xaa atposition 13 is Phe, Ser, His, Thr or Pro;” Modified-site 16 /note= “Xaaat position 16 is Lys, Pro, Ser, thr or His;” Modified-site 17 /note=“Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyr or Arg;”Modified-site 18 /note= “Xaa at position 18 is Leu, Thr, Pro, His, Ileor Cys;” Modified-site 22 /note= “Xaa at position 22 is Arg, Tyr, Ser,Thr or Ala;” Modified-site 24 /note= “Xaa at position 24 is Ile, Pro,Tyr or Leu;” Modified-site 27 /note= “Xaa at position 27 is Asp, orGly;” Modified-site 30 /note= “Xaa at position 30 is Ala, Ile, Leu orGly;” Modified-site 34 /note= “Xaa at position 34 is Lys or Ser;”Modified-site 36 /note= “Xaa at position 36 is Cys or Ser;”Modified-site 42 /note= “Xaa at position 42 is Cys or Ser;”Modified-site 43 /note= “Xaa at position 43 is His, Thr, Gly, Val, Lys,Trp, Ala, Arg, Cys, or Leu;” Modified-site 44 /note= “Xaa at position 44is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;” Modified-site46 /note= “Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala;”Modified-site 47 /note= “Xaa at position 47 is Leu or Thr;”Modified-site 49 /note= “Xaa at position 49 is Leu, Phe, Arg or Ser;”Modified-site 50 /note= “Xaa at position 50 is Leu, Ile, His, Pro orTyr;” Modified-site 54 /note= “Xaa at position 54 is Leu or His;”Modified-site 64 /note= “Xaa at position 64 is Cys or Ser;”Modified-site 67 /note= “Xaa at position 67 is Gln, Lys, Leu or Cys;”Modified-site 70 /note= “Xaa at position 70 is Gln, Pro, Leu, Arg orSer;” Modified-site 74 /note= “Xaa at position 74 is Cys or Ser;”Modified-site 104 /note= “Xaa at position 104 is Asp, Gly or Val;”Modified-site 108 /note= “Xaa at position 108 is Leu, Ala, Val, Arg,Trp, Gln or Gly;” Modified-site 115 /note= “Xaa at position 115 is Thr,His, Leu or Ala;” Modified-site 123 /note= “Xaa at position 123 is Glu,Arg, Phe or Thr” Modified-site 144 /note= “Xaa at position 144 is Phe,His, Arg, Pro, Leu, Gln or Glu;” Modified-site 146 /note= “Xaa atposition 146 is Arg or Gln;” Modified-site 147 /note= “Xaa at position147 is Arg or Gln;” Modified-site 156 /note= “Xaa at position 156 isHis, Gly or Ser;” Modified-site 159 /note= “Xaa at position 159 is Ser,Arg, Thr, Tyr, Val or Gly;” Modified-site 162 /note= “Xaa at position162 is Glu, Leu, Gly or Trp;” Modified-site 163 /note= “Xaa at position163 is Val, Gly, Arg or Ala;” Modified-site 169 /note= “Xaa at position169 is Arg, Ser, Leu, Arg or Cys;” Modified-site 170 /note= “Xaa atposition 170 is His, Arg or Ser;” 1 Xaa Xaa Xaa Gly Pro Ala Ser Ser LeuPro Gln Ser Xaa Leu Leu Xa 1 5 10 15 Xaa Xaa Glu Gln Val Xaa Lys Xaa GlnGly Xaa Gly Ala Xaa Leu Gl 20 25 30 Glu Xaa Leu Xaa Ala Thr Tyr Lys LeuXaa Xaa Xaa Glu Xaa Xaa Va 35 40 45 Xaa Xaa Gly His Ser Xaa Gly Ile ProTrp Ala Pro Leu Ser Ser Xa 50 55 60 Pro Ser Xaa Ala Leu Xaa Leu Ala GlyXaa Leu Ser Gln Leu His Se 65 70 75 80 Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Se 85 90 95 Pro Glu Leu Gly Pro Thr Leu XaaThr Leu Gln Xaa Asp Val Ala As 100 105 110 Phe Ala Xaa Thr Ile Trp GlnGln Met Glu Xaa Leu Gly Met Ala Pr 115 120 125 Ala Leu Gln Pro Thr GlnGly Ala Met Pro Ala Phe Ala Ser Ala Xa 130 135 140 Gln Xaa Xaa Ala GlyGly Val Leu Val Ala Ser Xaa Leu Gln Xaa Ph 145 150 155 160 Leu Xaa XaaSer Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro 165 170 133 amino acidsamino acid single linear protein Modified-site 17 /note= “Xaa atposition 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;” Modified-site 18/note= “Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;”Modified-site 19 /note= “Xaa at position 19 is Met, Phe, Ile, Arg, Gly,Ala, or Cys;” Modified-site 20 /note= “Xaa at position 20 is Ile, Cys,Gln, Glu, Arg, Pro, or Ala;” Modified-site 21 /note= “Xaa at position 21is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;”Modified-site 22 /note= “Xaa at position 22 is Glu, Trp, Pro, Ser, Ala,His, Asp, Asn, Gln, Leu, Val or Gly;” Modified-site 23 /note= “Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;”Modified-site 24 /note= “Xaa at position 24 is Ile, Gly, Val, Arg, Ser,Phe, Leu;” Modified-site 25 /note= “Xaa at position 25 is Thr, His, Gly,Gln, Arg, Pro, or Ala;” Modified-site 26 /note= “Xaa at position 26 isHis, Thr, Phe, Gly, Arg, Ala, Trp;” Modified-site 27 /note= “Xaa atposition 27 is Leu, Gly, Arg, Thr, Ser, or Ala;” Modified-site 28 /note=“Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;”Modified-site 29 /note= “Xaa at position 29 is Gln, Asn, Leu, Pro, Arg,or Val;” Modified-site 30 /note= “Xaa at position 30 is Pro, His, Thr,Gly, Asp, Gln, Ser, Leu, or L...” Modified-site 31 /note= “Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;” Modified-site 32/note= “Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, orGlu;” Modified-site 33 /note= “Xaa at position 33 is Pro, Leu, Gln, Ala,Thr, or Glu;” Modified-site 34 /note= “Xaa at position 34 is Leu, Val,Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;” Modified-site35 /note= “Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;”Modified-site 36 /note= “Xaa at position 36 is Asp, Leu, or Val;”Modified-site 37 /note= “Xaa at position 37 is Phe, Ser, Pro, Trp, orIle;” Modified-site 38 /note= “Xaa at position 38 is Asn, or Ala;”Modified-site 40 /note= “Xaa at position 40 is Leu, Trp, or Arg;”Modified-site 41 /note= “Xaa at position 41 is Asn, Cys, Arg, Leu, His,Met, or pro;” Modified-site 42 /note= “Xaa at position 42 is Gly, Asp,Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;”Modified-site 43 /note= “Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe,Asp, Ala, Cys, Gln, Arg, Thr, Gly, or Ser;” Modified-site 44 /note= “Xaaat position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln,Ala or Pro;” Modified-site 45 /note= “Xaa at position 45 is Gln, Pro,Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu orHis;” Modified-site 46 /note= “Xaa at position 46 is Asp, Phe, Ser, Thr,Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;” Modified-site47 /note= “Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;”Modified-site 48 /note= “Xaa at position 48 is Leu, Ser, Cys, Arg, Ile,His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;” Modified-site 49 /note=“Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;”Modified-site 50 /note= “Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr,Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;” Modified-site 51/note= “Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or his;”Modified-site 52 /note= “Xaa at position 52 is Asn, His, Arg, Leu, Gly,Ser, or Thr;” Modified-site 53 /note= “Xaa at position 53 is Leu, Thr,Ala, Gly, Glu, Pro, Lys, Ser, or M...” Modified-site 54 /note= “Xaa atposition 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala orLeu;” Modified-site 55 /note= “Xaa at position 55 is Arg, Thr, Val, Ser,Leu, or Gly;” Modified-site 56 /note= “Xaa at position 56 is Pro, Gly,Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;”Modified-site 57 /note= “Xaa at position 57 is Asn or Gly;”Modified-site 58 /note= “Xaa at position 58 is Leu, Ser, Asp, Arg, Gln,Val, or Cys;” Modified-site 59 /note= “Xaa at position 59 is Glu, Tyr,His, Leu, Pro, or Arg;” Modified-site 60 /note= “Xaa at position 60 isAla, Ser, Pro, Tyr, Asn, or Thr;” Modified-site 61 /note= “Xaa atposition 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;” Modified-site 62/note= “Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, orIle;” Modified-site 63 /note= “Xaa at position 63 is Arg, Tyr, Trp, Lys,Ser, His, Pro, or Val;” Modified-site 64 /note= “Xaa at position 64 isAla, Asn, Pro, Ser, or Lys;” Modified-site 65 /note= “Xaa at position 65is Val, Thr, Pro, His, Leu, Phe, or Ser;” Modified-site 66 /note= “Xaaat position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;” Modified-site67 /note= “Xaa at postion 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro,or His;” Modified-site 68 /note= “Xaa at position 68 is Leu, Val, Trp,Ser, Ile, Phe, Thr, or His;” Modified-site 69 /note= “Xaa at position 69is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or L...” Modified-site 70/note= “Xaa at position 70 is Asn, Leu, Val, Trp, pro, or Ala;”Modified-site 71 /note= “Xaa at position 71 is Ala, Met, Leu, Pro, Arg,Glu, Thr, Gln, Trp, or Asn;” Modified-site 72 /note= “Xaa at position 72is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;” Modified-site 73 /note=“Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;”Modified-site 74 /note= “Xaa at position 74 is Ile, Met, Thr, Pro, Arg,Gly, Ala;” Modified-site 75 /note= “Xaa at position 75 is Glu, Lys, Gly,Asp, Pro, Trp, Arg, Ser, Gln, or Leu;” Modified-site 76 /note= “Xaa atposition 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or A...”Modified-site 77 /note= “Xaa at position 77 is Ile, Ser, Arg, Thr, orLeu;” Modified-site 78 /note= “Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg;” Modified-site 79 /note= “Xaa at position 79 is Lys,Thr, Asn, Met, Arg, Ile, Gly, or Asp;” Modified-site 80 /note= “Xaaposition at 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;”Modified-site 81 /note= “Xaa at position 81 is Leu, Gln, Gly, Ala, Trp,Arg, Val, or Lys;” Modified-site 82 /note= “Xaa at position 82 is Leu,Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile,Met or Val;” Modified-site 83 /note= “Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met;” Modified-site 84 /note= “Xaa at position 84 isCys, Glu, Gly, Arg, Met, or Val;” Modified-site 85 /note= “Xaa atposition 85 is Leu, Asn, Val, or Gln;” Modified-site 86 /note= “Xaa atposition 86 is Pro, Cys, Arg, Ala, or Lys;” Modified-site 87 /note= “Xaaat position 87 is Leu, Ser, Trp, or Gly;” Modified-site 88 /note= “Xaaat position 88 is Ala, Lys, Arg, Val, or Trp;” Modified-site 89 /note=“Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or S...”Modified-site 90 /note= “Xaa at position 90 is Ala, Pro, Ser, Thr, Gly,Asp, Ile, or ,Met;” Modified-site 91 /note= “Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His;” Modified-site 92 /note= “Xaa atposition 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;”Modified-site 93 /note= “Xaa at position 93 is Thr, Asp, Ser, Asn, Pro,Ala, Leu, or Arg;” Modified-site 94 /note= “Xaa at position 94 is Arg,Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;” Modified-site 95/note= “Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr,Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;” Modified-site 96 /note= “Xaaat position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;” Modified-site 97/note= “Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;” Modified-site98 /note= “Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu,Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr, or Pro;” Modified-site 99 /note=“Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe,or His;” Modified-site 100 /note= “Xaa at position 100 is Lys, Tyr, Leu,His, Arg, Ile, Ser, Gln, or ...” Modified-site 101 /note= “Xaa atposition is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala,Gly, Ile, Leu, or Gln;” Modified-site 102 /note= “Xaa at position 102 isGly, Leu, Glu, Lys, Ser, Tyr, or Pro;” Modified-site 103 /note= “Xaa atposition 103 is Asp, or Ser;” Modified-site 104 /note= “Xaa at position104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, orGly;” Modified-site 105 /note= “Xaa at position 105 is Asn, Pro, Ala,Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;” Modified-site 106/note= “Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, orPro;” Modified-site 108 /note= “Xaa at position 108 is Arg, Lys, Asp,Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;” Modified-site 109 /note= “Xaaat position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;”Modified-site 110 /note= “Xaa at position 110 is Lys, Ala, Asn, Thr,Leu, Arg, Gln, His, Glu, Ser, or Trp;” Modified-site 111 /note= “Xaa atposition 111 is Leu, Ile, Arg, Asp, or Met;” Modified-site 112 /note=“Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;”Modified-site 113 /note= “Xaa at position 113 is Phe, Ser, Cys, His,Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;” Modified-site 114 /note=“Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;”Modified-site 115 /note= “Xaa at position 115 is Leu, Asn, Val, Pro,Arg, Ala, His, Thr, Trp, or Met;” Modified-site 116 /note= “Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile;” Modified-site 117 /note= “Xaa atposition 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;” Modified-site 118/note= “Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, orTyr;” Modified-site 119 /note= “Xaa at position 119 is Glu, Ser, Lys,Pro, leu, Thr, Tyr, or Arg;” Modified-site 120 /note= “Xaa at position120 is Asn, Ala, Pro, Leu, His, Val, or Gln;” Modified-site 121 /note=“Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;”Modified-site 122 /note= “Xaa at position 122 is Gln, Ser, Met, Trp,Arg, Phe, Pro, His, Ile, Tyr, or Cys;” Modified-site 123 /note= “Xaa atposition 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;” 2 Ala ProMet Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cy 1 5 10 15 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa 20 25 30 Xaa XaaXaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa 35 40 45 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa 50 55 60 Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa 65 70 75 80 XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa 85 90 95 XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xa 100 105 110Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Le 115 120125 Ser Leu Ala Ile Phe 130 332 amino acids amino acid unknown unknownprotein Modified-site 112 /note= “position 112 is deleted or Leu, Ala,Val, Ile, Pro, Phe, Trp, or M...” Modified-site 113 /note= “position 113is deleted or Pro, Phe, Ala, Leu, Ile, Trp, or Met” Modified-site 114/note= “position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp orMet” Modified-site 115 /note= “position 115 is deleted or Gln, Gly, Ser,Thr, Tyr or Asn” 3 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu SerLys Leu Le 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln CysPro Glu Va 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val AspPhe Ser Le 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala GlnAsp Ile Le 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala AlaArg Gly Gl 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly GlnLeu Ser Gly Gl 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu LeuGly Thr Gln Xa 100 105 110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys AspPro Asn Ala Ile Ph 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly LysVal Arg Phe Leu Met Le 130 135 140 Val Gly Gly Ser Thr Leu Cys Val ArgArg Ala Pro Pro Thr Thr Al 145 150 155 160 Val Pro Ser Arg Thr Ser LeuVal Leu Thr Leu Asn Glu Leu Pro As 165 170 175 Arg Thr Ser Gly Leu LeuGlu Thr Asn Phe Thr Ala Ser Ala Arg Th 180 185 190 Thr Gly Ser Gly LeuLeu Lys Trp Gln Gln Gly Phe Arg Ala Lys Il 195 200 205 Pro Gly Leu LeuAsn Gln Thr Ser Arg Ser Leu Asp Gln Ile Pro Gl 210 215 220 Tyr Leu AsnArg Ile His Glu Leu Leu Asn Gly Thr Arg Gly Leu Ph 225 230 235 240 ProGly Pro Ser Arg Arg Thr Leu Gly Ala Pro Asp Ile Ser Ser Gl 245 250 255Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu Gln Pro Gly Tyr Se 260 265270 Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr Thr Leu Phe Pro Le 275280 285 Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu His Pro Leu Leu Pr290 295 300 Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser Pro Leu Leu AsnTh 305 310 315 320 Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu Gly 325330 5 base pairs nucleic acid unknown unknown peptide 4 GYSRN 5 3 aminoacids amino acid unknown unknown peptide Peptide 1 /note= “wherex=(glyglyglyglyser)n and where n is an interger” 5 Xaa Ala Ala 1 3 aminoacids amino acid unknown unknown peptide Peptide 1 Peptide 1 /note=“where Xaa =(glyglyglyglyglyser)n and where n is an integer” 6 Xaa AlaAla 1 3 amino acids amino acid unknown unknown peptide Peptide 1 /note=“where xaa = (gly(n)ser)m and where n is an integer and m is an int...”7 Xaa Ala Ala 1 3 amino acids amino acid unknown unknown peptide Peptide1 /note= “where Xaa=(alaglyser)n and where n is an integer” 8 Xaa AlaAla 1 36 amino acids amino acid unknown linear protein 9 Gly Gly Gly SerGly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gl 1 5 10 15 Ser Glu Gly GlyGly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Se 20 25 30 Gly Gly Gly Ser35 24 amino acids amino acid unknown unknown peptide 10 Ile Ser Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pr 1 5 10 15 Ser Lys Glu SerHis Lys Ser Pro 20 28 amino acids amino acid unknown unknown peptide 11Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile As 1 5 10 15Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 25 4 amino acidsamino acid unknown unknown peptide 12 Gly Gly Gly Ser 1 45 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”13 ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGCACTCC GAGTC 45 30 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”14 ATGCACGAAT TCCCTGACGC AGAGGGTGGA 30 33 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 15 TGACAAGCTTACCTGACGCA GAGGGTGGAC CCT 33 10 base pairs nucleic acid single linearother nucleic acid /desc = “DNA (synthetic)” 16 AATTCGGCAA 10 10 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 17 CATGTTGCCG 10 13 base pairs nucleic acid single linearother nucleic acid /desc = “DNA (synthetic)” 18 AATTCGGCGG CAA 13 13base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 19 CATGTTGCCG CCG 13 22 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 20 AATTCGGCGGCAACGGCGGC AA 22 22 base pairs nucleic acid single linear other nucleicacid /desc = “DNA (synthetic)” 21 CATGTTGCCG CCGTTGCCGC CG 22 27 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 22 CGATCCATGG AGGTTCACCC TTTGCCT 27 29 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 23GATCAAGCTT ATGGGCACTG GCTCAGTCT 29 27 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 24 CGATACATGTTGCCTACACC TGTCCTG 27 29 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 25 GATCAAGCTT AAGGGTGAACCTCTGGGCA 29 27 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 26 CGATCCATGG TCCTGCTGCC TGCTGTG 27 29 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 27 GATCAAGCTT AAGGTGTAGG CAAAGGGTG 29 30 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 28CGATCCATGG CTGTGGACTT TAGCTTGGGA 30 29 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 29 GATCAAGCTTAAGGCAGCAG GACAGGTGT 29 27 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 30 CGATCCATGG ACTTTAGCTT GGGAGAA27 29 base pairs nucleic acid single linear other nucleic acid /desc =“DNA (synthetic)” 31 GATCAAGCTT ACACAGCAGG CAGCAGGAC 29 27 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”32 CGATCCATGG GAGAATGGAA AACCCAG 27 29 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 33 GATCAAGCTTACAAGCTAAA GTCCACAGC 29 27 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 34 CGATCCATGG GACCCACTTG CCTCTCA27 29 base pairs nucleic acid single linear other nucleic acid /desc =“DNA (synthetic)” 35 GATCAAGCTT ACAGTTGTCC CCGTGCTGC 29 27 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”36 CAGTCCATGG GAACCCAGCT TCCTCCA 27 29 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 37 GATCAAGCTTAAAGGAGGCT CTGCAGGGC 29 27 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 38 CGATCCATGG GCAGGACCAC AGCTCAC27 30 base pairs nucleic acid single linear other nucleic acid /desc =“DNA (synthetic)” 39 GATCAAGCTT ACTGTGGAGG AAGCTGGGTT 30 30 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”40 CGATCCATGG CTCACAAGGA TCCCAATGCC 30 29 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 41 GATCAAGCTTATGTGGTCCT GCGCTGTGG 29 30 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 42 CGATCCATGG ATCCCAATGCCATCTTCCTG 30 29 base pairs nucleic acid single linear other nucleicacid /desc = “DNA (synthetic)” 43 GATCAAGCTT ACTTGTGAGC TGTGGTCCT 29 30base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 44 CGATCCATGG CCATCTTCCT GAGCTTCCAA 30 32 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”45 GATCAAGCTT AATTGGGATC CTTGTGAGCT GT 32 83 base pairs nucleic acidunknown unknown other nucleic acid /desc = “SYNTHETIC” 46 AATTCCGTCGTAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60 ACGTAGAGGGCGGTGGAGGC TCC 83 83 base pairs nucleic acid single linear other nucleicacid /desc = “DNA (synthetic)” 47 CCGGGGAGCC TCCACCGCCC TCTACGTACTGTTGAGCCTG CGCGTTCTCC AAGGTTTTCA 60 GATAGAAGGT CAGTTTACGA CGG 83 59 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 48 GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTCTATAATGAT 59 56 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 49 CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTCCTGCGCTTGC TCAAGG 56 80 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 50 GTTACCCTTG AGCAAGCGCAGGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC 60 GGTTCTAACT GCTCTATAAT 8080 base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 51 CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCACCACCCTGTT 60 GTTCCTGCGC TTGCTCAAGG 80 30 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 52 GATCGACCATGGCTCTGGAC CCGAACAACC 30 28 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 53 CTCGATTACG TACAAAGGTG CAGGTGGT28 32 base pairs nucleic acid single linear other nucleic acid /desc =“DNA (synthetic)” 54 GATCGACCAT GGCTAATGCA TCAGGTATTG AG 32 28 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 55 CTCGATTACG TATTCTAAGT TCTTGACA 28 32 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 56GATCGACCAT GGCTGCACCC TCTCGACATC CA 32 28 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 57 CTCGATTACGTAGGCCGTGG CAGAGGGC 28 32 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 58 GATCGACCAT GGCTGCAGGTGACTGGCAAG AA 32 28 base pairs nucleic acid single linear other nucleicacid /desc = “DNA (synthetic)” 59 CTCGATTACG TACTTGATGA TGATTGGA 28 54base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 60 GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAACGCG 54 54 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 61 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGCTCAAGTCTTT AGAG 54 18 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 62 GGGCTGCGCA AGGTGGCG 18 21 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 63 ACACCATTGG GCCCTGCCAG C 21 32 base pairs nucleic acidsingle linear other nucleic acid /desc = “DNA (synthetic)” 64 GATCGACCATGGCTTACAAG CTGTGCCACC CC 32 36 base pairs nucleic acid single linearother nucleic acid /desc = “DNA (synthetic)” 65 CGATCGAAGC TTATTAGGTGGCACACAGCT TCTCCT 36 32 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 66 GATCGACCAT GGCTCCCGAGTTGGGTCCCA CC 32 36 base pairs nucleic acid single linear other nucleicacid /desc = “DNA (synthetic)” 67 CGATCGAAGC TTATTAGGAT ATCCCTTCCAGGGCCT 36 32 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 68 GATCGACCAT GGCTATGGCC CCTGCCCTGC AG 32 36base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 69 CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT 36 32 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”70 GATCGACCAT GGCTACCCAG GGTGCCATGC CG 32 36 base pairs nucleic acidsingle linear other nucleic acid /desc = “DNA (synthetic)” 71 CGATCGAAGCTTATTAGGGC TGCAGGGCAG GGGCCA 36 36 base pairs nucleic acid single linearother nucleic acid /desc = “DNA (synthetic)” 72 CGATCGAAGC TTATTAGGGCTGCAGGGCAG GGGCCA 36 36 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 73 CGATCGAAGC TTATTAGGCGAAGGCCGGCA TGGCAC 36 21 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 74 GTAGAGGGCG GTGGAGGCTC C 21 25base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 75 CCGGGGAGCC TCCACCGCCC TCTAC 25 53 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 76TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG 53 53 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 77 CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTAGAA 53 439 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 78 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACTTAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTATCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGAACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCTCTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAATTCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACGTAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGTCTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGT 439 465 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 79TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTC 465 927 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”80 TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGC 480TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCA 540GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 600CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 660CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 720CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 780CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCC 840AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCT 900GTAGGAGGGT CCACCCTCTG CGTCAGG 927 936 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 81 TCCCCAGCTCCACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACAGCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120 CTGCCTGCTGTGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180 CAGGACATTCTGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240 CTGGGACCCACTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300 CTTGGGGCCCTGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360 CACAAGGATCCCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420 TTCCTGATGCTTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CATGGCGTC 480 CCCGCTCCGCCTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CTCCCATGT 540 CTTCACAGCAGACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TGTCCTGCT 600 CCTGCTGTGGACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CAAGGCACA 660 GACATTCTGGGAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GGGACAACT 720 GGACCCACTTGCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TCTCCTCCT 780 GGGGCCCTGCAGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CACAGCTCA 840 AAGGATCCCAATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTT 900 CTGATGCTTGTAGGAGGGTC CACCCTCTGC GTCAGG 936 939 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 82 TCCCCAGCTCCACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACAGCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120 CTGCCTGCTGTGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180 CAGGACATTCTGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240 CTGGGACCCACTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300 CTTGGGGCCCTGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360 CACAAGGATCCCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420 TTCCTGATGCTTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGC 480 TCTCCCGCTCCGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCA 540 GTCCTTCACAGCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 600 CTGCCTGCTGTGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 660 CAGGACATTCTGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 720 CTGGGACCCACTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 780 CTTGGGGCCCTGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 840 CACAAGGATCCCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 900 TTCCTGATGCTTGTAGGAGG GTCCACCCTC TGCGTCAGG 939 948 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 83 TCCCCAGCGCCGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACAGCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120 CTGCCTGCTGTGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180 CAGGACATTCTGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240 CTGGGACCCACTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300 CTTGGGGCCCTGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360 CACAAGGATCCCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420 TTCCTGATGCTTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACGGCGG 480 AACATGGCGTCCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCG 540 GACTCCCATGTCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTAC 600 CCTGTCCTGCTGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGA 660 ACCAAGGCACAGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGC 720 CGGGGACAACTGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGT 780 CGTCTCCTCCTTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAG 840 ACCACAGCTCACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GCTCCGAGG 900 AAGGTGCGTTTCCTGATGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG 948 688 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 84CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAA 120CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCAT 180AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCAC 240CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGA 300GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCT 360TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TGCTGGACC 420GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GACTTCCAA 480CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAA 540TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAA 600CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT ATCTGGTTA 660CCTTGAGCAA GCGCAGGAAC AACAGTAC 688 712 base pairs nucleic acid unknownunknown other nucleic acid /desc = “SYNTHETIC” 85 CATGGCTAAC TGCTCTATAATGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60 ACCTTTGCTG GACCCGAACAACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAA 120 CCTTCGACTT CCAAACCTGGAGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCAT 180 AGGTATTGAG GCAATTCTTCGTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCAC 240 CTCTCGACAT CCAATCATCATCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGA 300 GTTCTATCTG GTTACCCTTGAGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTG 360 CAGCGGCGGC GGTTCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGA 420 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGA 480 GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAG 540 AAATGCATCA GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCA 600 GGCCGCACCC TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGG 660 AAAACTGACG TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT AC 712 975 base pairs nucleic acidsingle linear other nucleic acid /desc = “DNA (synthetic)” 86 ATGGCTCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 120 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 180 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 240 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTC 300 ATAATGATCGATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GTACGTAGA 360 GGCGGTGGAGGCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCC 420 CCGTCTAAAGAATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTT 480 GCCTCTGCTTTCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTT 540 CTGGAGGTGTCGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGG 600 TCTCAGAGCTTCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGC 660 GCGCTCCAGGAGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCT 720 CTCGGACACTCTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCT 780 CAGCTGGCAGGCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCT 840 CAGGCCCTGGAAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGA 900 GTCGCCGACTTTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGC 960 CTGCAGCCCTAATAA 975 975 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 87 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCTCTATCCTGAT GGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCAAGAACTTAGA AAATGCATC 120 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACC 180 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGAC 240 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGGGTGGTGGCTC TAACTGCTC 300 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCACCTGCACCTTT GTACGTAGA 360 GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCTCTACTATCAA CCCGTCTCC 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCCAGGGTGCCAT GCCGGCCTT 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTGCTAGCCATCT GCAGAGCTT 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGCCCTCTGGCGG CTCTGGCGG 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAAAGATCCAGGG CGATGGCGC 660 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCCACCCCGAGGA GCTGGTGCT 720 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCTCCTGCCCCAG CCAGGCCCT 780 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTTTCCTCTACCA GGGGCTCCT 840 CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCTTGGACACACT GCAGCTGGA 900 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAGAACTGGGAAT GGCCCCTGC 960 CTGCAGCCCT AATAA 975 975 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 88ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG 60GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGG 120TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACC 180TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 240CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 300ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CTACGTAGA 360GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCC 420CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTT 480GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTT 540CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGG 600TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGC 660GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCT 720CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCT 780CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCT 840CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGA 900GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGC 960CTGCAGCCCT AATAA 975 975 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 89 ATGGCTGCAG GTGACTGGCAAGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 60 GAGCAAGCGC AGGAACAACAGGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAAT 120 ATACATCACT TAAAGAGACCACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGA 180 GACGTCTCTA TCCTGATGGACCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAG 240 GCTGTCAAGA ACTTAGAAAATGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACC 300 TGTCTGCCCT CTGCCACGGCCGCACCCTCT CGACATCCAA TCATCATCAA GTACGTAGA 360 GGCGGTGGAG GCTCCCCGGGTGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCC 420 CCGTCTAAAG AATCTCATAAATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTT 480 GCCTCTGCTT TCCAGCGCCGGGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTT 540 CTGGAGGTGT CGTACCGCGTTCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGG 600 TCTCAGAGCT TCCTGCTCAAGTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGC 660 GCGCTCCAGG AGAAGCTGTGTGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCT 720 CTCGGACACT CTCTGGGCATCCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCT 780 CAGCTGGCAG GCTGCTTGAGCCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCT 840 CAGGCCCTGG AAGGGATATCCCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGA 900 GTCGCCGACT TTGCCACCACCATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGC 960 CTGCAGCCCT AATAA 975 999base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 90 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 120 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 180 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 240 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTCTGGCGGTGG 300 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCACTTAAAGAG 360 CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACCGTCTGGTCC 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCCAAACATGGC 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGGAGGGGTCCT 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACGCCACCTTGC 600 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 999 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 91 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATGTCTGCCCTCT 60 GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTGGCAAGAATT 120 CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACAACAGGGTGG 180 GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGATGAAATTAT 240 CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAATGACGAAGA 300 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTTCGTAAGGGC 360 GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACCGTCTGGTCC 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCCAAACATGGC 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGGAGGGGTCCT 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACGCCACCTTGC 600 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 999 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 92 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCAAGAATTCCGG 60 GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACAGGGTGGTGG 120 TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGAAATTATACA 180 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGACGAAGACGT 240 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGTAAGGGCTGT 300 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCAACCATGTCT 360 CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACCGTCTGGTCC 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCCAAACATGGC 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGGAGGGGTCCT 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACGCCACCTTGC 600 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 999 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 93 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCTGGTTACCCTT 60 GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGGCGGTTCTAA 120 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGCACCTTTGCT 180 GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAACCTTCGACT 240 CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATCAGGTATTGA 300 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACCCTCTCGACA 360 CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACCGTCTGGTCC 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCCAAACATGGC 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGGAGGGGTCCT 540 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACGCCACCTTGC 600 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 660 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 720 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 780 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 840 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 900 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 960 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999 918 basepairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 94 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTGCCACCCCGA 420 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAGCTCCTGCCC 480 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCTTTTCCTCTA 540 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACAC 600 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGGG 660 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTCTGCTTTCCA 720 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGAGGTGTCGTA 780 CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCAGAGCTTCCT 840 CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCTCCAGGAGAA 900 CTGTGTGCCA CCTAATAA 918 963 base pa irs nucleic acidsingle linear other nucleic acid /desc = “DNA (synthetic)” 95 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCT 480 GGACACTCTCTGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCA 540 CTGGCAGGCTGCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCA 600 GCCCTGGAAGGGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGT 660 GCCGACTTTGCCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCT 720 CAGCCCACCCAGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGG 780 GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCA 840 CTTGCGCAGCCCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGA 900 CAAGTGAGAAAGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTA 960 TAA 963 918base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 96 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGGTCCCACCTT 420 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCAGATGGAAGA 480 CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTTCGCCTCTGC 540 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTTCCTGGAGGT 600 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGGCTCTCAGAG 660 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGCAGCGCTCCA 720 GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCTGCTCGGACA 780 TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCTGCAGCTGGC 840 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCTGCAGGCCCT 900 GAAGGGATAT CCTAATAA 918 963 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 97 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCT 480 GACGTCGCCGACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCC 540 GCCCTGCAGCCCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGC 600 GGAGGGGTCCTGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCT 660 CGCCACCTTGCGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTC 720 TTAGAGCAAGTGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGC 780 ACCTACAAGCTGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCC 840 TGGGCTCCCCTGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCA 900 CTCCATAGCGGCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTA 960 TAA 963 918base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 98 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGCCCTGCAGCC 420 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGGAGGGGTCCT 480 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACGCCACCTTGC 540 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 600 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 660 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 720 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 780 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 840 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 900 GAAGAACTGG GATAATAA 918 963 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 99 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCAT 480 CCGGCCTTCGCCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCT 540 CAGAGCTTCCTGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGG 600 TCTGGCGGCTCTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGG 660 GATGGCGCAGCGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGA 720 CTGGTGCTGCTCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAG 780 CAGGCCCTGCAGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCA 840 GGGCTCCTGCAGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACT 900 CAGCTGGACGTCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATA 960 TAA 963 918base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 100 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGCCATGCCGGC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCATCTGCAGAG 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGGCGGCTCTGG 540 GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCAGGGCGATGG 600 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGAGGAGCTGGT 660 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCCCAGCCAGGC 720 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTACCAGGGGCT 780 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACACACTGCAGCT 840 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGGAATGGCCCC 900 GCCCTGCAGC CCTAATAA 918 963 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 101 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTT 480 CAGCGCCGGGCAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTC 540 TACCGCGTTCTACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTT 600 CTGCTCAAGTCTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGA 660 AAGCTGTGTGCCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTC 720 CTGGGCATCCCCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGG 780 TGCTTGAGCCAACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGA 840 GGGATATCCCCCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTT 900 GCCACCACCATCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTA 960 TAA 963 918base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 102 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCAGCGCCGGGC 420 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTACCGCGTTCT 480 CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCTGCTCAAGTC 540 TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAAGCTGTGTGC 600 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCTGGGCATCCC 660 TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTGCTTGAGCCA 720 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGGGATATCCCC 780 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGCCACCACCAT 840 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCAGGGTGCCAT 900 CCGGCCTTCG CCTAATAA 918 963 base pairs nucleic acidunknown unknown other nucleic acid /desc = “SYNTHETIC” 103 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGT 480 GCTAGCCATCTGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCA 540 CCCTCTGGCGGCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAG 600 AAGATCCAGGGCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTG 660 CACCCCGAGGAGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAG 720 TCCTGCCCCAGCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCT 780 TTCCTCTACCAGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCAC 840 TTGGACACACTGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGA 900 GAACTGGGAATGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTA 960 TAA 963 927base pairs nucleic acid single linear other nucleic acid /desc = “DNA(synthetic)” 104 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTGCCACCCCGA 420 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAGCTCCTGCCC 480 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCTTTTCCTCTA 540 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACAC 600 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGGG 660 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTCTGCTTTCCA 720 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGAGGTGTCGTA 780 CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTCCCTGCCCCA 840 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGGCGCAGCGCT 900 CAGGAGAAGC TGTGTGCCAC CTAATAA 927 972 base pairs nucleicacid single linear other nucleic acid /desc = “DNA (synthetic)” 105ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCT 480GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCA 540CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCA 600GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGT 660GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCT 720CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGG 780GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCA 840CTTGCGCAGC CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAA 900TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTG 960GCCACCTAAT AA 972 927 base pairs nucleic acid single linear othernucleic acid /desc = “DNA (synthetic)” 106 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTT 420 GACACACTGC AGCTGGACGTCGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGA 480 CTGGGAATGG CCCCTGCCCTGCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGC 540 TTCCAGCGCC GGGCAGGAGGGGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGT 600 TCGTACCGCG TTCTACGCCACCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCT 660 CCCCAGAGCT TCCTGCTCAAGTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGC 720 GCGCTCCAGG AGAAGCTGTGTGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCT 780 CTCGGACACT CTCTGGGCATCCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCT 840 CAGCTGGCAG GCTGCTTGAGCCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCT 900 CAGGCCCTGG AAGGGATATCCTAATAA 927 972 base pairs nucleic acid single linear other nucleic acid/desc = “DNA (synthetic)” 107 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTAAGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAACCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGTGACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAGGAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCTACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTCCCGAGTTGGGTCCCA CCTTGGACAC ACTGCAGCT 480 GACGTCGCCG ACTTTGCCAC CACCATCTGGCAGCAGATGG AAGAACTGGG AATGGCCCC 540 GCCCTGCAGC CCACCCAGGG TGCCATGCCGGCCTTCGCCT CTGCTTTCCA GCGCCGGGC 600 GGAGGGGTCC TGGTTGCTAG CCATCTGCAGAGCTTCCTGG AGGTGTCGTA CCGCGTTCT 660 CGCCACCTTG CGCAGCCCAC ACCATTGGGCCCTGCCAGCT CCCTGCCCCA GAGCTTCCT 720 CTCAAGTCTT TAGAGCAAGT GAGAAAGATCCAGGGCGATG GCGCAGCGCT CCAGGAGAA 780 CTGTGTGCCA CCTACAAGCT GTGCCACCCCGAGGAGCTGG TGCTGCTCGG ACACTCTCT 840 GGCATCCCCT GGGCTCCCCT GAGCTCCTGCCCCAGCCAGG CCCTGCAGCT GGCAGGCTG 900 TTGAGCCAAC TCCATAGCGG CCTTTTCCTCTACCAGGGGC TCCTGCAGGC CCTGGAAGG 960 ATATCCTAAT AA 972 927 base pairsnucleic acid single linear other nucleic acid /desc = “DNA (synthetic)”108 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CCTGCAGCC 420ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCT 480GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGC 540CAGCCCACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTT 600GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCAC 660TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTG 720GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACT 780CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGA 840TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTG 900CAGCAGATGG AAGAACTGGG ATAATAA 927 972 base pairs nucleic acid singlelinear other nucleic acid /desc = “DNA (synthetic)” 109 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCAT 480 CCGGCCTTCGCCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCT 540 CAGAGCTTCCTGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATT 600 GGCCCTGCCAGCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAA 660 ATCCAGGGCGATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCA 720 CCCGAGGAGCTGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTC 780 TGCCCCAGCCAGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTT 840 CTCTACCAGGGGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTT 900 GACACACTGCAGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGA 960 CTGGGATAAT AA972 927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 110 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGCCATGCCGGC 420 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCATCTGCAGAG 480 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACCATTGGGCCC 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAGAAAGATCCA 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTGCCACCCCGA 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAGCTCCTGCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCTTTTCCTCTA 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACAC 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGGG 900 ATGGCCCCTG CCCTGCAGCC CTAATAA 927 972 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 111 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTT 480 CAGCGCCGGGCAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTC 540 TACCGCGTTCTACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCC 600 CAGAGCTTCCTGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGC 660 CTCCAGGAGAAGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCT 720 GGACACTCTCTGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCA 780 CTGGCAGGCTGCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCA 840 GCCCTGGAAGGGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGT 900 GCCGACTTTGCCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCT 960 CAGCCCTAAT AA972 927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 112 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCAGCGCCGGGC 420 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTACCGCGTTCT 480 CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCAGAGCTTCCT 540 CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCTCCAGGAGAA 600 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGGACACTCTCT 660 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCTGGCAGGCTG 720 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGCCCTGGAAGG 780 ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGCCGACTTTGC 840 ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCAGCCCACCCA 900 GGTGCCATGC CGGCCTTCGC CTAATAA 927 972 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 113 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGT 480 GCTAGCCATCTGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCA 540 CCCACACCATTGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGA 600 CAAGTGAGAAAGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTA 660 AAGCTGTGCCACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGC 720 CCCCTGAGCTCCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCA 780 AGCGGCCTTTTCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTT 840 GGTCCCACCTTGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCA 900 CAGATGGAAGAACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGC 960 TTCGCCTAAT AA972 963 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 114 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCAGCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAATGGACAATAA 120 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCAGAATGCATC 180 GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCACGGCCGCACC 240 ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCGTAAACTGAC 300 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGCCTCTGCTTT 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCTGGAGGTGTC 540 TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTCTCAGAGCTT 600 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGCGCTCCAGGA 660 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCTCGGACACTC 720 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCAGCTGGCAGG 780 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCAGGCCCTGGA 840 GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGTCGCCGACTT 900 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCTGCAGCCCTA 960 TAA 963 972 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 115 ATGGCTAACT GCTCTAACAT GATCGATGAAATCATCACCC ACCTGAAGCA GCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGTGAAGACCAAG ATATCCTGAT GGAAAATAA 120 CTTCGTCGTC CAAACCTCGA GGCATTCAACCGTGCTGTCA AGTCTCTGCA GAATGCATC 180 GCAATTGAGA GCATTCTTAA AAATCTCCTGCCATGTCTGC CCCTGGCCAC GGCCGCACC 240 ACGCGACATC CAATCATCAT CCGTGACGGTGACTGGAATG AATTCCGTCG TAAACTGAC 300 TTCTATCTGA AAACCTTGGA GAACGCGCAGGCTCAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCTACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAGGGTGCCATGC CGGCCTTCGC CTCTGCTTT 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCTAGCCATCTGC AGAGCTTCCT GGAGGTGTC 540 TACCGCGTTC TACGCCACCT TGCGCAGCCCACACCATTGG GCCCTGCCAG CTCCCTGCC 600 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAAGTGAGAAAGA TCCAGGGCGA TGGCGCAGC 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAGCTGTGCCACC CCGAGGAGCT GGTGCTGCT 720 GGACACTCTC TGGGCATCCC CTGGGCTCCCCTGAGCTCCT GCCCCAGCCA GGCCCTGCA 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGCGGCCTTTTCC TCTACCAGGG GCTCCTGCA 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGTCCCACCTTGG ACACACTGCA GCTGGACGT 900 GCCGACTTTG CCACCACCAT CTGGCAGCAGATGGAAGAAC TGGGAATGGC CCCTGCCCT 960 CAGCCCTAAT AA 972 963 base pairsnucleic acid single linear other nucleic acid /desc = “synthetic” 116ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAA 120CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATC 180GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACC 240ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGAC 300TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGG 360TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTT 480CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTC 540TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTT 600CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGA 660AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTC 720CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGG 780TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGA 840GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTT 900GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTA 960 TAA963 972 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 117 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCAGCCACCGCTG 60 CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAATGGACAATAA 120 CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCAGAATGCATC 180 GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCACGGCCGCACC 240 ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCGTAAACTGAC 300 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGCCTCTGCTTT 480 CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCTGGAGGTGTC 540 TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAGCTCCCTGCC 600 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGATGGCGCAGC 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCTGGTGCTGCT 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCAGGCCCTGCA 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGGGCTCCTGCA 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCAGCTGGACGT 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGCCCCTGCCCT 960 CAGCCCTAAT AA 972 918 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 118 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGAGGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGT 480 GACTTTAGCT TGGGAGAATGGAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCT 540 GGAGCAGTGA CCCTTCTGCTGGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCAC 600 TGCCTCTCAT CCCTCCTGGGGCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCT 660 CAGAGCCTCC TTGGAACCCAGCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCC 720 AATGCCATCT TCCTGAGCTTCCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCT 780 GTAGGAGGGT CCACCCTCTGCGTCAGGGAA TTCGGCGGCA ACATGGCGTC TCCCGCTCC 840 CCTGCTTGTG ACCTCCGAGTCCTCAGTAAA CTGCTTCGTG ACTCCCATGT CCTTCACAG 900 AGACTGAGCC AGTGCCCA 918918 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 119 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGACTTTAGCTT 480 GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGGAGCAGTGAC 540 CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTGCCTCTCATC 600 CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCAGAGCCTCCT 660 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAATGCCATCTT 720 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGTAGGAGGGTC 780 ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCCTGCTTGTGA 840 CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAGACTGAGCCA 900 TGCCCAGAGG TTCACCCT 918 918 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 120 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGTCCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAA 480 ACCCAGATGG AGGAGACCAAGGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGA 540 GGAGTGATGG CAGCACGGGGACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCA 600 CTTTCTGGAC AGGTCCGTCTCCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCT 660 CCTCCACAGG GCAGGACCACAGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCA 720 CACCTGCTCC GAGGAAAGGTGCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGT 780 AGGGAATTCG GCGGCAACATGGCGTCTCCC GCTCCGCCTG CTTGTGACCT CCGAGTCCT 840 AGTAAACTGC TTCGTGACTCCCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGT 900 CACCCTTTGC CTACACCT 918918 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 121 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAACCCAGATGGA 480 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGGAGTGATGGC 540 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCTTTCTGGACA 600 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCCTCCACAGGG 660 AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACACCTGCTCCG 720 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAGGGAATTCGG 780 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAGTAAACTGCT 840 CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCACCCTTTGCC 900 ACACCTGTCC TGCTGCCT 918 918 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 122 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGACTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGAC 480 AAGGCACAGG ACATTCTGGGAGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACG 540 GGACAACTGG GACCCACTTGCCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCG 600 CTCCTCCTTG GGGCCCTGCAGAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGAC 660 ACAGCTCACA AGGATCCCAATGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAA 720 GTGCGTTTCC TGATGCTTGTAGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAA 780 ATGGCGTCTC CCGCTCCGCCTGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGA 840 TCCCATGTCC TTCACAGCAGACTGAGCCAG TGCCCAGAGG TTCACCCTTT GCCTACACC 900 GTCCTGCTGC CTGCTGTG 918907 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 123 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGTGGAGGCTCC 360 CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTAAAGAATCTC 420 TAAACTCCAA ACATGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGCACAGGACAT 480 CTGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAACTGGGACCC 540 CTTGCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCCTTGGGGCCC 600 GCAGGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCACAAGGATCC 660 AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTCCTGATGCTT 720 TAGGGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTCCCGCTCCGC 780 TGCTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCTTCACAGCAG 840 CTGACCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCTGCTGTGGAC 900 TTAGTTG 907 918 base pairs nucleic acid single linearother nucleic acid /desc = “synthetic” 124 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGGACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGG 480 CAGGTCCGTC TCCTCCTTGGGGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACA 540 GGCAGGACCA CAGCTCACAAGGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCT 600 CGAGGAAAGG TGCGTTTCCTGATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATT 660 GGCGGCAACA TGGCGTCTCCCGCTCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACT 720 CTTCGTGACT CCCATGTCCTTCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCTTT 780 CCTACACCTG TCCTGCTGCCTGCTGTGGAC TTTAGCTTGG GAGAATGGAA AACCCAGAT 840 GAGGAGACCA AGGCACAGGACATTCTGGGA GCAGTGACCC TTCTGCTGGA GGGAGTGAT 900 GCAGCACGGG GACAACTG 918848 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 125 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCACAGCTCACAA 480 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGTGCGTTTCCT 540 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACATGGCGTCTCC 600 GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTCCCATGTCCT 660 CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGTCCTGCTGCC 720 GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAAGGCACAGGA 780 ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGGACAACTGGG 840 CCCACTTG 848 918 base pairs nucleic acid single linearother nucleic acid /desc = “synthetic” 126 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGGCAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCT 480 AGCTTCCAAC ACCTGCTCCGAGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCAC 540 CTCTGCGTCA GGGAATTCGGCGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCT 600 CGAGTCCTCA GTAAACTGCTTCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTG 660 CCAGAGGTTC ACCCTTTGCCTACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGG 720 GAATGGAAAA CCCAGATGGAGGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCT 780 CTGCTGGAGG GAGTGATGGCAGCACGGGGA CAACTGGGAC CCACTTGCCT CTCATCCCT 840 CTGGGGCAGC TTTCTGGACAGGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGG 900 ACCCAGCTTC CTCCACAG 918918 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 127 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAGCTTCCAACA 480 CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCTCTGCGTCAG 540 GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCGAGTCCTCAG 600 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCCAGAGGTTCA 660 CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGAATGGAAAAC 720 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCTGCTGGAGGG 780 GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCTGGGGCAGCT 840 TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAACCCAGCTTCC 900 CCACAGGGCA GGACCACA 918 918 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 128 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGATCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCG 480 GGAAAGGTGC GTTTCCTGATGCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGG 540 GGCAACATGG CGTCTCCCGCTCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCT 600 CGTGACTCCC ATGTCCTTCACAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCC 660 ACACCTGTCC TGCTGCCTGCTGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGA 720 GAGACCAAGG CACAGGACATTCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGC 780 GCACGGGGAC AACTGGGACCCACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACA 840 GTCCGTCTCC TCCTTGGGGCCCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGG 900 AGGACCACAG CTCACAAG 918918 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 129 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCGAGGAAAGGT 480 CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGGCGGCAACAT 540 GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCTTCGTGACTC 600 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCCTACACCTGT 660 CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGAGGAGACCAA 720 GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGCAGCACGGGG 780 CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACAGGTCCGTCT 840 CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGGCAGGACCAC 900 GCTCACAAGG ATCCCAAT 918 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 130 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGAGGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGT 480 GACTTTAGCT TGGGAGAATGGAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCT 540 GGAGCAGTGA CCCTTCTGCTGGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCAC 600 TGCCTCTCAT CCCTCCTGGGGCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCT 660 CAGAGCCTCC TTGGAACCCAGCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCC 720 AATGCCATCT TCCTGAGCTTCCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCT 780 GTAGGAGGGT CCACCCTCTGCGTCAGGGAA TTCGGCAACA TGGCGTCTCC CGCTCCGCC 840 GCTTGTGACC TCCGAGTCCTCAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAG 900 CTGAGCCAGT GCCCA 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 131 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGACTTTAGCTT 480 GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGGAGCAGTGAC 540 CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTGCCTCTCATC 600 CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCAGAGCCTCCT 660 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAATGCCATCTT 720 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGTAGGAGGGTC 780 ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGCTTGTGACCT 840 CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACTGAGCCAGTG 900 CCAGAGGTTC ACCCT 915 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 132 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGTCCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAA 480 ACCCAGATGG AGGAGACCAAGGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGA 540 GGAGTGATGG CAGCACGGGGACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCA 600 CTTTCTGGAC AGGTCCGTCTCCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCT 660 CCTCCACAGG GCAGGACCACAGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCA 720 CACCTGCTCC GAGGAAAGGTGCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGT 780 AGGGAATTCG GCAACATGGCGTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAG 840 AAACTGCTTC GTGACTCCCATGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCA 900 CCTTTGCCTA CACCT 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 133 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAACCCAGATGGA 480 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGGAGTGATGGC 540 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCTTTCTGGACA 600 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCCTCCACAGGG 660 AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACACCTGCTCCG 720 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAGGGAATTCGG 780 AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAAACTGCTTCG 840 GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCCTTTGCCTAC 900 CCTGTCCTGC TGCCT 915 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 134 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGACTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGAC 480 AAGGCACAGG ACATTCTGGGAGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACG 540 GGACAACTGG GACCCACTTGCCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCG 600 CTCCTCCTTG GGGCCCTGCAGAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGAC 660 ACAGCTCACA AGGATCCCAATGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAA 720 GTGCGTTTCC TGATGCTTGTAGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCAACAT 780 GCGTCTCCCG CTCCGCCTGCTTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTC 840 CATGTCCTTC ACAGCAGACTGAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGT 900 CTGCTGCCTG CTGTG 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 135 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAAGGCACAGGA 480 ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGGACAACTGGG 540 CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCTCCTCCTTGG 600 GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCACAGCTCACAA 660 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGTGCGTTTCCT 720 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGCGTCTCCCGC 780 CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCATGTCCTTCA 840 AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCTGCTGCCTGC 900 GTGGACTTTA GCTTG 915 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 136 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGGACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGG 480 CAGGTCCGTC TCCTCCTTGGGGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACA 540 GGCAGGACCA CAGCTCACAAGGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCT 600 CGAGGAAAGG TGCGTTTCCTGATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATT 660 GGCAACATGG CGTCTCCCGCTCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCT 720 CGTGACTCCC ATGTCCTTCACAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCC 780 ACACCTGTCC TGCTGCCTGCTGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGA 840 GAGACCAAGG CACAGGACATTCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGC 900 GCACGGGGAC AACTG 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 137 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCACAGCTCACAA 480 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGTGCGTTTCCT 540 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGCGTCTCCCGC 600 CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCATGTCCTTCA 660 AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCTGCTGCCTGC 720 GTGGACTTTA GCTTGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGCACAGGACAT 780 CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACAACTGGGACC 840 ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCTCCTTGGGGC 900 CTGCAGAGCC TCCTT 915 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 138 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGGCAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCT 480 AGCTTCCAAC ACCTGCTCCGAGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCAC 540 CTCTGCGTCA GGGAATTCGGCAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCG 600 GTCCTCAGTA AACTGCTTCGTGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCC 660 GAGGTTCACC CTTTGCCTACACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGA 720 TGGAAAACCC AGATGGAGGAGACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCT 780 CTGGAGGGAG TGATGGCAGCACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCT 840 GGGCAGCTTT CTGGACAGGTCCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAAC 900 CAGCTTCCTC CACAG 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 139 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAGCTTCCAACA 480 CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCTCTGCGTCAG 540 GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTGCTTGTG ACCTCCGAGTCCTCAGTAA 600 CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCAGAGGTTCACCC 660 TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATGGAAAACCCA 720 ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCTGGAGGGAGT 780 ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGGGCAGCTTTC 840 GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCAGCTTCCTCC 900 CAGGGCAGGA CCACA 915 915 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 140 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAGCTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAATCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAAGGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCAAGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCCAATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGATCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCG 480 GGAAAGGTGC GTTTCCTGATGCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGG 540 AACATGGCGT CTCCCGCTCCGCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCG 600 GACTCCCATG TCCTTCACAGCAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTAC 660 CCTGTCCTGC TGCCTGCTGTGGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGA 720 ACCAAGGCAC AGGACATTCTGGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGC 780 CGGGGACAAC TGGGACCCACTTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGT 840 CGTCTCCTCC TTGGGGCCCTGCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAG 900 ACCACAGCTC ACAAG 915 915base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 141 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCGAGGAAAGGT 480 CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGGCAACATGGC 540 TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCGTGACTCCCA 600 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTACACCTGTCCT 660 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGAGACCAAGGC 720 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGCACGGGGACA 780 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGTCCGTCTCCT 840 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAGGACCACAGC 900 CACAAGGATC CCAAT 915 921 base pairs nucleic acid singlelinear other nucleic acid /desc = “synthetic” 142 GCTAACTGCT CTATAATGATCGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCTCAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 GACTTCCAAA CCTGGAGAGCTTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGT 180 TGAGGCAATT CTTCGTAATCTCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTC 240 CATCCAATCA TCATCAAGGCAGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTA 300 TGGTTACCCT TGAGCAAGCGCAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCG 360 TAACCGTCTG GTCCAATCTCTACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAA 420 TCTCCAAACA TGGAGGTTCACCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTT 480 AGCTTGGGAG AATGGAAAACCCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGC 540 GTGACCCTTC TGCTGGAGGGAGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCT 600 TCATCCCTCC TGGGGCAGCTTTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAG 660 CTCCTTGGAA CCCAGCTTCCTCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGC 720 ATCTTCCTGA GCTTCCAACACCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGG 780 GGGTCCACCC TCTGCGTCAGGGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGC 840 CCGCCTGCTT GTGACCTCCGAGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCA 900 AGCAGACTGA GCCAGTGCCC A921 927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 143 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGACTTTAGCTT 480 GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGGAGCAGTGAC 540 CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTGCCTCTCATC 600 CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCAGAGCCTCCT 660 GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAATGCCATCTT 720 CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGTAGGAGGGTC 780 ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCCAGCGCCGCC 840 GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCTTCACAGCAG 900 CTGAGCCAGT GCCCAGAGGT TCACCCT 927 927 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 144 GCTAACTGCTCTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACCCGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAAACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAATTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAATCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTACCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAACCGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTCCAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAA 480 ACCCAGATGGAGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGA 540 GGAGTGATGGCAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCA 600 CTTTCTGGACAGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCT 660 CCTCCACAGGGCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCA 720 CACCTGCTCCGAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGT 780 AGGGAATTCGGCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCT 840 CGAGTCCTCAGTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTG 900 CCAGAGGTTCACCCTTTGCC TACACCT 927 927 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 145 GCTAACTGCT CTATAATGAT CGATGAAATTATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAAGACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGGGCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCATGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGACTGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAACAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACTATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGC TGTGGACTTTAGCTTGGGAG AATGGAAAAC CCAGATGGA 480 GAGACCAAGG CACAGGACAT TCTGGGAGCAGTGACCCTTC TGCTGGAGGG AGTGATGGC 540 GCACGGGGAC AACTGGGACC CACTTGCCTCTCATCCCTCC TGGGGCAGCT TTCTGGACA 600 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGCCTCCTTGGAA CCCAGCTTCC TCCACAGGG 660 AGGACCACAG CTCACAAGGA TCCCAATGCCATCTTCCTGA GCTTCCAACA CCTGCTCCG 720 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGAGGGTCCACCC TCTGCGTCAG GGAATTCGG 780 GGCAACGGCG GCAACATGGC GTCCCCAGCGCCGCCTGCTT GTGACCTCCG AGTCCTCAG 840 AAACTGCTTC GTGACTCCCA TGTCCTTCACAGCAGACTGA GCCAGTGCCC AGAGGTTCA 900 CCTTTGCCTA CACCTGTCCT GCTGCCT 927927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 146 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGATGGAGGAGAC 480 AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGATGGCAGCACG 540 GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGGACAGGTCCG 600 CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACAGGGCAGGAC 660 ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCTCCGAGGAAA 720 GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATTCGGCGGCAA 780 GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCTCAGTAAACT 840 CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGTTCACCCTTT 900 CCTACACCTG TCCTGCTGCC TGCTGTG 927 927 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 147 GCTAACTGCTCTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACCCGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAAACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAATTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAATCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTACCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAACCGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTCCAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGA 480 ATTCTGGGAGCAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGG 540 CCCACTTGCCTCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGG 600 GCCCTGCAGAGCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAA 660 GATCCCAATGCCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCT 720 ATGCTTGTAGGAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACAT 780 GCGTCCCCAGCGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTC 840 CATGTCCTTCACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGT 900 CTGCTGCCTGCTGTGGACTT TAGCTTG 927 927 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 148 GCTAACTGCT CTATAATGAT CGATGAAATTATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAAGACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGGGCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCATGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGACTGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAACAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACTATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGG ACCCACTTGCCTCTCATCCC TCCTGGGGCA GCTTTCTGG 480 CAGGTCCGTC TCCTCCTTGG GGCCCTGCAGAGCCTCCTTG GAACCCAGCT TCCTCCACA 540 GGCAGGACCA CAGCTCACAA GGATCCCAATGCCATCTTCC TGAGCTTCCA ACACCTGCT 600 CGAGGAAAGG TGCGTTTCCT GATGCTTGTAGGAGGGTCCA CCCTCTGCGT CAGGGAATT 660 GGCGGCAACG GCGGCAACAT GGCGTCCCCAGCGCCGCCTG CTTGTGACCT CCGAGTCCT 720 AGTAAACTGC TTCGTGACTC CCATGTCCTTCACAGCAGAC TGAGCCAGTG CCCAGAGGT 780 CACCCTTTGC CTACACCTGT CCTGCTGCCTGCTGTGGACT TTAGCTTGGG AGAATGGAA 840 ACCCAGATGG AGGAGACCAA GGCACAGGACATTCTGGGAG CAGTGACCCT TCTGCTGGA 900 GGAGTGATGG CAGCACGGGG ACAACTG 927927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 149 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCACAGCTCACAA 480 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGTGCGTTTCCT 540 ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGGCGGCAACAT 600 GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCTTCGTGACTC 660 CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCCTACACCTGT 720 CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGAGGAGACCAA 780 GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGCAGCACGGGG 840 CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACAGGTCCGTCT 900 CTCCTTGGGG CCCTGCAGAG CCTCCTT 927 927 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 150 GCTAACTGCTCTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACCCGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAAACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAATTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAATCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTACCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAACCGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTCCAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCT 480 AGCTTCCAACACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCAC 540 CTCTGCGTCAGGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GCCGCCTGC 600 TGTGACCTCCGAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACT 660 AGCCAGTGCCCAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTT 720 AGCTTGGGAGAATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGC 780 GTGACCCTTCTGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCT 840 TCATCCCTCCTGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAG 900 CTCCTTGGAACCCAGCTTCC TCCACAG 927 927 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 151 GCTAACTGCT CTATAATGAT CGATGAAATTATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAAGACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGGGCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCATGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGACTGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAACAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACTATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGC TCACAAGGATCCCAATGCCA TCTTCCTGAG CTTCCAACA 480 CTGCTCCGAG GAAAGGTGCG TTTCCTGATGCTTGTAGGAG GGTCCACCCT CTGCGTCAG 540 GAATTCGGCG GCAACGGCGG CAACATGGCGTCCCCAGCGC CGCCTGCTTG TGACCTCCG 600 GTCCTCAGTA AACTGCTTCG TGACTCCCATGTCCTTCACA GCAGACTGAG CCAGTGCCC 660 GAGGTTCACC CTTTGCCTAC ACCTGTCCTGCTGCCTGCTG TGGACTTTAG CTTGGGAGA 720 TGGAAAACCC AGATGGAGGA GACCAAGGCACAGGACATTC TGGGAGCAGT GACCCTTCT 780 CTGGAGGGAG TGATGGCAGC ACGGGGACAACTGGGACCCA CTTGCCTCTC ATCCCTCCT 840 GGGCAGCTTT CTGGACAGGT CCGTCTCCTCCTTGGGGCCC TGCAGAGCCT CCTTGGAAC 900 CAGCTTCCTC CACAGGGCAG GACCACA 927927 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 152 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAATC 420 CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACACCTGCTCCG 480 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAGGGAATTCGG 540 GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCGAGTCCTCAG 600 AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCCAGAGGTTCA 660 CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGAATGGAAAAC 720 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCTGCTGGAGGG 780 GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCTGGGGCAGCT 840 TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAACCCAGCTTCC 900 CCACAGGGCA GGACCACAGC TCACAAG 927 927 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 153 GCTAACTGCTCTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACCCGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAAACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAATTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAATCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTACCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAACCGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTCCAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGT 480 CGTTTCCTGATGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGG 540 GGCAACATGGCGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCT 600 CGTGACTCCCATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCC 660 ACACCTGTCCTGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGA 720 GAGACCAAGGCACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGC 780 GCACGGGGACAACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACA 840 GTCCGTCTCCTCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGG 900 AGGACCACAGCTCACAAGGA TCCCAAT 927 906 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 154 GCTAACTGCT CTATAATGAT CGATGAAATTATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAAGACGTCTCTA TCCTGATGGA CCGAAACCT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGGGCTGTCAAGA ACTTAGAAAA TGCATCAGG 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCATGTCTGCCCT CTGCCACGGC CGCACCCTC 240 CGACATCCAA TCATCATCAA GGCAGGTGACTGGCAAGAAT TCCGGGAAAA ACTGACGTT 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAACAACAGTACG TAGAGGGCGG TGGAGGCTC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACTATCAACCCGT CTCCTCCGTC TAAAGAATC 420 CATAAATCTC CAAACATGGA TCCCAATGCCATCTTCCTGA GCTTCCAACA CCTGCTCCG 480 GGAAAGGTGC GTTTCCTGAT GCTTGTAGGAGGGTCCACCC TCTGCGTCAG GGAATTCGG 540 GGCAACATGG CGTCTCCCGC TCCGCCTGCTTGTGACCTCC GAGTCCTCAG TAAACTGCT 600 CGTGACTCCC ATGTCCTTCA CAGCAGACTGAGCCAGTGCC CAGAGGTTCA CCCTTTGCC 660 ACACCTGTCC TGCTGCCTGC TGTGGACTTTAGCTTGGGAG AATGGAAAAC CCAGATGGA 720 GAGACCAAGG CACAGGACAT TCTGGGAGCAGTGACCCTTC TGCTGGAGGG AGTGATGGC 780 GCACGGGGAC AACTGGGACC CACTTGCCTCTCATCCCTCC TGGGGCAGCT TTCTGGACA 840 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGCCTCCTTGGAA CCCAGGGCAG GACCACAGC 900 CACAAG 906 993 base pairs nucleicacid single linear other nucleic acid /desc = “synthetic” 155 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTCCAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGGCAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATCCAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAATCTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCT 480 GGACACTCTCTGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCA 540 CTGGCAGGCTGCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCA 600 GCCCTGGAAGGGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGT 660 GCCGACTTTGCCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCT 720 CAGCCCACCCAGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGG 780 GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCA 840 CTTGCGCAGCCCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCT 900 CCCCAGAGCTTCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGC 960 GCGCTCCAGGAGAAGCTGTG TGCCACCTAA TAA 993 993 base pairs nucleic acid single linearother nucleic acid /desc = “synthetic” 156 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGTCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCT 480 GACGTCGCCG ACTTTGCCACCACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCC 540 GCCCTGCAGC CCACCCAGGGTGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGC 600 GGAGGGGTCC TGGTTGCTAGCCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCT 660 CGCCACCTTG CGCAGCCCGGCGGCGGCTCT GACATGGCTA CACCATTAGG CCCTGCCAG 720 TCCCTGCCCC AGAGCTTCCTGCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGA 780 GGCGCAGCGC TCCAGGAGAAGCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCT 840 GTGCTGCTCG GACACTCTCTGGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCA 900 GCCCTGCAGC TGGCAGGCTGCTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGG 960 CTCCTGCAGG CCCTGGAAGGGATATCCTAA TAA 993 993 base pairs nucleic acid single linear othernucleic acid /desc = “synthetic” 157 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTAAGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAACCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGTGACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAGGAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCTACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GTCTTCTGCTTTCCAGCGCC GGGCAGGAGG GGTCCTGGT 480 GCTAGCCATC TGCAGAGCTT CCTGGAGGTGTCGTACCGCG TTCTACGCCA CCTTGCGCA 540 CCCGGCGGCG GCTCTGACAT GGCTACACCATTAGGCCCTG CCAGCTCCCT GCCCCAGAG 600 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGGAAGATCCAGG GCGATGGCGC AGCGCTCCA 660 GAGAAGCTGT GTGCCACCTA CAAGCTGTGCCACCCCGAGG AGCTGGTGCT GCTCGGACA 720 TCTCTGGGCA TCCCCTGGGC TCCCCTGAGCTCCTGCCCCA GCCAGGCCCT GCAGCTGGC 780 GGCTGCTTGA GCCAACTCCA TAGCGGCCTTTTCCTCTACC AGGGGCTCCT GCAGGCCCT 840 GAAGGGATAT CCCCCGAGTT GGGTCCCACCTTGGACACAC TGCAGCTGGA CGTCGCCGA 900 TTTGCCACCA CCATCTGGCA GCAGATGGAAGAACTGGGAA TGGCCCCTGC CCTGCAGCC 960 ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA993 993 base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 158 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCAGGGTGCCAT 480 CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGCTAGCCATCT 540 CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCCCGGCGGCGG 600 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTTCCTGCTCAA 660 TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGAGAAGCTGTG 720 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTCTCTGGGCAT 780 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGGCTGCTTGAG 840 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGAAGGGATATC 900 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTTTGCCACCAC 960 ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA 993 993 base pairsnucleic acid single linear other nucleic acid /desc = “synthetic” 159ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTT 480CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTC 540TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATT 600GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAA 660ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCA 720CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTC 780TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTT 840CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTT 900GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGA 960CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 993 1027 base pairs nucleic acidsingle linear other nucleic acid /desc = “synthetic” 160 ATGGCTACACCATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 60 GAGCAAGTGAGGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCAC 120 TACAAGCTGTGCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTG 180 GCTCCCCTGAGCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACT 240 CATAGCGGCCTTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGA 300 TTGGGTCCCACCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTG 360 CAGCAGATGGAAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCC 420 GCCTTCGCCTCTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCA 480 AGCTTCCTGGAGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTC 540 GACATGGCTACACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTC 600 TTAGAGCAAGTGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGC 660 ACCTACAAGCTGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCC 720 TGGGCTCCCCTGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCA 780 CTCCATAGCGGCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCC 840 GAGTTGGGTCCCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCAT 900 TGGCAGCAGATGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TCCTGGTTG 960 TAGCCATCTGCAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAG 1020 CTGATAA 1027155 amino acids amino acid unknown unknown peptide 161 Ser Pro Ala ProPro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 1 5 10 15 Arg Asp Ser HisVal Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 20 25 30 His Pro Leu ProThr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 35 40 45 Gly Glu Trp LysThr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 50 55 60 Gly Ala Val ThrLeu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 65 70 75 80 Leu Gly ProThr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95 Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le 100 105 110 Pro ProGln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Ph 115 120 125 LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le 130 135 140Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 145 150 155 309 amino acidsamino acid unknown unknown peptide 162 Ser Pro Ala Pro Pro Ala Cys AspLeu Arg Val Leu Ser Lys Leu Le 1 5 10 15 Arg Asp Ser His Val Leu His SerArg Leu Ser Gln Cys Pro Glu Va 20 25 30 His Pro Leu Pro Thr Pro Val LeuLeu Pro Ala Val Asp Phe Ser Le 35 40 45 Gly Glu Trp Lys Thr Gln Met GluGlu Thr Lys Ala Gln Asp Ile Le 50 55 60 Gly Ala Val Thr Leu Leu Leu GluGly Val Met Ala Ala Arg Gly Gl 65 70 75 80 Leu Gly Pro Thr Cys Leu SerSer Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95 Val Arg Leu Leu Leu Gly AlaLeu Gln Ser Leu Leu Gly Thr Gln Le 100 105 110 Pro Pro Gln Gly Arg ThrThr Ala His Lys Asp Pro Asn Ala Ile Ph 115 120 125 Leu Ser Phe Gln HisLeu Leu Arg Gly Lys Val Arg Phe Leu Met Le 130 135 140 Val Gly Gly SerThr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Al 145 150 155 160 Ser ProAla Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 165 170 175 ArgAsp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 180 185 190His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 195 200205 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 210215 220 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu SerGly Gl 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu GlyThr Gln Gl 260 265 270 Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile PheLeu Ser Phe Gl 275 280 285 His Leu Leu Arg Gly Lys Val Arg Phe Leu MetLeu Val Gly Gly Se 290 295 300 Thr Leu Cys Val Arg 305 312 amino acidsamino acid unknown unknown peptide 163 Ser Pro Ala Pro Pro Ala Cys AspLeu Arg Val Leu Ser Lys Leu Le 1 5 10 15 Arg Asp Ser His Val Leu His SerArg Leu Ser Gln Cys Pro Glu Va 20 25 30 His Pro Leu Pro Thr Pro Val LeuLeu Pro Ala Val Asp Phe Ser Le 35 40 45 Gly Glu Trp Lys Thr Gln Met GluGlu Thr Lys Ala Gln Asp Ile Le 50 55 60 Gly Ala Val Thr Leu Leu Leu GluGly Val Met Ala Ala Arg Gly Gl 65 70 75 80 Leu Gly Pro Thr Cys Leu SerSer Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95 Val Arg Leu Leu Leu Gly AlaLeu Gln Ser Leu Leu Gly Thr Gln Le 100 105 110 Pro Pro Gln Gly Arg ThrThr Ala His Lys Asp Pro Asn Ala Ile Ph 115 120 125 Leu Ser Phe Gln HisLeu Leu Arg Gly Lys Val Arg Phe Leu Met Le 130 135 140 Val Gly Gly SerThr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Se 145 150 155 160 Pro AlaPro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Ar 165 170 175 AspSer His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val Hi 180 185 190Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gl 195 200205 Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gl 210215 220 Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Le225 230 235 240 Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser GlyGln Va 245 250 255 Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly ThrGln Leu Pr 260 265 270 Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro AsnAla Ile Phe Le 275 280 285 Ser Phe Gln His Leu Leu Arg Gly Lys Val ArgPhe Leu Met Leu Va 290 295 300 Gly Gly Ser Thr Leu Cys Val Arg 305 310313 amino acids amino acid unknown unknown peptide 164 Ser Pro Ala ProPro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 1 5 10 15 Arg Asp Ser HisVal Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 20 25 30 His Pro Leu ProThr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 35 40 45 Gly Glu Trp LysThr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 50 55 60 Gly Ala Val ThrLeu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 65 70 75 80 Leu Gly ProThr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95 Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le 100 105 110 Pro ProGln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Ph 115 120 125 LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le 130 135 140Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Al 145 150155 160 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le165 170 175 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro GluVa 180 185 190 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp PheSer Le 195 200 205 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala GlnAsp Ile Le 210 215 220 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met AlaAla Arg Gly Gl 225 230 235 240 Leu Gly Pro Thr Cys Leu Ser Ser Leu LeuGly Gln Leu Ser Gly Gl 245 250 255 Val Arg Leu Leu Leu Gly Ala Leu GlnSer Leu Leu Gly Thr Gln Le 260 265 270 Pro Pro Gln Gly Arg Thr Thr AlaHis Lys Asp Pro Asn Ala Ile Ph 275 280 285 Leu Ser Phe Gln His Leu LeuArg Gly Lys Val Arg Phe Leu Met Le 290 295 300 Val Gly Gly Ser Thr LeuCys Val Arg 305 310 316 amino acids amino acid unknown unknown peptide165 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 1 510 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 2025 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 3540 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 5055 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 6570 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le100 105 110 Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala IlePh 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe LeuMet Le 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly GlyAsn Gly Gl 145 150 155 160 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys AspLeu Arg Val Leu Se 165 170 175 Lys Leu Leu Arg Asp Ser His Val Leu HisSer Arg Leu Ser Gln Cy 180 185 190 Pro Glu Val His Pro Leu Pro Thr ProVal Leu Leu Pro Ala Val As 195 200 205 Phe Ser Leu Gly Glu Trp Lys ThrGln Met Glu Glu Thr Lys Ala Gl 210 215 220 Asp Ile Leu Gly Ala Val ThrLeu Leu Leu Glu Gly Val Met Ala Al 225 230 235 240 Arg Gly Gln Leu GlyPro Thr Cys Leu Ser Ser Leu Leu Gly Gln Le 245 250 255 Ser Gly Gln ValArg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gl 260 265 270 Thr Gln LeuPro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro As 275 280 285 Ala IlePhe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Ph 290 295 300 LeuMet Leu Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 315 302 amino acidsamino acid unknown unknown peptide 166 Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu ArgLeu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly GlySer Pro Gly Gly Gly Ser Gly Gly Gly Se 115 120 125 Asn Met Ala Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gl 130 135 140 His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl 145 150 155 160 Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph 165 170 175 LeuTyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le 180 185 190Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th 195 200205 Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl 210215 220 Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar225 230 235 240 Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe LeuGlu Va 245 250 255 Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser GlyGly Ser Gl 260 265 270 Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Il 275 280 285 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys LeuCys Ala Thr 290 295 300 317 amino acids amino acid unknown unknownpeptide 167 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSe 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVa 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLe 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerAr 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe ArgGlu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPro Ile Se 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Ser Pro As 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly Hi 145 150 155 160 Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys Pro Ser Gln Al 165 170 175 Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Le 180 185 190 Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gl 195 200 205 Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Th 210 215 220 Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr 225 230 235 240 Thr Gln GlyAla Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al 245 250 255 Gly GlyVal Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Se 260 265 270 TyrArg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gl 275 280 285Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl 290 295300 Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 305 310 315 302amino acids amino acid unknown unknown peptide 168 Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu GlyGly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Se 115 120 125 Asn MetAla Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As 130 135 140 ValAla Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl 145 150 155160 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al 165170 175 Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Le180 185 190 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGl 195 200 205 Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu LysSer Le 210 215 220 Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Ly 225 230 235 240 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Le 245 250 255 Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Se 260 265 270 Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Le 275 280 285 Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser 290 295 300 317 amino acids amino acid unknownunknown peptide 169 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Se 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro As 130 135 140 Met Ala Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Va 145 150 155 160 Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly Me 165 170 175 Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Se 180 185 190 Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gl 195 200 205 Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr 210 215 220 Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Gl 225 230 235 240 GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le 245 250 255Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl 260 265270 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl 275280 285 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph290 295 300 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser 305 310315 302 amino acids amino acid unknown unknown peptide 170 Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 ValGlu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Se 115 120 125Asn Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pr 130 135140 Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Al 145150 155 160 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHi 165 170 175 Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser PheLeu Le 180 185 190 Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Le 195 200 205 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Le 210 215 220 Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Se 225 230 235 240 Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu Hi 245 250 255 Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Il 260 265 270 Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Al 275 280 285 Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Leu Gly 290 295 300 317 amino acids amino acidunknown unknown peptide 171 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Se 115 120 125 Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Ser Pro As 130 135 140 Met Ala Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Al 145 150 155 160 Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Se 165 170 175 His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Le 180 185 190 Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly 195 200 205 Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gl 210 215 220 GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Va 225 230 235240 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cy 245250 255 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Se260 265 270 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly IleSe 275 280 285 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla As 290 295 300 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly305 310 315 302 amino acids amino acid unknown unknown peptide 172 AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Se 115120 125 Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl130 135 140 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLe 145 150 155 160 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gl 165 170 175 Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGlu Gln Val Ar 180 185 190 Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Th 195 200 205 Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Le 210 215 220 Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gl 225 230 235 240 Leu Ala Gly Cys Leu Ser GlnLeu His Ser Gly Leu Phe Leu Tyr Gl 245 250 255 Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Th 260 265 270 Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr 275 280 285 Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro 290 295 300 317 amino acidsamino acid unknown unknown peptide 173 Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu ArgLeu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly GlySer Pro Gly Glu Pro Ser Gly Pro Ile Se 115 120 125 Thr Ile Asn Pro SerPro Pro Ser Lys Glu Ser His Lys Ser Pro As 130 135 140 Met Ala Thr GlnGly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Ar 145 150 155 160 Arg AlaGly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Gl 165 170 175 ValSer Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Se 180 185 190Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly 195 200205 Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty 210215 220 Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl225 230 235 240 Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Le 245 250 255 Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gl 260 265 270 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu LeuGly Pro Thr Le 275 280 285 Asp Thr Leu Gln Leu Asp Val Ala Asp Phe AlaThr Thr Ile Trp Gl 290 295 300 Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pro 305 310 315 302 amino acids amino acid unknown unknownpeptide 174 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSe 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVa 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLe 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerAr 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe ArgGlu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser GlyGly Gly Se 115 120 125 Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Leu Val Al 130 135 140 Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg Hi 145 150 155 160 Leu Ala Gln Pro Ser Gly Gly Ser GlyGly Ser Gln Ser Phe Leu Le 165 170 175 Lys Ser Leu Glu Gln Val Arg LysIle Gln Gly Asp Gly Ala Ala Le 180 185 190 Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Le 195 200 205 Val Leu Leu Gly His SerLeu Gly Ile Pro Trp Ala Pro Leu Ser Se 210 215 220 Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu Hi 225 230 235 240 Ser Gly LeuPhe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Il 245 250 255 Ser ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Al 260 265 270 AspPhe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Al 275 280 285Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala 290 295 300 317amino acids amino acid unknown unknown peptide 175 Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Se 115 120 125 Thr IleAsn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro As 130 135 140 MetAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Se 145 150 155160 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Le 165170 175 Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Ly180 185 190 Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGl 195 200 205 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Va 210 215 220 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cy 225 230 235 240 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Se 245 250 255 Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Se 260 265 270 Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala As 275 280 285 Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pr 290 295 300 Ala Leu Gln Pro Thr Gln GlyAla Met Pro Ala Phe Ala 305 310 315 305 amino acids amino acid unknownunknown peptide 176 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly GlySer Gly Gly Gly Se 115 120 125 Asn Met Ala Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gl 130 135 140 His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gl 145 150 155 160 Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Ph 165 170 175 Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Ser Pro Glu Le 180 185 190 Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Th 195 200 205 Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl 210 215 220 Pro Thr GlnGly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Ar 225 230 235 240 AlaGly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Va 245 250 255Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pr 260 265270 Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va 275280 285 Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al290 295 300 Thr 305 320 amino acids amino acid unknown unknown peptide177 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pr 1 510 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 2025 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 3540 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 5055 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 6570 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro IleSe 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys SerPro As 130 135 140 Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly Hi 145 150 155 160 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Al 165 170 175 Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Le 180 185 190 Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gl 195 200 205 Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Th 210 215 220 Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pr 225 230 235 240 Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al 245 250 255 Gly Gly Val LeuVal Ala Ser His Leu Gln Ser Phe Leu Glu Val Se 260 265 270 Tyr Arg ValLeu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Al 275 280 285 Ser SerLeu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Ar 290 295 300 LysIle Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Th 305 310 315320 305 amino acids amino acid unknown unknown peptide 178 Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 ValGlu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Se 115 120 125Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As 130 135140 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl 145150 155 160 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAl 165 170 175 Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Le 180 185 190 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gl 195 200 205 Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Le 210 215 220 Lys Ser Leu Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Le 225 230 235 240 Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Le 245 250 255 Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Se 260 265 270 Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu Hi 275 280 285 Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Il 290 295 300 Ser 305 320 aminoacids amino acid unknown unknown peptide 179 Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn LeuArg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu GluAsn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys LeuPro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile LysAla Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu ValThr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly GlyGly Ser Pro Gly Glu Pro Ser Gly Pro Ile Se 115 120 125 Thr Ile Asn ProSer Pro Pro Ser Lys Glu Ser His Lys Ser Pro As 130 135 140 Met Ala ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va 145 150 155 160 AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me 165 170 175Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se 180 185190 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gl 195200 205 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr210 215 220 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLy 225 230 235 240 Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly AlaAla Leu Gl 245 250 255 Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His ProGlu Glu Leu Va 260 265 270 Leu Leu Gly His Ser Leu Gly Ile Pro Trp AlaPro Leu Ser Ser Cy 275 280 285 Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Se 290 295 300 Gly Leu Phe Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Se 305 310 315 320 305 amino acids amino acidunknown unknown peptide 180 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro GlyGly Gly Ser Gly Gly Gly Se 115 120 125 Asn Met Ala Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pr 130 135 140 Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Al 145 150 155 160 Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg Hi 165 170 175 Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se 180 185 190 Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl 195 200 205 Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr 210 215 220 GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr 225 230 235240 Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Se 245250 255 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Le260 265 270 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu GlnLe 275 280 285 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Le 290 295 300 Gly 305 320 amino acids amino acid unknown unknownpeptide 181 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys ArgPr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSe 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVa 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLe 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerAr 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe ArgGlu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPro Ile Se 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Ser Pro As 130 135 140 Met Ala Met Ala Pro Ala Leu Gln Pro Thr GlnGly Ala Met Pro Al 145 150 155 160 Phe Ala Ser Ala Phe Gln Arg Arg AlaGly Gly Val Leu Val Ala Se 165 170 175 His Leu Gln Ser Phe Leu Glu ValSer Tyr Arg Val Leu Arg His Le 180 185 190 Ala Gln Pro Thr Pro Leu GlyPro Ala Ser Ser Leu Pro Gln Ser Ph 195 200 205 Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Al 210 215 220 Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl 225 230 235 240 Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le 245 250 255 Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl 260 265 270 LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl 275 280 285Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As 290 295300 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl 305310 315 320 305 amino acids amino acid unknown unknown peptide 182 AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105110 Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Se 115120 125 Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gl130 135 140 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser PheLe 145 150 155 160 Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProThr Pro Le 165 170 175 Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Gl 180 185 190 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Le 195 200 205 Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gl 210 215 220 His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gl 225 230 235 240 Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Ph 245 250 255 Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Ser Pro Glu Le 260 265 270 Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Th 275 280 285 Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl 290 295 300 Pro 305 320amino acids amino acid unknown unknown peptide 183 Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Se 115 120 125 Thr IleAsn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro As 130 135 140 MetAla Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Ar 145 150 155160 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Gl 165170 175 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gl180 185 190 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu GluGl 195 200 205 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cy 210 215 220 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly Hi 225 230 235 240 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Ser Gln Al 245 250 255 Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Le 260 265 270 Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gl 275 280 285 Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Th 290 295 300 Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pr 305 310 315 320 305 amino acids aminoacid unknown unknown peptide 184 Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Asp Glu Asp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser ProGly Gly Gly Ser Gly Gly Gly Se 115 120 125 Asn Met Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Al 130 135 140 Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Arg Val Leu Arg Hi 145 150 155 160 Leu Ala Gln ProThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Se 165 170 175 Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gl 180 185 190 Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pr 195 200 205 GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr 210 215 220Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Se 225 230235 240 Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Le245 250 255 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu GlnLe 260 265 270 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Le 275 280 285 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala MetPro Ala Ph 290 295 300 Ala 305 320 amino acids amino acid unknownunknown peptide 185 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pr 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Se 20 25 30 Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Va 35 40 45 Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Le 50 55 60 Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Ar 65 70 75 80 His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Ly 85 90 95 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gln Gln Ty 100 105 110 Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Se 115 120 125 Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Ser Pro As 130 135 140 Met Ala Ser Ala Phe Gln Arg Arg AlaGly Gly Val Leu Val Ala Se 145 150 155 160 His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Le 165 170 175 Ala Gln Pro Thr Pro LeuGly Pro Ala Ser Ser Leu Pro Gln Ser Ph 180 185 190 Leu Leu Lys Ser LeuGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Al 195 200 205 Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Gl 210 215 220 Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Le 225 230 235 240 SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gl 245 250 255Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Gl 260 265270 Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu As 275280 285 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl290 295 300 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAl 305 310 315 320 321 amino acids amino acid unknown unknown peptide186 Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met As 1 510 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly 2025 30 Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gl 3540 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Il 5055 60 Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Ty 6570 75 80 Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser As85 90 95 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pr100 105 110 Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSe 115 120 125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer Hi 130 135 140 Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Se 145 150 155 160 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gl 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pr 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln SerPhe Leu Leu Lys Ser Leu Gl 195 200 205 Gln Val Arg Lys Ile Gln Gly AspGly Ala Ala Leu Gln Glu Lys Le 210 215 220 Cys Ala Thr Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gl 225 230 235 240 His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gl 245 250 255 Ala Leu Gln LeuAla Gly Cys Leu Ser Gln Leu His Ser Gly Leu Ph 260 265 270 Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Le 275 280 285 Gly ProThr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Th 290 295 300 ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl 305 310 315320 Pro 321 amino acids amino acid unknown unknown peptide 187 Asn AlaSer Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Le 1 5 10 15 Pro SerAla Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Al 20 25 30 Gly AspTrp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th 35 40 45 Leu GluGln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Il 50 55 60 Met IleAsp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Le 65 70 75 80 LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met As 85 90 95 ArgAsn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Ly 100 105 110Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Se 115 120125 Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser Hi 130135 140 Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Se145 150 155 160 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gl 165 170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pr 180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu LeuLys Ser Leu Gl 195 200 205 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Le 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gl 225 230 235 240 His Ser Leu Gly Ile Pro Trp AlaPro Leu Ser Ser Cys Pro Ser Gl 245 250 255 Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Ph 260 265 270 Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Ser Pro Glu Le 275 280 285 Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Th 290 295 300 Thr Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gl 305 310 315 320 Pro 321amino acids amino acid unknown unknown peptide 188 Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Gl 1 5 10 15 Phe Arg Glu Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gl 20 25 30 Glu Gln Gln Gly GlyGly Ser Asn Cys Ser Ile Met Ile Asp Glu Il 35 40 45 Ile His His Leu LysArg Pro Pro Ala Pro Leu Leu Asp Pro Asn As 50 55 60 Leu Asn Asp Glu AspVal Ser Ile Leu Met Asp Arg Asn Leu Arg Le 65 70 75 80 Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Al 85 90 95 Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Se 100 105 110 Ala Thr AlaTyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Se 115 120 125 Gly ProIle Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser Hi 130 135 140 LysSer Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Se 145 150 155160 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gl 165170 175 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr180 185 190 Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser LeuGl 195 200 205 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Le 210 215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gl 225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu SerSer Cys Pro Ser Gl 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser GlnLeu His Ser Gly Leu Ph 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Le 275 280 285 Gly Pro Thr Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala Th 290 295 300 Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gl 305 310 315 320 Pro 321 amino acidsamino acid unknown unknown peptide 189 Ala Gly Asp Trp Gln Glu Phe ArgGlu Lys Leu Thr Phe Tyr Leu Va 1 5 10 15 Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Asn Cys Se 20 25 30 Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg Pro Pro Ala Pr 35 40 45 Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu Asp Val Ser Ile Leu Me 50 55 60 Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Va 65 70 75 80 Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Ile Leu Arg Asn Le 85 90 95 Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Ser Arg His Pro Il 100 105 110 Ile Ile Lys Tyr Val GluGly Gly Gly Gly Ser Pro Gly Glu Pro Se 115 120 125 Gly Pro Ile Ser ThrIle Asn Pro Ser Pro Pro Ser Lys Glu Ser Hi 130 135 140 Lys Ser Pro AsnMet Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Se 145 150 155 160 Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gl 165 170 175 SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pr 180 185 190Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Gl 195 200205 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le 210215 220 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl225 230 235 240 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gl 245 250 255 Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His SerGly Leu Ph 260 265 270 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly IleSer Pro Glu Le 275 280 285 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Th 290 295 300 Thr Ile Trp Gln Gln Met Glu Glu Leu GlyMet Ala Pro Ala Leu Gl 305 310 315 320 Pro 329 amino acids amino acidunknown unknown peptide 190 Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met As 1 5 10 15 Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Ly 20 25 30 Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gl 35 40 45 Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerArg His Pro Ile Il 50 55 60 Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Ty 65 70 75 80 Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln Gly Gly Gly Ser Gl 85 90 95 Gly Gly Ser Gly Gly Gly Ser Asn Cys SerIle Met Ile Asp Glu Il 100 105 110 Ile His His Leu Lys Arg Pro Pro AlaPro Leu Tyr Val Glu Gly Gl 115 120 125 Gly Gly Ser Pro Gly Glu Pro SerGly Pro Ile Ser Thr Ile Asn Pr 130 135 140 Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Thr Gl 145 150 155 160 Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl 165 170 175 Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar 180 185 190 Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gl 195 200 205 Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly As 210 215 220 GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Hi 225 230 235240 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Al 245250 255 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le260 265 270 Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAl 275 280 285 Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gl 290 295 300 Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Gl 305 310 315 320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 329amino acids amino acid unknown unknown peptide 191 Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Le 1 5 10 15 Pro Ser Ala Thr AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Al 20 25 30 Gly Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Th 35 40 45 Leu Glu Gln Ala GlnGlu Gln Gln Gly Gly Gly Ser Gly Gly Gly Se 50 55 60 Gly Gly Gly Ser AsnCys Ser Ile Met Ile Asp Glu Ile Ile His Hi 65 70 75 80 Leu Lys Arg ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn As 85 90 95 Glu Asp Val SerIle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Le 100 105 110 Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gl 115 120 125 Gly GlySer Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pr 130 135 140 SerPro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gl 145 150 155160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl 165170 175 Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar180 185 190 Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGl 195 200 205 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile GlnGly As 210 215 220 Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys Hi 225 230 235 240 Pro Glu Glu Leu Val Leu Leu Gly His Ser LeuGly Ile Pro Trp Al 245 250 255 Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Le 260 265 270 Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu Leu Gln Al 275 280 285 Leu Glu Gly Ile Ser Pro Glu LeuGly Pro Thr Leu Asp Thr Leu Gl 290 295 300 Leu Asp Val Ala Asp Phe AlaThr Thr Ile Trp Gln Gln Met Glu Gl 305 310 315 320 Leu Gly Met Ala ProAla Leu Gln Pro 325 329 amino acids amino acid unknown unknown peptide192 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Gl 1 510 15 Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gl 2025 30 Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser As 3540 45 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pr 5055 60 Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Il 6570 75 80 Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Ar85 90 95 Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Ar100 105 110 Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu GlyGl 115 120 125 Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr IleAsn Pr 130 135 140 Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn MetAla Thr Gl 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gl 165 170 175 Val Leu Val Ala Ser His Leu Gln Ser PheLeu Glu Val Ser Tyr Ar 180 185 190 Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gl 195 200 205 Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly As 210 215 220 Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys Hi 225 230 235 240 Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Al 245 250 255 Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le 260 265 270 Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al 275 280 285 Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl 290 295 300 LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl 305 310 315320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 299 amino acids amino acidunknown unknown peptide 193 Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser IleMet Ile Asp Glu Il 1 5 10 15 Ile His His Leu Lys Arg Pro Pro Ala Pro LeuLeu Asp Pro Asn As 20 25 30 Leu Asn Asp Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Le 35 40 45 Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Asn Al 50 55 60 Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu GlnPro Cys Leu Pro Se 65 70 75 80 Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Tyr Val Gl 85 90 95 Gly Gly Gly Gly Ser Pro Gly Glu Pro SerGly Pro Ile Ser Thr Il 100 105 110 Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Al 115 120 125 Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Al 130 135 140 Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Phe Leu Glu Val Se 145 150 155 160 Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gl 165 170 175 Ser Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl 180 185 190 Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le 195 200 205 Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr 210 215 220 TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl 225 230 235240 Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le 245250 255 Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th260 265 270 Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMe 275 280 285 Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 290 295 329amino acids amino acid unknown unknown peptide 194 Met Ala Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile SerThr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 ProAsn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Le 145 150 155160 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se 165170 175 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le180 185 190 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser ProGl 195 200 205 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala AspPhe Al 210 215 220 Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Le 225 230 235 240 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe AlaSer Ala Phe Gln Ar 245 250 255 Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Gl 260 265 270 Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pro Gly Gly Gly Se 275 280 285 Asp Met Ala Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Ph 290 295 300 Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Al 305 310 315 320 Ala Leu Gln Glu LysLeu Cys Ala Thr 325 329 amino acids amino acid unknown unknown peptide195 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Ly 1 510 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 2025 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 3540 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 5055 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 6570 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Se 130 135 140 Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Le 145 150 155 160 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Le 165 170 175 Gly Met Ala Pro Ala Leu Gln Pro Thr GlnGly Ala Met Pro Ala Ph 180 185 190 Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser Hi 195 200 205 Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg His Leu Al 210 215 220 Gln Pro Gly Gly Gly Ser AspMet Ala Thr Pro Leu Gly Pro Ala Se 225 230 235 240 Ser Leu Pro Gln SerPhe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly 245 250 255 Ile Gln Gly AspGly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty 260 265 270 Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl 275 280 285 Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le 290 295 300 AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl 305 310 315320 Leu Leu Gln Ala Leu Glu Gly Ile Ser 325 329 amino acids amino acidunknown unknown peptide 196 Met Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Va 145 150 155 160 Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Ar 165 170 175 His Leu Ala GlnPro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gl 180 185 190 Pro Ala SerSer Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gl 195 200 205 Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cy 210 215 220 AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly Hi 225 230 235240 Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Al 245250 255 Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le260 265 270 Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu LeuGl 275 280 285 Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe AlaThr Th 290 295 300 Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pr 305 310 315 320 Thr Gln Gly Ala Met Pro Ala Phe Ala 325 329amino acids amino acid unknown unknown peptide 197 Met Ala Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile SerThr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 ProAsn Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Me 145 150 155160 Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Va 165170 175 Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Ar180 185 190 His Leu Ala Gln Pro Gly Gly Gly Ser Asp Met Ala Thr Pro LeuGl 195 200 205 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser LeuGlu Gl 210 215 220 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cy 225 230 235 240 Ala Thr Tyr Lys Leu Cys His Pro Glu Glu LeuVal Leu Leu Gly Hi 245 250 255 Ser Leu Gly Ile Pro Trp Ala Pro Leu SerSer Cys Pro Ser Gln Al 260 265 270 Leu Gln Leu Ala Gly Cys Leu Ser GlnLeu His Ser Gly Leu Phe Le 275 280 285 Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gl 290 295 300 Pro Thr Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala Thr Th 305 310 315 320 Ile Trp Gln Gln MetGlu Glu Leu Gly 325 329 amino acids amino acid unknown unknown peptide198 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Ly 1 510 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 2025 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 3540 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 5055 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 6570 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Se 130 135 140 Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe AlaSer Ala Ph 145 150 155 160 Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Ph 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln Pro Gly Gl 180 185 190 Gly Ser Asp Met Ala Thr Pro Leu GlyPro Ala Ser Ser Leu Pro Gl 195 200 205 Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly As 210 215 220 Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys Hi 225 230 235 240 Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Al 245 250 255 Pro Leu Ser SerCys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Le 260 265 270 Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Al 275 280 285 Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gl 290 295 300 LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Gl 305 310 315320 Leu Gly Met Ala Pro Ala Leu Gln Pro 325 319 amino acids amino acidunknown unknown peptide 199 Met Ala Asn Cys Ser Asn Met Ile Asp Glu IleIle Thr His Leu Ly 1 5 10 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn AsnLeu Asn Gly Glu As 20 25 30 Gln Asp Ile Leu Met Asp Asn Asn Leu Arg ArgPro Asn Leu Glu Al 35 40 45 Phe Asn Arg Ala Val Lys Ser Leu Gln Asn AlaSer Ala Ile Glu Se 50 55 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro LeuAla Thr Ala Ala Pr 65 70 75 80 Thr Arg His Pro Ile His Ile Lys Asp GlyAsp Trp Asn Glu Phe Ar 85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr LeuGlu Asn Ala Gln Ala Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Thr Gln GlyAla Met Pro Ala Phe Ala Ser Ala Ph 145 150 155 160 Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His Leu Gln Ser Ph 165 170 175 Leu Glu Val SerTyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gl 180 185 190 Gly Ser GlyGly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Va 195 200 205 Arg LysIle Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al 210 215 220 ThrTyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Se 225 230 235240 Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Le 245250 255 Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Ty260 265 270 Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPr 275 280 285 Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Il 290 295 300 Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro 305 310 315 322 amino acids amino acid unknown unknown peptide200 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Ly 1 510 15 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu As 2025 30 Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Al 3540 45 Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Se 5055 60 Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pr 6570 75 80 Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Ar85 90 95 Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gl100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Se 130 135 140 Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe AlaSer Ala Ph 145 150 155 160 Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Ph 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln Pro Thr Pr 180 185 190 Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Le 195 200 205 Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Ly 210 215 220 Leu Cys Ala Thr Tyr Lys LeuCys His Pro Glu Glu Leu Val Leu Le 225 230 235 240 Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Se 245 250 255 Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le 260 265 270 Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl 275 280 285 Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al 290 295 300 ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le 305 310 315320 Gln Pro 319 amino acids amino acid unknown unknown peptide 201 MetAla Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Ly 1 5 10 15 GlnPro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu As 20 25 30 GlnAsp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Al 35 40 45 PheAsn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Se 50 55 60 IleLeu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pr 65 70 75 80Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Ar 85 90 95Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gl 100 105110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se130 135 140 Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser AlaPh 145 150 155 160 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His LeuGln Ser Ph 165 170 175 Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Ser Gl 180 185 190 Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu LysSer Leu Glu Gln Va 195 200 205 Arg Lys Ile Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Al 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Se 225 230 235 240 Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Le 245 250 255 Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Ty 260 265 270 Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pr 275 280 285 Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Il 290 295 300 Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 305 310 315 322 aminoacids amino acid unknown unknown peptide 202 Met Ala Asn Cys Ser Asn MetIle Asp Glu Ile Ile Thr His Leu Ly 1 5 10 15 Gln Pro Pro Leu Pro Leu LeuAsp Phe Asn Asn Leu Asn Gly Glu As 20 25 30 Gln Asp Ile Leu Met Asp AsnAsn Leu Arg Arg Pro Asn Leu Glu Al 35 40 45 Phe Asn Arg Ala Val Lys SerLeu Gln Asn Ala Ser Ala Ile Glu Se 50 55 60 Ile Leu Lys Asn Leu Leu ProCys Leu Pro Leu Ala Thr Ala Ala Pr 65 70 75 80 Thr Arg His Pro Ile HisIle Lys Asp Gly Asp Trp Asn Glu Phe Ar 85 90 95 Arg Lys Leu Thr Phe TyrLeu Lys Thr Leu Glu Asn Ala Gln Ala Gl 100 105 110 Gln Tyr Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr IleAsn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn MetAla Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Ph 145 150 155 160 GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Ph 165 170 175Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pr 180 185190 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le 195200 205 Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLe 225 230 235 240 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser SerCys Pro Se 245 250 255 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Le 260 265 270 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Gl 275 280 285 Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Al 290 295 300 Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Le 305 310 315 320 Gln Pro 306 amino acids aminoacid unknown unknown peptide 203 Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met Glu Val His ProLeu Pro Thr Pro Val Leu Leu Pro Ala Va 145 150 155 160 Asp Phe Ser LeuGly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al 165 170 175 Gln Asp IleLeu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Al 180 185 190 Ala ArgGly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl 195 200 205 LeuSer Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le 210 215 220Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pr 225 230235 240 Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu PheGl 260 265 270 Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu ArgVal Le 275 280 285 Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser ArgLeu Ser Gl 290 295 300 Cys Pro 305 306 amino acids amino acid unknownunknown peptide 204 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly GluPro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pr 130 135 140 Asn Met Leu Pro Thr Pro Val Leu LeuPro Ala Val Asp Phe Ser Le 145 150 155 160 Gly Glu Trp Lys Thr Gln MetGlu Glu Thr Lys Ala Gln Asp Ile Le 165 170 175 Gly Ala Val Thr Leu LeuLeu Glu Gly Val Met Ala Ala Arg Gly Gl 180 185 190 Leu Gly Pro Thr CysLeu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 195 200 205 Val Arg Leu LeuLeu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le 210 215 220 Pro Pro GlnGly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Ph 225 230 235 240 LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le 245 250 255Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Al 260 265270 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 275280 285 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va290 295 300 His Pro 305 306 amino acids amino acid unknown unknownpeptide 205 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysAr 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVa 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPh 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIl 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSe 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro SerGly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pr 130 135 140 Asn Met Val Leu Leu Pro Ala Val Asp Phe SerLeu Gly Glu Trp Ly 145 150 155 160 Thr Gln Met Glu Glu Thr Lys Ala GlnAsp Ile Leu Gly Ala Val Th 165 170 175 Leu Leu Leu Glu Gly Val Met AlaAla Arg Gly Gln Leu Gly Pro Th 180 185 190 Cys Leu Ser Ser Leu Leu GlyGln Leu Ser Gly Gln Val Arg Leu Le 195 200 205 Leu Gly Ala Leu Gln SerLeu Leu Gly Thr Gln Leu Pro Pro Gln Gl 210 215 220 Arg Thr Thr Ala HisLys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gl 225 230 235 240 His Leu LeuArg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Se 245 250 255 Thr LeuCys Val Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pr 260 265 270 ProAla Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser Hi 275 280 285Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pr 290 295300 Thr Pro 305 306 amino acids amino acid unknown unknown peptide 206Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 7580 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 9095 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys SerPr 130 135 140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr GlnMet Gl 145 150 155 160 Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Val ThrLeu Leu Leu Gl 165 170 175 Gly Val Met Ala Ala Arg Gly Gln Leu Gly ProThr Cys Leu Ser Se 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val ArgLeu Leu Leu Gly Ala Le 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu ProPro Gln Gly Arg Thr Thr Al 210 215 220 His Lys Asp Pro Asn Ala Ile PheLeu Ser Phe Gln His Leu Leu Ar 225 230 235 240 Gly Lys Val Arg Phe LeuMet Leu Val Gly Gly Ser Thr Leu Cys Va 245 250 255 Arg Glu Phe Gly GlyAsn Met Ala Ser Pro Ala Pro Pro Ala Cys As 260 265 270 Leu Arg Val LeuSer Lys Leu Leu Arg Asp Ser His Val Leu His Se 275 280 285 Arg Leu SerGln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Le 290 295 300 Leu Pro305 306 amino acids amino acid unknown unknown peptide 207 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th 145150 155 160 Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu GlyVa 165 170 175 Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser SerLeu Le 180 185 190 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly AlaLeu Gln Se 195 200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg ThrThr Ala His Ly 210 215 220 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln HisLeu Leu Arg Gly Ly 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly GlySer Thr Leu Cys Val Arg Gl 245 250 255 Phe Gly Gly Asn Met Ala Ser ProAla Pro Pro Ala Cys Asp Leu Ar 260 265 270 Val Leu Ser Lys Leu Leu ArgAsp Ser His Val Leu His Ser Arg Le 275 280 285 Ser Gln Cys Pro Glu ValHis Pro Leu Pro Thr Pro Val Leu Leu Pr 290 295 300 Ala Val 305 306 aminoacids amino acid unknown unknown peptide 208 Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met GlyGlu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln As 145 150 155 160 IleLeu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Ar 165 170 175Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Se 180 185190 Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Th 195200 205 Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Al210 215 220 Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg PheLe 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu PheGly Gly As 245 250 255 Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu ArgVal Leu Ser Ly 260 265 270 Leu Leu Arg Asp Ser His Val Leu His Ser ArgLeu Ser Gln Cys Pr 275 280 285 Glu Val His Pro Leu Pro Thr Pro Val LeuLeu Pro Ala Val Asp Ph 290 295 300 Ser Leu 305 306 amino acids aminoacid unknown unknown peptide 209 Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met Gly Pro Thr CysLeu Ser Ser Leu Leu Gly Gln Leu Ser Gl 145 150 155 160 Gln Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl 165 170 175 Leu Pro ProGln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il 180 185 190 Phe LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Me 195 200 205 LeuVal Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Me 210 215 220Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Le 225 230235 240 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Gl245 250 255 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp PheSe 260 265 270 Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala GlnAsp Il 275 280 285 Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met AlaAla Arg Gl 290 295 300 Gln Leu 305 306 amino acids amino acid unknownunknown peptide 210 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly GluPro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pr 130 135 140 Asn Met Gly Thr Gln Leu Pro Pro GlnGly Arg Thr Thr Ala His Ly 145 150 155 160 Asp Pro Asn Ala Ile Phe LeuSer Phe Gln His Leu Leu Arg Gly Ly 165 170 175 Val Arg Phe Leu Met LeuVal Gly Gly Ser Thr Leu Cys Val Arg Gl 180 185 190 Phe Gly Gly Asn MetAla Ser Pro Ala Pro Pro Ala Cys Asp Leu Ar 195 200 205 Val Leu Ser LysLeu Leu Arg Asp Ser His Val Leu His Ser Arg Le 210 215 220 Ser Gln CysPro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pr 225 230 235 240 AlaVal Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th 245 250 255Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va 260 265270 Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Le 275280 285 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se290 295 300 Leu Leu 305 306 amino acids amino acid unknown unknownpeptide 211 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysAr 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVa 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPh 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIl 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSe 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro SerGly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pr 130 135 140 Asn Met Gly Arg Thr Thr Ala His Lys Asp ProAsn Ala Ile Phe Le 145 150 155 160 Ser Phe Gln His Leu Leu Arg Gly LysVal Arg Phe Leu Met Leu Va 165 170 175 Gly Gly Ser Thr Leu Cys Val ArgGlu Phe Gly Gly Asn Met Ala Se 180 185 190 Pro Ala Pro Pro Ala Cys AspLeu Arg Val Leu Ser Lys Leu Leu Ar 195 200 205 Asp Ser His Val Leu HisSer Arg Leu Ser Gln Cys Pro Glu Val Hi 210 215 220 Pro Leu Pro Thr ProVal Leu Leu Pro Ala Val Asp Phe Ser Leu Gl 225 230 235 240 Glu Trp LysThr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gl 245 250 255 Ala ValThr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Le 260 265 270 GlyPro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Va 275 280 285Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pr 290 295300 Pro Gln 305 306 amino acids amino acid unknown unknown peptide 212Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 7580 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 9095 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys SerPr 130 135 140 Asn Met Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser PheGln Hi 145 150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu ValGly Gly Ser Th 165 170 175 Leu Cys Val Arg Glu Phe Gly Gly Asn Met AlaSer Pro Ala Pro Pr 180 185 190 Ala Cys Asp Leu Arg Val Leu Ser Lys LeuLeu Arg Asp Ser His Va 195 200 205 Leu His Ser Arg Leu Ser Gln Cys ProGlu Val His Pro Leu Pro Th 210 215 220 Pro Val Leu Leu Pro Ala Val AspPhe Ser Leu Gly Glu Trp Lys Th 225 230 235 240 Gln Met Glu Glu Thr LysAla Gln Asp Ile Leu Gly Ala Val Thr Le 245 250 255 Leu Leu Glu Gly ValMet Ala Ala Arg Gly Gln Leu Gly Pro Thr Cy 260 265 270 Leu Ser Ser LeuLeu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Le 275 280 285 Gly Ala LeuGln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Ar 290 295 300 Thr Thr305 306 amino acids amino acid unknown unknown peptide 213 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Ar 145150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu CysVa 165 170 175 Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro AlaCys As 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His ValLeu His Se 195 200 205 Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu ProThr Pro Val Le 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu TrpLys Thr Gln Met Gl 225 230 235 240 Glu Thr Lys Ala Gln Asp Ile Leu GlyAla Val Thr Leu Leu Leu Gl 245 250 255 Gly Val Met Ala Ala Arg Gly GlnLeu Gly Pro Thr Cys Leu Ser Se 260 265 270 Leu Leu Gly Gln Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Le 275 280 285 Gln Ser Leu Leu Gly ThrGln Leu Pro Pro Gln Gly Arg Thr Thr Al 290 295 300 His Lys 305 306 aminoacids amino acid unknown unknown peptide 214 Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met AlaIle Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va 145 150 155 160 ArgPhe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Ph 165 170 175Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Va 180 185190 Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Se 195200 205 Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Al210 215 220 Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu ThrLy 225 230 235 240 Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu GluGly Val Me 245 250 255 Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu SerSer Leu Leu Gl 260 265 270 Gln Leu Ser Gly Gln Val Arg Leu Leu Leu GlyAla Leu Gln Ser Le 275 280 285 Leu Gly Thr Gln Leu Pro Pro Gln Gly ArgThr Thr Ala His Lys As 290 295 300 Pro Asn 305 305 amino acids aminoacid unknown unknown peptide 215 Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met Glu Val His ProLeu Pro Thr Pro Val Leu Leu Pro Ala Va 145 150 155 160 Asp Phe Ser LeuGly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Al 165 170 175 Gln Asp IleLeu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Al 180 185 190 Ala ArgGly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl 195 200 205 LeuSer Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le 210 215 220Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pr 225 230235 240 Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Ar245 250 255 Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu PheGl 260 265 270 Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg ValLeu Se 275 280 285 Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg LeuSer Gln Cy 290 295 300 Pro 305 305 amino acids amino acid unknownunknown peptide 216 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly GluPro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pr 130 135 140 Asn Met Leu Pro Thr Pro Val Leu LeuPro Ala Val Asp Phe Ser Le 145 150 155 160 Gly Glu Trp Lys Thr Gln MetGlu Glu Thr Lys Ala Gln Asp Ile Le 165 170 175 Gly Ala Val Thr Leu LeuLeu Glu Gly Val Met Ala Ala Arg Gly Gl 180 185 190 Leu Gly Pro Thr CysLeu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 195 200 205 Val Arg Leu LeuLeu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Le 210 215 220 Pro Pro GlnGly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Ph 225 230 235 240 LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le 245 250 255Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Se 260 265270 Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Ar 275280 285 Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val Hi290 295 300 Pro 305 305 amino acids amino acid unknown unknown peptide217 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 510 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 2025 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 3540 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 5055 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 6570 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly ProIl 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His LysSer Pr 130 135 140 Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu GlyGlu Trp Ly 145 150 155 160 Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLeu Gly Ala Val Th 165 170 175 Leu Leu Leu Glu Gly Val Met Ala Ala ArgGly Gln Leu Gly Pro Th 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gln LeuSer Gly Gln Val Arg Leu Le 195 200 205 Leu Gly Ala Leu Gln Ser Leu LeuGly Thr Gln Leu Pro Pro Gln Gl 210 215 220 Arg Thr Thr Ala His Lys AspPro Asn Ala Ile Phe Leu Ser Phe Gl 225 230 235 240 His Leu Leu Arg GlyLys Val Arg Phe Leu Met Leu Val Gly Gly Se 245 250 255 Thr Leu Cys ValArg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pr 260 265 270 Ala Cys AspLeu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Va 275 280 285 Leu HisSer Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Th 290 295 300 Pro305 305 amino acids amino acid unknown unknown peptide 218 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Gl 145150 155 160 Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu LeuGl 165 170 175 Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys LeuSer Se 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu LeuGly Ala Le 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln GlyArg Thr Thr Al 210 215 220 His Lys Asp Pro Asn Ala Ile Phe Leu Ser PheGln His Leu Leu Ar 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu ValGly Gly Ser Thr Leu Cys Va 245 250 255 Arg Glu Phe Gly Asn Met Ala SerPro Ala Pro Pro Ala Cys Asp Le 260 265 270 Arg Val Leu Ser Lys Leu LeuArg Asp Ser His Val Leu His Ser Ar 275 280 285 Leu Ser Gln Cys Pro GluVal His Pro Leu Pro Thr Pro Val Leu Le 290 295 300 Pro 305 305 aminoacids amino acid unknown unknown peptide 219 Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met AspPhe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th 145 150 155 160 LysAla Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Va 165 170 175Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Le 180 185190 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Se 195200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly210 215 220 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg GlyLy 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu CysVal Arg Gl 245 250 255 Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala CysAsp Leu Arg Va 260 265 270 Leu Ser Lys Leu Leu Arg Asp Ser His Val LeuHis Ser Arg Leu Se 275 280 285 Gln Cys Pro Glu Val His Pro Leu Pro ThrPro Val Leu Leu Pro Al 290 295 300 Val 305 305 amino acids amino acidunknown unknown peptide 220 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala SerGly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser ProGly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met Gly Glu Trp Lys ThrGln Met Glu Glu Thr Lys Ala Gln As 145 150 155 160 Ile Leu Gly Ala ValThr Leu Leu Leu Glu Gly Val Met Ala Ala Ar 165 170 175 Gly Gln Leu GlyPro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Se 180 185 190 Gly Gln ValArg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Th 195 200 205 Gln LeuPro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Al 210 215 220 IlePhe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Le 225 230 235240 Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Me 245250 255 Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Le260 265 270 Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys ProGl 275 280 285 Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val AspPhe Se 290 295 300 Leu 305 305 amino acids amino acid unknown unknownpeptide 221 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysAr 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu AspVa 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPh 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIl 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSe 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro SerGly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pr 130 135 140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu LeuGly Gln Leu Ser Gl 145 150 155 160 Gln Val Arg Leu Leu Leu Gly Ala LeuGln Ser Leu Leu Gly Thr Gl 165 170 175 Leu Pro Pro Gln Gly Arg Thr ThrAla His Lys Asp Pro Asn Ala Il 180 185 190 Phe Leu Ser Phe Gln His LeuLeu Arg Gly Lys Val Arg Phe Leu Me 195 200 205 Leu Val Gly Gly Ser ThrLeu Cys Val Arg Glu Phe Gly Asn Met Al 210 215 220 Ser Pro Ala Pro ProAla Cys Asp Leu Arg Val Leu Ser Lys Leu Le 225 230 235 240 Arg Asp SerHis Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 245 250 255 His ProLeu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 260 265 270 GlyGlu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 275 280 285Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 290 295300 Leu 305 305 amino acids amino acid unknown unknown peptide 222 AlaAsn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 SerIle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 ValArg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr130 135 140 Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala HisLy 145 150 155 160 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu LeuArg Gly Ly 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr LeuCys Val Arg Gl 180 185 190 Phe Gly Asn Met Ala Ser Pro Ala Pro Pro AlaCys Asp Leu Arg Va 195 200 205 Leu Ser Lys Leu Leu Arg Asp Ser His ValLeu His Ser Arg Leu Se 210 215 220 Gln Cys Pro Glu Val His Pro Leu ProThr Pro Val Leu Leu Pro Al 225 230 235 240 Val Asp Phe Ser Leu Gly GluTrp Lys Thr Gln Met Glu Glu Thr Ly 245 250 255 Ala Gln Asp Ile Leu GlyAla Val Thr Leu Leu Leu Glu Gly Val Me 260 265 270 Ala Ala Arg Gly GlnLeu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gl 275 280 285 Gln Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Le 290 295 300 Leu 305 305amino acids amino acid unknown unknown peptide 223 Ala Asn Cys Ser IleMet Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro LeuLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val LysAsn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu GlnPro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val GluGly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser ThrIle Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 AsnMet Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Le 145 150 155160 Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Va 165170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pr180 185 190 Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu ArgAs 195 200 205 Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu ValHis Pr 210 215 220 Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe SerLeu Gly Gl 225 230 235 240 Trp Lys Thr Gln Met Glu Glu Thr Lys Ala GlnAsp Ile Leu Gly Al 245 250 255 Val Thr Leu Leu Leu Glu Gly Val Met AlaAla Arg Gly Gln Leu Gl 260 265 270 Pro Thr Cys Leu Ser Ser Leu Leu GlyGln Leu Ser Gly Gln Val Ar 275 280 285 Leu Leu Leu Gly Ala Leu Gln SerLeu Leu Gly Thr Gln Leu Pro Pr 290 295 300 Gln 305 305 amino acids aminoacid unknown unknown peptide 224 Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Ser Pr 130 135 140 Asn Met Gly Arg Thr ThrAla His Lys Asp Pro Asn Ala Ile Phe Le 145 150 155 160 Ser Phe Gln HisLeu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Va 165 170 175 Gly Gly SerThr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pr 180 185 190 Ala ProPro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg As 195 200 205 SerHis Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pr 210 215 220Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Gl 225 230235 240 Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Al245 250 255 Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln LeuGl 260 265 270 Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly GlnVal Ar 275 280 285 Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr GlnLeu Pro Pr 290 295 300 Gln 305 305 amino acids amino acid unknownunknown peptide 225 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys Ar 1 5 10 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Va 20 25 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Ph 35 40 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Il 50 55 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr AlaAla Pro Se 65 70 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Gl 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gl 100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly GluPro Ser Gly Pro Il 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pr 130 135 140 Asn Met Asp Pro Asn Ala Ile Phe LeuSer Phe Gln His Leu Leu Ar 145 150 155 160 Gly Lys Val Arg Phe Leu MetLeu Val Gly Gly Ser Thr Leu Cys Va 165 170 175 Arg Glu Phe Gly Asn MetAla Ser Pro Ala Pro Pro Ala Cys Asp Le 180 185 190 Arg Val Leu Ser LysLeu Leu Arg Asp Ser His Val Leu His Ser Ar 195 200 205 Leu Ser Gln CysPro Glu Val His Pro Leu Pro Thr Pro Val Leu Le 210 215 220 Pro Ala ValAsp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Gl 225 230 235 240 ThrLys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gl 245 250 255Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Le 260 265270 Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gl 275280 285 Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala Hi290 295 300 Lys 305 305 amino acids amino acid unknown unknown peptide226 Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 510 15 Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 2025 30 Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 3540 45 Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 5055 60 Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 6570 75 80 Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl100 105 110 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly ProIl 115 120 125 Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His LysSer Pr 130 135 140 Asn Met Ala Ile Phe Leu Ser Phe Gln His Leu Leu ArgGly Lys Va 145 150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr LeuCys Val Arg Glu Ph 165 170 175 Gly Asn Met Ala Ser Pro Ala Pro Pro AlaCys Asp Leu Arg Val Le 180 185 190 Ser Lys Leu Leu Arg Asp Ser His ValLeu His Ser Arg Leu Ser Gl 195 200 205 Cys Pro Glu Val His Pro Leu ProThr Pro Val Leu Leu Pro Ala Va 210 215 220 Asp Phe Ser Leu Gly Glu TrpLys Thr Gln Met Glu Glu Thr Lys Al 225 230 235 240 Gln Asp Ile Leu GlyAla Val Thr Leu Leu Leu Glu Gly Val Met Al 245 250 255 Ala Arg Gly GlnLeu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gl 260 265 270 Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Le 275 280 285 Gly ThrGln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pr 290 295 300 Asn305 309 amino acids amino acid unknown unknown peptide 227 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 145150 155 160 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLe 165 170 175 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala ArgGly Gl 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln LeuSer Gly Gl 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu LeuGly Thr Gln Le 210 215 220 Pro Pro Gln Gly Arg Thr Thr Ala His Lys AspPro Asn Ala Ile Ph 225 230 235 240 Leu Ser Phe Gln His Leu Leu Arg GlyLys Val Arg Phe Leu Met Le 245 250 255 Val Gly Gly Ser Thr Leu Cys ValArg Glu Phe Gly Gly Asn Gly Gl 260 265 270 Asn Met Ala Ser Pro Ala ProPro Ala Cys Asp Leu Arg Val Leu Se 275 280 285 Lys Leu Leu Arg Asp SerHis Val Leu His Ser Arg Leu Ser Gln Cy 290 295 300 Pro Glu Val His Pro305 309 amino acids amino acid unknown unknown peptide 228 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 145150 155 160 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLe 165 170 175 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala ArgGly Gl 180 185 190 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln LeuSer Gly Gl 195 200 205 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu LeuGly Thr Gln Le 210 215 220 Pro Pro Gln Gly Arg Thr Thr Ala His Lys AspPro Asn Ala Ile Ph 225 230 235 240 Leu Ser Phe Gln His Leu Leu Arg GlyLys Val Arg Phe Leu Met Le 245 250 255 Val Gly Gly Ser Thr Leu Cys ValArg Glu Phe Gly Gly Asn Gly Gl 260 265 270 Asn Met Ala Ser Pro Ala ProPro Ala Cys Asp Leu Arg Val Leu Se 275 280 285 Lys Leu Leu Arg Asp SerHis Val Leu His Ser Arg Leu Ser Gln Cy 290 295 300 Pro Glu Val His Pro305 309 amino acids amino acid unknown unknown peptide 229 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Ly 145150 155 160 Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala ValTh 165 170 175 Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu GlyPro Th 180 185 190 Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln ValArg Leu Le 195 200 205 Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln LeuPro Pro Gln Gl 210 215 220 Arg Thr Thr Ala His Lys Asp Pro Asn Ala IlePhe Leu Ser Phe Gl 225 230 235 240 His Leu Leu Arg Gly Lys Val Arg PheLeu Met Leu Val Gly Gly Se 245 250 255 Thr Leu Cys Val Arg Glu Phe GlyGly Asn Gly Gly Asn Met Ala Se 260 265 270 Pro Ala Pro Pro Ala Cys AspLeu Arg Val Leu Ser Lys Leu Leu Ar 275 280 285 Asp Ser His Val Leu HisSer Arg Leu Ser Gln Cys Pro Glu Val Hi 290 295 300 Pro Leu Pro Thr Pro305 309 amino acids amino acid unknown unknown peptide 230 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Gl 145150 155 160 Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu LeuGl 165 170 175 Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys LeuSer Se 180 185 190 Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu LeuGly Ala Le 195 200 205 Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln GlyArg Thr Thr Al 210 215 220 His Lys Asp Pro Asn Ala Ile Phe Leu Ser PheGln His Leu Leu Ar 225 230 235 240 Gly Lys Val Arg Phe Leu Met Leu ValGly Gly Ser Thr Leu Cys Va 245 250 255 Arg Glu Phe Gly Gly Asn Gly GlyAsn Met Ala Ser Pro Ala Pro Pr 260 265 270 Ala Cys Asp Leu Arg Val LeuSer Lys Leu Leu Arg Asp Ser His Va 275 280 285 Leu His Ser Arg Leu SerGln Cys Pro Glu Val His Pro Leu Pro Th 290 295 300 Pro Val Leu Leu Pro305 309 amino acids amino acid unknown unknown peptide 231 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Th 145150 155 160 Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu GlyVa 165 170 175 Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser SerLeu Le 180 185 190 Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly AlaLeu Gln Se 195 200 205 Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg ThrThr Ala His Ly 210 215 220 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln HisLeu Leu Arg Gly Ly 225 230 235 240 Val Arg Phe Leu Met Leu Val Gly GlySer Thr Leu Cys Val Arg Gl 245 250 255 Phe Gly Gly Asn Gly Gly Asn MetAla Ser Pro Ala Pro Pro Ala Cy 260 265 270 Asp Leu Arg Val Leu Ser LysLeu Leu Arg Asp Ser His Val Leu Hi 275 280 285 Ser Arg Leu Ser Gln CysPro Glu Val His Pro Leu Pro Thr Pro Va 290 295 300 Leu Leu Pro Ala Val305 309 amino acids amino acid unknown unknown peptide 232 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln As 145150 155 160 Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala AlaAr 165 170 175 Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly GlnLeu Se 180 185 190 Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser LeuLeu Gly Th 195 200 205 Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His LysAsp Pro Asn Al 210 215 220 Ile Phe Leu Ser Phe Gln His Leu Leu Arg GlyLys Val Arg Phe Le 225 230 235 240 Met Leu Val Gly Gly Ser Thr Leu CysVal Arg Glu Phe Gly Gly As 245 250 255 Gly Gly Asn Met Ala Ser Pro AlaPro Pro Ala Cys Asp Leu Arg Va 260 265 270 Leu Ser Lys Leu Leu Arg AspSer His Val Leu His Ser Arg Leu Se 275 280 285 Gln Cys Pro Glu Val HisPro Leu Pro Thr Pro Val Leu Leu Pro Al 290 295 300 Val Asp Phe Ser Leu305 309 amino acids amino acid unknown unknown peptide 233 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl 145150 155 160 Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly ThrGl 165 170 175 Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro AsnAla Il 180 185 190 Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val ArgPhe Leu Me 195 200 205 Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu PheGly Gly Asn Gl 210 215 220 Gly Asn Met Ala Ser Pro Ala Pro Pro Ala CysAsp Leu Arg Val Le 225 230 235 240 Ser Lys Leu Leu Arg Asp Ser His ValLeu His Ser Arg Leu Ser Gl 245 250 255 Cys Pro Glu Val His Pro Leu ProThr Pro Val Leu Leu Pro Ala Va 260 265 270 Asp Phe Ser Leu Gly Glu TrpLys Thr Gln Met Glu Glu Thr Lys Al 275 280 285 Gln Asp Ile Leu Gly AlaVal Thr Leu Leu Leu Glu Gly Val Met Al 290 295 300 Ala Arg Gly Gln Leu305 309 amino acids amino acid unknown unknown peptide 234 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Ly 145150 155 160 Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg GlyLy 165 170 175 Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys ValArg Gl 180 185 190 Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala ProPro Ala Cy 195 200 205 Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp SerHis Val Leu Hi 210 215 220 Ser Arg Leu Ser Gln Cys Pro Glu Val His ProLeu Pro Thr Pro Va 225 230 235 240 Leu Leu Pro Ala Val Asp Phe Ser LeuGly Glu Trp Lys Thr Gln Me 245 250 255 Glu Glu Thr Lys Ala Gln Asp IleLeu Gly Ala Val Thr Leu Leu Le 260 265 270 Glu Gly Val Met Ala Ala ArgGly Gln Leu Gly Pro Thr Cys Leu Se 275 280 285 Ser Leu Leu Gly Gln LeuSer Gly Gln Val Arg Leu Leu Leu Gly Al 290 295 300 Leu Gln Ser Leu Leu305 309 amino acids amino acid unknown unknown peptide 235 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Le 145150 155 160 Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met LeuVa 165 170 175 Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn GlyGly As 180 185 190 Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg ValLeu Ser Ly 195 200 205 Leu Leu Arg Asp Ser His Val Leu His Ser Arg LeuSer Gln Cys Pr 210 215 220 Glu Val His Pro Leu Pro Thr Pro Val Leu LeuPro Ala Val Asp Ph 225 230 235 240 Ser Leu Gly Glu Trp Lys Thr Gln MetGlu Glu Thr Lys Ala Gln As 245 250 255 Ile Leu Gly Ala Val Thr Leu LeuLeu Glu Gly Val Met Ala Ala Ar 260 265 270 Gly Gln Leu Gly Pro Thr CysLeu Ser Ser Leu Leu Gly Gln Leu Se 275 280 285 Gly Gln Val Arg Leu LeuLeu Gly Ala Leu Gln Ser Leu Leu Gly Th 290 295 300 Gln Leu Pro Pro Gln305 309 amino acids amino acid unknown unknown peptide 236 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln Hi 145150 155 160 Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly SerTh 165 170 175 Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met AlaSer Pr 180 185 190 Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys LeuLeu Arg As 195 200 205 Ser His Val Leu His Ser Arg Leu Ser Gln Cys ProGlu Val His Pr 210 215 220 Leu Pro Thr Pro Val Leu Leu Pro Ala Val AspPhe Ser Leu Gly Gl 225 230 235 240 Trp Lys Thr Gln Met Glu Glu Thr LysAla Gln Asp Ile Leu Gly Al 245 250 255 Val Thr Leu Leu Leu Glu Gly ValMet Ala Ala Arg Gly Gln Leu Gl 260 265 270 Pro Thr Cys Leu Ser Ser LeuLeu Gly Gln Leu Ser Gly Gln Val Ar 275 280 285 Leu Leu Leu Gly Ala LeuGln Ser Leu Leu Gly Thr Gln Leu Pro Pr 290 295 300 Gln Gly Arg Thr Thr305 309 amino acids amino acid unknown unknown peptide 237 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Ar 145150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu CysVa 165 170 175 Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro AlaPro Pr 180 185 190 Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg AspSer His Va 195 200 205 Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val HisPro Leu Pro Th 210 215 220 Pro Val Leu Leu Pro Ala Val Asp Phe Ser LeuGly Glu Trp Lys Th 225 230 235 240 Gln Met Glu Glu Thr Lys Ala Gln AspIle Leu Gly Ala Val Thr Le 245 250 255 Leu Leu Glu Gly Val Met Ala AlaArg Gly Gln Leu Gly Pro Thr Cy 260 265 270 Leu Ser Ser Leu Leu Gly GlnLeu Ser Gly Gln Val Arg Leu Leu Le 275 280 285 Gly Ala Leu Gln Ser LeuLeu Gly Thr Gln Leu Pro Pro Gln Gly Ar 290 295 300 Thr Thr Ala His Lys305 309 amino acids amino acid unknown unknown peptide 238 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Va 145150 155 160 Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg GluPh 165 170 175 Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro AlaCys As 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His ValLeu His Se 195 200 205 Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu ProThr Pro Val Le 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu TrpLys Thr Gln Met Gl 225 230 235 240 Glu Thr Lys Ala Gln Asp Ile Leu GlyAla Val Thr Leu Leu Leu Gl 245 250 255 Gly Val Met Ala Ala Arg Gly GlnLeu Gly Pro Thr Cys Leu Ser Se 260 265 270 Leu Leu Gly Gln Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Le 275 280 285 Gln Ser Leu Leu Gly ThrGln Leu Pro Pro Gln Gly Arg Thr Thr Al 290 295 300 His Lys Asp Pro Asn305 302 amino acids amino acid unknown unknown peptide 239 Ala Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Ar 1 5 10 15 Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Va 20 25 30 Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Ph 35 40 45 Val Arg AlaVal Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Il 50 55 60 Leu Arg AsnLeu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Se 65 70 75 80 Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Gl 85 90 95 Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gl 100 105 110 TyrVal Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Il 115 120 125Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pr 130 135140 Asn Met Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Ar 145150 155 160 Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu CysVa 165 170 175 Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro AlaCys As 180 185 190 Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His ValLeu His Se 195 200 205 Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu ProThr Pro Val Le 210 215 220 Leu Pro Ala Val Asp Phe Ser Leu Gly Glu TrpLys Thr Gln Met Gl 225 230 235 240 Glu Thr Lys Ala Gln Asp Ile Leu GlyAla Val Thr Leu Leu Leu Gl 245 250 255 Gly Val Met Ala Ala Arg Gly GlnLeu Gly Pro Thr Cys Leu Ser Se 260 265 270 Leu Leu Gly Gln Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Le 275 280 285 Gln Ser Leu Leu Gly ThrGln Gly Arg Thr Thr Ala His Lys 290 295 300 83 base pairs nucleic acidsingle linear other nucleic acid /desc = “synthetic” 240 AATTCCGTCGTAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60 ACGTAGAGGGCGGTGGAGGC TCC 83 83 base pairs nucleic acid single linear other nucleicacid /desc = “synthetic” 241 CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTGCGCGTTCTCC AAGGTTTTCA 60 GATAGAAGGT CAGTTTACGA CGG 83 8 amino acidsamino acid unknown unknown peptide 242 Gly Gly Gly Ser Gly Gly Gly Ser 15 12 amino acids amino acid unknown unknown peptide 243 Gly Gly Gly SerGly Gly Gly Ser Gly Gly Gly Ser 1 5 10 7 amino acids amino acid unknownunknown peptide 244 Ser Gly Gly Ser Gly Gly Ser 1 5 6 amino acids aminoacid unknown unknown peptide 245 Glu Phe Gly Asn Met Ala 1 5 7 aminoacids amino acid unknown unknown peptide 246 Glu Phe Gly Gly Asn Met Ala1 5 10 amino acids amino acid unknown unknown peptide 247 Glu Phe GlyGly Asn Gly Gly Asn Met Ala 1 5 10 7 amino acids amino acid unknownunknown peptide 248 Gly Gly Ser Asp Met Ala Gly 1 5 459 base pairsnucleic acid unknown unknown other nucleic acid /desc = “SYNTHETIC” 249TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 459 447 base pairs nucleicacid unknown unknown other nucleic acid /desc = “SYNTHETIC” 250TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCC 360AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCT 420GTAGGAGGGT CCACCCTCTG CGTCAGG 447 459 base pairs nucleic acid unknownunknown other nucleic acid /desc = “SYNTHETIC” 251 TCCCCAGCGC CGCCTGCTTGTGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60 GTCCTTCACA GCAGACTGAGCCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCT 120 CTGCCTGCTG TGGACTTTAGCTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGC 180 CAGGACATTC TGGGAGCAGTGACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACA 240 CTGGGACCCA CTTGCCTCTCATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCT 300 CTTGGGGCCC TGCAGAGCCTCCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGC 360 CACAAGGATC CCAATGCCATCTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCG 420 TTCCTGATGC TTGTAGGAGGGTCCACCCTC TGCGTCAGG 459 153 amino acids amino acid unknown unknownpeptide 252 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys LeuLe 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro GluVa 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe SerLe 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLe 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg GlyGl 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu SerGly Gl 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly ThrGln Le 100 105 110 Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro AsnAla Ile Ph 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val ArgPhe Leu Met Le 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 150149 amino acids amino acid unknown unknown peptide 253 Ser Pro Ala ProPro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Le 1 5 10 15 Arg Asp Ser HisVal Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 20 25 30 His Pro Leu ProThr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 35 40 45 Gly Glu Trp LysThr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 50 55 60 Gly Ala Val ThrLeu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 65 70 75 80 Leu Gly ProThr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95 Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Gl 100 105 110 Arg ThrThr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gl 115 120 125 HisLeu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Se 130 135 140Thr Leu Cys Val Arg 145 153 amino acids amino acid unknown unknownpeptide 254 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys LeuLe 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro GluVa 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe SerLe 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLe 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg GlyGl 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu SerGly Gl 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly ThrGln Le 100 105 110 Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro AsnAla Ile Ph 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val ArgPhe Leu Met Le 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145 15064 base pairs nucleic acid unknown unknown other nucleic acid /desc =“SYNTHETIC” 255 GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGTCCGCCCCGCC 60 ATGG 64 153 amino acids amino acid unknown unknown proteinModified-site 112 /note= “position 112 is deleted or Leu, Ala,VAl, Ile,Pro, Phe, Trp or Met” Modified-site 113 /note= “positoin 113 is deletedor Pro, Phe, Ala, Val, Leu, Ile, Trp or Met” Modified-site 114 /note=“position 114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp or Met”Modified-site 115 /note= “positon 115 is deleted or Gln, Gly, Ser, Thr,Tyr, or Asn” 256 Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser LysLeu Le 1 5 10 15 Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys ProGlu Va 20 25 30 His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp PheSer Le 35 40 45 Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln AspIle Le 50 55 60 Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala ArgGly Gl 65 70 75 80 Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln LeuSer Gly Gl 85 90 95 Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu GlyThr Gln Xa 100 105 110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp ProAsn Ala Ile Ph 115 120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys ValArg Phe Leu Met Le 130 135 140 Val Gly Gly Ser Thr Leu Cys Val Arg 145150 464 base pairs nucleic acid unknown unknown other nucleic acid /desc= “SYNTHETIC” 257 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAGAGACCACCTG 60 CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTGATGGATCGA 120 ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTAGAAAATGCA 180 CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCCACGGCCGCA 240 CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGGGAAAAACTG 300 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAGGGCGGTGGA 360 GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCTCCGTCTAAA 420 AATCTCATAA ATCTCCAAAC ATGTAAGGTA CCGCATGCAA GCTT 464 100base pairs nucleic acid unknown unknown other nucleic acid /desc =“SYNTHETIC” 258 AAAACAAGAA GAAAGGCGAT AAAAAGGTTG TGGTAAGAGA AATGGATAAAAAGGGGTCGG 60 GGAAGGAAGG TGGGAGTTAA AAAAGAGGAA GTAGGTCAAG 100 11808 basepairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 259 ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCACTTAAAGAGA 60 CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTCTATCCTGAT 120 GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAAGAACTTAGA 180 AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCCCTCTGCCAC 240 GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGAATTCCGGGA 300 AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTACGTAGAGGG 360 GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCCGTCTCCTCC 420 TCTAAAGAAT CTCATAAATC TCCAAACATG GCTTTAGGCC CTGCCAGCTCCCTGCCCCA 480 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGGCGCAGCGCT 540 CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGTGCTGCTCGG 600 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGCCCTGCAGCT 660 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCTCCTGCAGGC 720 CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCTGGACGTCGC 780 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCCTGCCCTGCA 840 CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGCAGGAGGGGT 900 CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCTACGCCACCT 960 GCGCAGCCCG ACATGGCTAC ACCAACGTAC TCCATGGCTA ACTGCTCTATAATGATCG 1020 GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAACAACCTCA 1080 GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCTGGAGAGCT 1140 GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCTTCGTAATC 1200 CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCATCATCAAGG 1260 GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCTTGAGCAAG 1320 CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTCTGGTCCAA 1380 TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAACATGGCTC 1440 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGGCGCAGCGC 1500 CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGTGCTGCTCG 1560 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGCCCTGCAGC 1620 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCTCCTGCAGG 1680 CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCTGGACGTCG 1740 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCCTGCCCTGC 1800 CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGCAGGAGGGG 1860 CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCTACGCCACC 1920 GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCACGTACTCCA 1980 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCAC 2040 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGATCGAAACC 2100 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAG 2160 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCT 2220 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGT 2280 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCT 2340 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAAT 2400 CATAAATCTC CAAACATGGC TTTCCTGCTC AAGTCTTTAG AGCAAGTGAGGAAGATCC 2460 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTGCCACCCCG 2520 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAGCTCCTGCC 2580 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCTTTTCCTCT 2640 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACA 2700 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGG 2760 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTCTGCTTTCC 2820 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGAGGTGTCGT 2880 CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCCTGCCAGCT 2940 CTGCCCCAGA GCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGAAATTATAC 3000 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGACGAAGACG 3060 TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGTAAGGGCTG 3120 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCAACCATGTC 3180 CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGGTGACTGGC 3240 GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCAGGAACAAC 3300 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTCTACTATCA 3360 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTGAGCAAGTGAGGA 3420 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAAGCTGTGCC 3480 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCCCCTGAGCT 3540 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAGCGGCCTTT 3600 CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGGTCCCACCT 3660 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCAGATGGAAG 3720 CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTTCGCCTCTG 3780 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTTCCTGGAGG 3840 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGACATGG CTACACCATTAGGCCCTG 3900 AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAACGT ACTCCATGGCTAACTGCT 3960 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTTGCTGGACC 4020 AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCGACTTCCAA 4080 CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTATTGAGGCAA 4140 CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCGACATCCAA 4200 ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTATCTGGTTA 4260 CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCCGGGTGAAC 4320 TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCATAAATCTC 4380 AACATGGCTC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAGCTCCTGCC 4440 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCTTTTCCTCT 4500 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACA 4560 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGG 4620 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTCTGCTTTCC 4680 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGAGGTGTCGT 4740 CGCGTTCTAC GCCACCTTGC GCAGCCCGAC ATGGCTACAC CATTAGGCCCTGCCAGCT 4800 CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GGAAGATCCAGGGCGATG 4860 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGAGGAGCTGG 4920 ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCACTTAAAGA 4980 CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTCTATCCTGA 5040 GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAAGAACTTAG 5100 AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCCCTCTGCCA 5160 GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGAATTCCGGG 5220 AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTACGTAGAGG 5280 GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCCGTCTCCTC 5340 TCTAAAGAAT CTCATAAATC TCCAAACATG GCTCCCCTGA GCTCCTGCCCCAGCCAGG 5400 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTACCAGGGGC 5460 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACACACTGCAGC 5520 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGGAATGGCCC 5580 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCAGCGCCGGG 5640 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTACCGCGTTC 5700 CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTCCCTGCCCC 5760 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGGCGCAGCGC 5820 CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGTGCTGCTCG 5880 CACTCTCTGG GCATCCCCTG GGCTACGTAC TCCATGGCTA ACTGCTCTATAATGATCG 5940 GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAACAACCTCA 6000 GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCTGGAGAGCT 6060 GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCTTCGTAATC 6120 CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCATCATCAAGG 6180 GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCTTGAGCAAG 6240 CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTCTGGTCCAA 6300 TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAACATGGCTC 6360 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCTCTACCAGG 6420 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGACACACTGC 6480 CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACTGGGAATGG 6540 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTTCCAGCGCC 6600 GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTCGTACCGCG 6660 CTACGCCACC TTGCGCAGCC CGACATGGCT ACACCATTAG GCCCTGCCAGCTCCCTGC 6720 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGA TCCAGGGCGATGGCGCAG 6780 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCTGGTGCTGC 6840 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCACGTACTCCA 6900 GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACCACCTGCAC 6960 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGATCGAAACC 7020 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAG 7080 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGCCGCACCCT 7140 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAAACTGACGT 7200 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGGTGGAGGCT 7260 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTCTAAAGAAT 7320 CATAAATCTC CAAACATGGC TCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCG 7380 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTC 7440 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGA 7500 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCCGGCCTTCG 7560 TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCAGAGCTTCC 7620 GAGGTGTCGT ACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTACACCATTAG 7680 CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGTGAGGAAGA 7740 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCTGTGCCACC 7800 GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCTGAGCTCCT 7860 CCCAGCCAGG CCACGTACTC CATGGCTAAC TGCTCTATAA TGATCGATGAAATTATAC 7920 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGACGAAGACG 7980 TCTATCCTGA TGGATCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGTAAGGGCTG 8040 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCAACCATGTC 8100 CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGGTGACTGGC 8160 GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCAGGAACAAC 8220 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTCTACTATCA 8280 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTCTGGCAGGCTGCT 8340 AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCTGGAAGGGA 8400 TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGACTTTGCCA 8460 ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCCCACCCAGG 8520 GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCTGGTTGCTA 8580 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGCGCAGCCCG 8640 ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCTCAAGTCTT 8700 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCTGTGTGCCA 8760 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGGCATCCCCT 8820 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGACGT ACTCCATGGCTAACTGCT 8880 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTTGCTGGACC 8940 AACAACCTCA ATGACGAAGA CGTCTCTATC CTGATGGATC GAAACCTTCGACTTCCAA 9000 CTGGAGAGCT TCGTAAGGGC TGTCAAGAAC TTAGAAAATG CATCAGGTATTGAGGCAA 9060 CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCGACATCCAA 9120 ATCATCAAGG CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTATCTGGTTA 9180 CTTGAGCAAG CGCAGGAACA ACAGTACGTA GAGGGCGGTG GAGGCTCCCCGGGTGAAC 9240 TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCATAAATCTC 9300 AACATGGCTG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGCCATGCCGG 9360 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCATCTGCAGA 9420 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACATGGCTACAC 9480 TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGAGCAAGTGA 9540 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTGT 9600 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGCTCCCCTGA 9660 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCATAGCGGCC 9720 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCCA 9780 TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATGG 9840 ACGTACTCCA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCACTTAAAGA 9900 CCACCTGCAC CTTTGCTGGA CCCGAACAAC CTCAATGACG AAGACGTCTCTATCCTGA 9960 GATCGAAACC TTCGACTTCC AAACCTGGAG AGCTTCGTAA GGGCTGTCAAGAACTTA 10020 AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCCCTCTGCC 10080 GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGAATTCCGG 10140 AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAGTACGTAGAG 10200 GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCCGTCTCCT 10260 TCTAAAGAAT CTCATAAATC TCCAAACATG GCTGGAATGG CCCCTGCCCTGCAGCCC 10320 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGGGGTCCTG 10380 GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCACCTTGCG 10440 CCCGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTTCCTGCTC 10500 TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGAGAAGCTG 10560 GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTCTCTGGGC 10620 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGGCTGCTTG 10680 CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGAAGGGATA 10740 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTTTGCCACC 10800 ATCTGGCAGC AGATGGAAGA ACTGACGTAC TCCATGGCTA ACTGCTCTATAATGATC 10860 GAAATTATAC ATCACTTAAA GAGACCACCT GCACCTTTGC TGGACCCGAACAACCTC 10920 GACGAAGACG TCTCTATCCT GATGGATCGA AACCTTCGAC TTCCAAACCTGGAGAGC 10980 GTAAGGGCTG TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCTTCGTAAT 11040 CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCATCATCAAG 11100 GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCTTGAGCAA 11160 CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG GTGAACCGTCTGGTCCA 11220 TCTACTATCA ACCCGTCTCC TCCGTCTAAA GAATCTCATA AATCTCCAAACATGGCT 11280 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACATGGCTACA 11340 TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGAGCAAGTG 11400 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTG 11460 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGCTCCCCTG 11520 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCATAGCGGC 11580 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCC 11640 TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATG 11700 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGCCTTCGCC 11760 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAG 11808975 base pairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 260 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTCAGAGC TTCCTGCTCA AGTCTTTAGAGCAAGTGAG 480 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTGTG 540 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGCTCCCCTGAG 600 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCATAGCGGCCT 660 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCCAC 720 TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATGGA 780 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGCCTTCGCCTC 840 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAGCTTCCTGGA 900 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACCATTAGGCCC 960 GCCAGCTCCC TGCCC 975 975 base pairs nucleic acid unknownunknown other nucleic acid /desc = “synthetic” 261 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGGCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAG 480 AAGATCCAGG GCGATGGCGCAGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTG 540 CACCCCGAGG AGCTGGTGCTGCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAG 600 TCCTGCCCCA GCCAGGCCCTGCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCT 660 TTCCTCTACC AGGGGCTCCTGCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCAC 720 TTGGACACAC TGCAGCTGGACGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGA 780 GAACTGGGAA TGGCCCCTGCCCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTC 840 GCTTTCCAGC GCCGGGCAGGAGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGA 900 GTGTCGTACC GCGTTCTACGCCACCTTGCG CAGCCCGACA TGGCTACACC ATTAGGCCC 960 GCCAGCTCCC TGCCC 975 975base pairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 262 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTGAGCAA GTGAGGAAGA TCCAGGGCGATGGCGCAGC 480 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCTGGTGCTGCT 540 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCAGGCCCTGCA 600 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGGGCTCCTGCA 660 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCAGCTGGACGT 720 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGCCCCTGCCCT 780 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCGGGCAGGAGG 840 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGTTCTACGCCA 900 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCCCCAGAGCTT 960 CTGCTCAAGT CTTTA 975 975 base pairs nucleic acid unknownunknown other nucleic acid /desc = “synthetic” 263 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGGCTCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCC 480 CTGAGCTCCT GCCCCAGCCAGGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAG 540 GGCCTTTTCC TCTACCAGGGGCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGG 600 CCCACCTTGG ACACACTGCAGCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCA 660 ATGGAAGAAC TGGGAATGGCCCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTT 720 GCCTCTGCTT TCCAGCGCCGGGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTT 780 CTGGAGGTGT CGTACCGCGTTCTACGCCAC CTTGCGCAGC CCGACATGGC TACACCATT 840 GGCCCTGCCA GCTCCCTGCCCCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAA 900 ATCCAGGGCG ATGGCGCAGCGCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCA 960 CCCGAGGAGC TGGTG 975 975base pairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 264 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTCCCCTG AGCTCCTGCC CCAGCCAGGCCCTGCAGCT 480 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCTCCTGCAGGC 540 CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCTGGACGTCGC 600 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCCTGCCCTGCA 660 CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGCAGGAGGGGT 720 CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCTACGCCACCT 780 GCGCAGCCCG ACATGGCTAC ACCATTAGGC CCTGCCAGCT CCCTGCCCCAGAGCTTCCT 840 CTCAAGTCTT TAGAGCAAGT GAGGAAGATC CAGGGCGATG GCGCAGCGCTCCAGGAGAA 900 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGGACACTCTCT 960 GGCATCCCCT GGGCT 975 975 base pairs nucleic acid unknownunknown other nucleic acid /desc = “synthetic” 265 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGGCTCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACT 480 CATAGCGGCC TTTTCCTCTACCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGA 540 TTGGGTCCCA CCTTGGACACACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTG 600 CAGCAGATGG AAGAACTGGGAATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCC 660 GCCTTCGCCT CTGCTTTCCAGCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCA 720 AGCTTCCTGG AGGTGTCGTACCGCGTTCTA CGCCACCTTG CGCAGCCCGA CATGGCTAC 780 CCATTAGGCC CTGCCAGCTCCCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGT 840 AGGAAGATCC AGGGCGATGGCGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCT 900 TGCCACCCCG AGGAGCTGGTGCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCT 960 AGCTCCTGCC CCAGC 975 975base pairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 266 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTCTGCAG CTGGCAGGCT GCTTGAGCCAACTCCATAG 480 GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCCCGAGTTGGG 540 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCATCTGGCAGCA 600 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCATGCCGGCCTT 660 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCTGCAGAGCTT 720 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCGACATGGCTACACCATT 780 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCAAGTGAGGAA 840 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAAGCTGTGCCA 900 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCCCCTGAGCTC 960 TGCCCCAGCC AGGCC 975 975 base pairs nucleic acid unknownunknown other nucleic acid /desc = “synthetic” 267 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGGCTCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCT 480 TTCCTCTACC AGGGGCTCCTGCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCAC 540 TTGGACACAC TGCAGCTGGACGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGA 600 GAACTGGGAA TGGCCCCTGCCCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTC 660 GCTTTCCAGC GCCGGGCAGGAGGGGTCCTG GTTGCTAGCC ATCTGCAGAG CTTCCTGGA 720 GTGTCGTACC GCGTTCTACGCCACCTTGCG CAGCCCGACA TGGCTACACC ATTAGGCCC 780 GCCAGCTCCC TGCCCCAGAGCTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GAAGATCCA 840 GGCGATGGCG CAGCGCTCCAGGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGA 900 GAGCTGGTGC TGCTCGGACACTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCC 960 AGCCAGGCCC TGCAG 975 975base pairs nucleic acid single linear other nucleic acid /desc =“synthetic” 268 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTGAACTG GGAATGGCCC CTGCCCTGCAGCCCACCCA 480 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGTCCTGGTTGC 540 AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCTTGCGCAGCC 600 GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCTGCTCAAGTC 660 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAAGCTGTGTGC 720 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCTGGGCATCCC 780 TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTGCTTGAGCCA 840 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGGGATATCCCC 900 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGCCACCACCAT 960 TGGCAGCAGA TGGAA 975 975 base pairs nucleic acid unknownunknown other nucleic acid /desc = “synthetic” 269 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAA 120 CTTCGACTTC CAAACCTGGAGAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATC 180 GGTATTGAGG CAATTCTTCGTAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACC 240 TCTCGACATC CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGAC 300 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGG 360 TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGA 420 TCTCATAAAT CTCCAAACATGGCTGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGC 480 ATGCCGGCCT TCGCCTCTGCTTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCA 540 CTGCAGAGCT TCCTGGAGGTGTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCCGACAT 600 GCTACACCAT TAGGCCCTGCCAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGA 660 CAAGTGAGGA AGATCCAGGGCGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTA 720 AAGCTGTGCC ACCCCGAGGAGCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGC 780 CCCCTGAGCT CCTGCCCCAGCCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCA 840 AGCGGCCTTT TCCTCTACCAGGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTT 900 GGTCCCACCT TGGACACACTGCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCA 960 CAGATGGAAG AACTG 975 975base pairs nucleic acid unknown unknown other nucleic acid /desc =“synthetic” 270 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAGACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGATCGAAA 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGAAAATGCATC 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGAC 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGGCGGTGGAGG 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCCGTCTAAAGA 420 TCTCATAAAT CTCCAAACAT GGCTAGCTTC CTGGAGGTGT CGTACCGCGTTCTACGCCA 480 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCCCCAGAGCTT 540 CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGCGCTCCAGGA 600 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCTCGGACACTC 660 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCAGCTGGCAGG 720 TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCAGGCCCTGGA 780 GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGTCGCCGACTT 840 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCTGCAGCCCAC 900 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC GGGCAGGAGGGGTCCTGGT 960 GCTAGCCATC TGCAG 975 325 amino acids amino acid unknownunknown peptide 271 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Leu Gly Pro Ala SerSer Leu Pro Gln Ser Phe Le 145 150 155 160 Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Al 165 170 175 Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Gl 180 185 190 Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Se 195 200 205 Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le 210 215 220 His Ser GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl 225 230 235 240 IleSer Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va 245 250 255Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me 260 265270 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Se 275280 285 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gl290 295 300 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala GlnPr 305 310 315 320 Asp Met Ala Thr Pro 325 325 amino acids amino acidunknown unknown peptide 272 Met Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe Le 145 150 155 160 Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Al 165 170 175 Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl 180 185 190 Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se 195 200 205 Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le 210 215 220 HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl 225 230 235240 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va 245250 255 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Me260 265 270 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe AlaSe 275 280 285 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gl 290 295 300 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pr 305 310 315 320 Asp Met Ala Thr Pro 325 325 amino acids aminoacid unknown unknown peptide 273 Met Ala Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu ArgLeu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly GlySer Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro SerPro Pro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys Il 145 150 155 160 Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Ly 165 170 175 Leu Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Il 180 185 190 Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Al 195 200 205 GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Le 210 215 220Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu As 225 230235 240 Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gl245 250 255 Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln GlyAl 260 265 270 Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Le 275 280 285 Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Le 290 295 300 Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro LeuGly Pro Ala Se 305 310 315 320 Ser Leu Pro Gln Ser 325 325 amino acidsamino acid unknown unknown peptide 274 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly GlyGly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile AsnPro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met AlaGlu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Al 145 150 155 160 Leu GlnGlu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Gl 165 170 175 LeuVal Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Se 180 185 190Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le 195 200205 His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gl 210215 220 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Va225 230 235 240 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly Me 245 250 255 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala Se 260 265 270 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gl 275 280 285 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pr 290 295 300 Asp Met Ala Thr Pro Leu Gly Pro Ala SerSer Leu Pro Gln Ser Ph 305 310 315 320 Leu Leu Lys Ser Leu 325 325 aminoacids amino acid unknown unknown peptide 275 Met Ala Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp ArgAsn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr IleAsn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn MetAla Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pr 145 150 155 160 LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Se 165 170 175Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Le 180 185190 Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Le 195200 205 Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Le210 215 220 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPh 225 230 235 240 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser Hi 245 250 255 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val LeuArg His Leu Al 260 265 270 Gln Pro Asp Met Ala Thr Pro Leu Gly Pro AlaSer Ser Leu Pro Gl 275 280 285 Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly As 290 295 300 Gly Ala Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys Hi 305 310 315 320 Pro Glu Glu Leu Val 325 325amino acids amino acid unknown unknown peptide 276 Met Ala Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr ValGlu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125 Ile SerThr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135 140 ProAsn Met Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le 145 150 155160 Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl 165170 175 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le180 185 190 Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGl 195 200 205 Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro ThrGln Gl 210 215 220 Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg AlaGly Gly Va 225 230 235 240 Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Va 245 250 255 Leu Arg His Leu Ala Gln Pro Asp Met AlaThr Pro Leu Gly Pro Al 260 265 270 Ser Ser Leu Pro Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Ar 275 280 285 Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Th 290 295 300 Tyr Lys Leu Cys His Pro GluGlu Leu Val Leu Leu Gly His Ser Le 305 310 315 320 Gly Ile Pro Trp Ala325 325 amino acids amino acid unknown unknown peptide 277 Met Ala AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Ly 1 5 10 15 Arg Pro ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 Val Ser IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80 Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95 Glu LysLeu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105 110 GlnTyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115 120 125Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se 130 135140 Pro Asn Met Ala Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Le 145150 155 160 His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGl 165 170 175 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Va 180 185 190 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Me 195 200 205 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met ProAla Phe Ala Se 210 215 220 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gl 225 230 235 240 Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pr 245 250 255 Asp Met Ala Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Ph 260 265 270 Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Al 275 280 285 Ala Leu Gln Glu Lys LeuCys Ala Thr Tyr Lys Leu Cys His Pro Gl 290 295 300 Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Le 305 310 315 320 Ser Ser CysPro Ser 325 325 amino acids amino acid unknown unknown peptide 278 MetAla Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Ly 1 5 10 15 ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 20 25 30 ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 35 40 45 PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 50 55 60 IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 65 70 75 80Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar 85 90 95Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl 100 105110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pr 115120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Se130 135 140 Pro Asn Met Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu HisSe 145 150 155 160 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Se 165 170 175 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala As 180 185 190 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pr 195 200 205 Ala Leu Gln Pro Thr Gln Gly Ala Met ProAla Phe Ala Ser Ala Ph 210 215 220 Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gln Ser Ph 225 230 235 240 Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Asp Me 245 250 255 Ala Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe Leu Le 260 265 270 Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Le 275 280 285 Gln Glu Lys LeuCys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Le 290 295 300 Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Se 305 310 315 320 CysPro Ser Gln Ala 325 325 amino acids amino acid unknown unknown peptide279 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Ly 1 510 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu As 2025 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Se 3540 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Al 5055 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pr 6570 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Ar85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gl100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser GlyPr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser HisLys Se 130 135 140 Pro Asn Met Ala Leu Ala Gly Cys Leu Ser Gln Leu HisSer Gly Le 145 150 155 160 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Gl 165 170 175 Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Al 180 185 190 Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Le 195 200 205 Gln Pro Thr Gln Gly Ala Met ProAla Phe Ala Ser Ala Phe Gln Ar 210 215 220 Arg Ala Gly Gly Val Leu ValAla Ser His Leu Gln Ser Phe Leu Gl 225 230 235 240 Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Asp Met Ala Th 245 250 255 Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Se 260 265 270 Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl 275 280 285 Lys LeuCys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le 290 295 300 LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pr 305 310 315320 Ser Gln Ala Leu Gln 325 325 amino acids amino acid unknown unknownpeptide 280 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLy 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAs 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSe 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAl 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys GluSer His Lys Se 130 135 140 Pro Asn Met Ala Glu Leu Gly Met Ala Pro AlaLeu Gln Pro Thr Gl 145 150 155 160 Gly Ala Met Pro Ala Phe Ala Ser AlaPhe Gln Arg Arg Ala Gly Gl 165 170 175 Val Leu Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Ar 180 185 190 Val Leu Arg His Leu Ala GlnPro Asp Met Ala Thr Pro Leu Gly Pr 195 200 205 Ala Ser Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Va 210 215 220 Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu Cys Al 225 230 235 240 Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Se 245 250 255 Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Le 260 265 270 GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Ty 275 280 285Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pr 290 295300 Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Il 305310 315 320 Trp Gln Gln Met Glu 325 325 amino acids amino acid unknownunknown peptide 281 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser GlyIle Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Gly Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Al 145 150 155 160 Met Pro Ala Phe Ala Ser AlaPhe Gln Arg Arg Ala Gly Gly Val Le 165 170 175 Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Le 180 185 190 Arg His Leu Ala GlnPro Asp Met Ala Thr Pro Leu Gly Pro Ala Se 195 200 205 Ser Leu Pro GlnSer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Ly 210 215 220 Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Ty 225 230 235 240 LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gl 245 250 255Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Le 260 265270 Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gl 275280 285 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Le290 295 300 Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGl 305 310 315 320 Gln Met Glu Glu Leu 325 325 amino acids amino acidunknown unknown peptide 282 Met Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Ly 1 5 10 15 Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu As 20 25 30 Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Se 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Al 50 55 60 Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pr 65 70 75 80 Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Ar 85 90 95 Glu Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gl 100 105 110 Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pr 115 120 125 Ile Ser Thr Ile Asn Pro Ser ProPro Ser Lys Glu Ser His Lys Se 130 135 140 Pro Asn Met Ala Ser Phe LeuGlu Val Ser Tyr Arg Val Leu Arg Hi 145 150 155 160 Leu Ala Gln Pro AspMet Ala Thr Pro Leu Gly Pro Ala Ser Ser Le 165 170 175 Pro Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl 180 185 190 Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le 195 200 205 Cys HisPro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr 210 215 220 TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gl 225 230 235240 Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Le 245250 255 Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Th260 265 270 Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMe 275 280 285 Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln GlyAla Me 290 295 300 Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Leu Va 305 310 315 320 Ala Ser His Leu Gln 325 153 amino acids aminoacid unknown unknown peptide Modified-site 7 /note= “Xaa at position 7is Ser or Ala;” Modified-site 112 /note= “Xaa at position 112 is deletedor Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met;” Modified-site 113 /note=“Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, orMet;” Modified-site 114 /note= “Xaa at position 114 is deleted or Pro,Phe, Ala, Val, Leu, Ile, Trp, or Met;” Modified-site 115 /note= “Xaa atposition 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn;”Modified-site 151 /note= “Xaa at position 151 is Ser or Ala;” 283 SerPro Ala Pro Pro Ala Xaa Asp Leu Arg Val Leu Ser Lys Leu Le 1 5 10 15 ArgAsp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Va 20 25 30 HisPro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Le 35 40 45 GlyGlu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Le 50 55 60 GlyAla Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gl 65 70 75 80Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gl 85 90 95Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Xa 100 105110 Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Ph 115120 125 Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Le130 135 140 Val Gly Gly Ser Thr Leu Xaa Val Arg 145 150 162 amino acidsamino acid unknown unknown peptide 284 Met Ala Gly Arg Thr Thr Ala HisLys Asp Pro Asn Ala Ile Phe Le 1 5 10 15 Ser Phe Gln His Leu Leu Arg GlyLys Val Arg Phe Leu Met Leu Va 20 25 30 Gly Gly Ser Thr Leu Ala Val ArgGlu Phe Gly Gly Asn Met Ala Se 35 40 45 Pro Ala Pro Pro Ala Ala Asp LeuArg Val Leu Ser Lys Leu Leu Ar 50 55 60 Asp Ser His Val Leu His Ser ArgLeu Ser Gln Cys Pro Glu Val Hi 65 70 75 80 Pro Leu Pro Thr Pro Val LeuLeu Pro Ala Val Asp Phe Ser Leu Gl 85 90 95 Glu Trp Lys Thr Gln Met GluGlu Thr Lys Ala Gln Asp Ile Leu Gl 100 105 110 Ala Val Thr Leu Leu LeuGlu Gly Val Met Ala Ala Arg Gly Gln Le 115 120 125 Gly Pro Thr Cys LeuSer Ser Leu Leu Gly Gln Leu Ser Gly Gln Va 130 135 140 Arg Leu Leu LeuGly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pr 145 150 155 160 Pro Gln162 amino acids amino acid unknown unknown peptide 285 Met Ala Gly ProThr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gl 1 5 10 15 Gln Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gl 20 25 30 Leu Pro Pro GlnGly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Il 35 40 45 Phe Leu Ser PheGln His Leu Leu Arg Gly Lys Val Arg Phe Leu Me 50 55 60 Leu Val Gly GlySer Thr Leu Ala Val Arg Glu Phe Gly Gly Asn Me 65 70 75 80 Ala Ser ProAla Pro Pro Ala Ala Asp Leu Arg Val Leu Ser Lys Le 85 90 95 Leu Arg AspSer His Val Leu His Ser Arg Leu Ser Gln Cys Pro Gl 100 105 110 Val HisPro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Se 115 120 125 LeuGly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Il 130 135 140Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gl 145 150155 160 Gln Leu 180 amino acids amino acid unknown unknown peptide 286Ala Thr Gly Gly Cys Thr Gly Gly Ala Cys Cys Cys Ala Cys Thr Th 1 5 10 15Gly Cys Cys Thr Cys Thr Cys Ala Thr Cys Cys Cys Thr Cys Cys Th 20 25 30Gly Gly Gly Gly Cys Ala Gly Cys Thr Thr Thr Cys Thr Gly Gly Al 35 40 45Cys Ala Gly Gly Thr Cys Cys Gly Thr Cys Thr Cys Cys Thr Cys Cy 50 55 60Thr Thr Gly Gly Gly Gly Cys Cys Cys Thr Gly Cys Ala Gly Ala Gl 65 70 7580 Cys Cys Thr Cys Cys Thr Thr Gly Gly Ala Ala Cys Cys Cys Ala Gl 85 9095 Cys Thr Thr Cys Cys Thr Cys Cys Ala Cys Ala Gly Gly Gly Cys Al 100105 110 Gly Gly Ala Cys Cys Ala Cys Ala Gly Cys Thr Cys Ala Cys Ala Al115 120 125 Gly Gly Ala Thr Cys Cys Cys Ala Ala Thr Gly Cys Cys Ala ThrCy 130 135 140 Thr Thr Cys Cys Thr Gly Ala Gly Cys Thr Thr Cys Cys AlaAla Cy 145 150 155 160 Ala Cys Cys Thr Gly Cys Thr Cys Cys Gly Ala GlyGly Ala Ala Al 165 170 175 Gly Gly Thr Gly 180 486 base pairs nucleicacid unknown unknown other nucleic acid /desc = ”synthetic“ 287ATGGCTGGCA GGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 60CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CGCCGTCAG 120GAATTCGGCG GCAACATGGC GTCTCCGGCG CCGCCTGCTG CTGACCTCCG AGTCCTCAG 180AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCA 240CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAAC 300CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGG 360GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCT 420TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCC 480CCACAG 486 531 base pairs nucleic acid unknown unknown other nucleicacid /desc = ”synthetic“ 288 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGGAAGATCCAGGGCGA TGGCGCAGCG 60 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACCCCGAGGAGCT GGTGCTGCT 120 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCTGCCCCAGCCA GGCCCTGCA 180 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCCTCTACCAGGG GCTCCTGCA 240 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGGACACACTGCA GCTGGACGT 300 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAACTGGGAATGGC CCCTGCCCT 360 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTTTCCAGCGCCG GGCAGGAGG 420 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGTCGTACCGCGT TCTACGCCA 480 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCAGCTCCCTGCC C 531 531 base pairs nucleic acid unknown unknown othernucleic acid /desc = ”synthetic“ 289 GAACTGGGAA TGGCCCCTGC CCTGCAGCCCACCCAGGGTG CCATGCCGGC CTTCGCCTCT 60 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTGGTTGCTAGCC ATCTGCAGAG CTTCCTGGA 120 GTGTCGTACC GCGTTCTACG CCACCTTGCGCAGCCCGACA TGGCTACACC ATTAGGCCC 180 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTCAAGTCTTTAG AGCAAGTGAG GAAGATCCA 240 GGCGATGGCG CAGCGCTCCA GGAGAAGCTGTGTGCCACCT ACAAGCTGTG CCACCCCGA 300 GAGCTGGTGC TGCTCGGACA CTCTCTGGGCATCCCCTGGG CTCCCCTGAG CTCCTGCCC 360 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTGAGCCAACTCC ATAGCGGCCT TTTCCTCTA 420 CAGGGGCTCC TGCAGGCCCT GGAAGGGATATCCCCCGAGT TGGGTCCCAC CTTGGACAC 480 CTGCAGCTGG ACGTCGCCGA CTTTGCCACCACCATCTGGC AGCAGATGGA A 531 531 base pairs nucleic acid unknown unknownother nucleic acid /desc = ”synthetic“ 290 GGAATGGCCC CTGCCCTGCAGCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 60 CAGCGCCGGG CAGGAGGGGTCCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTC 120 TACCGCGTTC TACGCCACCTTGCGCAGCCC GACATGGCTA CACCATTAGG CCCTGCCAG 180 TCCCTGCCCC AGAGCTTCCTGCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGA 240 GGCGCAGCGC TCCAGGAGAAGCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCT 300 GTGCTGCTCG GACACTCTCTGGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCA 360 GCCCTGCAGC TGGCAGGCTGCTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGG 420 CTCCTGCAGG CCCTGGAAGGGATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCA 480 CTGGACGTCG CCGACTTTGCCACCACCATC TGGCAGCAGA TGGAAGAACT G 531 531 base pairs nucleic acidunknown unknown other nucleic acid /desc = ”synthetic“ 291 TTCCTGCTCAAGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG 60 GAGAAGCTGTGTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACA 120 TCTCTGGGCATCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGC 180 GGCTGCTTGAGCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCT 240 GAAGGGATATCCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGA 300 TTTGCCACCACCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCC 360 ACCCAGGGTGCCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCT 420 GTTGCTAGCCATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGC 480 CAGCCCGACATGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG C 531 531 base pairs nucleicacid unknown unknown other nucleic acid /desc = ”synthetic“ 292AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGA CATGGCTACA 60CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGT 120AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCT 180TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCT 240AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGG 300CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCC 360ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGAT 420GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCC GGCCTTCGC 480TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G 531 531 basepairs nucleic acid unknown unknown other nucleic acid /desc =”synthetic“ 293 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGACATGGCTACA 60 CCATTAGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTTAGAGCAAGT 120 AGGAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCACCTACAAGCT 180 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTGGGCTCCCCT 240 AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACTCCATAGCGG 300 CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGAGTTGGGTCC 360 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTGGCAGCAGAT 420 GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCACCCAGG GTGCCATGCCGGCCTTCGC 480 TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA G531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 294 TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGAGCAAGTGAGG 60 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTGTG 120 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGCTCCCCTGAG 180 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCATAGCGGCCT 240 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCCAC 300 TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATGGA 360 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGCCTTCGCCTC 420 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAGCTTCCTGGA 480 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACA TGGCTACACC A531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 295 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCCCAGCCAGGCC 60 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTACCAGGGGCT 120 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACACACTGCAGCT 180 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGGAATGGCCCC 240 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCAGCGCCGGGC 300 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTACCGCGTTCT 360 CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTCCCTGCCCCA 420 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGGCGCAGCGCT 480 CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT G531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 296 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAGCCAACTCCAT 60 AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATCCCCCGAGTT 120 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCACCATCTGGCA 180 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGCCATGCCGGC 240 TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCATCTGCAGAG 300 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCGACATGGCTACACC 360 TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGAGCAAGTGAG 420 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTGTG 480 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC T531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 297 CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTTCCTCTACCAG 60 GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTTGGACACACT 120 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGAACTGGGAAT 180 GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGCTTTCCAGCG 240 CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGTGTCGTACCG 300 GTTCTACGCC ACCTTGCGCA GCCCGACATG GCTACACCAT TAGGCCCTGCCAGCTCCCT 360 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGGCGATGGCGC 420 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGAGCTGGTGCT 480 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG C531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 298 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTACCAGGGGCTC 60 CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACACACTGCAGCT 120 GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGGAATGGCCCC 180 GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCAGCGCCGGGC 240 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTACCGCGTTCT 300 CGCCACCTTG CGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTCCCTGCCCCA 360 AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGGCGCAGCGCT 420 CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGTGCTGCTCGG 480 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC C531 531 base pairs nucleic acid unknown unknown other nucleic acid /desc= ”synthetic“ 299 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGGGCTCCTGCAG 60 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCAGCTGGACGT 120 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGCCCCTGCCCT 180 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCGGGCAGGAGG 240 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGTTCTACGCCA 300 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCA GCTCCCTGCCCCAGAGCTT 360 CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGCGCTCCAGGA 420 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCTCGGACACTC 480 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA G531 177 amino acids amino acid unknown unknown peptide 300 Gln Ser PheLeu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gl 1 5 10 15 Asp Gly AlaAla Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cy 20 25 30 His Pro GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr 35 40 45 Ala Pro LeuSer Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cy 50 55 60 Leu Ser GlnLeu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gl 65 70 75 80 Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Le 85 90 95 Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Gl 100 105 110 GluLeu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pr 115 120 125Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Al 130 135140 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg Hi 145150 155 160 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser SerLe 165 170 175 Pro 177 amino acids amino acid unknown unknown peptide301 Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pr 1 510 15 Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Al 2025 30 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg Hi 3540 45 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Le 5055 60 Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gl 6570 75 80 Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Le85 90 95 Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pr100 105 110 Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGl 115 120 125 Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Le 130 135 140 Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Th 145 150 155 160 Leu Gln Leu Asp Val Ala Asp Phe Ala Thr ThrIle Trp Gln Gln Me 165 170 175 Glu 177 amino acids amino acid unknownunknown peptide 302 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala MetPro Ala Ph 1 5 10 15 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu ValAla Ser Hi 20 25 30 Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Al 35 40 45 Gln Pro Asp Met Ala Thr Pro Leu Gly Pro Ala Ser SerLeu Pro Gl 50 55 60 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys IleGln Gly As 65 70 75 80 Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys Hi 85 90 95 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Al 100 105 110 Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Le 115 120 125 Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Al 130 135 140 Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gl 145 150 155 160 Leu Asp Val Ala Asp Phe AlaThr Thr Ile Trp Gln Gln Met Glu Gl 165 170 175 Leu 177 amino acids aminoacid unknown unknown peptide 303 Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gl 1 5 10 15 Ala Ala Leu Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pr 20 25 30 Glu Glu Leu Val Leu Leu Gly His Ser LeuGly Ile Pro Trp Ala Pr 35 40 45 Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Se 50 55 60 Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Le 65 70 75 80 Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gln Le 85 90 95 Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Glu Le 100 105 110 Gly Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Ph 115 120 125 Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser Hi 130 135 140 Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Al 145 150 155 160 Gln Pro Asp MetAla Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gl 165 170 175 Ser 177 aminoacids amino acid unknown unknown peptide 304 Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pr 1 5 10 15 Asp Met Ala Thr Pro Leu GlyPro Ala Ser Ser Leu Pro Gln Ser Ph 20 25 30 Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Al 35 40 45 Ala Leu Gln Glu Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Gl 50 55 60 Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Le 65 70 75 80 Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gl 85 90 95 Leu His Ser Gly Leu PheLeu Tyr Gln Gly Leu Leu Gln Ala Leu Gl 100 105 110 Gly Ile Ser Pro GluLeu Gly Pro Thr Leu Asp Thr Leu Gln Leu As 115 120 125 Val Ala Asp PheAla Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gl 130 135 140 Met Ala ProAla Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Al 145 150 155 160 SerAla Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Le 165 170 175Gln 177 amino acids amino acid unknown unknown peptide 305 Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly 1 5 10 15 Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Le 20 25 30 Gly His SerLeu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se 35 40 45 Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le 50 55 60 Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl 65 70 75 80 Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al 85 90 95 Thr ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Le 100 105 110 GlnPro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Ar 115 120 125Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Gl 130 135140 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Th 145150 155 160 Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSe 165 170 175 Leu 177 amino acids amino acid unknown unknown peptide306 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Le 1 510 15 Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Ly 2025 30 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Le 3540 45 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Se 5055 60 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Le 6570 75 80 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Gl85 90 95 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Al100 105 110 Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLe 115 120 125 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Ar 130 135 140 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Gl 145 150 155 160 Val Ser Tyr Arg Val Leu Arg His Leu Ala GlnPro Asp Met Ala Th 165 170 175 Pro 177 amino acids amino acid unknownunknown peptide 307 Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cy 1 5 10 15 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser GlnLeu His Se 20 25 30 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Se 35 40 45 Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala As 50 55 60 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu GlyMet Ala Pr 65 70 75 80 Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Ph 85 90 95 Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Ph 100 105 110 Leu Glu Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pro Asp Me 115 120 125 Ala Thr Pro Leu Gly Pro Ala Ser Ser LeuPro Gln Ser Phe Leu Le 130 135 140 Lys Ser Leu Glu Gln Val Arg Lys IleGln Gly Asp Gly Ala Ala Le 145 150 155 160 Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Le 165 170 175 Val 177 amino acids aminoacid unknown unknown peptide 308 Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Le 1 5 10 15 Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Al 20 25 30 Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu Gl 35 40 45 Leu Asp Val Ala Asp Phe Ala Thr Thr IleTrp Gln Gln Met Glu Gl 50 55 60 Leu Gly Met Ala Pro Ala Leu Gln Pro ThrGln Gly Ala Met Pro Al 65 70 75 80 Phe Ala Ser Ala Phe Gln Arg Arg AlaGly Gly Val Leu Val Ala Se 85 90 95 His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg His Le 100 105 110 Ala Gln Pro Asp Met Ala Thr ProLeu Gly Pro Ala Ser Ser Leu Pr 115 120 125 Gln Ser Phe Leu Leu Lys SerLeu Glu Gln Val Arg Lys Ile Gln Gl 130 135 140 Asp Gly Ala Ala Leu GlnGlu Lys Leu Cys Ala Thr Tyr Lys Leu Cy 145 150 155 160 His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Tr 165 170 175 Ala 177 aminoacids amino acid unknown unknown peptide 309 Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Le 1 5 10 15 Phe Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Ser Pro Gl 20 25 30 Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Al 35 40 45 Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Le 50 55 60 Gln Pro Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Ar 65 70 75 80 Arg Ala Gly Gly Val LeuVal Ala Ser His Leu Gln Ser Phe Leu Gl 85 90 95 Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pro Asp Met Ala Th 100 105 110 Pro Leu Gly Pro AlaSer Ser Leu Pro Gln Ser Phe Leu Leu Lys Se 115 120 125 Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Gl 130 135 140 Lys Leu CysAla Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Le 145 150 155 160 LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pr 165 170 175Ser 177 amino acids amino acid unknown unknown peptide 310 Leu Gln LeuAla Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Le 1 5 10 15 Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gl 20 25 30 Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Th 35 40 45 Ile Trp GlnGln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pr 50 55 60 Thr Gln GlyAla Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Al 65 70 75 80 Gly GlyVal Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Se 85 90 95 Tyr ArgVal Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro Le 100 105 110 GlyPro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Gl 115 120 125Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Le 130 135140 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gl 145150 155 160 His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGl 165 170 175 Ala 177 amino acids amino acid unknown unknown peptide311 Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gl 1 510 15 Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Th 2025 30 Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Tr 3540 45 Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gl 5055 60 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gl 6570 75 80 Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Ar85 90 95 Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pr100 105 110 Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVa 115 120 125 Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys LeuCys Al 130 135 140 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Se 145 150 155 160 Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Le 165 170 175 Gln 177 amino acids amino acid unknownunknown peptide 312 His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly ProAla Ser Se 1 5 10 15 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Il 20 25 30 Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Ly 35 40 45 Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His SerLeu Gly Il 50 55 60 Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Al 65 70 75 80 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Le 85 90 95 Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu As 100 105 110 Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gl 115 120 125 Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Al 130 135 140 Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Le 145 150 155 160 Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Le 165 170 175 Arg 531 base pairsnucleic acid unknown unknown other nucleic acid /desc = ”synthetic“ 313CACCTTGCGC AGCCCGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 60TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCA 120GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACA 180TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGC 240GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCT 300GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGA 360TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCC 420ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCT 480GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG C 531

We claim the following:
 1. A hematopoietic protein comprising; an aminoacid sequence of the formula: R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁wherein R₁ and R₂ are independently selected from the group consistingof: (I) A polypeptide comprising a modified human G-CSF amino acidsequence selected from the group consisting of: (a) an amino acidsequence of the formula: 1                                   10 (SEQ IDNO: 1) Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gln Ser Xaa                        20 Leu Leu Xaa Xaa Xaa Glu Gln Val Xaa Lys XaaGln Gly Xaa Gly     30                                      40 Ala XaaLeu Gln Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                        50 Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser XaaGly Ile Pro Trp     60                                      70 Ala ProLeu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly                        80 Xaa Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu     90                                      100 Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu                        110 Xaa Thr Leu Gln Xaa Asp Val Ala Asp Phe AlaXaa Thr Ile Trp     120                                     130 Gln GlnMet Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gln Pro Thr                        140 Gln Gly Ala Met Pro Ala Phe Ala Ser Ala XaaGln Xaa Xaa Ala     150                                     160 Gly GlyVal Leu Val Ala Ser Xaa Leu Gln Xaa Phe Leu Xaa Xaa                        170 Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser; wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can optionally bedeleted from said modified human G-CSF amino acid sequence; and whereinthe N-terminus is joined to the C-terminus directly or through a linkercapable of joining the N-terminus to the C-terminus and having new C-and N-termini at amino acids: 38-39 39-40 40-41 41-42 42-43 43-44 45-4648-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-59 59-60 60-61 61-6262-63 63-64 64-65 65-66 66-67 67-68 68-69 69-70 70-71 71-72 91-92 92-9393-94 94-95 95-96 96-97 97-98 98-99  99-100 123-124 124-125 125-126126-127 128-129 128-129 129-130 130-131 131-132 132-133 133-134 134-135135-136 136-137 137-138 138-139 139-140 140-141 141-142 or 142-143respectively; and

(b) an amino acid sequence of the formula:1                                   10 (SEQ ID NO: 1) Xaa Xaa Xaa GlyPro Ala Ser Ser Leu Pro Gln Ser Xaa                         20 Leu LeuXaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly    30                                      40 Ala Xaa Leu Gln Glu XaaLeu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa GluXaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp    60                                      70 Ala Pro Leu Ser Ser XaaPro Ser Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu    90                                      100 Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu                         110 Xaa ThrLeu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp    120                                     130 Gln Gln Met Glu Xaa XaaGly Met Ala Pro Ala Leu Gln Pro Thr                         140 Gln GlyAla Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala    150                                     160 Gly Gly Val Leu Val AlaSer Xaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser TyrArg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser, wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can be deleted; whereinthe N-terminus is joined to the C-terminus directly or through a linkercapable of joining the N-terminus to the C-terminus and having new C-and N-terminus at amino acids: 2-3 10-11 12-13 18-19 122-123 158-159169-170; (II) A polypeptide comprising; a modified human IL-3 amino acidsequence of the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr SerTrp Val Asn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu; wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence;wherein from 0 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂), capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2727-28 28-29 29-30 30-31 31-32 32-33 33-34 34-35 35-36 36-37 37-38 38-3939-40 40-41 41-42 49-50 50-51 51-52 52-53 53-54 54-55 64-65 65-66 66-6767-68 68-69 69-70 70-71 71-72 72-73 82-83 83-84 84-85 85-86 86-87 87-8888-89 89-90 90-91 91-92 92-93 97-98 98-99  99-100 100-101 101-102102-103 or 103-104 respectively;

(III) A polypeptide comprising; a modified human c-mpl ligand amino acidsequence selected from the group consisiting of: (a) an amino acidsequence of the formula:SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ ID NO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlepheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg 153

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2727-28 28-29 29-30 30-31 32-33 33-34 34-35 36-37 37-38 38-39 40-41 41-4242-43 43-44 44-45 46-47 47-48 48-49 50-51 51-52 52-53 53-54 54-55 55-5656-57 57-58 58-59 59-60 78-79 79-80 80-81 81-82 82-83 83-84 84-85 85-8686-87 87-88 88-89 108-109 109-110 110-111 111-112 112-113 113-114114-115 115-116 116-117 117-118 118-119 119-120 120-121 121-122 122-123123-124 124-125 125-126 126-127 or 127-128 respectively; and

(b) an amino acid sequence of the formula:SerProAlaProProAlaXaaAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ ID NO:283) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuXaaVal   135            140            145            150 Arg 153

wherein Xaa at position 7 is Ser or Ala; Xaa at position 112 is deletedor Leu, Ala, Val, Ile, Pro, Phe, Trp, or Met; Xaa at position 113 isdeleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa at position114 is deleted or Pro, Phe, Ala, Val, Leu, Ile, Trp, or Met; Xaa atposition 115 is deleted or Gln, Gly, Ser, Thr, Tyr, or Asn; Xaa atposition 151 is Ser or Ala, wherein the N-terminus is joined to theC-terminus directly or through a linker capable of joining theN-terminus to the C-terminus and having new C- and N-termini at aminoacids: 26-27 27-28 28-29 29-30 30-31 32-33 33-34 34-35 36-37 37-38 38-3940-41 41-42 42-43 43-44 44-45 46-47 47-48 48-49 50-51 51-52 52-53 53-5454-55 55-56 56-57 57-58 58-59 59-60 78-79 79-80 80-81 81-82 82-83 83-8484-85 85-86 86-87 87-88 88-89 108-109 109-110 110-111 111-112 112-113113-114 114-115 115-116 116-117 117-118 118-119 119-120 120-121 121-122122-123 123-124 124-125 125-126 126-127 or 127-128;

(IV) A polypeptide comprising; a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence; andwherein from 1 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3; and (V) a colony stimulating factor; and wherein L₁ is alinker capable of linking R₁ to R₂; with the proviso that at least R₁ orR₂ is selected from the polypeptide of formula (I), (II), or (III); andsaid hematopoietic protein can optionally be immediately preceded by(methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).
 2. Ahematopoietic protein comprising; an amino acid sequence of the formula:R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ and R₂ are independentlyselected from the group consisting of: (I) A polypeptide comprising; amodified human G-CSF amino acid sequence of the formula:1                                   10 (SEQ ID NO: 1) Xaa Xaa Xaa GlyPro Ala Ser Ser Leu Pro Gln Ser Xaa                         20 Leu LeuXaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly30                                      40 Ala Xaa Leu Gln Glu Xaa LeuXaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa Glu XaaXaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp60                                      70 Ala Pro Leu Ser Ser Xaa ProSer Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu90                                      100 Leu Gln Ala Leu Glu Gly IleSer Pro Glu Leu Gly Pro Thr Leu                         110 Xaa Thr LeuGln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp120                                     130 Gln Gln Met Glu Xaa Xaa GlyMet Ala Pro Ala Leu Gln Pro Thr                         140 Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala150                                     160 Gly Gly Val Leu Val Ala SerXaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser Tyr ArgVal Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser, wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can optionally bedeleted from said modified human G-CSF amino acid sequence; and whereinthe N-terminus is joined to the C-terminus directly or through a linkercapable of joining the N-terminus to the C-terminus and having new C-and N-termini at amino acids; 38-39 39-40 40-41 41-42 42-43 43-44 45-4648-49 49-50 52-53 53-54 54-55 55-56 56-57 57-58 58-59 59-60 60-61 61-6262-63 63-64 64-65 65-66 66-67 67-68 68-69 69-70 70-71 71-72 91-92 92-9393-94 94-95 95-96 96-97 97-98 98-99  99-100 123-124 124-125 125-126126-127 128-129 128-129 129-130 130-131 131-132 132-133 133-134 134-135135-136 136-137 137-138 138-139 139-140 140-141 141-142 or 142-143respectively;

(II) A polypeptide comprising; a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe; Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile Leu; Xaa at position 93 is Thr, Asp,Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile, Ser,Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 is His,Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, orTyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaa atposition 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence;wherein from 0 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂), capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2749-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-3153-54 87-88 31-32 54-55 88-89 32-33 64-65 89-90 33-34 65-66 90-91 34-3566-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38-3970-71  99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83102-103 or 103-104 respectively;

(III) A polypeptide comprising; a modified human c-mpl ligand amino acidsequence of the formula:SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ ID NO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg 153

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn, wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2751-52 108-109 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-11534-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-12243-44 83-84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87125-126 48-49 87-88 126-127 50-51 88-89 or 127-128 respectively;

(IV) A polypeptide comprising; a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu; wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence; andwherein from 1 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3; and (V) a colony stimulating factor wherein L₁ is alinker capable of linking R₁ to R₂ with the proviso that at least R₁ orR₂ is selected from the polypeptide of formula (I), (II), or (III) andsaid hematopoietic protein can optionally be immediately preceded by(methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).
 3. Ahematopoietic protein comprising an amino acid sequence of the formula:R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ and R₂ are independentlyselected from the group consisting of: (I) A polypeptide comprising; amodified human G-CSF amino acid sequence of the formula:1                                   10 Xaa Xaa Xaa Gly Pro Ala Ser SerLeu Pro Gln Ser Xaa (SEQ ID NO: 1)                         20 Leu LeuXaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly    30                                      40 Ala Xaa Leu Gln Glu XaaLeu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa GluXaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp    60                                      70 Ala Pro Leu Ser Ser XaaPro Ser Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu    90                                      100 Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu                         110 Xaa ThrLeu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp    120                                     130 Gln Gln Met Glu Xaa XaaGly Met Ala Pro Ala Leu Gln Pro Thr                         140 Gln GlyAla Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala    150                                     160 Gly Gly Val Leu Val AlaSer Xaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser TyrArg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser, wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can be deleted from saidmodified human G-CSF amino acid sequence; and wherein the N-terminus isjoined to the C-terminus directly or through a linker capable of joiningthe N-terminus to the C-terminus and having new C- and N-termini atamino acids: 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-12641-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-13353-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-14060-61 98-99 140-141 61-62  99-100 141-142 or 142-143 respectively;

(II) A polypeptide comprising; a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence; andwherein from 0 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2749-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-3153-54 87-88 31-32 54-55 88-89 32-33 64-65 89-90 33-34 65-66 90-91 34-3566-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38-3970-71  99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83102-103 or 103-104 respectively;

(III) A polypeptide comprising; a modified human c-mpl ligand amino acidsequence of the formula:SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ ID NO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg 153

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 52-53108-109 53-54 109-110 54-55 110-111 55-56 111-112 56-57 112-113 57-58113-114 58-59 114-115 59-60 115-116 78-79 116-117 79-80 117-118 80-81118-119 81-82 119-120 82-83 120-121 83-84 121-122 84-85 122-123 85-86123-124 86-87 124-125 87-88 125-126 88-89 126-127 or 127-128respectively;

(IV) A polypeptide comprising; a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human IL-3 amino acid sequence; andwherein from 1 to 44 of the amino acids designated by Xaa are differentfrom the corresponding amino acids of native (1-133) humaninterleukin-3, and (V) a colony stimulating factor; and wherein L₁ is alinker capable of linking R₁ to R₂ with the proviso that at least R₁ orR₂ is selected from the polypeptide of formula (I), (II), or (III); andsaid hematopoietic protein can optionally be immediately preceded by(methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).
 4. Thehematopoietic protein as recited in claim 1 wherein the polypeptide of(IV) is selected from the from the group consisting of: Ala Asn Cys SerIle Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO: 225) Arg Pro ProAla Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ile Leu MetGlu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys LeuPro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly AspTrp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln AlaGln Glu Gln Gln; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys (SEQ ID NO: 226) Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu AsnSer Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu LeuAla Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln; Ala Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys (SEQ ID NO: 227) Val Pro Pro Ala ProLeu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu ArgAsn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu GluAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro SerAla Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gln; and Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg(SEQ ID NO: 228) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln.


5. The hematopoietic protein as recited in claim 2 wherein thepolypeptide of (IV) is selected from the from the group consisting of:Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO:225) Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp ValAsp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln; Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys (SEQ ID NO: 226) Arg Pro Pro Asn Pro Leu Leu Asp ProAsn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg ThrPro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln; Ala AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO: 227) ValPro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp IleLeu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln; and Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg (SEQ ID NO: 228) Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerArg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln.


6. The hematopoietic protein as recited in claim 3 wherein thepolypeptide of (IV) is selected from the from the group consisting of:Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO:225) Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp ValAsp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln; Ala Asn Cys Ser Ile Met Ile Asp Glu IleIle His His Leu Lys (SEQ ID NO: 226) Arg Pro Pro Asn Pro Leu Leu Asp ProAsn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg ThrPro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser GlyIle Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala AlaPro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln; Ala AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO: 227) ValPro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met Asp IleLeu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln; and Asn Cys Ser Ile Met Ile Asp Glu Ile Ile HisHis Leu Lys Arg (SEQ ID NO: 228) Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro SerArg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys LeuThr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln.


7. A hematopoietic protein comprising; an amino acid sequence of theformula: R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ is a polypeptidecomprising; a modified human G-CSF amino acid sequence of the formula:1                                   10 Xaa Xaa Xaa Gly Pro Ala Ser SerLeu Pro Gln Ser Xaa (SEQ ID NO: 1)                         20 Leu LeuXaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly    30                                      40 Ala Xaa Leu Gln Glu XaaLeu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa GluXaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp    60                                      70 Ala Pro Leu Ser Ser XaaPro Ser Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu    90                                      100 Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu                         110 Xaa ThrLeu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp    120                                     130 Gln Gln Met Glu Xaa XaaGly Met Ala Pro Ala Leu Gln Pro Thr                         140 Gln GlyAla Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala    150                                     160 Gly Gly Val Leu Val AlaSer Xaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser TyrArg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser, wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can be deleted from saidmodified human G-CSF amino acid sequence; and wherein the N-terminus isjoined to the C-terminus directly or through a linker capable of joiningthe N-terminus to the C-terminus and having new C- and N-termini atamino acids: 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-12641-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-13353-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-14060-61 98-99 140-141 61-62  99-100 141-142

or 142-143 respectively, wherein R₂ is a polypeptide comprising; amodified human IL-3 amino acid sequence of the formula: Ala Pro Met ThrGln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn (SEQ ID NO: 2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human interleukin-3 amino acidsequence; and wherein from 0 to 44 of the amino acids designated by Xaaare different from the corresponding amino acids of native (1-133) humaninterleukin-3 and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2749-50 83-84 27-28 50-51 84-85 28-29 51-52 85-86 29-30 52-53 86-87 30-3153-54 87-88 31-32 54-55 88-89 32-33 64-65 89-90 33-34 65-66 90-91 34-3566-67 91-92 35-36 67-68 92-93 36-37 68-69 97-98 37-38 69-70 98-99 38-3970-71  99-100 39-40 71-72 100-101 40-41 72-73 101-102 41-42 82-83102-103 or 103-104 respectively;

wherein L₁ is a linker capable of linking R₁ to R₂ and saidhematopoietic protein can optionally be immediately preceded by(methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).
 8. Ahematopoietic protein comprising; an amino acid sequence of the formula:R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ is a polypeptidecomprising; a modified human G-CSF amino acid sequence of the formula:1                                   10 Xaa Xaa Xaa Gly Pro Ala Ser SerLeu Pro Gln Ser Xaa (SEQ ID NO: 1)                         20 Leu LeuXaa Xaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly    30                                      40 Ala Xaa Leu Gln Glu XaaLeu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa GluXaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp    60                                      70 Ala Pro Leu Ser Ser XaaPro Ser Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu    90                                      100 Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu                         110 Xaa ThrLeu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp    120                                     130 Gln Gln Met Glu Xaa XaaGly Met Ala Pro Ala Leu Gln Pro Thr                         140 Gln GlyAla Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala    150                                     160 Gly Gly Val Leu Val AlaSer Xaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser TyrArg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser; wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can be deleted from saidmodified human G-CSF amino acid sequence and wherein the N-terminus isjoined to the C-terminus directly or through a linker capable of joiningthe N-terminus to the C-terminus and having new C- and N-termini atamino acids: 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-12641-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-13353-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-14060-61 98-99 140-141 61-62  99-100 141-142 or 142-143 respectively;

R₂ is a polypeptide comprising a modified human IL-3 amino acid sequenceof the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp ValAsn (SEQ ID NO:2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                  130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus; and wherein from 1 to 44 of the amino acidsdesignated by Xaa are different from the corresponding amino acids ofnative (1-133) human interleukin-3 and L₁ is a linker capable of linkingR₁ to R₂ and additionally said hematopoietic protein can be immediatelypreceded by (methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹). 9.A hematopoietic protein comprising an amino acid sequence of theformula: R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ is a polypeptidecomprising; a modified human G-CSF amino acid sequence of the formula:1                                   10 (SEQ ID NO:1) Xaa Xaa Xaa Gly ProAla Ser Ser Leu Pro Gln Ser Xaa                         20 Leu Leu XaaXaa Xaa Glu Gln Val Xaa Lys Xaa Gln Gly Xaa Gly    30                                      40 Ala Xaa Leu Gln Glu XaaLeu Xaa Ala Thr Tyr Lys Leu Xaa Xaa                         50 Xaa GluXaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly Ile Pro Trp    60                                      70 Ala Pro Leu Ser Ser XaaPro Ser Xaa Ala Leu Xaa Leu Ala Gly                         80 Xaa LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu    90                                      100 Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu                         110 Xaa ThrLeu Gln Xaa Asp Val Ala Asp Phe Ala Xaa Thr Ile Trp    120                                     130 Gln Gln Met Glu Xaa XaaGly Met Ala Pro Ala Leu Gln Pro Thr                         140 Gln GlyAla Met Pro Ala Phe Ala Ser Ala Xaa Gln Xaa Xaa Ala    150                                     160 Gly Gly Val Leu Val AlaSer Xaa Leu Gln Xaa Phe Leu Xaa Xaa                         170 Ser TyrArg Val Leu Xaa Xaa Leu Ala Gln Pro

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position2 is Pro or Leu; Xaa at position 3 is Leu, Arg, Tyr or Ser; Xaa atposition 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys,Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, Ile, Tyror Arg; Xaa at position 18 is Leu, Thr, Pro, His, Ile or Cys; Xaa atposition 22 is Arg, Tyr, Ser, Thr or Ala; Xaa at position 24 is Ile,Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly; Xaa at position 30is Ala, Ile, Leu or Gly; Xaa at position 34 is Lys or Ser; Xaa atposition 36 is Cys or Ser; Xaa at position 42 is Cys or Ser; Xaa atposition 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu; Xaaat position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gln, or Thr;Xaa at position 46 is Glu, Arg, Phe, Arg, Ile or Ala; Xaa at position 47is Leu or Thr; Xaa at position 49 is Leu, Phe, Arg or Ser; Xaa atposition 50 is Leu, Ile, His, Pro or Tyr; Xaa at position 54 is Leu orHis; Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gln, Lys,Leu or Cys; Xaa at position 70 is Gln, Pro, Leu, Arg or Ser; Xaa atposition 74 is Cys or Ser; Xaa at position 104 is Asp, Gly or Val; Xaaat position 108 is Leu, Ala, Val, Arg, Trp, Gln or Gly; Xaa at position115 is Thr, His, Leu or Ala; Xaa at position 120 is Gln, Gly, Arg, Lysor His Xaa at position 123 is Glu, Arg, Phe or Thr Xaa at position 144is Phe, His, Arg, Pro, Leu, Gln or Glu; Xaa at position 146 is Arg orGln; Xaa at position 147 is Arg or Gln; Xaa at position 156 is His, Glyor Ser; Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa atposition 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly,Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa atposition 170 is His, Arg or Ser, wherein optionally 1-11 amino acidsfrom the N-terminus and 1-5 from the C-terminus can be deleted from saidmodified human G-CSF amino acid sequence and wherein the N-terminus isjoined to the C-terminus directly or through a linker capable of joiningthe N-terminus to the C-terminus and having new C- and N-termini atamino acids: 38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-12641-42 65-66 126-127 42-43 66-67 128-129 43-44 67-68 128-129 45-46 68-69129-130 48-49 69-70 130-131 49-50 70-71 131-132 52-53 71-72 132-13353-54 91-92 133-134 54-55 92-93 134-135 55-56 93-94 135-136 56-57 94-95136-137 57-58 95-96 137-138 58-59 96-97 138-139 59-60 97-98 139-14060-61 98-99 140-141 61-62  99-100 141-142 or 142-143 respectively;

R₂ is a polypeptide comprising a modified human c-mpl ligand amino acidsequence of the formula:SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ IDNO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn, and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2751-52 108-109 27-28 52-53 109-110 28-29 53-54 110-111 29-30 54-55111-112 30-31 55-56 112-113 32-33 56-57 113-114 33-34 57-58 114-11534-35 58-59 115-116 36-37 59-60 116-117 37-38 78-79 117-118 38-39 79-80118-119 40-41 80-81 119-120 41-42 81-82 120-121 42-43 82-83 121-12243-44 83-84 122-123 44-45 84-85 123-124 46-47 85-86 124-125 47-48 86-87125-126 48-49 87-88 126-127 50-51 88-89 or  127-128;

wherein L₁ is a linker capable of linking R₁ to R₂ and additionally saidhematopoietic protein can be immediately preceded by (methionine⁻¹),(alanine⁻¹) or (methionine⁻², alanine⁻¹).
 10. A hematopoietic proteincomprising; an amino acid sequence of the formula: R₁—L₁—R₂, R₂—L₁—R₁,R₁—R₂, or R₂—R₁ wherein R₁ is a polypeptide comprising a modified humanc-mpl ligand amino acid sequence of the formula:SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQ IDNO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg 153

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn, and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2727-28 28-29 29-30 30-31 32-33 33-34 34-35 36-37 37-38 38-39 40-41 41-4242-43 43-44 44-45 46-47 47-48 48-49 50-51 51-52 52-53 53-54 54-55 55-5656-57 57-58 58-59 59-60 78-79 79-80 80-81 81-82 82-83 83-84 84-85 85-8686-87 87-88 88-89 108-109 109-110 110-111 111-112 112-113 113-114114-115 115-116 116-117 117-118 118-119 119-120 120-121 121-122 122-123123-124 124-125 125-126 126-127 or 127-128;

wherein R₂ is a polypeptide comprising a modified human IL-3 amino acidsequence of the formula: Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr SerTrp Val Asn (SEQ ID NO:2)1               5                   10                  15 Cys Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                20                  25                  30 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa                35                  40                  45 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                50                  55                  60 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                65                  70                  75 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                80                  85                  90 Xaa Xaa XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                95                  100                 105 Xaa Phe XaaXaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa                110                 115                 120 Xaa Xaa XaaGln Gln Thr Thr Leu Ser Leu Ala Ile Phe                125                 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg; Xaaat position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln; Xaa at position19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys; Xaa at position 20 is Ile,Cys, Gln, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys,Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val; Xaa at position 22 isGlu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly; Xaa atposition 23 is Ile, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg; Xaaat position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position25 is Thr, His, Gly, Gln, Arg, Pro, or Ala; Xaa at position 26 is His,Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg,Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro,Val or Trp; Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val; Xaaat position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys; Xaa atposition 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln; Xaa at position 32is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro,Leu, Gln, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser,Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met; Xaa at position 35 isLeu, Ala, Gly, Asn, Pro, Gln, or Val; Xaa at position 36 is Asp, Leu, orVal; Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile; Xaa at position38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg; Xaa atposition 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Metor Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,Gln, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg,Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro; Xaa at position 45 isGln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala,Ile, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu,Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly; Xaa at position 47 isIle, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser,Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa atposition 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa atposition 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,His, Phe, Met or Gln; Xaa at position 51 is Asn, Arg, Met, Pro, Ser,Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His,Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaaat position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr,Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys; Xaa at position 59 is GluTyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr,Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile; Xaa atposition 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa atposition 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val,Thr, Pro, His, Leu, Phe, or Ser; Xaa at position 66 is Lys, Ile, Arg,Val, Asn, Glu, or Ser; Xaa at position 67 is Ser, Ala, Phe, Val, Gly,Asn, Ile, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, Ile,Phe, Thr, or His; Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg,Trp, Gly, or Leu; Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, orAsn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; Xaa atposition 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala; Xaa at position 75 isGlu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu; Xaa at position 76is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 isIle, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu,Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile,Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, orArg; Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr,Ser, Ala, Tyr, Phe, Ile, Met or Val; Xaa at position 83 is Pro, Ala,Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, orVal; Xaa at position 85 is Leu, Asn, Val, or Gln; Xaa at position 86 isPro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly;Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 isThr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser; Xaa at position 90 isAla, Pro, Ser, Thr, Gly, Asp, Ile, or Met; Xaa at position 91 is Ala,Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe,Arg, Ser, Lys, His, Ala, Gly, Ile or Leu; Xaa at position 93 is Thr,Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, Ile,Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro; Xaa at position 95 isHis, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe,Ile, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr; Xaaat position 97 is Ile, Val, Lys, Ala, or Asn; Xaa at position 98 is His,Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg,Tyr or Pro; Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg,Ile, Ser, Gln, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His,Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln; Xaa atposition 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met,Pro, Leu, Gln, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro,Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His; Xaa atposition 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro; Xaa atposition 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa atposition 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, orTrp; Xaa at position 111 is Leu, Ile, Arg, Asp, or Met; Xaa at position112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 isPhe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn; Xaaat position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa atposition 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser,Asn, His, Ala, Tyr, Phe, Gln, or Ile; Xaa at position 117 is Thr, Ser,Asn, Ile, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala,Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu,Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val,or Gln; Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, orGly; Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile,Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr,or Leu, wherein from 1 to 14 amino acids can optionally be deleted fromthe N-terminus and/or from 1 to 15 amino acids can optionally be deletedfrom the C-terminus of said modified human interleukin-3 amino acidsequence; and wherein from 1 to 44 of the amino acids designated by Xaaare different from the corresponding amino acids of native (1-133) humaninterleukin-3; wherein L₁ is a linker capable of linking R₁ to R₂; andsaid hematopoietic protein can optionally be immediately preceded by(methionine⁻¹), (alanine⁻¹) or (methionine⁻², alanine⁻¹).
 11. Thehematopoeitic protein of claim 8 or 10 wherein R₂ is selected from thegroup consisting of: Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His HisLeu Lys (SEQ ID NO:225) Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn LeuAsn Ala Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu AlaIle Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser ArgHis Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu ThrPhe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln; Ala Asn Cys Ser IleMet Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO:226) Arg Pro Pro AsnPro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp Ile Leu Met GluArg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His LeuGlu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gln Gln; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys(SEQ ID NO:227) Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn SerGlu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu AlaPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln; and Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:228) Pro Pro Ala Pro LeuLeu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg AsnLeu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu AsnAla Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser AlaThr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln GluPhe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu GlnGln.


12. A hematopoietic protein comprising; an amino acid sequence of theformula: R₁-L₁-R₂, R₂-L₁-R₁, R₁-R₂, or R₂-R₁ wherein R₁ is a polypeptidecomprising; a modified human c-mpl ligand amino acid sequence of theformula: SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer (SEQID NO:256) 1           5              10             15HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro20             25             30             35ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu   40             45             50             55ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla      60             65             70             75AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly         80             85             90             95GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa            100            105            110XaaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis115            120            125            130LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal   135            140            145            150 Arg 153

wherein Xaa at position 112 is deleted or Leu, Ala, Val, Ile, Pro, Phe,Trp, or Met; Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu,Ile, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,Leu, Ile, Trp, or Met; Xaa at position 115 is deleted or Gln, Gly, Ser,Thr, Tyr, or Asn; and wherein the N-terminus is joined to the C-terminusdirectly or through a linker (L₂) capable of joining the N-terminus tothe C-terminus and having new C- and N-termini at amino acids: 26-2727-28 28-29 29-30 30-31 32-33 33-34 34-35 36-37 37-38 38-39 40-41 41-4242-43 43-44 44-45 46-47 47-48 48-49 50-51 51-52 52-53 53-54 54-55 55-5656-57 57-58 58-59 59-60 78-79 79-80 80-81 81-82 82-83 83-84 84-85 85-8686-87 87-88 88-89 108-109 109-110 110-111 111-112 112-113 113-114114-115 115-116 116-117 117-118 118-119 119-120 120-121 121-122 122-123123-124 124-125 125-126 126-127 or 127-128 respectively;

wherein R₂ is G-CSF or G-CSF Ser¹⁷ wherein L₁ is a linker capable oflinking R₁ to R₂; and said hematopoietic protein can optionally beimmediately preceded by (methionine⁻¹), (alanine⁻¹) or (methionine⁻²,alanine⁻¹).
 13. The hematopoietic protein as recited in claim 1, 2, 3,4, 5, 6, 7, 8, 9, 10 or 12 wherein said linker (L₂) is selected from thegroup consisting of; GlyGlyGlySer; (SEQ ID NO:12)GlyGlyGlySerGlyGlyGlySer; (SEQ ID NO:242)GlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ ID NO:243) Ser;SerGlyGlySerGlyGlySer; (SEQ ID NO:244) GluPheGlyAsnMetAla; (SEQ IDNO:245) GluPheGlyGlyAsnMetAla; (SEQ ID NO:246)GluPheGlyGlyAsnGlyGlyAsnMetAla; (SEQ ID NO:247) andGlyGlySerAspMetAlaGly. (SEQ ID NO:248)


14. The hematopoietic protein as recited in claim 11 wherein said linker(L2) is selected from the group consisting of: GlyGlyGlySer; (SEQ IDNO:12) GlyGlyGlySerGlyGlyGlySer; (SEQ ID NO:242)GlyGlyGlySerGlyGlyGlySerGlyGlyGly (SEQ ID NO:243) Ser;SerGlyGlySerGlyGlySer; (SEQ ID NO:244) GluPheGlyAsnMetAla; (SEQ IDNO:245) GluPheGlyGlyAsnMetAla; (SEQ ID NO:246)GluPheGlyGlyAsnGlyGlyAsnMetAla; (SEQ ID NO:247) andGlyGlySerAspMetAlaGly. (SEQ ID NO:248)


15. The hematopoietic protein as recited in claim 1 wherein said proteinis selected from the group consisting of: Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg (SEQ ID NO:166) Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn LeuArg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln GlnTyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser AsnMet Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser LeuGly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu AlaGly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu GlnAla Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln LeuAsp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly MetAla Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly GlySer Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly AspGly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr; Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg (SEQ ID NO:167) Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn LeuArg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln GlnTyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln SerPhe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr; Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Arg (SEQ ID NO:168) Pro Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu LysLeu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val GluGly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala ProGlu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro ThrGln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly ValLeu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu ArgHis Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser; Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys Arg (SEQ ID NO:169) Pro Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu LysLeu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val GluGly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg (SEQ ID NO:170) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly GlyGly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro AlaLeu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln SerPhe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala AlaLeu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro SerGln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu Gly; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg (SEQ ID NO:171) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu AsnAsp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu GluSer Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala IleLeu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg HisPro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr PheTyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly GlyGly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly GlyVal Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val LeuArg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu LeuLys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln GluLys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln GlyLeu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu GluLeu Gly; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg(SEQ ID NO:172) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala Met ProAla Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln ProSer Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile ProTrp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys LeuSer Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro AlaLeu Gln Pro; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg(SEQ ID NO:173) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp GluAsp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly SerPro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe AlaSer Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln SerPhe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly GlySer Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys IleGln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe AlaThr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro;Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:177) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu GlnGlu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu LeuGly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln AlaLeu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu AspThr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met GluGlu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala PheAla; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:175) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val LeuVal Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg HisLeu Ala Gln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys SerLeu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys LeuCys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His SerLeu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln LeuAla Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu LeuGln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu GlyMet Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala; Asn CysSer Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ ID NO:176) ProPro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile LeuMet Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala GlyAsp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu GlnAla Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly SerGly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:177) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val LeuLeu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu TyrGln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln MetGlu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro ThrPro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:179) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu GlnLeu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu GlyMet Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser AlaPhe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe LeuGlu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg LysIle Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys LeuCys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp AlaPro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser GlnLeu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly IleSer; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:181) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGlu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu SerHis Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gln Pro Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu LysSer Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu GlnLeu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu LeuGly; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg (SEQ IDNO:182) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp ValSer Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val ArgAla Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn LeuGln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile IleLys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val ThrLeu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly Ser Pro GlyGly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr ProLeu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala ProAla Leu Gln Pro; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg (SEQ ID NO:183) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly GlySer Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro SerLys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu GlnSer Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Thr ProLeu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala ProAla Leu Gln Pro; Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg (SEQ ID NO:184) Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn AspGlu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu SerPhe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile LeuArg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His ProIle Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe TyrLeu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly GlySer Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gln ArgArg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg His Leu Ala Gln Pro Thr Pro Leu Gly Pro Ala Ser SerLeu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His ProGlu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His SerGly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro GluLeu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr GlnGly Ala Met Pro Ala Phe Ala;MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:194) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr;MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:195) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSer;MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:196) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAla;MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:197) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGly;MetAlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAla (SEQ IDNO:198) ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro; Ala Asn Cys Ser Ile Met Ile Asp Glu Ile IleHis His Leu Lys (SEQ ID NO:209) Arg Pro Pro Ala Pro Leu Leu Asp Pro AsnAsn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu ProAsn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly IleGlu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu LysLeu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val GluGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro SerPro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Gly Pro Thr Cys Leu SerSer Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu GlnSer Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys AspPro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg PheLeu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn MetAla Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu ArgAsp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro LeuPro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys ThrGln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu LeuGlu Gly Val Met Ala Ala Arg Gly Gln Leu; Ala Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys (SEQ ID NO:210) Arg Pro Pro Ala Pro Leu LeuAsp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn LeuArg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn AlaSer Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala ThrAla Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gln Glu PheArg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln Glu Gln GlnTyr Val Glu Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr IleAsn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Gly Thr GlnLeu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe LeuSer Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly GlySer Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro ProAla Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu HisSer Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu LeuPro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr LysAla Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala AlaArg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser GlyGln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu; Ala Asn Cys Ser IleMet Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO:211) Arg Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn LeuGlu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu ProSer Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala GlnGlu Gln Gln Tyr Val Glu Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro IleSer Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn MetGly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln HisLeu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu CysVal Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp LeuArg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu SerGln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val AspPhe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp IleLeu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln LeuGly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg LeuLeu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln; Ala AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys (SEQ ID NO:212) ArgPro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser IleLeu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Ser Pro Gly Glu Pro SerGly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys SerPro Asn Met Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His LeuLeu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys ValArg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu ArgVal Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser GlnCys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp PheSer Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile LeuGly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu GlyPro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu LeuLeu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg ThrThr; Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met (SEQ IDNO:186) Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala ValLys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu GluGln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp GluIle Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly GlyGly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro ProSer Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala Met Pro AlaPhe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro SerGly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr LysLeu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro TrpAla Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala AspPhe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro; Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys(SEQ ID NO:187) Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile IleIle Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu ValThr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp ProAsn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu GlyGly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro SerPro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala SerHis Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala GlnPro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu Glu GlnVal Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala ThrTyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly IlePro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly CysLeu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala LeuGlu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala ProAla Leu Gln Pro; Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp TrpGln (SEQ ID NO:189) Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr LeuGlu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Asn Cys Ser Ile Met Ile AspGlu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn AsnLeu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro AsnLeu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val GluGly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro; Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser IleLeu Met (SEQ ID NO:190) Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser PheVal Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu ArgAsn Leu Gln Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro IleIle Ile Lys Ala Gly Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr LeuVal Thr Leu Glu Gln Ala Gln Glu Gln Gln Gly Gly Gly Ser Gly Gly Gly SerGly Gly Gly Ser Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu LysArg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu ProSer Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro Ser Lys Glu Ser His LysSer Pro Asn Met Ala Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu ValSer Tyr Arg Val Leu Arg His Leu Ala Gln Pro Ser Gly Gly Ser Gly Gly SerGln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu GluLeu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser CysPro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly LeuPhe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu GlyPro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro; Asn Ala Ser GlyIle Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys (SEQ ID NO:191) Leu Pro SerAla Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp GlnGlu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gln Ala Gln GluGln Gln Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser IleMet Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu AspPro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu ArgLeu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val GluGly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn ProSer Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gln Gly AlaMet Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu AlaGln Pro Ser Gly Gly Ser Gly Gly Ser Gln Ser Phe Leu Leu Lys Ser Leu GluGln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys AlaThr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu GlyIle Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala GlyCys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln AlaLeu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu AspVal Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu Gln Pro;MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:199) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro;MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:200) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro;MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:201) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleIleIleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro;MetAlaAsnCysSerAsnMetIleAspGluIleIleThrHisLeuLysGlnProProLeu (SEQ IDNO:202) ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlyIleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlyIleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrIleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:221) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:222) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:223 LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ ID NO:234) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:235) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:236) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:237) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:238) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsn;AlaAsnCysSerIleMetIleAspGluIleIleHisHisLeuLysArgProProAlaPro (SEQ IDNO:239) LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerIleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGlyIleGluAlaIleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIleIleIleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrIleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLys; 1Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:271) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaLeu Gly 151 Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu166 Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 181 LeuCys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 196 Leu Gly HisSer Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys 211 Pro Ser Gln Ala LeuGln Leu Ala Gly Cys Leu Ser Gln Leu His 226 Ser Gly Leu Phe Leu Tyr GlnGly Leu Leu Gln Ala Leu Glu Gly 241 Ile Ser Pro Glu Leu Gly Pro Thr LeuAsp Thr Leu Gln Leu Asp 256 Val Ala Asp Phe Ala Thr Thr Ile Trp Gln GlnMet Glu Glu Leu 271 Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala MetPro Ala 286 Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala301 Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg 316 HisLeu Ala Gln Pro Asp Met Ala Thr Pro; 1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:272) 16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly 31 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Leu Gly 151 Pro Ala Ser Ser Leu ProGln Ser Phe Leu Leu Lys Ser Leu Glu 176 Gln Val Arg Lys Ile Gln Gly AspGly Ala Ala Leu Gln Glu Lys 191 Leu Cys Ala Thr Tyr Lys Leu Cys His ProGlu Glu Leu Val Leu 206 Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro LeuSer Ser Cys 221 Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln LeuHis 236 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly 251Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp 266 Val AlaAsp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu 281 Gly Met Ala ProAla Leu Gln Pro Thr Gln Gly Ala Met Pro Ala 296 Phe Ala Ser Ala Phe GlnArg Arg Ala Gly Gly Val Leu Val Ala 311 Ser His Leu Gln Ser Phe Leu GluVal Ser Tyr Arg Val Leu Arg 326 His Leu Ala Gln Pro Asp Met Ala Thr Pro;1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:273) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaPhe Leu 151 Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala166 Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 181 GluGlu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala 196 Pro Leu SerSer Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys 211 Leu Ser Gln Leu HisSer Gly Leu Phe Leu Tyr Gln Gly Leu Leu 226 Gln Ala Leu Glu Gly Ile SerPro Glu Leu Gly Pro Thr Leu Asp 241 Thr Leu Gln Leu Asp Val Ala Asp PheAla Thr Thr Ile Trp Gln 256 Gln Met Glu Glu Leu Gly Met Ala Pro Ala LeuGln Pro Thr Gln 271 Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg ArgAla Gly 286 Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser301 Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp Met Ala Thr Pro 316 LeuGly Pro Ala Ser Ser Leu Pro Gln Ser; 1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:274) 16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Glu Gln 151 Val Arg Lys Ile Gln GlyAsp Gly Ala Ala Leu Gln Glu Lys Leu 166 Cys Ala Thr Tyr Lys Leu Cys HisPro Glu Glu Leu Val Leu Leu 181 Gly His Ser Leu Gly Ile Pro Trp Ala ProLeu Ser Ser Cys Pro 196 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser GlnLeu His Ser 211 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu GlyIle 226 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val 241Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly 256 Met AlaPro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe 271 Ala Ser Ala PheGln Arg Arg Ala Gly Gly Val Leu Val Ala Ser 286 His Leu Gln Ser Phe LeuGlu Val Ser Tyr Arg Val Leu Arg His 301 Leu Ala Gln Pro Asp Met Ala ThrPro Leu Gly Pro Ala Ser Ser 316 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu;1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:275) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaLeu Leu 151 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro166 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser 181 GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile 196 Ser Pro GluLeu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val 211 Ala Asp Phe Ala ThrThr Ile Trp Gln Gln Met Glu Glu Leu Gly 226 Met Ala Pro Ala Leu Gln ProThr Gln Gly Ala Met Pro Ala Phe 241 Ala Ser Ala Phe Gln Arg Arg Ala GlyGly Val Leu Val Ala Ser 256 His Leu Gln Ser Phe Leu Glu Val Ser Tyr ArgVal Leu Arg His 271 Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly Pro AlaSer Ser 286 Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys301 Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr 316 TyrLys Leu Cys His Pro Glu Glu Leu Val; 1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:276) 16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Pro Leu 151 Ser Ser Cys Pro Ser GlnAla Leu Gln Leu Ala Gly Cys Leu Ser 166 Gln Leu His Ser Gly Leu Phe LeuTyr Gln Gly Leu Leu Gln Ala 181 Leu Glu Gly Ile Ser Pro Glu Leu Gly ProThr Leu Asp Thr Leu 196 Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile TrpGln Gln Met 211 Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln GlyAla 226 Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val 241Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg 256 Val LeuArg His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu Gly 271 Pro Ala Ser SerLeu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu 286 Gln Val Arg Lys Ile GlnGly Asp Gly Ala Ala Leu Gln Glu Lys 301 Leu Cys Ala Thr Tyr Lys Leu CysHis Pro Glu Glu Leu Val Leu 316 Leu Gly His Ser Leu Gly Ile Pro Trp Ala;1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:277) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaGln Ala 151 Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe166 Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu 181 LeuGly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe 196 Ala Thr ThrIle Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro 211 Ala Leu Gln Pro ThrGln Gly Ala Met Pro Ala Phe Ala Ser Ala 226 Phe Gln Arg Arg Ala Gly GlyVal Leu Val Ala Ser His Leu Gln 241 Ser Phe Leu Glu Val Ser Tyr Arg ValLeu Arg His Leu Ala Gln 256 Pro Asp Met Ala Thr Pro Leu Gly Pro Ala SerSer Leu Pro Gln 271 Ser Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys IleGln Gly 286 Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu301 Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile 316 ProTrp Ala Pro Leu Ser Ser Cys Pro Ser; 1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:278) 16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Leu Gln 151 Leu Ala Gly Cys Leu SerGln Leu His Ser Gly Leu Phe Leu Tyr 166 Gln Gly Leu Leu Gln Ala Leu GluGly Ile Ser Pro Glu Leu Gly 181 Pro Thr Leu Asp Thr Leu Gln Leu Asp ValAla Asp Phe Ala Thr 196 Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met AlaPro Ala Leu 211 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala PheGln 226 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe 241Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Asp 256 Met AlaThr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe 271 Leu Leu Lys SerLeu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly 286 Ala Ala Leu Gln Glu LysLeu Cys Ala Thr Tyr Lys Leu Cys His 301 Pro Glu Glu Leu Val Leu Leu GlyHis Ser Leu Gly Ile Pro Trp 316 Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala;1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:279) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaLeu Ala 151 Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly166 Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr 181 LeuAsp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile 196 Trp Gln GlnMet Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro 211 Thr Gln Gly Ala MetPro Ala Phe Ala Ser Ala Phe Gln Arg Arg 226 Ala Gly Gly Val Leu Val AlaSer His Leu Gln Ser Phe Leu Glu 241 Val Ser Tyr Arg Val Leu Arg His LeuAla Gln Pro Asp Met Ala 256 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro GlnSer Phe Leu Leu 271 Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Asp GlyAla Ala 286 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu301 Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro 316 LeuSer Ser Cys Pro Ser Gln Ala Leu Gln; 1 Met Ala Asn Cys Ser Ile Met IleAsp Glu Ile Ile His His Leu (SEQ ID NO:280) 16 Lys Arg Pro Pro Ala ProLeu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu Met AspArg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val Lys AsnLeu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro CysLeu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys AlaGly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 106Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 Ser ProGly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro Ser LysGlu Ser His Lys Ser Pro Asn Met Ala Glu Leu 151 Gly Met Ala Pro Ala LeuGln Pro Thr Gln Gly Ala Met Pro Ala 166 Phe Ala Ser Ala Phe Gln Arg ArgAla Gly Gly Val Leu Val Ala 181 Ser His Leu Gln Ser Phe Leu Glu Val SerTyr Arg Val Leu Arg 196 His Leu Ala Gln Pro Asp Met Ala Thr Pro Leu GlyPro Ala Ser 211 Ser Leu Pro Gln Ser Phe Leu Leu Lys Ser Leu Glu Gln ValArg 226 Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala 241Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 256 Ser LeuGly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln 271 Ala Leu Gln LeuAla Gly Cys Leu Ser Gln Leu His Ser Gly Leu 286 Phe Leu Tyr Gln Gly LeuLeu Gln Ala Leu Glu Gly Ile Ser Pro 301 Glu Leu Gly Pro Thr Leu Asp ThrLeu Gln Leu Asp Val Ala Asp 316 Phe Ala Thr Thr Ile Trp Gln Gln Met Glu;1 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu (SEQ IDNO:281) 16 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp31 Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 46 LeuGlu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser 61 Gly Ile GluAla Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser 76 Ala Thr Ala Ala ProSer Arg His Pro Ile Ile Ile Lys Ala Gly 91 Asp Trp Gln Glu Phe Arg GluLys Leu Thr Phe Tyr Leu Val Thr 106 Leu Glu Gln Ala Gln Glu Gln Gln TyrVal Glu Gly Gly Gly Gly 121 Ser Pro Gly Glu Pro Ser Gly Pro Ile Ser ThrIle Asn Pro Ser 136 Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met AlaGly Met 151 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala166 Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 181 LeuGln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 196 Ala Gln ProAsp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu 211 Pro Gln Ser Phe LeuLeu Lys Ser Leu Glu Gln Val Arg Lys Ile 226 Gln Gly Asp Gly Ala Ala LeuGln Glu Lys Leu Cys Ala Thr Tyr 241 Lys Leu Cys His Pro Glu Glu Leu ValLeu Leu Gly His Ser Leu 256 Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys ProSer Gln Ala Leu 271 Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly LeuPhe Leu 286 Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu301 Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala 316 ThrThr Ile Trp Gln Gln Met Glu Glu Leu; and 1 Met Ala Asn Cys Ser Ile MetIle Asp Glu Ile Ile His His Leu (SEQ ID NO:282) 16 Lys Arg Pro Pro AlaPro Leu Leu Asp Pro Asn Asn Leu Asn Asp 31 Glu Asp Val Ser Ile Leu MetAsp Arg Asn Leu Arg Leu Pro Asn 46 Leu Glu Ser Phe Val Arg Ala Val LysAsn Leu Glu Asn Ala Ser 61 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln ProCys Leu Pro Ser 76 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile LysAla Gly 91 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr106 Leu Glu Gln Ala Gln Glu Gln Gln Tyr Val Glu Gly Gly Gly Gly 121 SerPro Gly Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser 136 Pro Pro SerLys Glu Ser His Lys Ser Pro Asn Met Ala Ser Phe 151 Leu Glu Val Ser TyrArg Val Leu Arg His Leu Ala Gln Pro Asp 166 Met Ala Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe 181 Leu Leu Lys Ser Leu Glu Gln Val ArgLys Ile Gln Gly Asp Gly 196 Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr TyrLys Leu Cys His 211 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly IlePro Trp 226 Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly241 Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu 256 LeuGln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 271 Asp Thr LeuGln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp 286 Gln Gln Met Glu GluLeu Gly Met Ala Pro Ala Leu Gln Pro Thr 301 Gln Gly Ala Met Pro Ala PheAla Ser Ala Phe Gln Arg Arg Ala 316 Gly Gly Val Leu Val Ala Ser His LeuGln.


16. The hematopoeitic protein as recieted in claim 1 wherein said c-mplreceptor agonist is selected from the group consisiting of:MetAlaGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHis (SEQ ID NO:284) LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGln; andMetAlaGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu (SEQ ID NO:285) LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIlePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuAlaValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaAlaAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeu


17. The hematopoietic protein of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11or 12 wherein said colony stimulating factor is selected from the groupconsisting of GM-CSF, G-CSF, G-CSF Ser¹⁷, c-mpl ligand (TPO), M-CSF,erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8,IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3/flk2 ligand, humangrowth hormone, B-cell growth factor, B-cell differentiation factor,eosinophil differentiation factor and stem cell factor (SCF).
 18. Thehematopoietic protein of claim 17 wherein said colony stimulating factoris selected from the group consisting of G-CSF, G-CSF Ser¹⁷ and c-mplligand (TPO).
 19. A nucleic acid molecule encoding said hematopoieticprotein of claim
 1. 20. A nucleic acid molecule encoding saidhematopoietic protein of claim
 2. 21. A nucleic acid molecule encodingsaid hematopoietic protein of claim
 3. 22. A nucleic acid moleculeencoding said hematopoietic protein of claim
 4. 23. A nucleic acidmolecule encoding said hematopoietic protein of claim
 5. 24. A nucleicacid molecule encoding said hematopoietic protein of claim
 6. 25. Anucleic acid molecule encoding said hematopoietic protein of claim 7.26. A nucleic acid molecule encoding said hematopoietic protein of claim8.
 27. A nucleic acid molecule encoding said hematopoietic protein ofclaim
 9. 28. A nucleic acid molecule encoding said hematopoietic proteinof claim
 10. 29. A nucleic acid molecule encoding said hematopoieticprotein of claim
 11. 30. A nucleic acid molecule encoding saidhematopoietic protein of claim
 12. 31. A nucleic acid molecule encodingsaid hematopoietic protein of claim
 13. 32. A nucleic acid moleculeencoding said hematopoietic protein of claim
 14. 33. A nucleic acidmolecule encoding said hematopoietic protein of claim
 15. 34. A nucleicacid molecule encoding said hematopoietic protein of claim
 16. 35. Anucleic acid molecule encoding said hematopoietic protein of claim 17.36. The nucleic acid molecule according to claim 30 selected from groupconsisting of: 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 94) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACACTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601 CTGCAGCTGGACCTCCCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTGCCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAC CGCCGGGCAGGAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTACGCCACCTTGC 801 GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT851 TAGAGCAAGT GAGAAACATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 901CTGTGTGCCA CCTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG (SEQ ID NO: 95) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAACCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTCTGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601GCCCTGCAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTCGCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTGCAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGGGTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCACCTTGCGCAGC 851 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG901 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 951TGCCACCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 96) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGTCGCCGACTTT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC 551GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601 TCGTACCGCGTTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG 651 CTCTCAGAGC TTCCTGCTCAAGTCTTTAGA GCAAGTGAGA AAGATCCAGG 701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGTGTGCCACCTA CAAGCTGTGC 751 CACCCCGACG AGCTGGTGCT GCTCGGACAC TCTCTGGGCATCCCCTGGGC 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 901GAAGGGATAT CCTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAC (SEQ ID NO: 97) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCCAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCACGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGCTTACCCTTGA GCAAGCCCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCGACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCCCCT CTGCTTTCCA GCGCCGGGCA 601GGAGGGCTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTACGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 701 AGAGCTTCCT GCTCAAGTCTTTAGAGCAAG TGAGAAAGAT CCAGGGCGAT 751 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCCACCTACAAGC TGTCCCACCC 801 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCCTGGGCTCCCC 851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG 951GATATCCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 98) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTA 401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGCCTTCGCCTCT 451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG 551GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 601 AGAAAGATCCAGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC 651 CTACAAGCTG TGCCACCCCGAGGAGCTGGT GCTGCTCGGA CACTCTCTGG 701 GCATCCCCTG GGCTCCCCTG AGCTCCTGCCCCAGCCAGGC CCTGCAGCTG 751 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCTACCAGGGGCT 801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 901GAAGAACTGG GATAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG (SEQ ID NO: 99) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCCTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCGCCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 601TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA 651 GATCCAGGGCGATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA 701 AGCTGTGCCA CCCCGAGGAGCTGGTGCTGC TCGGACACTC TCTGGGCATC 751 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGCCAGGCCCTGC AGCTGGCAGG 801 CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAGGGGCTCCTGC 851 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG901 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA 951ACTGGGATAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 100) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCGCCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG501 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA 551GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 601 GCAGCGCTCCAGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA 651 GGAGCTGGTG CTGCTCGGACACTCTCTGGG CATCCCCTGG GCTCCCCTGA 701 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGGCAGGCTGCTT GAGCCAACTC 751 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCCTGGAAGGGAT 801 ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG851 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 901GCCCTGCAGC CCTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG (SEQ ID NO: 101) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAGAAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCTCTGCGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGCTGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAAGGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951GCAGCCCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 102) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAGCCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG 551TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 601 ACCTACAAGCTGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT 651 GGGCATCCCC TGGGCTCCCCTGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 701 TGGCAGGCTG CTTGAGCCAA CTCCATAGCGGCCTTTTCCT CTACCAGGGG 751 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTCCCACCTTGGA 801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 901CCGGCCTTCG CCTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG (SEQ ID NO: 107) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCGACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTACGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT 701 CCCTGCCCCA GAGCTTCCTGCTCAAGTCTT TAGAGCAAGT GAGAAAGATC 751 CAGGGCGATG GCGCAGCGCT CCAGGAGAAGCTGTGTGCCA CCTACAAGCT 801 GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTGGGCATCCCCT 851 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC901 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC 951CCTGGAAGGG ATATCCTAAT AA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATCACTTAAAGAG (SEQ ID NO: 103) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAACCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGAGAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGGTTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATCTGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG551 GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 601AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA 651 CAAGCTGTGCCACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA 701 TCCCCTGGGC TCCCCTGAGCTCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 751 GGCTGCTTGA GCCAACTCCA TAGCGGCCTTTTCCTCTACC AGGGGCTCCT 801 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACCTTGGACACAC 851 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA901 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC 951CTTCGCCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 104) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGGCGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACACTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCACGCCC TGCAGCTGGC501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGCGTCCCAC CTTGGACACA 601 CTGCAGCTGGACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTGCCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAGGAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTACGCCACCTTGC 801 GCAGCCCACA CCATTGGGCC CTCCCAGCTC CCTGCCCCAG AGCTTCCTGC851 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC 901CAGGAGAAGC TGTGTGCCAC CTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG (SEQ ID NO: 105) 51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA ACAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAC GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT CGCTTACAAG 451 CTGTGCCACC COGAGGAGCT GGTGCTGCTCGGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAGCTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGCCCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCGGGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGTTCTACGCCAC CTTGCGCAGC 851 CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTTCCTGCTCAAG 901 TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA951 GAAGCTGTGT GCCACCTAAT AA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG (SEQ ID NO: 109) 51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATGCCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCCG GCAGGAGGGG TCCTGGTTGC TAGCCATCTGCAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 651AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG 701 CCACCTACAAGCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 751 CTGGGCATCC CCTGGGCTCCCCTGAGCTCC TGCCCCAGCC AGGCCCTGCA 801 GCTGGCAGGC TGCTTGAGCC AACTCCATAGCGGCCTTTTC CTCTACCAGG 851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGGTCCCACCTTG 901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA951 GATGGAAGAA CTGGGATAAT AA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG (SEQ ID NO: 110) 51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCCTTCGCCTCTG CTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGCTTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCTGCCAGCTCCC 551 TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG601 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG 651CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG 701 CTCCCCTGAGCTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 751 AGCCAACTCC ATAGCGGCCTTTTCCTCTAC CAGGGGCTCC TGCAGGCCCT 801 GGAAGGGATA TCCCCCGAGT TGGGTCCCACCTTGGACACA CTGCAGCTGG 851 ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGAAGAACTGGGA 901 ATGGCCGCTG CCCTGCAGCC CTAATAA; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 111) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGCCTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCTGGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAGCTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC 701CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCTGCCCCAGCCA GGCCCTGCAG CTGCCAGGCT GCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCCTCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTCGACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAACTGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 112) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCAGCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 451 AGCTTCCTGG AGGTGTCGTACCGCGTTCTA CGCCACCTTG CGCAGCCCAC 501 ACCATTGGGC CCTGCCAGCT CCCTGCCCCAGAGCTTCCTG CTCAAGTCTT 551 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCTCCAGGAGAAG 601 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG651 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG 701CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 751 TACCAGGGGCTCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC 801 CACCTTGGAC ACACTGCAGCTGGACGTCGC CGACTTTGCC ACCACCATCT 851 GGCAGCAGAT GGAAGAACTG GGAATGGCCCCTGCCCTGCA GCCCACCCAC 901 GGTGCCATGC CGGCCTTCGC CTAATAA; 1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 155) 51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG 451 CTGTGCCACCCCGAGCAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCTGCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCCTCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGGACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751GCCTCTGCTT TCCAGCGCCC GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTCCTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCGGCGGCGG CTCTGACATGGCTACACCAT TAGGCCCTGC CAGCTCCCTG 901 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAGCAACTGAGGA AGATCCAGGG 951 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAATAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG (SEQ IDNO: 156) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCAAGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTGG 201 TAATCTCCAA CCATGTCTGCCCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAGAATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG 451TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGGCAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTCCAGC 551 CCACCCAGGG TGCCATGCCGGCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAGAGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCTGACATGGCTA 701 CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT751 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA 801GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG 851 GACACTCTCTGGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 901 GCCCTGCAGC TGGCAGGCTGCTTGAGCCAA CTCCATAGCG GCCTTTTCCT 951 CTACCAGGGG CTCCTGCAGG CCCTGGAAGGGATATCCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG(SEQ ID NO: 157) 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGACGAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCATCAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGAGCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGTCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT501 CCTCGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCCCAG CCCGGCGGCG 551GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 601 TTCCTGCTCAAGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC 651 AGCGCTCCAG GAGAAGCTGTGTGCCACCTA CAAGCTGTGC CACCCCGAGG 701 AGCTGGTGCT GCTCGGACAC TCTCTGGGCATCCCCTGGGC TCCCCTGAGC 751 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGAGCCAACTCCA 801 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT851 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 901TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC 951 CCTGCAGCCCACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA; 1 ATGGCTAACT GCTCTATAAT GATCGATGAAATTATACATC ACTTAAAGAG (SEQ ID NO: 158) 51 ACCACCTGCA CCTTTGCTGGACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAAC CTTCGACTTCCAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGGCAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGCTCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAATCTCATAAAT CTCCAAACAT GTCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATGCCGGCCTTCG CCTCTGCTTT 501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTGCAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC601 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT 651CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG 701 CGCTCCAGGAGAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 751 CTGGTGCTGC TCGGACACTCTCTGGGCATC CCCTGGGCTC CCCTGAGCTC 801 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGGCTGCTTGAGC CAACTCCATA 851 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGAAGGGATATCC 901 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT951 TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA; 1 ATGGCTAACTGCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 159) 51ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGATGGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG 451 GGTGCCATGCCGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGCAGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC GGCGGCGGCTCTGACATGGC TACACCATTA 601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGTCTTTAGAGCA 651 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG701 CCACCTACAA GCTCTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 751CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA 801 GCTGGCAGGCTGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG 851 GGCTCCTGCA GGCCCTGGAAGGGATATCCC CCGAGTTGGG TCCCACCTTG 901 GACACACTGC AGCTGGACGT CGCCGACTTTGCCACCACCA TCTGGCAGCA 951 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAATAA; GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCT (SEQID NO: 124) TTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCGGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGACCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCT (SEQ ID NO:125) TTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCGGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCT (SEQ ID NO:126) TTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGCCGGCAACATGGCGTCTCCGGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTCGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGCGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCT (SEQ ID NO:127) TTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGATCTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGCCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCGGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCACCTTCCTCCACAGGGCAGGACCACA;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCT (SEQ ID NO:128) TTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCGGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATCTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG; 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCCACCTGAAGCA (SEQ ID NO: 114) 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAACCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGAGGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGAAAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTGAACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAATCTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAGAAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCTCTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGCTGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAAGGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951GCAGCCCTAA TAA; 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA(SEQ ID NO: 115) 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGTGAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251 CAATCATCATCCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGAGAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCCTGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGAAGCTGTGTGC CACCTACAAG CTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTC GGACACTCTCTGGGCATCCC CTGGGCTCCC 751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCTGCTTGAGCCA 801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 901GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTGCAGCCCTAAT AA; 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA(SEQ ID NO: 116) 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGTGAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251 CAATCATCATCCGTGACGCT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGAGAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGCC TCCCCGGGTG AACCGTCTGGTCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACATGGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGTCTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAG AAGCTGTGTGCCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCT CTGGGCATCCCCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCCAACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 901GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951 GCAGCCCTAATAA; 1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA (SEQ IDNO: 117) 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCAAGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGCCGCTAGCCAC GGCCGCACCC ACGCGACATC 251 CAATCCATAT CAAGGACGGT GACTGGAATGAATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGTACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCTAGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCCACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAAGTGAGAAAGA TCCAGGGCGA 651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAGCTGTGCCACC 701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA 801ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCCCGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 901 GCCGACTTTG CCACCACCATCTGGCAGCAG ATGGAAGAAC TGGGAATGGC 951 CCCTGCCCTG CAGCCCTAAT AA; 1ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT (SEQ ID NO: 86)51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC CAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTCTAACTGCTCT 301 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCCAGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGCCCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAAAGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCATAGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTGGGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAGCAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA; 1 ATGGCTAATGCATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG (SEQ ID NO: 87) 51TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101 CAGGTGACTGGCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAG CGCAGGAACAACAGGGTGGT GGCTCTAACT GCTCTATAAT 201 GATCGATGAT ATTATACATC ACTTAAAGAGACCACCTGCA CCTTTGCTGG 251 ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGATGGACCGAAAC 301 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA351 ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCCAGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGCCCTCTGGCGG CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAAAGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCATAGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCGAGTTGGGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAGCAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA; 1 ATGGCTGCACCCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA (SEQ ID NO: 88) 51AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC 101 AGGAACAACAGGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT 151 ATACATCACT TAAAGAGACCACCTGCACCT TTGCTGGACC CGAACAACCT 201 CAATGACGAA GACGTCTCTA TCCTGATGGACCGAAACCTT CGACTTCCAA 251 ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAATGCATCAGGT 301 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC351 CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 451 ATGGCTACCCAGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG 501 GGCAGGAGGG GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGCCCTCTGGCGC CTCTGGCGGC 601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAAAGATCCAGGG 651 CGATCGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 751CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCATAGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG 851 AAGGGATATC CCCCCAGTTGGGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAGCAGATGGAAG AACTGGGAAT 951 GGCCCCTGCC CTGCAGCCCT AATAA; 1 ATGGCTCTGCACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT (SEQ ID NO: 90) 51CGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCCTA AGGGCTCTCA 101 AGAACTTAGAAAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCACGGCCGCACCC TCTCGACATC CAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGAAAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTCTGGCGGTGGC 301 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA351 CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC 401CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTCATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGCGCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACCGCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGCTCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTGGCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCCCTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCCGACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAGCCCTAATAA; 1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG (SEQID NO: 91) 51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAGCGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG 201 CGGCGGTTCT AACTGCTCTATAATGATCGA TGAAATTATA CATCACTTAA 251 AGAGACCACC TGCACCTTTG CTGGACCCGAACAACCTCAA TGACGAAGAC 301 CTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACCTGGAGAGCTT 351 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCTGCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTACCC 551 ATCTGCAGAG CTTCCTGGAGGTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAGAGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC ACGGCGATGG CGCAGCGCTCCAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCTCCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCTGGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG CAATGGCCCCTGCCCTGCAG CCCTAATAA;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 136) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGCCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTACCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 137) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 148) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACACCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 149) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGACAGCTTCGTAAGGGCTCTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCCCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGCTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCAGAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTT;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 150) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGCTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 151) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 152) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCGTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAG;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 153) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGCGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT;GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTT (SEQ IDNO: 154) GCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAG; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 259) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTAGGC 451 CCTGCCAGCT CCCTGCCCCAGAGCTTCCTG CTCAAGTCTT TAGAGCAAGT 501 GAGGAAGATC CAGGGCGATG GCGCAGCGCTCCAGGAGAAG CTGTGTGCCA 551 CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGGACACTCTCTG 601 GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT651 GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC 701TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 751 ACACTGCAGCTGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT 801 GGAAGAACTG GGAATGGCCCCTGCCCTGCA GCCCACCCAG GGTGCCATGC 851 CGGCCTTCGC CTCTGCTTTC CAGCGCCGGGCAGGAGGGGT CCTGGTTGCT 901 AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTCTACGCCACCT 951 TGCGCAGCCC GACATGGCTA CACCA; 1 ATGGCTAACT GCTCTATAATGATCCATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 260) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGAGC 451 TTCCTGCTCA AGTCTTTAGAGCAAGTGAGG AAGATCCAGG CCGATGGCGC 501 AGCGCTCCAG GAGAAGCTGT GTGCCACCTACAAGCTGTGC CACCCCGAGG 551 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGCTCCCCTGAGC 601 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA651 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT 701CCCCCGAGTT CGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 751 TTTGCCACCACCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC 801 CCTGCAGCCC ACCCAGGGTGCCATGCCGGC CTTCGCCTCT GCTTTCCAGC 851 GCCGGGCAGG AGGGGTCCTG GTTGCTAGCCATCTGCAGAG CTTCCTGGAG 901 GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCGACATGGCTACACC 951 ATTAGGCCCT GCCAGCTCCC TGCCC; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 261) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTTCCTG 451 CTCAAGTCTT TAGAGCAAGTGAGGAAGATC CAGGGCGATG GCGCAGCGCT 501 CCAGGAGAAG CTGTGTGCCA CCTACAAGCTGTGCCACCCC GAGGAGCTGG 551 TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCTGAGCTCCTGC 601 CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG651 CCTTTTCCTC TACCAGGGCC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG 701AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC 751 ACCACCATCTGGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA 801 GCCCACCCAG GGTGCCATGCCGGCCTTCGC CTCTGCTTTC CAGCGCCGGG 851 CAGGAGGGGT CCTGGTTGCT AGCCATCTGCAGAGCTTCCT GGAGGTGTCG 901 TACCGCGTTC TACGCCACCT TGCGCAGCCC GACATGGCTACACCATTAGG 951 CCCTGCCAGC TCCCTGCCCC AGAGC; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 262) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACACT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAGCAA 451 GTGAGGAAGA TCCAGGGCGATGGCGCAGCG CTCCAGGAGA AGCTGTGTGC 501 CACCTACAAG CTGTGCCACC CCGAGGAGCTGGTGCTGCTC GGACACTCTC 551 TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCAGGCCCTGCAG 601 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG651 GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG 701ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 751 ATGGAAGAACTGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT 801 GCCGGCCTTC GCCTCTGCTTTCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 851 CTAGCCATCT GCAGAGCTTC CTGGAGGTGTCGTACCGCGT TCTACGCCAC 901 CTTGCGCAGC CCGACATGGC TACACCATTA GGCCCTGCCAGCTCCCTGCC 951 CCAGAGCTTC CTGCTCAAGT CTTTA; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 263) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTCTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCTC 451 GGACACTCTC TGGGCATCCCCTGGGCTCCC CTGAGCTCCT GCCCCAGCCA 501 GGCCCTGCAG CTGGCAGGCT GCTTGAGCCAACTCCATAGC GGCCTTTTCC 551 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCCCGAGTTGGGT 601 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT651 CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC 701AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 751 GTCCTGGTTGCTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT 801 TCTACGCCAC CTTGCGCAGCCCGACATGGC TACACCATTA GGCCCTGCCA 851 GCTCCCTGCC CCAGAGCTTC CTGCTCAAGTCTTTAGAGCA AGTGAGGAAG 901 ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTGCCACCTACAA 951 GCTGTGCCAC CCCGAGGAGC TGGTG; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 264) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCCTG 451 AGCTCCTGCC CCAGCCAGGCCCTGCAGCTG GCAGGCTGCT TGAGCCAACT 501 CCATAGCGGC CTTTTCCTCT ACCAGGGGCTCCTGCAGGCC CTGGAAGGGA 551 TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCTGGACGTCGCC 601 GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC651 TGCCCTGCAG CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC 701AGCGCCGGGC AGGAGGGGTC CTGGTTGCTA GCCATCTGCA GAGCTTCCTG 751 GAGGTGTCGTACCGCGTTCT ACGCCACCTT GCGCAGCCCG ACATGGCTAC 801 ACCATTAGGC CCTGCCAGCTCCCTGCCCCA GAGCTTCCTG CTCAAGTCTT 851 TAGAGCAAGT GAGGAAGATC CAGGGCGATGGCGCAGCGCT CCAGGAGAAG 901 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGGTGCTGCTCGG 951 ACACTCTCTG GGCATCCCCT GGGCT; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 265) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCAGGCC 451 CTGCAGCTGG CAGGCTGCTTGAGCCAACTC CATAGCGGCC TTTTCCTCTA 501 CCAGGGGCTC CTGCAGGCCC TGGAAGGGATATCCCCCGAG TTGGGTCCCA 551 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCACCACCATCTGG 601 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG651 TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC 701TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 751 CGCCACCTTGCGCAGCCCGA CATGGCTACA CCATTAGGCC CTGCCAGCTC 801 CCTGCCCCAG AGCTTCCTGCTCAAGTCTTT AGAGCAAGTG AGGAAGATCC 851 AGGGCGATGG CGCAGCCCTC CAGGAGAAGCTGTGTGCCAC CTACAAGCTG 901 TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGGGCATCCCCTG 951 GGCTCCCCTG AGCTCCTGCC CCAGC; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 266) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTCGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTCG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGCAG 451 CTGGCAGGCT GCTTGAGCCAACTCCATAGC GGCCTTTTCC TCTACCAGGG 501 GCTCCTGCAG GCCCTGGAAG GGATATCCCCCGAGTTGGGT CCCACCTTGG 551 ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCATCTGGCAGCAG 601 ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT651 GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG 701CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 751 CTTGCGCAGCCCGACATGGC TACACCATTA GGCCCTCCCA GCTCCCTGCC 801 CCAGAGCTTC CTGCTCAAGTCTTTAGAGCA AGTGAGGAAG ATCCAGGGCG 851 ATGGCGCAGC GCTCCAGGAG AAGCTGTGTGCCACCTACAA GCTGTGCCAC 901 CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCCCCTGGGCTCC 951 CCTGAGCTCC TGCCCCAGCC AGGCC; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 267) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAACCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCTGGCA 451 GGCTGCTTGA GCCAACTCCATAGCGGCCTT TTCCTCTACC AGGGGCTCCT 501 GCAGGCCCTG GAAGGGATAT CCCCCGAGTTGGGTCCCACC TTGGACACAC 551 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCAGCAGATGGAA 601 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC651 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 701ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 751 CAGCCCGACATGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG 801 CTTCCTGCTC AAGTCTTTAGAGCAAGTGAG GAAGATCCAG GGCGATGGCG 851 CAGCGCTCCA GGAGAAGCTG TGTGCCACCTACAAGCTGTG CCACCCCGAG 901 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGGCTCCCCTGAG 951 CTCCTGCCCC AGCCAGGCCC TGCAG; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 268) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGAACTG 451 GGAATGGCCC CTGCCCTGCAGCCCACCCAG GGTGCCATGC CGGCCTTCGC 501 CTCTGCTTTC CAGCGCCGGG CAGGAGGGGTCCTGGTTGCT AGCCATCTGC 551 AGAGCTTCCT GGAGGTGTCG TACCGCGTTC TACGCCACCTTGCGCAGCCC 601 GACATGGCTA CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT651 GCTCAAGTCT TTACAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC 701TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG 751 GTGCTGCTCGGACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG 801 CCCCAGCCAG GCCCTGCAGCTGGCAGGCTG CTTGAGCCAA CTCCATAGCG 851 GCCTTTTCCT CTACCAGGGG CTCCTGCAGGCCCTGGAAGG GATATCCCCC 901 GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCGCCGACTTTGC 951 CACCACCATC TGGCAGCAGA TGGAA; 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 269) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTGGAATG 451 GCCCCTGCCC TGCAGCCCACCCAGGGTGCC ATGCCGGCCT TCGCCTCTGC 501 TTTCCAGCGC CGGGCAGGAG GGGTCCTGGTTGCTAGCCAT CTGCAGAGCT 551 TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCAGCCCGACATG 601 GCTACACCAT TAGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA651 GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA GCGCTCCAGG 701AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 751 CTCGGACACTCTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG 801 CCAGGCCCTG CAGCTGGCAGGCTGCTTGAG CCAACTCCAT AGCGGCCTTT 851 TCCTCTACCA GGGGCTCCTG CAGGCCCTGGAAGGGATATC CCCCGAGTTG 901 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACTTTGCCACCAC 951 CATCTGGCAG CAGATGGAAG AACTG; and 1 ATGGCTAACT GCTCTATAATGATCGATGAA ATTATACATC ACTTAAAGAG (SEQ ID NO: 270) 51 ACCACCTGCACCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGATCGAAACCTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCAGGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCCTCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCCGTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAGCTTC 451 CTGGAGGTGT CGTACCGCGTTCTACGCCAC CTTGCGCAGC CCGACATGGC 501 TACACCATTA GGCCCTGCCA GCTCCCTGCCCCAGAGCTTC CTGCTCAAGT 551 CTTTAGAGCA AGTGAGGAAG ATCCAGGGCG ATGGCGCAGCGCTCCAGGAG 601 AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCCAGGAGC TGGTGCTGCT651 CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC 701AGGCCCTCCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 751 CTCTACCAGGGGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG 801 TCCCACCTTG GACACACTGCAGCTGGACGT CGCCGACTTT GCCACCACCA 851 TCTGGCAGCA GATGGAAGAA CTGGGAATGGCCCCTGCCCT GCAGCCCACC 901 CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCCGGGCAGGAGG 951 GGTCCTGGTT GCTAGCCATC TGCAG.


37. The nucleic acid molecule according to claim 34 selected from groupconsisting of: 1 ATGGCTGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA(SEQ ID NO:286) 51 GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGAACCCAGCTTC 101 CTCCACAGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG151 AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG 201AGGGTCCACC CTCGCCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCGG 251 CGCCGCCTGCTGCTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 301 CATGTCCTTC ACAGCAGACTGAGCCAGTGC CCAGAGGTTC ACCCTTTGCC 351 TACACCTGTC CTGCTGCCTG CTGTGGACTTTAGCTTGGGA GAATGGAAAA 401 CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGCAGTGACCCTT 451 CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTG; and 1 ATGGCTGGCAGGACCACAGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG (SEQ ID NO:287) 51CTTCCAACAC CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG 101 GGTCCACCCTCGCCGTCAGG GAATTCGGCG GCAACATGGC GTCTCCGGCG 151 CCGCCTGCTG CTGACCTCCGAGTCCTCAGT AAACTGCTTC GTGACTCCCA 201 TGTCCTTCAC AGCAGACTGA GCCAGTGCCCAGAGGTTCAC CCTTTGCCTA 251 CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGAATGGAAAACC 301 CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT351 GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT 401CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC 451 CTGCAGAGCCTCCTTGGAAC CCAGCTTCCT CCACAG.


38. A method of producing a hematopoietic protein comprising: growingunder suitable nutrient conditions, a host cell transformed ortransfected with a replicable vector comprising a nucleic acid moleculeof claim 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 33, 34, 36 or 37 in amanner allowing expression of said hematopoietic protein and recoveringsaid hematopoietic protein.
 39. A pharmaceutical composition comprising;the hematopoietic protein according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 12, 15 or 16 and a pharmaceutically acceptable carrier.
 40. A methodof stimulating the production of hematopoietic cells in a patientcomprising the step of; administering an effective amount of thehematopoietic protein as recited in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,12, 15, or 16 to said patient.
 41. A method of stimulating theproduction of hematopoietic cells in a patient comprising the step ofadministering an effective amount of the hematopoietic protein asrecited in claim 13 to said patient.
 42. A method for selective ex vivoexpansion of stem cells, comprising the steps of: (a) separating stemcells from other cells; (b) culturing said separated stem cells with aselected culture medium-comprising; the hematopoietic protein of claim1; and (c) harvesting said cultured cells.
 43. A method for treatment ofa patient having a hematopoietic disorder, comprising the steps of: (a)removing stem cells; (b) separating stem cells from other cells; (c)culturing said separated stem cells with a selected culture mediumcomprising; the hematopoietic protein of claim 1; (d) harvesting saidcultured cells; and (e) transplanting said cultured cells into saidpatient.
 44. A method of human gene therapy, comprising the steps of:(a) removing stem cells from a patient; (b) separating said stem cellsfrom other cells; (c) culturing said separated stem cells with aselected culture medium comprising; the hematopoietic protein of claim1; (d) introducing DNA into said cultured cells; (e) harvesting saidtransduced cells; and (f) transplanting said transduced cells into saidpatient.
 45. A method of human gene therapy, comprising the steps of:(a) removing stem cells from a patient; (b) separating said stem cellsfrom other cells; (c) culturing said separated stem cells with aselected culture medium comprising; the hematopoietic protein of claim1; (d) introducing DNA into said cultured cells; (e) harvesting saidtransduced cells; and (f) transplanting said transduced cells into saidpatient.
 46. A method of human gene therapy, comprising the steps of:(a) removing stem cells from a patient; (b) separating said stem cellsfrom other cells; (c) culturing said separated stem cells with aselected culture medium comprising; the hematopoietic protein of claim11; (d) introducing DNA into said cultured cells; (e) harvesting saidtransduced cells; and (f) transplanting said transduced cells into saidpatient.
 47. A method of human gene therapy, comprising the steps of:(a) removing stem cells from a patient; (b) separating said stem cellsfrom other cells; (c) culturing said separated stem cells with aselected culture medium comprising; the hematopoietic protein of claim11; (d) introducing DNA into said cultured cells; (e) harvesting saidtransduced cells; and (f) transplanting said transduced cells into saidpatient.